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ABSTRACT
Amyotrophic lateral sclerosis (ALS) is a  neurodegenerative disease characterised 
by progressive loss of motor neurons in the cortex, brainstem  and spinal cord. 
This leads to w eakness and m uscular atrophy th a t evolves to paralysis and 
death. Studies on patients and animal models of ALS suggest th a t the pathology 
is the consequence of the unbalance between pro-degenerative (p38MAPK) and 
pro-survival (Akt) pathways in motor neurons. In order to re-equilibrate this 
complex interplay, the major objective of this study was to develop a  gene-based 
approach to target, in vivo, these two intracellular signaling proteins.
We dem onstrated for the first time th a t a  construct derived from Hb9 prom oter 
can be used  in lentivectors to restrict transgene expression to motor neurons in 
vivo; moreover we found th a t induction of Akt pathway, through expression of 
constitutively activated Akt3 in motor neurons, prevents neuronal loss in 
SOD1G93A mice, although it does not influence their prem ature death. On the 
other hand, we used  RNAi to downregulate p38MAPKalpha in a  m ouse model of 
ALS. We revealed th a t expression of p38MAPK-targeted shRNA in the spinal cord 
of presym ptom atic mice reduces motor neuronal loss in the early phases of the 
pathology, b u t then  it is not able to su sta in  neuronal survival during disease 
progression, eventually resulting in worsening of symptoms and shortening of life 
span. We found preliminary evidences th a t hyperactivation of microglial cells 
may be responsible for th is more aggressive phenotype, suggesting th a t a  fine 
tuning of microglial reactivity may be im portant to avoid pro-degenerative effects. 
Overall these data  support the hypothesis th a t m odulation of pro-degenerative 
and  pro-survival pathways may help counteracting motor neuronal degeneration, 
and  strengthen the evidence th a t preservation of neuronal perikaria is not 
sufficient to ameliorate disease progression in ALS. The peripheral com partm ent 
(axons, muscles) should be regarded as an  additional target for potential 
therapeutic approaches.
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CHAPTER 1 
GENERAL INTRODUCTION
1.1 AMYOTROPHIC LATERAL SCLEROSIS
Amyotrophic Lateral Sclerosis (ALS) initially known as Charcot's sclerosis, is a  
form of m uscular atrophy th a t was first described in 1869 by the French 
neurobiologist and clinician Jean-M artin Charcot. It belongs to a  wide group of 
syndrom es called Motor Neuron Diseases (Table 1.1). The term  “amyotrophicf 
refers to m uscle atrophy, w eakness and fasciculations appearing as a  
consequence of degeneration of the motor neurons. The term  “lateral sclerosis” 
derives from Charcot’s observation of a  distinct “myelin pallor” and hardness of 
the lateral colum ns of spinal cord, a t autopsy. This is due to the loss of axons of 
upper motor neurons as they descend from the brain to connect to the lower 
motor neurons within the spinal cord, and to the massive gliosis following 
degeneration of the cortico-spinal tract.
In the United S tates ALS is commonly term ed Lou Gehrig’s disease, after the 
fam ous baseball player who died of th is syndrome in the late 1930s. The term  
Motor Neuron Disease (MND) is instead mainly used  in the United Kingdom to 
refer to this pathology.
Currently ALS is defined as a  fatal progressive neurodegenerative disorder 
involving primarily the motor neurons of the cerebral cortex (upper motor 
neurons, UMN), brainstem  and spinal cord (lower motor neurons, LMN). This 
causes a  reduction of the input signals delivered to the voluntary m uscles, 
leading to initial w eakness. As the disease progresses, w idespread limb and 
tru n k  weakness and atrophy lead to a  dram atic decline in physical function, 
finally resulting in complete paralysis. Patients usually  die for respiratory failure, 
due to denervation of the diaphragm  and respiratory m uscles.
ALS is the m ost common motor neuron disease. The majority of ALS cases are 
sporadic (sporadic ALS or sALS), although in 5-10% of cases the pathology is
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inherited (familial ALS or fALS). Sporadic and familial forms share similar 
pathological hallm arks.
Despite extensive efforts to study and understand  the molecular m echanism s 
th a t lead to th is disease, ALS still lacks a  truly effective therapy (Boillee et a l, 
2006a; Aggarwal and Cudkowicz, 2008; Raibon et a l, 2008).
Table 1.1. Features o f Motor Neuron D iseases
Affected region Motor Neuron D isease
Combined UMN and LMN 
involvement Amyotrophic Lateral Sclerosis
Pure LMN involvement
Progressive Muscular Atrophy, Progressive Bulbar 
Palsy,
Spinal Muscular Atrophy
Pure UPM involvement Primary Lateral Sclerosis, Pseudo-bulbar Palsy, Hereditary Spastic Paraplegia
Mixed motor and sensory 
involvement
Charcot Marie Tooth Disease, Distal hereditary motor 
neuropathy, ALS with fronto-temporal dementia
1 .1 .1  SYMPTOMATOLOGY
Symptoms of ALS are associated with dysfunction of lower and  upper motor 
neurons (Figure 1.1). LMN involvement initially determ ines w eakness and 
fatigue. As disease progresses, m uscular deficits, due to loss of innervation, 
appear more evident: m uscular atrophy, reduced muscle tone and  absence of 
tendon reflexes, fasciculations (m uscular twitching and  shaking of contiguous 
groups of muscle fibers) and fibrillations (m uscular twitching and  shaking 
involving individual muscle fibers acting w ithout coordination). UMN involvement 
instead causes weakness, incoordination, stiffness and slowing of movement, 
with spasticity (persistent contraction of muscle), increased tendon reflexes, 
clonus (alternating contractions and relaxations) and extensor p lan ta r responses.
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ALS probably begins a  long time before its clinical m anifestations, since a 
substantia l num ber of motor neurons can be lost before any clinical signs 
develop. In fact, several studies on anim al models have shown th a t motor neuron 
dysfunction precedes the onset of symptoms and th a t com pensatory 
reinnervation from nearby motor neurons perm its a  good m aintenance of the 
motor function, although with an enlargem ent of motor units, un til more th an  
50% of motor un its  have been lost; a t th is point symptoms appear and  the 
num ber of motor un its  declines rapidly (Cote et a l, 1993; Kennel et a l, 1996).
No neuropathological, neurophysiological or biochemical m arkers are yet 
available to identify a  patient as potentially susceptible for ALS prior to symptom 
onset (Swash and Desai, 2000).
At the onset, ALS can appear with LMN involvement, UMN involvement or bu lbar 
involvement. Limb onset is the m ost frequent, and  is found in 75-80% of cases, 
while bulbar onset is evidenced in only 20-25% (Wijesekera and Leigh, 2009).
At the early stages of the pathology there is great variability in the extent and 
localization of motor system  involvement in different patients, th u s  complicating 
the diagnosis. However, as the disease progresses, the clinical expression of ALS 
becomes quite uniform, with extreme m uscu lar wasting, spasticity and  paralysis. 
The m ost common initial presentation of ALS is focal asymmetric distal w eakness 
and m uscular atrophy. For example, the patient may report a  h istory of 
unexpected tripping, dragging of a  foot and  ultim ately more diffuse w eakness of 
the leg. When upper limbs are involved, symptoms may appear as difficulty with 
buttoning clothes, tu rning keys in doors or simply poor coordination while 
performing fine movements.
Bulbar motor neuron degeneration leads to difficulty in swallowing (dysphagia) 
and breathing, and slurred or thick speech (dysarthria), associated with 
fasciculation of the tongue. Bulbar signs are often closely related to respiratory 
deficits, due to the involvement of the diaphragm. This leads to a  poor prognosis 
and to a  shorter life expectancy.
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With the progression of the illness, the disease spreads to contiguous muscle 
segments. The progressive loss of motor function resu lts in increasing disability 
and paralysis, ultim ately leading to a  bed-bound state.
Recent findings have revealed th a t the selectivity of ALS for the m otor system  is 
not absolute. In fact, some reports describe cognitive im pairm ent in a  subgroup 
of ALS patients. A battery of neuropsychological tests  has shown a  cognitive 
im pairm ent in about 30% of ALS patients, ranging from mild im pairm ent to 
frontotemporal lobar degeneration (FTLD). The main symptoms are executive 
dysfunction with deficits in verbal and non-verbal fluency and concept formation 
(Lomen-Hoerth et a l, 2003; Kilani et a l, 2004; Abrahams et a l, 2005; Schreiber et 
a l, 2005; Rippon et a l, 2006). However, in the majority of cases, the rate  of 
cognitive decline is very slow as compared to the devastating motor deterioration. 
Eye and bladder muscles, along with sexual function, are not normally affected. 
Average life expectancy for ALS patients is 2-5 years from diagnosis, with the 
cause of death being respiratory failure, m ost often hastened by pneum onia. 
When swallowing and respiratory m uscle activity appear to be insufficient during 
disease progression, patients need to use  tube feedings and  m echanised 
ventilation, respectively. Through these supporting system s patien ts can 
generally be m aintained for several years, although the quality of life is 
decreased.
Figure 1.1. O utline o f neuro-anatom ic pathways involved in ALS
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1 .1 .2  DIAGNOSIS
ALS is a very difficult disease to diagnose. Clinical findings early in the course of 
the disease are often variable, and to date there is no biological diagnostic 
m arker or procedure to ultimately establish the diagnosis of ALS. This often 
compromises the certainty of the diagnosis in clinical practice and therapeutic 
trials.
It is through a clinical examination and series of diagnostic tests, often ruling out 
other diseases tha t mimic ALS, tha t a  diagnosis can be established.
These tests include genetic screening (in case of suspected familiarity), muscle 
and nerve biopsy, spinal tap, X-rays, MRI's and electromyography (EMG).
A set of diagnostic criteria for ALS was established in 1994 by the World 
Federation of Neurology during a meeting in El Escorial, Spain, and it was 
subsequently updated a t Airlie Conference Center, W arrenton, Virginia in 1998.
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Based on these criteria, diagnosis of ALS requires:
S  The presence of:
1) Evidence of LMN degeneration, assessed by clinical, 
electrophysiological or neuropathological examination;
2) Evidence of UMN degeneration, by clinical examination;
3) Progressive spread of symptoms or signs within a  region or to 
other regions, as determ ined by history or examination;
v' Together with the absence of:
1) Electrophysiological or pathological evidence of o ther disease 
processes th a t m ight explain the signs of LMN a n d /o r  UMN 
degeneration;
2) Neuroimaging evidence of other disease processes th a t might 
explain the observed clinical and electrophysiological signs.
The so-called “Revised El-Escorial criteria” (Table 1.2) classify the probability for 
a  patien t to be affected by ALS according to the level of clinical certainty, as 
compared to other similar pathologies (Brooks et a t, 2000).
Table 1.2. Revised El Escorial Criteria
Level o f certainty Clinical presentation
Clinically definite ALS
Presence of UMN and LMN signs in the 
bulbar region and at least two spinal 
regions.
Alternatively, presence of UMN and LMN 
signs in three spinal regions
Clinically probable ALS
UMN and LMN signs in at least two 
regions with some UMN signs necessarily 
rostral to the already detected LMN signs
Clinically probable ALS -  
Laboratory supported
Clinical signs of UMN and LMN 
dysfunction are only in one region.
Alternatively, UMN signs alone are 
present in one region, and LMN signs 
(defined by EMG criteria) are present in 
at least two regions. Neuroimaging and 
clinical laboratory protocols m ust be 
applied in this case to exclude other 
causes.
Clinical Possible ALS
Signs of UMN and LMN dysfunction 
together in only one region.
Alternatively LMN signs are found rostral 
to UMN signs and the diagnosis of 
Clinically Probable ALS-Lab.supported 
cannot be proven in conjunction with 
laboratory studies.
When ALS occurs in association with other features, such as Parkinsonism  (5% 
of cases) or dem entia (3% of cases), or when there is a  pure UMN or LMN 
syndrome, it is often considered an atypical variant of Charcot ALS.
Atypical ALS cases are also characterised by one or more of the following 
features:
• Geographic clustering (Western Pacific, Guam, Kii Peninsula, North 
Africa, Madras)
• Extrapyramidal signs (bradykinesia; cogwheel rigidity; tremor)
• Cerebellar degeneration (spinocerebellar abnormalities)
• Autonomic nervous system  involvement (abnormal cardiovascular 
reflexes; bowel or bladder control problems)
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• Sensory abnorm alities (decreased vibration; sh arp /d u ll discrimination; 
blunting of cold sensation)
• O cular movement abnorm alities
• Syndromes th a t mimic ALS (adult onset proximal spinal m uscular 
atrophy; Kennedy syndrome; delayed post-poliomyelitis; multifocal 
motor neuropathy with or w ithout conduction block; endocrinopathies; 
lead intoxication; infections).
Such patients are usually  excluded from clinical trials (Eisen and Caine, 1992; 
Kew and Leigh, 1992; Brooks et al., 2000; Sw ash  and Desai, 2000).
1 .1 .3  NEUROPATHOLOGY
A better understanding  of the neuropathology of the disease h as taken  advantage 
of immunohistochemical and  u ltrastruc tu ra l studies performed on post m ortem  
tissues of ALS patients. However, post-m ortem  exam inations are conducted on 
tissues th a t represent the final stage of the pathology; th u s  the observed 
alterations reflect a  very advanced state  of neuronal degeneration and  give little 
information about the events th a t trigger cell death.
The major pathological features of ALS are:
1) Upper motor neuron abnorm alities
2) Myelin pallor in the corticospinal tracts
3) Reduction in both size and  num ber of lower motor neurons in the spinal 
ventral horns and in the bulbar nuclei (Robert H. Brown, 2000).
1) UMN involvem ent
Upper motor neurons localized in the motor cortex exert supranuclear control 
over lower motor neurons.
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The degree of degeneration observable a t autopsy in the m otor cortex of ALS 
patients is variable and may not always be evident, even in the presence of clear 
upper motor neuron signs. In the m ost severely affected cases, an  evident loss of 
giant Betz cells in cortical layer 5, associated with an  extensive astrogliosis and 
microgliosis, is reported. Since there are not good m arkers to d istinguish upper 
m otor neurons and other pyramidal cell types in the cortex, the identification of 
the Betz cell is often based on morphological and size criteria. Neuron cell bodies 
appear atrophied (Kieman and Hudson, 1991), with shorter fragm ented dendrites 
(Hammer et a t, 1979). Intracellular alterations are rarely identified in the spared 
Betz cells in classical ALS; occasionally, ubiquitinated neurofilam ent inclusions 
are reported. Pathological changes are rarely evident in som atosensory cortex, 
prefrontal cortex and prem otor areas (Kieman and Hudson, 1991).
2) Myelin pallor in the corticospinal tract
Axonal degeneration of the descending corticospinal trac t resu lts  in  clear 
demyelination. As a  consequence, the spinal cord of ALS patien ts shows a  pallor 
with myelin stain. Corticospinal fibers also show m arked axonal swelling and 
spheroids (Chou, 1992). An extensive gliosis is present, causing the typical 
sclerosis of lateral spinal cord tracts.
3) LMN involvem ent
Loss of large motor neurons localized in the lower brainstem  and in the spinal 
cord are clearly observed a t autopsy. Shrinkage and atrophy of the cell body 
precedes neuronal death (Kieman and Hudson, 1991)\ the phenom enon is 
associated with alterations of axon and dendrite structures, which become 
th inner (Nakano and Hirano, 1987).
Certain motor neuron groups, such as those controlling eye m ovem ents and  the 
O nufs nucleus of the sacral spinal cord (that regulates the pelvic floor 
m usculature) are largely spared by the disease.
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The rem aining motor neurons display several abnormalities, listed below.
Ubiquitinated inclusions
Ubiquitin-positive inclusions are found very frequently in the susceptible LMN 
groups of the spinal cord and brainstem  of m ost cases and are defined as skein­
like or Lew y body-like inclusions. The former are a  specific hallm ark of ALS 
w hereas the la tter are also found in other disorders, like Parkinson’s disease 
(Jellinger, 2008). Both inclusions probably represent two different morphological 
stages of protein aggregation, from diffuse filamentous forms to dense and 
com pact inclusions. The major protein constituent of these inclusions is 
unknow n, b u t they do not im m unostain for tau , alpha-synuclein or cystatin C, 
th a t represent components of inclusions in other neurodegenerative diseases 
(Ince, 2000). Besides phosphoiylated neurofilam ents and ubiquitin, in  some 
cases Lewy body-like inclusions also contain cyclin-dependent k inase 5 (CDK5) 
(Nakamura et al., 1997), or dorfin, a  RING finger-type E3 ubiquitin  ligase 
(Hishikawa et al., 2003).
More recently, the nuclear factor TDP-43 (TAR-DNA-binding protein 43) h as  been 
identified as a  m ajor component of ubiquitinated inclusions in sporadic ALS 
cases (Neumann et a l, 2006b). TDP-43 is thought to function as a  regulator of 
transcription and  alternative splicing (Buratti and Baralle, 2001; Buratti et al., 
2004; Mercado et al., 2005). Ubiquitin-positive inclusions are localized both  in 
norm al appearing motor neurons and in some shrunken  cells.
B unina bodies
B unina bodies are small, eosinophilic, irregularly shaped inclusions localized in 
the som a of m otor neurons; probably they have a  lysosomal derivation (Sasaki 
and Maruyama, 1993). At the u ltrastruc tu ra l analysis, they appear like electron- 
dense, am orphous structu res surrounded by vesicles, endoplasm ic reticulum
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(ER) fragments, lipofuscin granules. They im m unostain positive for cystatin C, a 
protein inhibitor of lysosomal cysteine proteases, and transferrin , an  iron- 
binding protein, b u t they are usually  negative for ubiquitin, and  do not contain 
TDP-43 (Okamoto et al., 2008). B unina bodies are reported to be p resen t in 30- 
50% of cases; since they are not described in other disorders, they seem to be 
specific for ALS.
Some authors have hypothesised th a t B unina Bodies may be a  special type of 
autophagic vacuole, probably deriving from altered m itochondria (Hart et a l, 
1977), or th a t they may originate from smooth endoplasmic reticulum  or the 
Golgi apparatus (Okamoto et al., 1993). However their pathogenesis and their 
relationship to neurodegeneration is controversial and has not yet been 
unravelled.
Golgi fragmentation
Both upper and  lower m otor neurons of ALS cases show signs of fragm entation of 
the Golgi apparatus, th a t is dispersed into num erous small isolated elem ents 
(Mourelatos et al., 1994; Fujita and Okamoto, 2005), as evidenced by MG-160 
staining, th a t recognises a  160-Kda sialoglycoprotein of medial cisternae of the 
Golgi apparatus (Mourelatos et a l, 1990).
Hyaline conglomerate inclusions
Hyaline conglomerate inclusions consist of large aggregates of phosphorylated 
and non phosphorylated neurofilam ents associated with other “entrapped” 
cytoplasmic proteins and organelles (Schochet et a l, 1969; Leigh et a l, 1989; 
Sasaki and Maruyama, 1991). They have been identified in sporadic and  familial 
ALS; however, they seem to be less specific for th is pathology, since they have 
been found in other neurological disorders, like multiple system  atrophy and  in 
normal patients (Leigh et a l, 1989; Sobue et al., 1990).
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Globules, spheroids and somatic accum ulation of phosphorylated neurofilam ents 
Diffuse accum ulation of phosphorylated neurofilam ents has been observed in the 
perikarya of motor neurons, especially in sporadic ALS (Hirano et a l, 1984). They 
can also be found packed in axonal swellings in the anterior horns of spinal cord 
of ALS patients (Corbo and Hays, 1992; Toyoshima et a l, 1998). Spheroids are 
larger structu re  th a t tend to be localized in proximal axons and dendrites, 
w hereas globules are sm aller and  usually  are more peripheral in the ventral 
horn. Both might represent focal abnorm alities of axonal cytoskeleton regulation 
due to a  failure of axonal transport.
Mitochondrial alterations
In recent years, morphological alterations of m itochondria in the m otor neurons 
of ALS patients have been observed. These include dense conglomerates of 
aggregates, dark  m itochondria, swelling and vacuolization (Hirano et a l, 1984; 
Swerdlow et a l, 1998).
4) Involvem ent o f other cell types
Clear morphological and neurochem ical evidence dem onstrates the proliferation 
and activation of the microglial and astrocytic populations in the areas 
characterized by motor neuronal loss (Kawamata et a l, 1992). The concept of 
selective motor neuronal death has  been challenged by studies reporting the loss 
of small neurons in the spinal cord of ALS cases (Oyanagi et a l, 1989; Raynor 
and Shefner, 1994). In a  recent report by Stephens and  colleagues, the 
m orphom etric examination of the lum bar spinal cord of sporadic ALS patien ts 
revealed a  substantia l loss of ventral interneurons in addition to m otor neurons. 
Therefore, the intem euronal population may degenerate to a  sim ilar extent and 
contem porary with the motor neuronal one (Stephens et a l, 2006).
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5) Non-motor system  pathology
Autopsy exam ination revealed in some ALS patients alterations in extra-motor 
regions of the CNS, such  as in the sensory system  (Hudson, 1981), substan tia  
nigra and  hippocam pus (Wharton, 2003).
6) Non-CNS pathology
Profound atrophy of the skeletal m uscles is one of the earliest pathological 
changes in ALS patients (Mitsumoto H, 1998). Interestingly, other alterations are 
reported in the skin, in which collagen cross-linking is changed (Kolde et a l, 
1996).
1 .1 .4  EPIDEMIOLOGY
Three classifications of ALS have been described:
• Sporadic - the m ost common form of ALS in the United S tates - 90 to 
95% of all cases.
• Familial - occurring more than  once in a  family lineage (genetic dom inant 
inheritance) accounts for a  veiy small num ber of cases in the United 
S tates - 5 to 10% of all cases.
• G uam anian - an extremely high incidence of ALS was observed in Guam 
and the T rust Territories of the Pacific in  the 1950's.
ALS is considered as a  rare disease: it occurs in about 1-3 people per 100,000
per year with a  prevalence of about 5-7 per 100,000, (McGuire et a t, 1996;
Mitsumoto H, 1998). The average survival for sporadic ALS patien ts is
approximately 3-5 years after the first symptoms. Onset of ALS in patien ts
younger th an  50 years of age is generally associated with a  longer survival.
The incidence of ALS increases with age, with a  peak occurring between 55 and
75 years of age; therefore, aging is the m ost significant risk  factor. ALS occurs
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predom inantly in males, with a  male to female ratio of 3:2. Male predominance is 
particularly m arked in some lower motor neuron variants. After the m enopause 
the male to female ratio approaches 1:1, suggesting a  neuro-protective effect 
exerted by estrogens (Worms, 2001; Mitchell and Borasio, 2007).
Environmental risk factors are inconsistently reported in ALS; this may reflect a  
complex interaction between several environm ental risk  factors and specific 
genetic susceptibilities.
People of all races and ethnic backgrounds are affected by ALS and, with the 
exception of specific endemic areas in the W estern Pacific, its worldwide 
frequency is uniform. Four geographic areas with a  high prevalence 
(approximately 100-150 fold higher th an  the other regions) of ALS are described 
(Kurland and Molgaard, 1982; Oyanagi and Wada, 1999):
• Guam and Rota islands
• 2 areas in the Kii peninsula
• Irian Jay a  (Indonesia)
• Area of the Gulf of Carpentaria (North Australia)
W estern Pacific ALS is considered a  distinct disease because it is often associated 
with Parkinsonism  Dementia, with pathological alterations resembling 
Alzheimer’s disease (neurofibrillary tangles).
Although familial ALS is alm ost indistinguishable from the sporadic form in 
term s of clinical phenotype, some features differentiate it from an epidemiological 
point of view (Mitsumoto H, 1998): the average onset of fALS cases is 
approximately 47 years, a  decade earlier th an  the sporadic type, and  the m ean 
survival is shorter; moreover, it occurs equally in males and females. Finally, in 
fALS, symptoms more frequently begin in the lower extremities com pared to 
sporadic ALS.
1.1.5 GENETICS
ALS is predom inantly sporadic; familial ALS accounts only for 5-10% of cases. 
Studies in families have led to identification of genes responsible for the disease 
and  of potential genetic loci (Table 1.3). Although these studies are not 
exhaustive, they helped identify molecular pathw ays th a t may be involved in the 
neuropathology of the sporadic forms of the disease.
Table 1.3. Causative genes and Mendelian loci for fam ilial ALS
Designation Genetic locus Gene Clinical features Main reference
ALS1 21q21 SOD1 Autosomal dominant; typical ALS (Rosen et al, 1993)
ALS2 2q33 ALSin
Autosomal recessive; 
jouvenile onset, slowly 
progressive
(Hadano et al, 
2001)
ALS3 18q21 Unknown Autosomal dominant (Hand et al, 2002)
ALS4 9q34 SETX
Autosomal dominant; 
juvenile onset, slowly 
progressive, non fatal
(Blair et al, 2000)
ALS5 15ql5.1-q21.1 Unknown
Autosomal recessive; 
juvenile onset, slowly 
progressive
(Hentati et al, 
1998)
ALS6 16ql2.1-ql2.2 FUS/TLS Autosomal dominant
(Ruddy et al, 2003; 
Kwiatkowski et al, 
2009; Vance et al, 
2009)
ALS7 20pter Unknown Autosomal dominant (Sapp et al, 2003)
ALS8 20ql3.3 VAPB Autosomal dominant (Nishimura et al, 2004)
ALS 10 
ALS/FTLDU lp36 TARDBP
Frontotemporal lobar 
degeneration with 
ubiquitinated tau- 
negative inclusions
(Sreedharan et al, 
2008)
ALS 11 6q21 FIG4
Autsomal recessive;
prominence of 
corticospinal tract 
involvement
(Chow et al, 2009)
ALS/FTD/P
17q21
9q21-22
MAPT Autosomal dominant ; 
frontotemporal 
dementia and 
parkinsonism with 
amyotrophy
(Siddique and 
Hentati, 1995; 
Hosier et al, 2000; 
Wilhelmsen et al, 
2004)
MND,
dynactin
type
2pl3 DCTN1
Autosomal dominant ;
adult onset, slowly 
progressive, with vocal 
cord paralysis
(Puls et al, 2003; 
Munch et al, 2005)
Recently 
identified 
genetic loci
12q24 DAO Autosomal dominant; typical ALS (Mitchell et al)
3 p ll .2 CHMP2B
Familial transmission 
not analysed; 
predominant LMN 
phenotype
(Cox et al)
1} ALS1: Copper-zinc superoxide dism utase gene (SOD 11
The first discovery of a  m utation in the SOD1 gene linked with ALS dates back to 
1993 (Rosen et al.} 1993). This is the m ost common form of inherited ALS, 
accounting for about 20% of all familial ALS forms (2-3% of all ALS cases).
SOD1 enzyme is a  superoxide dism utase: it scavanges superoxide ion, a  free 
radical th a t is formed during mitochondrial respiration, by catalyzing the 
reaction 4 0 2- + 2H+ H2O2 + O2 . SOD1 is a  153aa, homodimeric protein 
ubiquitously expressed. At the subcellular level it is found m ainly in the 
cytoplasm, b u t it has also been detected in the interm em brane space in 
m itochondria, and in the nucleus.
Up today 125 ALS-linked m utations have been identified in the SOD1 gene. They 
are distributed in all five exons of the protein, with practically no region being 
spared of m utations. The majority are m issense m utations; a  few m utations 
cause stop-codons leading to generation of a  truncated  protein (Andersen et a l, 
2003).
All m utations are associated with autosom al dom inant fALS, except for D90A 
and D96N, which can cause both dom inant and recessive ALS (Andersen et a l, 
1995; Robherecht et a l, 1996; Orrell, 2000). The m ost frequent SOD 1 m utation is 
A4V.
Penetrance, clinical manifestations, age of onset, disease progression and  
survival vary greatly among specific m utations. For example, A4V and  A4T are 
associated with an aggressive fALS type (Aksoy et al., 2003), w hereas G37R, 
D90A, G93C and G93V m utations show a  slower progression over 10-15 years 
(Arisato et a l, 2003).
These genetic studies have opened the field to the generation of transgenic mice 
overexpressing hum an SOD1 carrying the m utations found in hum an  ALS 
patients. These mice develop a  progressive motor syndrome th a t recapitu lates
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several aspects of the pathology and symptoms found in hum an ALS, described 
in section 1.2.2 (Gurney et al.} 1994).
Initially it was hypothesised th a t m utations in SOD1 led to a  loss of catalytic 
enzyme activity. However, subsequent studies on transgenic mice revealed th a t 
the enzymatic activity was not reduced, b u t was ra ther unchanged or even 
increased (Gurney et a l, 1994; Ripps et a l, 1995; Wong, 1995; Bruijn et a l, 
1997b). Moreover knock out of endogenous SOD1 in mice does not lead to 
spontaneous motor neuron disease (Reaume et a l, 1996). Collectively, this 
strongly suggests th a t reduced catalytic SOD1 activity does not account for the 
observed pathology.
Currently, it is believed th a t m utated  SOD1 either acquires a  toxic gain of 
function, or loses some protective property such  as the ability to reach the 
nucleus to scavenge DNA-damaging free radicals (Sau et a l, 2007).
2\ ALS2: ALSin
ALS2 variant is a  recessively inherited form of ALS characterized by juvenile 
onset and slow progression, with a  symptomatology in which spasticity of facial 
and limb m uscles are predom inant. In 2001 the gene linked with th is form of 
ALS was identified: ALSin (Hadano et a l, 2001; Yang et a l, 2001). Two 
transcrip ts of this gene can be detected: long alsin (1659 aminoacids) and short 
alsin (396 aminoacids). Alsin is predicted to have a  molecular m ass of 184 Kda; it 
is ubiquitously expressed and is abundan t in neurons, where it is localized to the 
cytosolic portion of the endosomal m em brane. With the exception of the liver, 
which appears to show selective augm entation of the short form, the distribution 
of both splice variants appears to be similar.
The aminoterminal of alsin contains three guanine exchange factor (GEF) 
domains: the RCCl-like (regulator of chromosome condensation 1) domain 
(termed RLD), a  diffuse B cell lymphoma (Dbl) hom ology/pleckstrin homology 
(DH/PH) domain, and a  vacuolar protein sorting 9 (VPS9) dom ain. The
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carboxyterminal of alsin contains two further domains, which are similar to 
those of the Rho G-protein family th a t m odulates dynamic actin assembly.
The majority of the m utations appear to resu lt in the generation of a  prem ature 
stop codon, leading to protein instability and a  loss of function (Yamanaka et a l,  
2003). However, although m utations in ALS2 lead to clinical variations of motor 
dysfunction in hum ans, mice lacking alsin surprisingly did not recapitulate the 
symptoms of motor neuron disease, b u t showed only subtle deficits in motor 
perform ances, probably because of potential compensatory m echanism s within 
the m ouse genome (Cai et a l, 2005; Hadano et al., 2006; Yamanaka et al., 2006). 
The function of alsin is not fully understood, although some recent studies have 
shed light on some of its activities. Alsin has been shown to act as an  exchange 
factor for the small GTPase Rab5 in vitro (Otomo et a l, 2003; Topp et a l, 2004), 
suggesting a  possible involvement in vesicle trafficking. In addition, alsin can 
in teract with the small Rho GTPase R acl (Otomo et al., 2003; Topp et al., 2004; 
Tudor et a l, 2005), m ediating actin dynamics related to neuritic outgrowth. 
Interestingly, it has been shown th a t alsin can bind to different m u tan t variants 
of SOD1 through the RhoGEF domain (Kanekura et al., 2004) and, in a  cell 
culture paradigm, alsin overexpression can suppress m u tan t SOD1 toxicity 
(Kanekura et al., 2005). Moreover, it has been dem onstrated th a t loss of alsin 
altered the subcellular localization of glutam ate receptor interacting protein 
(GRIP1), which correlated with a  reduction of GluR2 (a su b u n it of AMPA 
glutam ate receptors) a t the cell/ synaptic surface of A L S 2-/- neurons, resulting 
in an  increased vulnerability of these neurons to excitotoxicity (Lai et a l, 2006).
31 ALS4: Senataxin (SETX1
The gene encodes a  303 KDa protein th a t contains a  DNA/RNA helicase domain 
with strong homology to hum an RENT1 and  IGHMBP2, two proteins known to 
have roles in RNA processing (Chen et a l, 2004). Missense m utations in SETX 
cause an autosom al dominant, juvenile onset motor neuron disease with veiy
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slow progression of distal limb atrophy and m otor neuron loss; the lifespan is not 
reduced (Blair et a l, 2000).
41 ALS6: Fused in sarcom a/Translocation in liposarcoma (FUS/TLS1
FUS is an ubiquitously expressed, predom inantly nuclear, protein th a t is 
involved in DNA repair and the regulation of transcription, RNA splicing, and 
export to the cytoplasm. The N term inus has a  transcriptional activation domain 
and contains a  glycine rich region; the C term inus contains an  RNA recognition 
motif (RRM), an  Arg-Gly-Gly (RGG) repeat rich region, and zinc finger dom ains 
involved in RNA processing. FUS binds to the motor proteins kinesin (KIF5) and 
myosin-Va and is involved in mRNA transport. The vast majority of ALS-linked 
m utations are clustered in the extreme C term inus. M utations in FUS/TLS occur 
in 4-5% of familial ALS cases; m utations are all m issense changes except for two, 
both of which are located in the glycine-rich region and correspond to an 
insertion or a  deletion of two glycines in a  10 glycine-long trac t (Lagier-Tourenne 
and Cleveland, 2009). Patients develop classical ALS with no cognitive deficits. 
Except for the recessive m utation in a  family of Cape Verdean origin, the 
inheritance pattern  is dom inant.
Analysis of the brains and spinal cords of ALS patients with FUS/TLS m utations 
revealed norm al staining of FUS/TLS in the nuclei of m any neurons and  glial 
cells b u t aggregates of FUS/TLS in the cytoplasm of lower m otor neurons 
(Kwiatkowski et a l, 2009; Vance et a l, 2009).
51 ALS8: Vesicular associated protein B (VAPB1
VAPB gene encodes an ubiquitously expressed homodimer, which belongs to a  
family of intracellular vesicle-associated/m em brane-bound proteins. It associates 
with m icrotubules and is presum ed to regulate vesicle transport. In particular, 
VAPB has been shown to act during the transpo rt through the endoplasm ic 
reticulum , Golgi apparatus and secretion. The P56S m utation dram atically
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disrup ts the sub-cellular distribution of VAPB and induces the formation of 
intracellular protein aggregates (Nishimura et a l , 2004).
61 ALS 10: TAR DNA binding protein 43  (TARDBP1
TARDBP contains 6 exons; it encodes for an  ubiquitously expressed RNA/DNA 
binding protein, nam ed TDP-43. This protein exerts a  regulatory function for 
transcription and splicing, and probably also for miRNA biogenesis (Buratti and  
Baralle, 2008). It is a  414 amino acid nuclear protein with two highly conserved 
RNA recognition motifs (RRM1 and RRM2), a  nuclear-localisation signal, a  
predicted nuclear-export signal and a  C-terminal tail with a  typical glycine-rich 
region th a t mediates protein-protein interactions, including interactions with 
other heterogeneous ribonucleoprotein (hnRNP) family m embers. TDP-43 is the 
m ajor protein found in ubiquitinated inclusions in neurons and  glia in patien ts 
suffering of frontotemporal lobar degeneration (FTLD) and ALS. Ubiquitinated 
inclusions in the perikarion and  proximal axons of surviving spinal cord motor 
neurons represent a  pathological hallm ark of ALS, and are also prom inent in 
cortical neurons within the frontal and  temporal lobes in patients with tau- 
negative FTLD. Moreover, FTLD patients can develop ALS and ALS patien ts often 
suffer from a  dem entia consistent with FTLD, th u s  TDP-43 may provide a  
molecular link between these two types of disorder (Murphy et al., 2007). The 
brains and spinal cords of patients with TDP-43 proteinopathy presen t a  
biochemical signature th a t is characterized by abnorm al hyperphosphorylation 
and ubiquitination of TDP-43 and the production of ~25kDa C-term inal 
fragm ents th a t are missing their nuclear targeting domains, th u s  cytoplasmic 
sequestration of TDP-43 is supposed to play a  role in neurodegeneration (Arai et 
a l, 2006; Neumann et a l, 2006b).
Interestingly mislocalisation of TDP43 is found both in familial and  sporadic 
cases of ALS, th u s  representing a  common feature of the neurodegenerative 
process in ALS. A total of 30 different dom inant m utations are now known in 22
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unrelated  families (~3% of familial ALS cases) and in 29 sporadic cases of ALS 
(~1.5% of sporadic cases). All m utations are m issense, except Y374X th a t leads 
to a  truncation. It is now recognized th a t aberran t accum ulation of TDP-43 is not 
ju s t  a  byproduct of the neurodegenerative process, b u t it can represent a  prim ary 
cause of ALS (Lagier-Tourenne and Cleveland, 2009).
7\ ALS 11: phosphoinositide 5-phosphatase (FIG41
FIG4 is a  phosphoinositide 5-phosphatase also called SAC3. This enzyme 
regulates the cellular levels of PI(3,5)P2, a  lipid involved in signalling processes 
and retrograde trafficking of endosomal vescicles to the trans-Golgi network 
(Rutherford et a l, 2006). M utations in FIG4 are responsible for a  variant of 
Charcot Marie Tooth (CMT) disease, a  peripheral-nerve disorder (Chow et a l,
2007). Interestingly inactivation of FIG4 in mice determ ines massive degeneration 
of neurons in sensory nad  autonom ic ganglia, motor cortex, stria tum  and other 
regions of the CNS, recapitulating some of the pathologic features observed in 
hum an patients affected by CMT (Rutherford et al., 2006). M utations in FIG4 
have been recently identified also in patients with ALS, suggesting th a t th is gene 
is another contributor to th is disease (Chow et a l, 2009).
81 ALS/FTP/P: Microtubule associated protein Tau (MAPT1
Tau is a  member of the m icrotubule-associated protein family, which binds to 
tubulin  and has the principal function of stabilizing m icrotubules and  prom oting 
their assembly. In addition, tau  is likely to regulate motor protein-m ediated 
transport of vesicles and organelles along the m icrotubules by m odulating their 
stability (Sato-Harada et al., 1996; Ebneth et a l, 1998). In frontotem poral 
dem entia with parkinsonism  (FTD/P), the m utation of tau  gene affects the 
alternative splicing of exon 10, resulting in an  excess of four repeat tau  isoforms; 
th is may cause a  reduced binding of tau  to micro tubules in axons. No pure  ALS
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case has been associated with tau  m utations (Siddique and Hentati, 1995; Hosier 
et a l, 2000; Wilhelmsen et a l, 2004).
91 Dvnactin 1 tDCTNU
The gene encodes for the p i 50 subun it of the transporter dynactin. This protein 
is a  com ponent of the dynein complex, implicated in the retrograde axonal 
transport of vesicles and  organelles along microtubules. A dominantly 
transm itted m issense m utation (G59S) was identified in 2003. The m utation 
appears to affect the binding of the dynactin-dynein motor complex to 
micro tubules. It causes an adu lt onset, slowly progressive atypical motor neuron 
disorder with vocal cord paresis, and  w eakness of facial and hand  m uscles (Puls 
et al., 2003).
101 R ecently identified genes
In 2010 two new genes have been associated with ALS: charged m ultivescicular 
protein 2B (CHMP2B) (Cox et al.) and D-amino acid oxidase (DAO) (Mitchell et al). 
CHMP2B is a  m em ber of ESCRT-III (endosomal sorting complex required for 
transport III), which is required for formation of the m ultivesicular body, a  late 
endosomal structu re  involved in lysosome-mediated degradation of endocitosed 
proteins and in autophagy. It has been hypothesized th a t m utations of CHMP2B 
may contribute to motor neuron injury through dysfunction of the autophagic 
clearance of cellular proteins, and the formation of ubiquitin positive inclusions 
(Cox et al). DAO is an enzyme  which controls the levels of D-serine, a  coagonist 
a t the glycine site of the NMD A glutam ate receptor. Increased levels of D-serine 
and its producing enzyme, serine racem ase, have been found in the spinal cord 
of ALS patients and SOD1G93A mice (Sasabe et al., 2007). It h as been proposed 
th a t m utations in DAO, in ALS patients, participate to the buildup of D-serine in 
the CNS, th u s  contributing to excitotoxicity (Mitchell et al.).
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I l l  Susceptibility and modifier genes
Although a  num ber of genes have been identified as being causative in familial 
ALS (Table 1.3), the genetics of the sporadic form of the disease is poorly 
understood. Several candidate genes have been proposed to increase the risk  of 
ALS; a  list of these genes is provided below. Although the resu lts  are still 
controversial and  preliminary, studying these genes may give further insight into 
the possible pathogenetic m echanism s involved in ALS.
> V ascular endothelial growth factor (VEGF): identified as a  candidate gene 
on the basis of a  transgenic m ouse model th a t showed progressive motor 
neuron degeneration as a  consequence of deletion of the hypoxia response 
elem ent in the promoter of VEGF. A num ber of studies initially associated 
specific haplotypes of the VEGF promoter with increase risk  of ALS, 
however a  recent report failed to confirm any association between 
polymorphisms in the VEGF prom oter and sALS th u s  ruling out a  
causative role in the pathology (Oosthuyse et a l, 2001; Gros-Louis et a l, 
2003; Lambrechts et a l, 2003; Chen et a l, 2006).
> Apurinic endonuclease gene (APEX1): initially selected on the basis of its 
protective role against oxidative stress. A varian t of th is gene showed 
m oderate association with ALS (Hayward et a l, 1999).
> Angiogenin (ANG): an  angiogenesis factor th a t shares functional similarity 
with VEGF. It was selected because it is a  neighbouring gene found in the 
genetic locus of APEX1. A variant of th is gene was associated with 
increased risk of disease in the Irish and Scottish ALS populations, 
although th is observation was not confirmed in subsequent studies on a  
large cohort of patients from America, Sweden, England and  Italy. These 
data  are not sufficient to support the hypothesis th a t ANG is relevant in
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the pathogenesis of ALS (Greenway et a l, 2004; Greenway et al., 2006; 
Corrado et a l, 2007; Del Bo et a l, 2008).
> Peripherin (PRPH): an  interm ediate filament protein primarily expressed in 
autonom ic nerves and in peripheral sensory neurons. PRPH m utations 
have been found in two sporadic ALS patients. Imm unohistochem ical 
analysis of their spinal cord showed the presence of aggregates containing 
peripherin within surviving m otor neurons (Gros-Louis e t al., 2004; Leung 
et al., 2004).
> Survival motor neuron 1 and 2 fSMNl. SMN2): Survival m otor neuron is a  
neuron-specific protein involved in RNA processing. Deletions or 
m utations of SMN1 cause child-onset spinal m uscular atrophy, w hereas 
variations in SMN2 copy num ber affect disease severity. A study 
conducted on 600 sporadic ALS cases found th a t altered copy num bers of 
SMN1 occurred more frequently in cases th an  in controls. It has been 
suggested th a t disruptions to the genomic organization of the SMN region 
may resu lt in lower total SMN protein levels, th u s  increasing susceptibility 
of ALS (Corcia et al., 2002; Veldink et al., 2005; Corcia et al., 2006).
> Kinesin-Associated Protein 3 1KIFAP3): KIFAP3 is an  ubiquitously 
expressed protein th a t associates with kinesin to m ediate anterograde 
transport of vesicles along micro tubules. A wide genetic study conducted 
on sporadic ALS cases from the United States and Europe revealed two 
variants (one in the gene sequence and one in the promoter) th a t lead to 
reduced expression of KIFAP3 gene, and  conferred a  14 m onth survival 
advantage to the ALS patients. This suggests th a t decreased expression of 
KIFAP3 is associated with an  increase in survival in sporadic ALS (Landers 
et al., 2009).
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1.2. EXPERIMENTAL MODELS OF ALS
A num ber of studies have been performed on ALS patients to try to gain a  better 
understanding of the pathology of the disease. Approaches have involved the 
collection of cerebro-spinal fluid (CSF) and peripheral blood (Sussm uth et a l, 
2008; Bonetto et a l, 2009; Mantovani et a l, 2009; Wuolikainen et a l, 2009), 
neuroimaging techniques (Pyra et a l, 2009), and  histopathological studies on 
nerve and muscle biopsies or on post-m ortem  tissues (Belsh, 1999; Soraru et a l,
2008). Although these techniques can give useful information on the s ta tu s  of 
the pathology a t a  defined stage of the progression of the disease, they provide 
only a  ra ther limited contribution towards understanding  the overall pathogenic 
m echanism s.
One of the major breakthroughs in the field of ALS research derived from the 
development of anim al models of disease, th a t proved useful both for the study of 
pathogenetic m echanism s and for testing potential pharmacological approaches. 
Rodent models are clearly not precise replicas of the hum an condition, b u t the 
key issue in working with these models is th a t the cellular and  biochem ical 
pathways rem ain largely conserved between hum ans and mice.
In order to investigate the cellular processes involved in the pathology ALS, in 
vitro model system s such as prim ary neuronal cell cultures and spinal cord 
organotypic cultures have been developed. Although these experim ental m odels 
have intrinsic drawbacks, thanks to their relative ease of m anipulation they have 
often been regarded as the starting point for testing pharmacologic treatm ents, or 
for studying the toxic effects induced by expression of m u tan t genes linked with 
ALS.
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1.2.1 In vitro m odels o f MNP
The m ain advantage offered by in vitro system s is the possibility to dissect 
specific molecular pathw ays in defined cell populations.
> Cell cultures
In vitro cell cultures are the m ost widely used  system developed to study 
individual cell types under stress conditions. Several neuronal or glial cell lines 
have been created. Usually, to study features of ALS, these cell lines, derived 
from immortalization of neurons, astrocytes or microglial cells, are transiently  or 
stably transfected with hum an  m utated  SOD1 (Raimondi et al.} 2006; Liu et a t,
2009). As an  alternative approach, prim ary neuronal or glial cell cu ltures have 
been produced starting from transgenic anim als expressing hum an  m uta ted  
SOD1 (Spalloni et a l, 2004; Tortarolo et a l, 2004). Recently, with the aim  of 
deepening the knowledge of physiological as well as pathological interactions 
between neurons and the surrounding glial cells, co-cultures system s have been 
established (Ferri et a l, 2004; Bilsland et a l, 2008).
> Organotypic cultures
Organotypic spinal cord cultures are th in  slices of spinal cord (300-400 pm 
thickness) prepared from 9-days old m ouse pups. These cu ltures can  be 
m antained in vitro for up  to 3 m onths (Rothstein et a l, 1993). This system  is 
used  to analyze the reaction of motor neurons to pharmacological treatm ents, 
with the advantage th a t the slice preserves, a t least in part, the spinal cord 
architecture, with m aintanance of the interconnectivity between neuronal cells 
and surrounding glial cells. However, these culture system s have some 
drawbacks: to obtain the culture the slice m u st be removed from the anim al, 
which m eans th a t multiple axotomies are performed not only on peripheral 
connections of anterior horn cells, b u t also on descending tracts and  in p u ts  from
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dorsal ganglia, leaving the motor neurons deafferented; moreover, since the 
m otor neurons in the slice lack their target (the muscles), they project their large- 
caliber axons back into the white m atter of the spinal cord, th u s  producing 
artifactual axonal fascicula th a t encircle the slice culture. Recently technical 
improvements have led to the establishm ent of organotypic cell cu ltures from 
embryonic m ouse spinal cord, th a t contain some muscle fibres originating from 
peripheral tissues dissected during the explant. It h as been dem onstrated th a t 
th is culture system can represent a  valuable in vitro model to study  the 
m echanism s of neurogenesis, glial differentiation, myelination, m uscle formation, 
and synaptogenesis (Avossa et a l, 2003). The possibility of establishing 
organotypic cultures from the spinal cord of SOD1-G93A expressing mice h as 
further helped study the role of motor neuron vulnerability in ALS pathogenesis 
(Avossa et a l, 2006; Kosuge et a l, 2009).
1.2 .2  Animal m odels o f MNP
In vivo models can be subdivided into:
> spontaneous m utants, derived from na tu ra l m utations occurring in genes 
th a t lead to im pairm ent of the motor system;
> targeted m utants: transgenic anim als (mice and rats) expressing m utated  
genes linked with ALS or knock-out mice, in which one gene h as been 
deleted by homologous recombination;
> ENU-induced m utants, obtained by induction of point m utations in the 
genome through exposure to a  m utagen.
> Spontaneous m utants 
• MND m ouse
MND (motor neuron degeneration) is a  spontaneous, dom inant m utation  
localized to chromosome 8 in the coding region of the  gene Cln8,
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belonging to the family of neuronal ceroid lipofuscinose-related genes 
(Ranta et a l, 1999). MND mice exhibit an  adult-onset, progressive 
deterioration of motor function with spastic paralysis moving from caudal 
to cranial spinal cord levels. They undergo a  prem ature death  a t 10-12 
m onths (Messer et a l, 1987). However, the num ber of choline acetyl 
transferase (ChAT) immuno-positive lum bar motor neurons is not 
different from normal mice, consistent with the fact th a t these mice do 
not show the flaccid paralysis and muscle atrophy typical of skeletal 
muscle denervation due to spinal m otor neuron loss (Mennini e t a l, 
2002). Neuropathological hallm arks are inclusion bodies containing 
ubiquitin, m itochondrial alterations, lipofuscin accum ulation and 
neurofilam ent abnormalities. However, the presence of abnorm al 
autofluorescent cytoplasmic inclusions rich in lipofuscin found in 
neurons, as well as in m any other somatic organs, m akes these anim als 
a  useful model for hum an neuronal ceroid lipofuscinosis ra th e r th an  for 
ALS (Bronson et a l, 1993).
• PMN m ouse
PMN (paralyse na tu ra l m utant) mice carry an  autosom al recessive 
m utation on chromosome 13 (Brunialti et al., 1995). Two groups identified 
the PMN m utation as a  Trp to Gly substitu tion  a t the last residue of the 
tubulin-specific chaperone (Tbce) protein (Bommel et al., 2002; Martin et 
a l, 2002) th a t is essential for correct tubulin  assem bly and  for the 
m aintenance of micro tubules in motor axons. Distal axonopathy with 
paralysis of the limbs and m uscular atrophy are the m ost relevant 
clinical signs, while motor neuron cell bodies and proximal axons are 
relatively preserved (Schmalbruch et a l, 1991). Symptomatic phase 
begins a t 3 weeks of age and evolves rapidly to death  by 7 weeks of age.
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• Wasted m ouse
W asted (wst) is a  spontaneous autosom al recessive m utation in which 
the gene encoding translation elongation factor eEFlA2 is deleted 
(Chambers et a l, 1998). The symptom onset is around 2 weeks of age, 
with homozygous mice showing trem ors and disturbances of gait. The 
progression is very fast, leading to death within a  m onth. Recent studies 
have dem onstrated th a t spontaneous loss of eEFlA2 expression th a t 
occurs in Wst m u tan t mice triggers the dying-back pathways in lower 
motor neurons in vivo: synaptic loss a t the NMJ is an  early event, 
accompanied by gliosis in the spinal cord, followed by motor neuron 
pathology (with vacuolisation and  perikarial accum ulation of 
neurofilaments) with a  rostrocaudal progression, and  finally death 
(Newbery et a l, 2005; Murray et a l, 2008). Only spinal and brainstem  
motor neurons are lost, while UMN are not affected (Doble and Kennel, 
2000).
• Wobbler m ouse
The wobbler m ouse represents another model of motor neuron disease 
(Mitsumoto and Bradley, 1982). It shows a  progressive forelimb w eakness 
and atrophy, beginning a t about 1 m onth of age, accompanied by a  
m arked decrease of m uscular strength and  motor ability with no 
involvement of the hind limbs. The symptoms are associated with 
proximal axonal degeneration and  vacuolar changes within the motor 
neurons of the cervical spinal cord with little involvement of the brain. 
Death occurs a t about 1 year of age. In this case, the autosom al recessive 
genetic defect responsible for th is syndrome has been m apped on 
chromosome 11 and it has recently been identified as a  m issense 
m utation in Vps54 (Vacuolar Vesicular Protein Sorting) involved in the
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transport of vesicles from late endosomes to the Golgi apparatus (Schmitt- 
John et ah, 2005).
• NMD m ouse
NMD (neurom uscular degeneration) mice carry an  autosom al recessive 
m utation localized on the gene coding for the ATPase/DNA helicase, also 
known as SMbp2 (Cook et a t, 1995; Cox et a t, 1998). These mice develop 
rapidly progressive hind limb weakness, beginning a t 2 weeks of age. 
Pathological examination reveals motor neuron cell body degeneration in 
the spinal cord. Death occurs by 4 weeks of age.
^ Targeted m utants
To obtain transgenic animals, exogenous genes are introduced by microinjection 
of purified DNA in the male pronucleus of fertilized mouse eggs. The integration 
of foreign DNA is random, with multiple copies of DNA usually  integrating a t a  
single site. On the other hand, it is possible to delete a  gene (knock-out) in order 
to study the effect of its ablation on the organism. To obtain knock-out mice, a  
m urine stem  cell line is engineered in vitro to obtain substitu tion  of the gene of 
in terest with a  very similar sequence carrying modifications th a t m ake the gene 
inoperable. The knock-out stem  cells are then inserted into a  m ouse blastocyst 
and reim planted into a  foster mother. Mice carrying the gene deletion in germline 
cells are selected from the offspring and  used  for colony expansion.
The m ost widely used  animal model of ALS is represented by transgenic mice 
expressing hum an  SOD1 gene with m utations found in hum an  patien ts (see 
section 1.1.5). Recently transgenic ra ts  expressing hum an m u tan t SOD1 have 
been also generated. These models will be described in detail; o ther transgenic 
anim als showing features of motor neuron disease are listed in Table 1.4.
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• SOD1 mutant mice
To date seven lines expressing different m utations of SOD1 have been 
generated (Shibata, 2001). The m ost extensively studied are the lines over­
expressing hum an SOD1 with G93A, G37R or G85R m utations (Dal Canto 
and Gurney, 1994; Wong, 1995). A line expressing m ouse SOD1 with G86R 
m utation has been also produced (Ripps et al., 1995). These anim als develop 
a  phenotype th a t closely resembles ALS, with an adu lt onset progressive 
m otor paralysis, muscle w asting and reduced lifespan. Pathological changes 
mainly consist of depletion of motor neurons in the spinal cord, gliosis, 
axonal swelling and presence of ubiquitin-positive inclusions in surviving 
m otor neurons, and  m uscular atrophy. In contrast, mice overexpressing wild 
type SOD1 rem ain clinically normal, although some changes have been 
reported a t two years of age (Jaarsma et a t, 2000). Transgenic mice carrying 
23 copies of hum an SOD1 with Gly93Ala m utation (SOD1G93A mice) are 
considered the standard  model of ALS in therapeutic studies (Bendotti and  
Carri, 2004). The model develops a  motor system  disease prevalently affecting 
lower motor neurons. U ltrastructural and  microscopical analysis reveals th a t 
the earliest pathological sign in these mice is the vacuolization of large 
neurons in the anterior horns of the spinal cord (Bendotti et a t, 2001a); it 
h as been hypothesized th a t these vacuoles originate from the dilatation of 
rough endoplasmic reticulum  and from degenerating mitochondria. At the 
end stage, motor neuronal depletion is evident and hyaline, filam entous 
inclusions immuno-positive for ubiquitin and  neurofilam ents are p resen t in 
some of the surviving neurons (Gurney et a l, 1994; Migheli et a t, 1999). 
Transgenic mice expressing low levels of SOD1 G37R m u tan t show a  m otor 
disease restricted to lower motor neurons, w hereas higher copy num ber 
causes more severe abnorm alities and affects a  variety of o ther neuronal 
populations. The m ost evident cellular abnorm ality is the presence of
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vacuoles derived from degenerating m itochondria in axons and  dendrites 
(Wong, 1995).
Transgene expression of m u tan t hum an SOD1 G85R or its m urine 
counterpart G86R develops a  very aggressive pathology with a  rapid 
progression to paralysis and death within two weeks from the first 
symptoms. In G85R mice, inclusions th a t are immunopositive for ubiquitin  
and SOD1 appear within motor neurons and astrocytes (Bruijn et a l, 1997b). 
Differences in disease progression and survival in various SOD1 m u tan t mice 
is dependent on the m utation and the copy num ber of the transgene. The age 
of onset, the duration and  several pathological features also vary and  are 
dependent on the gender and  the m ouse stra in  in which the m utation is 
expressed; th is background effect suggests the existence of strong modifying 
genetic factors (Alexander et a l, 2004; Heiman-Patterson et a l, 2005).
• SOD1 m utant rats
Recently two lines of ra ts  expressing transgenes for m u tan t SOD1 protein 
with two different ALS-associated m utations (H46R and G93A) have been 
established. As in the hum an  disease and transgenic ALS mice, pathological 
analysis shows selective loss of motor neurons in the spinal cords of these 
transgenic rats. In addition, typical neuronal Lewy body-like hyaline 
inclusions as well as astrocytic hyaline inclusions are observed in  the spinal 
cords (Nagai et a l, 2001; Aoki et a l, 2005). An interesting feature of th is 
anim al model is the variability of phenotype m anifestation. For example 
motor deficits and atrophy can initially appear in the fore-limbs, or in the 
hind-limbs, and then  spread to other areas of the body. Alternatively 
symptoms can be more generalized, with both fore- and hind-lim bs affected. 
One of the reasons for this inter-individual variability of phenotype 
m anifestation is th a t these lines of ra ts  are on an  outbred genetic
background (Sprague-Dawley), suggesting th a t naturally  occurring 
polymorphisms in some genes may be implicated (Matsumoto et a l, 2006a).
Table 1.4. Mouse m odels w ith m otor neuron dysfunction
Mouse Symptomatology and pathologic changes References
Mutant NF-L
(point missense 
mutation in the 
gene for 
Neurofilament 
Light chain)
Perikaiyal and axonal NF accumulations with trapped 
organelles in motor neuron and sensory neurons.
No degeneration of sensory neurons but massive 
degeneration of spinal motor neurons.
Motor impairment and atrophy of skeletal muscles.
(Lee et al, 
1994b)
NF-L knock­
out
Perikaryal accumulation of NF-M and NF-H.
Loss of motor axons; decresed caliber of myelinated 
axons; altered nerve conductivity.
Mild sensorimotor dysfunction but no signs of paresis.
(Zhu et al, 
1997; Dubois 
et al, 2005)
hNF-H
overexpressor
Perikaryal accumulations and axonal atrophy.
Altered conductivity but no neuronal loss. 
Progressive axonopathy and muscle atrophy.
(Cote et al, 
1993; Krizet 
al, 2000)
Peripherin
overexpressor
Progressive accumulation of intermediate filament 
aggregates in perikarya and axons of motor neurons.
40% loss of spinal motor neurons, and manifestation 
of motor dysfunction late in life (after 2 years of age).
(Beaulieu et 
al, 1999)
Dynamitin
overxpressor
Late-onset progressive motor neuron degenerative 
disease characterized by decreased strength and 
endurance, motor neuron degeneration and loss, 
axonal intermediate filament swellings, and 
denervation of muscles.
(LaMonte et 
al, 2002)
Short Tau 
overexpressors
Spheroidal inclusions containing tau, NFs and 
tubulin.
Axonal degeneration of spinal neurons and motor 
weakness.
(Ishihara et 
al, 1999)
VEGF -/-
(deletion of 
Hypoxia 
responsive 
element within 
VEGF 
promoter)
Neurofilament accumulations in the spinal and 
brainstem motor neurons; vacuolisation and abnormal 
mitochondria and organelles in affected motor 
neurons.
Severe motor deficits at 5-7months of age with signs of 
severe muscle weakness and limb paresis.
(Oosthuyse et 
al, 2001)
Als2 knock­
out
Slow progressive loss of cerebellar Purkinje Cells and 
reduction in ventral motor axons during aging; 
astrogliosis and evidence of deficits in endosome 
trafficking.
Mild phenotype with age-dependent deficits in motor 
coordination.
(Cai et al, 
2005; Hadano 
et al, 2006)
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> ENU-induced mutants
N-Ehtyl-N-nitrosurea (ENU) is a  chemical m utagen th a t produces point 
m utations in the genome, which enables identification of the causal gene by 
m ethods such  as positional candidate cloning, and is currently being used  to 
generate new m ouse models of MND (Chen et al., 2000; Brown and Balling, 2001; 
H afezparast et al., 2003a). So far th is approach has successfully created the 
m ouse Legs a t odd angles (Loa), and  the cramping m ouse (Cral).
• Loa m ice
In these mice, a  m issense autosom al dom inant m utation in the 
cytoplasmic dynein heavy chain gene (Dnchcl) causes defects in 
retrograde axonal transport and motor neuron degeneration. Heterozygous 
mice display age-related progressive loss of muscle tone and  locomotor 
ability w ithout major reduction in life-span. Homozygous Loa mice show a 
more severe phenotype with an  inability to feed and move, and  die within 
24 hours of birth. Homozygous Loa/Loa anim als have neuronal inclusion 
bodies th a t are positive for SOD1, CDK5, neurofilam ents and  ubiquitin 
(Hafezparast et a t, 2003b).
• Cral m ice
These mice carry a  m issense autosom al dom inant m utation in gene 
D nchcl, different from the one described for Loa mice. Heterozygous mice 
show the sam e phenotype described for Loa. In homozygous C ra l anim als 
also large dorsal root ganglion neurons are affected (Hafezparast et a l, 
2003b).
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1.3. PATHOGENETIC HYPOTHESES OF ALS
To date, the aetiology of ALS rem ains unknow n. Most curren t knowledge on the 
m echanism s leading to the degeneration of m otor neurons in ALS has  come from 
the study of fALS cases, in which m utations in single genes have been identified. 
Since the discovery of SOD1 m utations as causative genetic factor for fALS, in 
1993, several hypotheses have been formulated on the possible m olecular players 
involved in the neurodegeneration; however, even in th is defined genetic 
subgroup the pathways leading to neuronal death  appear to be complex.
Studies performed on hum an ALS autopsy sam ples or on anim al models have 
suggested th a t ALS may be considered as a  multifactorial disease in which a  
complex interplay between multiple m echanism s including genetic factors, 
oxidative stress, excitotoxicity, mitochondrial damage, protein aggregation, and 
alterations of axonal transport determ ine the motor neuronal death. 
Interestingly, since the clinical and pathological profiles of sporadic and  familial 
ALS are similar, it can be predicted th a t evidence emerging from studies on ALS- 
causing gene m utations may apply also to sporadic ALS. However, one 
biochemical difference appears to be the absence of pathologic TDP-43 (a 
hallm ark of affected neurons in sALS and  frontotem poral dementia) in fALS cases 
due to SOD1 m utation (Mackenzie et al., 2007). However th is observation 
rem ains controversial since there are contrastating resu lts on hum an  cases and 
m u tan t SOD1 mice (Robertson et al., 2007; Turner et a l, 2008; Shan et al., 2009).
1.3.1 Oxidative stress
The role of oxidative stress in the pathogenesis of ALS rem ains controversial. 
Increases in m arkers of oxidative damage have been reported in h um an  patien ts 
affected by both sporadic and inherited forms of ALS (Beal et al., 1997; Ferrante
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et a l, 1997; Liu et a l, 1999) and in transgenic mouse models of the disease 
(Ferrante et a l, 1997; Andrus et a l, 1998). However in other independent studies 
no significant modifications of m arkers of oxidative damage were reported (Shaw  
et a l, 1995a; Bruijn et a l, 1997a).
Concerning ALS linked to SOD1 m utations, it has been hypothesized th a t 
m utated SOD1 may acquire a  toxic function, th u s  becoming the source of 
oxidative stress. It is possible th a t m utations may alter protein folding, leading 
to aberran t copper-mediated catalysis, or to the release of redox active m etals 
leading to unregulated oxidative reactions.
A num ber of chemical models have been proposed to explain m echanism s by 
which oxidative stress could be generated by m u tan t SOD1 (Figure 1.2):
> Peroxidase hypothesis: the reduced form of m utan t SOD1 (Cu1+-bound 
state) may accept hydrogen peroxide as a  substrate  th u s  producing 
hydroxyl radical OH- (an extraordinarily reactive oxigen species), leading to 
a  cascade of peroxidation (Wiedau-Pazos et a l, 1996);
> Peroxynitrite hypothesis: m u tan t SOD1 may accept abnorm al
substra tes such as peroxynitrite, provoking aberran t tyrosine nitration 
(Beckman et a l, 1993);
> Backward catalysis: m utations of SOD 1 may reduce the am ount of bound 
zinc, th u s  destabilizing the structu re  of the enzyme, and allowing a  rapid 
reduction of Cu2+ to C u1+. The reduced SOD1 m utan t would then  ru n  the 
norm al catalytic step backwards, converting oxygen to superoxide. Finally, 
the superoxide produced would combine in the enzymatic active site with 
freely diffusing nitric oxide, thereby producing peroxynitrite, which would 
promote intracellular damage, including protein nitration (Estevez et a l, 
1999).
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Figure 1.2. SODl-m ediated chem istry
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SOD1 enzyme normally uses superoxide ion as a substrate, producing H2O2 and molecular 
oxygen as products (a). fALS linked SOD1 mutants may acquire aberrant chemical 
reactivity, thus leading to production of highly reactive hydroxyl radicals (b) or to nitration 
of other proteins (c,d).
Several experiments in SOD1 m utan t mice have tried to address the question as 
to whether the toxicity of m u tan t SOD1 can be explained by aberran t oxidative 
chemistry.
In particular, m anipulation of wild type SOD1 activity levels in mice have 
provided some evidence th a t the peroxynitrite hypothesis is unlikely to play a  
central role in the pathology: in SOD1G85R mice (carrying a  m utation th a t 
confers only a  -10%  increase in SOD1 activity over the wild-type SOD1) neither 
elimination nor chronic elevation (by about sixfold) of wild-type SOD1 activity 
affected disease onset, progression or pathology (Bruijn et a l, 1998). In contrast, 
the expression of elevated levels of wild-type hum an SOD1 in SOD1G93A, L126Z 
or A4V mice unexpectedly accelerated the disease onset (Jaarsma et a l, 2000; 
Deng et a l, 2006). The fact th a t toxicity cannot be ameliorated by increased wild- 
type SOD 1 activity challenges the hypothesis th a t damage arises from superoxide 
or any reactive oxygen species derived from it, though it may be argued th a t 
oxidative stress contributes to the degenerative process.
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Another set of experim ents were aimed a t modifying copper loading into SOD 1 in 
vivo, to address the question w hether the toxic activity of m utated  SOD1 is 
dependent on aberran t chem istry catalyzed by the copper atom. One of the key 
players involved in copper loading into the en2yme is the copper chaperone 
(CCS). Deletion of CCS in mice has been shown to reduce copper loading into 
SOD1, th u s  affecting the enzyme activity (Wong et al., 2000). Interestingly, 
m u tan t SOD1 transgenic mice with a  CCS knock out possess only very low levels 
of SOD 1-bound copper and  have drastically reduced dism utase activity, b u t still 
develop motor neuron disease (Subramaniam et a l, 2002). However, CCS over­
expression in G93A mice produces severe mitochondrial pathology and strongly 
accelerates disease progression (Son et a l, 2007).
The m ost plausible interpretation is th a t copper-mediated oxyradical chem istry is 
not required for the motor neuron pathology provoked by m u tan t SOD1, 
although it h as  been proposed th a t m u tan t SOD1 m ight exert aberran t catalysis 
through copper loaded on the surface of the protein in a  CCS-independent 
fashion (Bush, 2002).
1.3 .2  E xcitotoxicity
G lutam ate-induced excitotoxicity is considered another m echanism  th a t m ay 
play a  major role in the aetiology of ALS. An over-stimulation of neuronal 
glutam ate receptors can cause neuronal death by increasing the calcium  influx 
in the cytosol, th u s  activating death pathways, involving calpain, protein kinase 
C, lipases, endonucleases, xanthine oxidase and nitric oxide synthase. This 
phenom enon may be exacerbated by the regulation of the activity or of the 
subun it composition of glutam ate receptors, which can render them  more 
permeable to Ca2+ and  Zn2+ influx.
To prevent the aberran t activation of glutam ate receptors, glial cells express 
glutam ate transporters th a t facilitate removal of glutam ate from the synaptic 
cleft. EAAT2 is the major glutam ate transporter, and  is localized exclusively in
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glia. Changes in the equilibrium of th is system m ay resu lt in harm ful events to 
the motor neurons in ALS.
Evidence of abnormalities in glutam ate handling in ALS arose from the discovery 
of large increases in the levels of glutam ate in the p lasm a (Plaitakis and Caroscio, 
1987) and in the cerebrospinal fluid of a  subset of ALS patients (Rothstein et a l, 
1991; Shaw  et a l, 1995b). Direct m easurem ent of functional glutam ate transport 
in ALS revealed a  m arked reduction in the affected brain regions, which was the 
resu lt of a  pronounced loss of the astroglial EAAT2 protein (Rothstein et a l, 
1995). Interestingly, EAAT2 is a  target for oxidative regulation and  glutam ate 
transport is impaired by m u tan t SOD1 in an in vitro model (Trotti et al., 1999). 
The loss of glutam ate transporters has been confirmed in m u tan t SOD1- 
transgenic mice and  ra ts  (Bendotti et a l, 2001 b; Howland et al., 2002). 
G lutam ate-induced excitotoxicity provides another possible explanation for the 
selective vulnerability of motor neurons in ALS. In fact, m otor neurons have a  
diminished capacity to buffer calcium (Alexianu et al., 1994). Additionally, 
although motor neurons express a  range of glutam ate receptors (NMDA, AMPA, 
kainate and metabotropic), in vitro studies have dem onstrated th a t they are 
particularly sensitive to glutam ate excitotoxicity m ediated through AMPA 
receptors (Carriedo et al., 1996). A defect in the RNA editing of the AMPA GluR2 
subunit, or a  lack of this receptor subunit, are likely to be involved in the 
selective vulnerability of motor neurons in ALS by conferring calcium 
permeability to AMPA-gated channels (Kawahara et al., 2004). Indeed, treatm ents 
with AMPA receptor antagonists slow the disease progression and  increase 
survival of m u tan t SOD1 transgenic mice, suggesting th a t AMPA receptors may 
represent promising targets for therapies (Van Damme et a l, 2003; Tortarolo et 
a l, 2006).
Riluzole, the only drug currently approved for treatm ent of ALS patien ts, is 
believed to antagonize glutam ate-m ediated excitotoxicity although the  precise 
m echanism  of action is ra ther controversial.
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1.3 .3  Mitochondrial dysfunction
Alterations in m itochondrial function are an  attractive candidate for involvement 
in ALS pathogenesis because changes in m itochondrial morphology are seen a t 
pre-symptomatic stages in SOD1 m utan t mice (Bendotti et a l, 2001a; Jung et a l, 
2002) and in cultured cells expressing the m u tan t protein (Carri et a l, 1997; Beal 
et a l, 2000). Interestingly, m itochondrial abnorm alities have also been observed 
in motor axon term inals of m uscle biopsies from patients with early-diagnosed 
sporadic ALS (Siklos et a l, 1996; Beal et a l, 2000) and in proximal axons (Hirano 
et a l, 1984) and in anterior horns of the spinal cord in post m ortem  tissues of 
sALS patients (Sasaki and Iwata, 1996). Biochemical studies have highlighted 
defects in the activity of the respiratory chain complex IV in sALS spinal motor 
neurons (Borthwick et al., 1999) and in complexes I and IV in spinal cord and 
brainstem  homogenates of G93A mice (Browne et al., 1998).
Recent studies have indicated th a t m u tan t SOD1 could directly damage 
m itochondria. The presence of SOD1 in m itochondria of eukaryotic cells h as 
been confirmed by several groups using a  variety of experimental approaches. In 
particular, using immuno-gold electron microscopy, it has been dem onstrated 
th a t both wild type and m u tan t SOD1 localize in the m itochondria of motor 
neurons in the spinal cord of transgenic mice (Jaarsma et al., 2001; Higgins et 
a l, 2002). Liu and colleagues have proposed th a t m u tan t SOD1 progressively 
accum ulates and aggregates on the m itochondrial outer m em brane, altering the 
protein translocation m achinery of the organelle (Liu et a l, 2004). It h a s  also 
been hypothesized th a t m u tan t SOD1 aggregates could dam age the 
m itochondrion through abnorm al interaction with m itochondrial proteins such  
as Bcl-2 (Pasinelli et al., 2004).
W hether mitochondrial dysfunction and  pathology represents a  prim ary or 
secondary pathological event is unknown, as mitochondrial abnorm alities can 
both resu lt from or cause oxidative toxicity. In either circum stance, the
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pathological m itochondria may contribute to cell death by releasing calcium into 
the cytoplasm, through bioenergetic failure due to production of inadequate 
levels of ATP, and  by releasing cytochrome c, a  trigger of pro-degenerative 
apoptotic pathways.
Interestingly, the disease in m u tan t SOD1 mice is slowed by interventions th a t 
improve m itochondrial function like for example, creatine, which inhibits opening 
of the m itochondrial transition pore, and minocycline, which blocks leakage of 
cytochrome c (Klivenyi et a t, 1999; Zhu et al., 2002).
1.3 .4  Protein aggregation
As previously described one of the pathological hallm arks of ALS, as well as of 
SOD1 m utan t mice, is the formation of proteinaceous inclusions in the motor 
neurons and sometimes in the surrounding astrocytes (Migheli et al., 1990; Bruijn 
et a t, 1997b; Kato et a t, 1999). These inclusions are composed of different 
proteins, such as SOD1, ubiquitin, dorfin, neurofilam ents, peripherin and  p38 
MAPK; additionally, chaperones and proteasome subun its  may also be 
sequestered (Watanabe et a l, 2001; Strong et a l, 2005).
Given th a t ubiquitin-containing aggregates are a  frequent feature both in 
sporadic and familial cases, th is could link the m echanism s of the two forms of 
ALS. As regards to fALS cases linked to SOD1 m utations, ano ther set of 
hypotheses propose th a t m u tan t SOD1 acquires conformational instability and 
becomes prone to aggregation.
Actually, SOD1 m utan ts  display a  general s truc tu ra l instability (Lindberg et a l, 
2002) and are less therm ostable than  the wild type enzyme (Rodriguez et al., 
2002). Some studies suggest th a t SOD1 m utations perturb  the folding pathw ay 
of the protein by destabilizing the precursor monom ers or weaken the dim er 
interface; the resu lt is a  shift of the folding equilibrium toward poorly struc tu red  
monomers. Another characteristic th a t could promote aggregation of m u tan t 
SOD1 is a  decrease of the net negative charge of the polypeptide observed in
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several ALS-associated m utations; th is phenom enon is further exacerbated in 
cellular environm ents th a t are more acidic th an  the cytosol, such  as 
m itochondria and the trans-Golgi network (Lindberg et a l, 2005).
Generally, the m utation can determine both local perturbations of the secondary, 
tertiary or quaternary  structu re  and the loss of m etal ion binding; the common 
resu lt is a  destabilization of the enzyme th a t leads to non-native interactions with 
itself, or other proteins, and  aggregation. Many in vitro and in vivo d a ta  support 
th is hypothesis. Studies in cell culture have shown that, in con trast to the stable 
wild type protein, the m u tan t protein oligomerizes to form sm all pore-like 
structu res (Chung et a l, 2003; Ray et a l, 2004; Matsumoto et a l, 2005; 
Matsumoto et a l, 2006b). Inclusions of SOD1 are found in prim ary cultured 
motor neurons expressing several different SOD1 m utations; the formation of 
such  inclusions correlates with a  loss of viability (Durham et a l, 1997).
Studies in the spinal cord of G93A mice have dem onstrated the progressive 
appearance of aggregates in dendrites, periaxonal processes of oligodendrocytes 
and  neuronal and  astrocytic perikarya (Stieber et al., 2000). The aggregation of 
SOD1 into insoluble high molecular weight species is an  early event occurring in 
G93A mice (Johnston et al., 2000) and their abundance increases as the disease 
progresses.
Correlations between protein aggregation and  clinical phenotype have been 
reported in familial ALS and m utations associated with more severe forms of the 
disease which present with a  short half-life are more likely to form aggregates 
(Lindberg et a l, 2005; Sato et al., 2005).
Aggregate formation could be a  prim ary event in the disease pathogenesis and 
could drive neurotoxicity. Alternatively, aggregation could occur secondary to the 
prim ary neurotoxic event and it has been hypothesized th a t inclusions could be 
the product of a  cellular defence m echanism  th a t occurs when the  burden  of 
misfolded or damaged protein exceeds the capacity of the protein degradation 
m achinery to eliminate them . The formation of inclusion bodies m ay act as a
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cellular defence m echanism  in the attem pt to actively reduce the concentration of 
smaller, more toxic aggregates (Ross and Poirier, 2005).
Various hypotheses have been proposed regarding the cytotoxicity of SOD1 
aggregates, including the disruption of axonal transport (Stokin et al., 2005), the 
aberran t binding of apoptosis regulators (Pasinelli et a l, 2004; Tomik et al., 
2005), perturbations in mitochondrial function and calcium hom eostasis 
(Heruias et al., 2006; Sumi et al., 2006) and  inhibition or overload of the 
ubiquitin-proteasom e pathway (Cleveland and Rothstein, 2001). Consistent with 
the la tter hypothesis, accum ulation of ubiquitinated aggregates have been 
detected in SOD1 m utan t mice (Stieber et a l, 2000; Watanabe et al., 2001; 
Bendotti et al., 2004). Since one of the roles of ubiquitin is to label and target 
misfolded and inactive proteins to the proteasom e machinery, it h as  been 
hypothesized th a t proteasome activity could be inhibited by SOD1, leading to 
accum ulation of aberrantly folded forms of SOD1 and other proteins (Cleveland 
and Rothstein, 2001).
1.3 .5  Alterations o f cytoskeleton  and axonal transport
The idea th a t cytoskeleton abnorm alities may play a  role in ALS pathology arises 
from early reports of neurofilam ent accum ulations in the cell bodies and 
proximal axons of motor neurons of both sporadic and  familial ALS (Hirano et a l, 
1984). Subsequent studies have shown th a t over-expression of NF-H or NF-L 
subun its  in mice causes the selective degeneration and death of m otor neurons 
(Cote et al., 1993; Xu et a l, 1993). O ther studies on transgenic mice have 
dem onstrated th a t neurofilam ent content and organization strongly influence the 
disease induced by m u tan t SOD1 (Couillard-Despres et al., 1998; Williamson et 
a l, 1998; Couillard-Despres et al., 2000; Kong and Xu, 2000). In particular, 
deletion of the NF-L subun it increases the survival of SOD1 m u tan t mice, while 
increased expression of the NF-L or NF-H subunits  slows SOD1 m utant-m ediated  
disease. The protective effects of increased NF-H content in perikarya m ay be due
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to the ability of neurofilam ents to “buffer” against a  cascade of aberran t and 
harm ful events in the cell body (Couillard-Despres et al., 1998). Mice th a t over­
express peripherin, another interm ediate filament protein, develop a  late onset 
motor neuron degeneration and show disruption of neurofilam ent assem bly 
(Beaulieu et al., 1999), however, alteration of peripherin levels in SOD1 m u tan t 
mice does not modify the disease course (Lariviere et al., 2003).
Currently it h as not yet been clarified w hether neurofilam ent disorganization 
represents a  secondaiy product of the pathological processes or w hether it 
directly contributes to the death of the motor neurons. However, it is clear th a t 
motor neurons are particularly dependent on axonal transport of molecules and 
organelles for their activity and survival (De Vos et al., 2008). For example, 
axonal proteins are synthesized in the cell body and  m ust be transported  in an  
anterograde m anner along the axons and dendrites to reach synapses, w hereas 
substances such  as trophic factors synthesized a t the m uscular level m u st be 
transported backward centrally from the synaptic regions by retrograde 
transport. Kinesin and the dynein-dynactin complex represent the molecular 
motors for anterograde and retrograde transport, respectively.
Several factors indicate th a t defects in axonal transport might contribute to the 
degeneration of motor neurons in ALS. First, anterograde transport is slowed in 
G93A and G37R transgenic mice prior to disease onset and  the deficits are 
exacerbated as the disease progresses (Borchelt et a l, 1998; Williamson and  
Cleveland, 1999). Also retrograde transport is disrupted in SOD1 m u tan t mice 
(Murakami et al., 2001).
It has been hypothesized th a t the aggregation of neurofilam ents in  proximal 
axons (spheroids) might physically compromise the transport ap p ara tu s  (Sasaki 
and Iwata, 1996). On the other hand, defects in retrograde transpo rt in ALS mice 
has been attributed  to the mis-localization and disruption of dynein function 
(Ligon et a l, 2005). In two lines of mice (Loa and C ral) point m utations in the 
dynein heavy chain impaired motor neuron functionality and viability (Witherden
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et a l, 2002; H afezparast et a l, 2003b). In addition, disruption of the dynein- 
dynactin complex in mice, by the forced expression of dynamitin, a  subun it of 
dynactin, also produces a  late onset motor neuron disease (LaMonte et a l, 2002). 
Interestingly, introduction of the dynein m utations th a t generate either the legs 
a t odd angles or the cram ping phenotypes into SOD1G93A ALS mice significantly 
ameliorates the motor neuron disease and the slowing of axonal transport (Kieran 
et a l, 2005; Teuchert et al., 2006). Consistent with these observations, a  recent 
study by Teuling and  collegues dem onstrated th a t neuron-specific expression of 
Bicaudal D2 N-terminus (a protein th a t chronically im pairs dynein/dynactin  
function) in SOD1G93A ALS transgenic mice increased life span  (Teuling et al., 
2008). The m echanism  underlying this is unclear, although the implication is 
th a t Loa and  Cra-m utant dyneins compensate or counteract axonal transport 
abnorm alities triggered by m u tan t SOD1 (Kieran et al., 2005). Alternatively, 
dynein/dynactin  inhibition may a ttenuate  functions th a t are potentially harm ful 
to m u tan t SOD 1-expressing motor neurons such  as retrograde transpo rt of 
axonal debris or protein aggregates (Johnston et a l, 2002; Ravikumar et al., 
2005), or deleterious retrograde signalling (Cavalli et al., 2005; H anz and  
Fainzilber, 2006). These diverse observations favour the view th a t d isturbances 
and attenuation of axonal transport might be a  u n itary  feature of all forms of ALS 
and potentially a  prim ary pathogenic event in th is disease.
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Figure 1.3.
Converging m olecular m echan ism s involved  
in  m otor neuron death in fALS
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M u tan t SOD1 m igh t a c t a t d iffe ren t le v e ls  to in d u ce  n eu ron a l d ea th : (i) b y  e x a c erb a tin g  th e  
p ro d u c tio n  o f  o x yg e n  ra d ic a ls  a n d  n itro ty ro sin e  w ith  co n se q u e n t a lte ra tio n s  o f  in trace llu la r  
p ro te in s  a n d  lip id s  (ox ida tive  s tr e ss );  (ii) b y  in du cin g  m itoch on dria l d y s fu n c tio n  a n d  th e  
fu r th e r  p ro d u c tio n  o f  rea c tive  o x yg en  sp e c ie s  (ROS), th e  a c tiva tio n  o f  c a s p a s e s  a n d  en erg y  
d ep le tio n , w h ich  re su lts  in th e  im p a irm en t o f  d ifferen t A T P -d ep en d en t ce llu la r  p r o c e s s e s , 
su c h  a s  th e  u b iq u itin -p ro tea so m e  p a th w a y  (UPP); (iii) b y  fa c ilita tin g  th e  fo rm a tio n  o f  
u b iq u itin a ted  a g g re g a te s  d u e  to  th e  m isfo ld in g  o f  m u ta n t p ro te in  a n d  in c re a se d  
p h o sp h o ry la tio n  o f  c y to sk e ie ta l p ro te in s;  (iv) b y  in h ib itin g  th e  a c tiv ity  o f  th e  g lia l g lu ta m a te  
tra n sp o r te r  EAAT2; (v) b y  a c tiva tin g  m icroglia  a n d  a s tr o c y te s  to p ro d u c e  a n d  r e le a se  p ro -  
in fla m m a to ry  c y to k in e s  a n d  o th er  p o te n tia l toxic fa c to r s  (nitric oxide, NO).
1.3 .6  Evidence for ALS as a non-cell au tonom ous d isease
Evidence from experimental models supports the view tha t a  functional cross­
talk between neurons and non-neuronal cells is crucial for the induction of motor 
neuronal death in ALS. Although motor neurons are induced to die by expression 
of m utan t SOD1, other cell types actively participate in the generation of the 
pathological phenotype by releasing neurotoxic factors, such as inflammatory 
cytokines, glutamate and nitric oxide (NO) (R a o u l e t  a l ,  2 0 0 2 ) .  An early event in 
the neurodegeneration process is the inflammatory response. Indeed,
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accum ulation of reactive microglia and astrocytes has been docum ented in the 
spinal cord and in the motor cortex of ALS patients and in pre-sym ptom atic 
anim al models of the disease (Kawamata et a l, 1992; Hall et a l, 1998). Moreover 
a  broad spectrum  up-regulation of pro-inflammatory genes, such  as COX-2 
(Cyclooxygenase 2), NOS (nitric oxide synthase) and cytokines, for example 
TNFD, is reported in the spinal cord of G93A mice (Hensley et a l, 2002). The 
concept th a t glial cells are activated early in fALS SOD1 mice suggests th a t 
neuroinflam m ation has a  relevant role in the cascade of events th a t trigger the 
death of motor neurons.
Several au thors have tried to dissect the features of the pathologic interplay 
between motor neurons and  surrounding glial cells, in ALS. The m ost interesting 
resu lts have emerged from the use of transgenic mice with expression of m u tan t 
SOD1 in specific cell populations of the nervous system (Table 1.5), or from 
chimeric mice with mixed populations of cells expressing either endogenous or 
transgenic m u tan t SOD1 (Table 1.6). Transgenic mice possessing SOD1 G37R 
cDNA under the prion gene prom oter express m u tan t SOD1 in neurons, 
astrocytes and muscles, b u t not in the m acrophage lineage. They develop motor 
neuron disease (Wang et al., 2005), th u s  indicating th a t the presence of the 
m u tan t protein in the motor neuron /m uscle  circuit, along with supporting 
astrocytes, is sufficient to induce the disease. However, expression of m u tan t 
SOD1 only in neurons or in glia failed to trigger motor neuron  degeneration 
(Gong et a l, 2000; Pramatarova et al., 2001). This might reflect insufficient 
expression of m u tan t SOD1 in these experimental paradigm s, as dem onstrated 
by a  subsequent study (Jaarsma et a l, 2008).
Interestingly, through chimeric mice it has been dem onstrated th a t the toxicity to 
motor neurons requires damage from m utan t SOD1 acting w ithin non-neuronal 
cells: in fact, wild type motor neurons surrounded by SOD1 m utated  glia showed 
ubiquitin-positive inclusions, indicative of neuronal stress, whereas, on the other 
hand, degeneration of motor neurons expressing m u tan t SOD1 w as delayed or
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prevented when they were surrounded by wild type glia (Clement et al., 2003). 
Consistent with these data, experiments in co-culture system s have recently 
provided evidence th a t astrocytes expressing m u tan t SOD1 are able to cause the 
death of both wild type and m u tan t motor neurons probably through release of 
soluble toxic factors (Di Giorgio et a t, 2007; Nagai et al., 2007).
Microglia also appear to be im portant in the pathological processes. Deletion of 
m u tan t SOD1 only in microglia and  peripheral macrophages did not change the 
onset of the disease, b u t increased the survival, whereas deletion of m u tan t 
SOD1 only within motor neurons extended survival by delaying the onset and  the 
early phase of disease process (Boillee et a l, 2006b). In another study the 
presence of G93A only in microglia was not capable of inducing m otor neuron 
disease, while the substitu tion of m utated  microglia with the wild type in G93A 
mice significantly slowed the motor neuron loss, prolonging the disease duration 
and the survival (Beers et al., 2006).
In a  recent paper from Fischer the au thors highlighted denervation of peripheral 
m uscles before loss of neuronal cell body occurred in SOD1 pre-sym tpom atic 
transgenic mice, and confirmed this observation in a  single hum an  sALS case 
(Fischer et al., 2004). These evidences support the hypothesis th a t the pathology 
presents feature of a  distal axonopathy, th u s  suggesting th a t alterations of 
peripheral nervous system  may also be involved in the neurodegenerative process 
in ALS. Actually, though the m u tan t SO D l-m ediated damage within m uscles h as  
been ruled out by recent studies (Miller et al., 2006), the contribution of Schw ann 
cells in the m aintenance and delivery of supporting factors to axons h as  emerged 
(Lobsiger et a l, 2009). Overall these da ta  support the hypothesis th a t alterations 
within motor neuronal cell body (as outlined in Figure 1.3) or in the peripheral 
axons, may be the triggering event of the pathologic process. Then ab erran t 
activation of glial cells and release of toxic factors may play a  role in the 
progression and worsening of the disease.
Table 1.5.
Effect o f selective expression o f m utant SOD1 
in neurons, astrocytes or m uscles
Mouse mSODl is expressed in... alterations of non­neuronal cells MN loss MND phenotype Reference
GFAP_S0D1g85R astrocytes astrocytosis no no Gong, J.Neurosc. 2000
nfl_ s o d iG87R motor neurons not described no no
Pramatarova, J.Neurosc. 
2001
Thyl.2_SODlG93A neurons astrocytosis yes yes
Jaarsma, J.Neurosc. 
2009
MLC_S0D1G93a muscles muscle atrophy no no
Dobrowolny Cell Metab. 
2008
Table 1.6.
Effect o f selective downregulation o f m utant SOD1 in specific cell types
Mouse mSODl is reduced in... Biochemical/histologicalalterations Disease progression Reference
Isll-Cre+ X Lox-SODl03™
motor and dorsal root ganglion 
neurons not described
delayed onset, extended 
survival
Boillee Science2006
CDllb-Cre+ x Lox-SOD1G37R microglial cells astrocytosis, microgliosis
no effect on onset, extended 
survival
Boillee Science 2006
GFAP-Cre+ x Lox-SODlG37R astrocytes astrocytosis, delayed microgliosis
no effect on onset, extended 
survival
Yamanaka NatNeurosc. 
2008
P0-Cre+ x Lox-SODlG37R schwann cells lack of IGF-I induction in sciatic nerves
no effect on onset, decreased 
survival
Lobsiger PNAS2009
MCK-Cre+ x Lox-SODlG37R scheletal muscles not described
no effects on onset and 
survival
Miller PNAS2006
1.3.7 Aberrant regulation o f pro-degenerative and anti-apoptotic pathways
Cells respond to a  m ultitude of external stimuli using a  limited num ber of 
signalling pathways activated by plasm a membrane receptors, such as G protein- 
coupled receptors (GPCRs), receptor tyrosine kinases (RTKs) and ligand-gated ion 
channels. These pathways do not simply transm it, b u t process, encode and 
integrate external signals with the events occurring a t different locations within 
the cytoplasm. Signalling by RTKs plays a  central role in the development and 
m aintenance of neurons and glia through a  wide range of processes, including 
survival, proliferation, differentiation, neurite outgrowth, and synaptogenesis 
(Romanelli and Wood, 2008).
Typically, upon stimulation, RTKs undergo dimerization and allosteric 
modification resulting in activation of the intrinsic tyrosine kinase catalytic
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activity. Subsequent phosphorylation of multiple tyrosine residues transm its a  
biochemical message to a  num ber of cytoplasmic proteins, in a  cascade fashion. 
Cascades of coupled phosphoiylation/dephosphorylation cycles, such as 
mitogen-activated protein kinase (MAPK) pathways, allows the integration and 
propagation of signals efficiently from the plasm a m em brane to intracellular 
target organelles, such as the nucleus. Typically, th is signalling cascade 
comprises MAPK, MAPK kinase (MAP2K) and MAP2K kinase (MAP3K). MAP2K is 
activated by MAP3K a t the cell m em brane and then  it in teracts with downstream  
MAPK phosphoiylating it on two conserved threonine and tyrosine residues. 
Various phosphatase activities oppose these phosphorylation events resulting in 
tightly regulated signalling. The specific outcome of the overall process is 
determ ined by the temporal and spatial dynamics of dow nstream  signalling 
com ponents (Kholodenko, 2006; Markevich et a l , 2006).
It can be easily argued th a t the neuron, being a  highly polarized cell, spend a  lot 
of energy and  take advantage of several molecular systems, like trafficking of 
phosphorylated kinases within endocytic vesicles or non-vesicular signaling 
complexes with molecular motors (Kholodenko, 2002; Perlson et a l , 2005), to 
assu re  signal propagation from periphery to the cellular body. This is particularly 
true for m otor neurons, th a t in some cases (like the neurons in the sciatic nerve) 
have to connect district th a t can be very far from each other (axons of LMN can 
be 1 m eter long in the hum an).
Taking into account the several m echanism s found to be implied in  ALS 
pathogenesis, and already described in the previous paragraphs, it can be 
hypothesized th a t excitotoxic stimuli, factors released by glial cells (like 
cytokines), or defects in the delivery of trophic factors from m uscles to the 
perikarion due to axonal transport im pairm ent or energy failure, m ay pertu rb  
hom eostasis of the motor neuronal cell, th u s  influencing the dynam ic of 
intracellular signalling pathways. In recent years great attention h as been
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concentrated on pathways th a t may account for the selective vulnerability of 
m otor neurons.
In particular, a  motoneuron-specific cell death pathway downstream  of the Fas 
death  receptor, in which synthesis of nitric oxide (NO) is an  obligate step has 
been described (Raoul et al., 1999; Raoul et al., 2005a). In cultured m otoneurons 
exogenous NO triggers expression of Fas ligand (FasL). Interestingly in 
m otoneurons from G93A and G85R mice th is up-regulation resu lts in activation 
of Fas, leading through Daxx to phosphorylation of p38MAPK and further NO 
synthesis. This Fas/NO feedback amplification loop is implicated in selective 
death of motor neurons in vitro. Consistent with these observations, G93A and 
G85R mice show increased accum ulation of Daxx in nuclear bodies w ithin motor 
neurons before disease onset. Moreover, FasL up-regulation is reduced in the 
presence of transgenic dominant-negative Daxx. It is possible th a t chronic low- 
level activation of the Fas/NO feedback loop may underlie the m otoneuron loss 
th a t characterizes familial ALS and may help to explain its slowly progressive 
natu re  (Raoul et a l, 2006).
Interestingly p38MAPK appears to be the converging key point of several pro- 
degenerative stimuli activated in ALS, including FasL and TNFa (Bendotti et al., 
2005). Activated p38MAPK (phospho-p38) has  been found in m otor neurons of 
post mortem spinal cord sam ples of ALS patients. Colocalization of p38MAPK 
with phosphoiylated neurofilam ents inside neuronal cell bodies h as  been also 
described (Ackerley et al., 2004). Analyses performed on spinal cord from 
SOD1G93A overexpressing mice report an  increase in both p38MAPK protein 
levels and phosphorylation s ta tu s  even a t a  presym ptom atic stage. Phospho-p38 
is mainly localized inside motor neurons and during disease progression it also 
appears in neurons with signs of degeneration (vacuolization and  perikaryal 
accum ulation of phosphorylated neurofilaments) and in reactive glial cells 
(hypertrophic astrocytes and  mostly activated microglia) (Tortarolo et al., 2003; 
Wengenack et a t, 2004). Moreover activation of p38 in both neuronal and  glial
- 70-
cells determ ines the transcription of several pro-degenerative genes: nitric-oxide 
synthase, IL-1, TNFa and TNFa receptors. This highlights an  active role for 
p38MAPK in the pathw ays th a t trigger neuronal death, or, a t least, in those 
processes th a t produce a  pro-degenerative environment around neurons. 
Consistent with these observations, treatm ent of SOD1G93A mice with 
minocycline or TNFa inhibitors retarded neuronal death and extended life span 
(Zhu et a l, 2002; West et a l, 2004). These effects have been linked to a  reduction 
of p38MAPK activation, suggesting th a t p38MAPK may be considered a  good 
target for the design of selective inhibitors of pro-degenerative pathways.
Although several lines of evidence highlight an  induction of pro-degenerative 
pathways in motor neurons in ALS, the extent of activation of pro-survival and 
anti-apoptotic pathways, such as the PI3K/Akt, are also worthy of consideration. 
In the nervous system, PI3K is usually  activated by binding of neurotrophic 
factors to the cognate receptors. Active PI3K produces phosphatidyl-inositol-3- 
phosphate (PIP3) th a t recruits Akt (a Ser/T hr kinase) to the cell m em brane via a  
plextrin homology domain. Akt is then  activated by phosphorylation by PDK1 
and PDK2, detaches from the m em brane and can rem ain in the cytosol or 
translocate to the nucleus, to exert anti-apoptotic activities. Studies on hum an  
post-m ortem  tissues have revealed th a t although PI3K was activated in 
homogenates from spinal cord of ALS patients, the levels of phospho-Akt were 
not altered. This suggests th a t there may be some obstacle in the transduction  of 
signals from PI3K to Akt in the spinal cord of ALS affected individuals (Wagey et 
a l, 1998). Moreover analyses on late onset SOD1G93A mice show th a t the total 
levels of Akt are reduced a t the onset of symptoms (Warita et a l, 2001).
Therefore, neuronal dysfunction and death in ALS may be determ ined no t only 
by the activation of pro-degenerative processes, b u t also by an  im paired 
activation of pro-survival pathways (Figure 1.4). Several neurotrophic factors are 
able to activate the Akt pathway. Indeed, viral m ediated deliver of GDNF and  IGF 
to spinal motor neurons in G93A mice, th a t produced amelioration of the
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pathology and elongation of life span, have been linked to the activation of Akt in 
the nervous system (W a n g  e t  a l . , 2 0 0 2 ;  K a s p a r  e t  a l ,  2 0 0 3 ) .
Figure 1.4.
D ysregulation o f  pro-degenerative and anti-apoptotic pathw ays 
in m otor neurons in ALS
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Several evidences point out the possibility tha t motor neuronal death may result 
from over-activation of pro-degenerative pathways, not counterbalanced by 
induction of anti-apoptotic molecules.
Since modulation of the p38MAPK and Akt pathways are the main aim of this 
thesis, further description of these pathways will be provided in the following 
sections.
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1.4 THE p38-MAPK PATHWAY
Mitogen-activated protein kinase (MAPK) pathways are utilised by cells to 
respond to extracellular stimuli. MAPKs are m em bers of discrete signalling 
cascades and  serve as focal points which a  variety of extracellular stim uli 
eventually converge on. Four distinct subgroups within the MAPK family have 
been described: 1) extracellular signal-regulated kinases (ERKs); 2) c-jun N- 
term inal kinases (JNKs), also called stress-activated protein kinases (SAPK); 3) 
ERK/big MAP kinase 1 (BMK1), and  4) the p38MAPK group of protein kinases.
1.4.1 Overview o f p38 MAPK pathway
p38 MAPK was first isolated as a  38KDa protein th a t is rapidly tyrosine 
phosphorylated in response to LPS stim ulation (Han et a l, 1994). To date four 
isoforms of the p38 MAPK family have been identified: p38MAPK alpha, 
p38MAPK beta, p38MAPK gamma (or ERK6, SAPK3), and p38MAPK delta (or 
SAPK4). Each isoform shares about 60% identity w ithin the p38MAPK group b u t 
only 40-45% to the members of other MAPK families (Zarubin and. Han, 2005).
All p38MAPK kinases are characterised by a  Thr-Gly-Tyr (TGY) dual 
phosphorylation motif. p38MAPK alpha and beta  are ubiquitously expressed, 
while p38gam m a is localized mainly in m uscles and  heart and p38MAPK delta is 
m ainly in kidneys and lungs.
S tructural features of p38MAPK
p38 MAPK is a  proline-directed serine/threonine kinase. Crystal s truc tu re  of 
p38MAPK alpha in the unphosphorylated, inactive, form has been resolved. The 
enzyme is characterized by two domains separated by a  deep channel where 
potential substra tes might bind. The N-terminal domain creates a  pocket for 
binding of the adenine ring of ATP. The C-terminal domain contains the
presum ed catalytic base, m agnesium  binding sites, and the phosphorylation lip, 
a  13 residues segment containing the Thr180-Gly-Tyr182 motif (Wilson et al.} 1996). 
Both Thr180 and Tyr182 are already exposed to solvent in p38MAPK structure; this 
suggests th a t these residues are readily accessible by the upstream  activating 
kinases. Moreover it is believed th a t the sequence and structu ra l variation of the 
lip among protein kinases could provide a  specific recognition elem ent for the 
upstream  kinases in the cellular activation cascade. Also each MAP kinase is 
specific for the site th a t recognises the target proline-containing peptide 
substrate  (P+l site). The position of the P+l site is known to be adjacent to the 
Lip, and the residues th a t form the P+l pocket (Val183-Arg189) are all conserved 
among the MAPKs.
Interestingly, the dom ains of p38 MAPK are oriented so th a t the side chains of 
some key catalytic residues are misaligned, and a  portion of the p38MAPK 
activation lip blocks the peptide substrate  binding channel. The com bination of 
these regulatory m echanism s ensures th a t the kinase activity of p38 MAPK is 
minimal before activation (Wilson et a t , 1996; Wang et al.} 1997).
Upstream  activators of p38 MAPK pathway
p38MAPK proteins are considered stress-activated kinases, as they are reported 
to be activated mainly by UV light exposure, heat, osmotic shock and 
inflammatory cytokines. The pathway th a t leads to the final activation of p38 
MAPK is a  m ultistep cascade th a t involves several upstream  kinases, each w ith a  
cell-type specific expression level and a  tightly regulated activity.
The canonical activation of p38 MAPKs occurs via dual phosphorylation of their 
Tyr-Gly-Thr motif, in the activation loop, by two MAP kinase k inases (MKKs), 
MKK3 and MKK6. In some circum stances, such  as ultraviolet radiation, MKK4, 
an upstream  kinase of JNK, can aid in the activation of p38MAPK alpha and  
p38MAPK delta in specific cell types (Jiang et a l, 1997; Brancho et al., 2003). A  
further upstream  step of regulation is represented by the MKK kinases (MAP3K).
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These include TAK1, ASK1 or MAPKKK5, MLKs, and some m em bers of the MEKK 
family (Ichijo et a l, 1997; Kyriakis and Avmch, 2001; Gallo and Johnson, 2002; 
Cheung et a l, 2003). MAP3K overexpression leads to activation of both p38 MAPK 
and JNK pathw ays (Ogura and Kitamura, 1998; Zarubin and  Han, 2005) 
suggesting th a t the selective induction of p38MAPK, and other MAPK pathw ays, 
is dependent on the specific m odulation of MKKs.
Interestingly low molecular weight GTP-binding proteins of the Rho family, such  
as R acl and  Cdc42, are also involved in upstream  activation of p38 MAPK. R acl 
binds to MEKK1 or MLK1 while Cdc42 can only bind to MLK1 and both resu lt in 
activation of p38 MAPK via MAP3Ks (Zhang et a l, 1995; Tibbies et al., 1996). P21- 
activated kinases (PAKs) are another reported group of p38MAPK activators 
(Bagrodia et al., 1995).
The major pathway for p38 MAPK regulation is via MKKK-MKK in m am m alian 
cells although two other possible m echanism s of activating p38MAPK alpha  have 
been described. In one case, MKK-independent activation is achieved by 
autophosphorylation of p38MAPK after its interaction with TAB1 (trasforming 
growth factor beta-activated protein kinase 1 (TAK1)-binding protein). This 
m echanism  appears to be involved in activation of p38MAPK alpha in ischemic 
heart (Li et al., 2005) although the overall importance of th is pathw ay in other 
cells/tissues is unknow n and in fibroblasts and epithelial cells th is  is not 
involved (Brancho et a l, 2003). O ther MKK-independent m echanism s of 
activation of p38 have been observed and  in T cells stim ulated through the T cell 
antigen receptor (TCR) phosphorylation of p38MAPK alpha on a  non-canonical 
residue, Tyr323, h as been reported (Salvador et a l, 2005).
Under physiological conditions, p38 MAPK activation occurs very rapidly, b u t is 
transien t and dephosphorylation of the kinase plays an  im portant role in  the 
downregulation of MAPK pathway. This process is mediated by dual-specificity 
MAP kinase phosphatases (MKPs), or by PP2C (Ser/Thr phosphatase) and  PTP 
(Tyr phosphatase) (Takekawa et al., 1998; Keyse, 2000). p38MAPK a lpha  and
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p38MAPK beta can be efficiently dephosphoiylated, bu t to date p38MAPK gamma 
and p38MAPK delta appear to be resistan t to all known MKP family members.
Figure 1.5. S ignaling cascad es leading to  activa tion  o f  th e  MAPKs.
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Downstream targets of p38MAPK pathway
p38MAPK has a  huge variety of downstream  targets, ranging from protein 
kinases, to other enzymes and transcription factors. Some p38MAPK alpha and 
beta physiological substrates are sum m arised in Figure 1.6. These are 
transcription factors, other protein kinases (such as MAPKAP-K2/3, or MNK1/2 
or MSK1 /2) th a t in tu rn  phosphorylate trascription factors, cytoskeletal proteins, 
com ponents of the translational machinery and other proteins such as metabolic 
enzymes, glycogen synthase or cytosolic phospholipase A2 (R o u x  a n d  B le n is ,
2 0 0 4 ) .  Na/H exchanger isoform-1 (NHE-1), Tau and Keratin 8, and  stathm in
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have also been reported as substrates for p38MAPK alpha (Z a ru b in  a n d  H a n , 
2 0 0 5 ) .
Figure 1.6. D ow nstream  ta rg e ts  o f p38 MAPK.
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Potential substrates of p38 alpha and p38 beta MAPKs, CHOP, CCAAT/enhancer-binding 
protein-homologous protein; MEF, myocyte enhancing factor; PGC, peroxisome 
proliferators activated receptor y coactivator; SAP, serum response factor accessory 
protein; HBP, high mobility group-box transcription factor; NFAT, nuclear factor of 
activated T-cells; ATF, activating transcription factor; MAPKAP-K, mitogen activated 
protein kinase activated protein kinase; MSK, mitogen and stress activated protein 
kinase; MNK, mitogen activated protein kinase-interacting protein; TAK, transforming 
growth factor-(3-activated kinase.
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1.4.2 Physiological roles o f p38 MAPK pathway
p38 MAPK is strongly activated in response to m any types of stress, like UV 
irradiation, osmotic and oxidative stress (Han et a l, 1994; Tibbies and Woodgett, 
1999). It is also activated in response to proinflammatory cytokines and is 
involved in cytokine synthesis. Indeed, p38MAPK is centrally involved in IL -lbeta 
and TNFa production in hum an monocytes following lipopolysaccharide 
treatm ent (Lee et al., 1994a). Recent work in knock-in mice in which either 
p38MAPK alpha or p38MAPK beta kinase carry a  m utation th a t provide 
resistance to the effects of specific inhibitors, has dem onstrated th a t specific 
inhibition of p38MAPK alpha in vivo is sufficient and necessary for suppression 
of increased peripheral proinflammatory cytokine levels after lipopolysaccharide 
challenge (O'Keefe et a t, 2007). p38MAPK alpha is generally thought to be the 
major isoform involved in m ediating cytokine production since mice lacking 
p38MAPK beta did not show deficits in cytokine production or in im m une 
function (Beardmore et a t, 2005). No involvement in inflammation h as been 
reported for the other two isoforms of p38MAPK.
An interesting m echanism  of regulation of inflammatory m ediators is exerted by 
p38 MAPK a t a  post-transcriptional level. In fact, several cytokines genes share 
an ARE (AU-rich element) in the 3 ’-un transla ted  region of their mRNA. The 
presence of th is elem ent is known to shorten the half-life of the mRNA and  in 
some cases, such  as for TNFa, blocks the translation. p38MAPK activation 
determines phosphorylation of specific ARE-binding proteins th a t aid in 
stabilizing the mRNA, th u s  enhancing its translation, and mice lacking the ARE 
of TNFa were incapable of p38-mediated TNFa translation after exposure to LPS 
(Kontoyiannis et a l, 1999).
In addition to im m une-m odulatory function, p38MAPK alpha h as been proposed 
to regulate some cellular processes unrelated  to the stress response, for example, 
the differentiation an d /o r survival of several cell types (Morooka and Nishida,
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1998; Cuenda and Cohen, 1999; Zetser et a l, 1999). Knockout mice for p38MAPK 
alpha have been generated; th is leads to a  lethal phenotype, mainly due to 
defects in placental organogenesis (Adams et a l, 2000). In contrast, p38MAPK 
beta, p38MAPK gamma, p38MAPK delta and double p38MAPK gam m a/delta  
knockout mice develop normally into adulthood, suggesting red u n tan t functions 
among these isoforms (Beardmore et al., 2005; Kim et a l, 2005; Sabio et a l,
2005). It appears th a t p38MAPK alpha is im portant for myogenesis, since 
myoblasts from mice lacking p38MAPK alpha, b u t not those lacking p38MAPK 
beta or p38MAPK delta, do not differentiate to m ultinucleated m yotubes 
(Perdiguero et a l, 2007). Given th a t p38MAPK gamma is highly expressed in 
skeletal muscle, and th a t endogenous p38MAPK gam m a protein levels increase 
as myoblasts differentiate, it is not surprising th a t p38MAPK gam m a also plays a  
key role in skeletal m uscle differentiation. Indeed, over-expression of p38MAPK 
gamma in skeletal m uscle cells leads to differentiation from m yoblast to 
myotubes, and a  dominant-negative m u tan t of p38MAPK gam m a prevents this 
differentiation process (Lechner et a l, 1996). A role for p38MAPK alpha in various 
aspects of cardiogenesis including the regulation of cardiomyocyte differentiation, 
apoptosis, and  hypertrophy has also been suggested (Wang et a l, 1998; Mackay 
and Mochly-Rosen, 1999; Davidson and Morange, 2000). Some reports have also 
suggested a  role for p38MAPK delta in keratinocyte differentiation, or in 
induction of cell death upon exposure to hydrogen peroxide (Eckert et a t, 2003; 
Efimova et a l, 2003). O ther processes in which p38 MAPKs have been im plicated 
in either positive or inhibitory roles are: early stages of osteoclastogenesis from 
bone marrow precursors (Huang et a l, 2006), adipogenesis (Aouadi et a t, 2006), 
in testinal epithelial cells differentiation (Houde et a l, 2001) cell proliferation 
(Maher, 1999), cytoskeletal reorganization (Rousseau et a l, 1997), cell-cycle 
regulation (Takenaka et a l, 1998) and neuronal plasticity (Butler et a l, 2004; 
Pickering et a l, 2005).
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1.4 .3  p38 MAPK pathway in physiology and pathology in the nervous 
system
p38MAPK alpha and p38MAPK beta are the two isoforms m ost abundan t in the 
nervous system. They are highly expressed in m ost brain  areas, including 
cerebral cortex, hippocam pus, cerebellum and a  few nuclei of the brainstem  (Lee 
et a l, 2000). In the spinal cord, p38MAPK alpha is found in m ost neurons, 
w hereas p38MAPK beta is localized in microglial cells throughout the spinal cord 
parenchym a and in ventral horn motor neurons (Svensson et a l, 2005). At the 
subcellular level p38MAPK alpha is localised in dendrites and  in cytoplasmic and 
nuclear regions of neuronal soma, while p38MAPK beta is concentrated in the 
nucleus of neurons, suggesting th a t the two isoforms may play different 
physiological functions in the CNS.
In the nervous system, in vitro studies have implicated the p38 MAPK pathw ay in 
neuronal cell fate decision, in migration during development, and  in the control 
of synaptic function and excitability. For example, p38 MAPK signaling has  been 
found to participate in NGF-induced neuronal differentiation of PC 12 cells and 
selective inhibition of p38 MAPK resu lts in defective NGF-induced neurite 
outgrowth in th is model. Moreover constitutive activation of ASK1, or expression 
of a  dom inant negative form of TAK1, both upstream  activators of p38 MAPK, 
leads to induction or inhibition of neurite outgrowth in PC 12 cells respectively 
(Takeda et a l, 2000; Yanagisawa et a l, 2001). In addition in MN9D dopaminergic 
neuronal cells expression of calbindin-D28K, a  m em ber of the calmodulin 
superfamily of calcium binding proteins, induces neurite outgrowth in a  p38- 
dependent m anner (Choi et a l, 2001).
p38 MAPK has been shown to regulate cytoskeletal reorganization in neuronal 
cells, during development of CNS. This role is m ediated prim arily by 
phosphorylation of Hsp27 and  Rac GTPase (Rousseau et a l, 1997). p38MAPK 
also participates in the induction of metabotropic glutam ate receptor (mGluR)- 
dependent long term  depression (LTD) a t excitatory synapses between CA3 and
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CA1 pyramidal neurons in the hippocam pus (Bolshakov et a t, 2000). Neuronal 
function is also regulated by p38 MAPK through the m odulation of recycling of 
AMPA subtype glutam ate receptors (AMPARs) which are internalized in  response 
to various extracellular stimuli and  are recycled back to the plasm a m em brane or 
targeted to the degradative pathway. This trafficking is thought to play a  critical 
role in synaptic plasticity (Carroll et a t, 2001). The small GTPase Rab5 is involved 
in this early endocytic trafficking of AMPARs. Interestingly, p38 MAPK h as been 
identified as activator of guanyl-nucleotide dissociation inhibitor (GDI), a  protein 
involved in relocalization of Rab5 to the appropriate target m em brane. The 
p38MAPK induced formation of GDI:Rab5 complex has been found to accelerate 
endocytosis (Cavalliet al., 2001).
Several studies have shown th a t the p38MAPK pathway may exert opposite 
effects on cell survival/death  decision, depending on the s tress-sta tu s  of the cell. 
Neuronal activity may control the p38MAPK pathw ay to mediate cell survival. 
For example, the p38MAPK pathw ay activates the MEF2 transcription factor in 
response to physiological calcium influx in cerebellar granule cells, and  activated 
MEF2 regulates neuronal survival (Mao et a t, 1999; Okamoto et a t, 2000). On the 
other hand, under pathophysiological conditions the p38MAPK pathw ay may be 
induced through activation of ASK1 to mediate neuronal degeneration 
(Matsuzawa and Ichijo, 2001).
Aberrant activation of the p38 MAPK pathw ay has been linked to several 
neurodegenerative diseases, such  as stroke, Alzheimer’s disease (AD) and  
Amyotrophic Lateral Sclerosis.
Acute neuronal injuries, such  as traum a or ischemia, are characterized by 
activation of microglial cells and the release of pro-inflammatory cytokines, th a t 
ultim ately contribute to the degenerative process observed in neurons in the 
affected area. The p38 MAPK pathw ay is involved in th is process, as 
dem onstrated by the fact th a t p38 MAPK inhibitors are protective in anim al 
models of ischem ia and reperfusion injury (Piao et a t, 2003; Melani e t a t, 2006;
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Bu et al.} 2007). It has also been proposed th a t the p38MAPK pathw ay is involved 
in the release of pro-inflammatory cytokines from aberrantly activated microglia 
in AD brains. In this case, microglial activation seems to be triggered by 
deposition of amyloid beta  peptide, a  hallm ark of the disease (Culbert et a l,
2006). Another pathological hallm ark of AD and other disorders called 
“tauopathies” is the accum ulation of neurofilam ents composed of the 
micro tubule-associated protein Tau. Hyperphosphorylation of Tau is one of the 
m echanism s leading to its aberran t accum ulation in neurons, and p38 MAPK is 
one of the kinases thought to be involved in this process (Ferrer et a l, 2005). 
Among the different proteins found altered in the degenerative process in ALS, 
p38 MAPK has acquired increasing importance. Activated p38 MAPK h as been 
found in degenerating motor neurons and reactive astrocytes of post mortem  
spinal cord sam ples of ALS patients: the intracellular im m unostaining appears in 
some neurons as filamentous skein-like and ball-like inclusions, with an 
im m unohistochem ical pa ttern  identical to th a t of ubiquitin  (Bendotti et a l, 2004). 
Another study found overlapping labelling of abnormally phosphorylated 
neurofilam ents and p38 MAPK alpha in the motor neurons of ALS patients, and 
provided evidence th a t the alpha isoform may be particularly relevant for the 
formation of perikarial aggregates in affected motor neurons (Ackerley et al.,
2004). Interestingly, p38 MAPK protein levels and phosphorylation h as been 
reported as enhanced in spinal cord hom ogenates from SOD1G93A 
overexpressing mice even a t a  presym ptom atic stage. Phospho-p38 
im m unostaining is mainly localized in motor neurons with phosphorylated 
neurofilam ents and vacuolized perikaria and neurites. During disease 
progression, active p38 MAPK also accum ulates in reactive glial cells 
(hypertrophic astrocytes and mostly activated microglia) (Tortarolo et al., 2003; 
Wengenack et al., 2004). Activation of p38 MAPK has been confirmed in cortical 
neurons of SOD1G93A anim als, th u s  strengthening the hypothesis th a t th is 
pathw ay may play a  role in the degeneration of both upper and  lower m otor
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neurons (Holasek et al., 2005). In a  recent report activation of the p38 MAPK 
pathw ay in spinal motor neurons of SOD1G93A mice was associated with 
selective upregulation of TNFa receptors (Veglianese et a t, 2006), moreover Fas- 
signalling pathw ay was found to converge on p38 MAPK activation selectively in 
motor neurons in SOD1G93A mice (Raoul et al., 2002; Raoul et al., 2006). These 
data  suggest th a t the p38 MAPK pathway may increase the susceptibility of 
motor neurons to inflammatory cytokines released by surrounding glial cells. In 
sum m ary, th is pathway may represent a  key factor in the degeneration of motor 
neurons in ALS, and may therefore be considered as a  good target for therapeutic  
intervention. Indeed, treatm ent of SOD1 m u tan t mice with anti-inflam m atory 
molecules, such  as minocycline, nordihydroguaiaretic acid, thalidom ide and  its 
analog lenalidomide, or Fas siRNAs and Semapimod, provide neuronal protection 
and extend life span  (Zhu et al., 2002; West et a l, 2004; Kiaei et al., 2006; Dewil 
et a l, 2007a; Locatelli et al., 2007). For treatm ent with minocycline, Fas siRNAs 
and Semapimod a  reduction in p38 MAPK activation has been reported. Moreover 
it has been recently dem onstrated in vitro th a t riluzole, the only drug  approved 
for treatm ent of ALS, is protective against glutam ate induced changes to 
neurofilam ent phosphorylation and  transport, through inhibition of p38 MAPK 
and ERK (Stevenson et a l, 2009).
1 .4 .4  Strategies for targeting p38MAPK
Aberrant production of inflammatory cytokines, and subsequent activation of the 
p38 MAPK pathway, has been linked with several inflammatory disorders, 
including chronic pathologies such as rheum atoid arthritis and C hron’s disease, 
or acute injuries such  as heart failure, ischaem ic retinopathies and  the 
development of insulin  resistance in diabetes (Cuenda and Rousseau, 2007). 
Because of this, commercial drug discovery program s have focussed considerable 
effort designing small inhibitory molecules targeting the p38 MAPK pathw ay. 
Generally the lead com pounds target p38 MAPK directly, although a  lack of
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selectivity for a  specific isoform is often reported. Moreover, m any molecules 
appear to in teract with other unrelated kinases, thereby causing adverse effects. 
Nevertheless some of these drugs have reached clinical application, mainly for 
treatm ent of reum atoid arthritis or Chron’s disease (Table 1.7).
Alternative approaches for targeting p38 MAPK have been developed in the last 
few years, although these have been only utilised in basic research and  have not 
yet been tested in a  clinical setting. For example, RNAi represents an  intriguing 
strategy for targetting p38 MAPK . Through the accurate design of siRNAs it is 
possible to selectively downregulate p38 MAPK a t the mRNA level, th u s  reducing 
the risk of non-specific effects (Hirose et a l, 2003; Gao et a l, 2004) and 
providing the opportunity to better dissect the role played by each p38 MAPK 
isoform in the pathologic process. As an alternative approach, dom inant 
negative m utan ts of p38 MAPK or its upstream  regulatory kinases (such as 
ASK1) have been generated. Usually these m u tan ts  are kinase-dead enzymes, 
which can be phosphorylated (activated) b u t are not able to catalyze the 
phosphorylation of their downstream  targets. This strategy has been effectively 
used  to dissect the role played by specific kinases in vitro (Muthumani et a l,
2005). These strategies have been used  to study the neurodegenerative process 
in ALS and have provided strong evidence for a  central role of p38 MAPK and  the 
upstream  kinase ASK1 (Raoul et a l, 2002; Raoul et al., 2006; Nishitoh et al., 
2008).
The design and use  of small molecule inhibitors will be described in  more detail 
as some of these com pounds have reached clinical application for peripheral 
inflammatory disorders although to date there are no reports of p38 MAPK 
inhibitors in clinical trials for neurodegeneration.
Pharmacological inhibition of the p38 MAPK pathway
Most of the available molecules targeting p38 MAPK have been designed for use  
in inflammatory disorders, since p38 MAPK h as been considered as  a  key player
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in the over-production of proinflam matory cytokines in these diseases. Some of 
these drugs have also been proposed as possible treatm ents for 
neurodegenerative diseases, although bioavailability particularly in relation to 
penetration of the blood-brain-barrier is a  challenge.
Pyridinil imidazoles
4-pyridinylimidazoles represent the main pharm acophore for p38 MAPK 
inhibitors. The lead structure  is the imidazothiazole SK&F 86002, originally 
conceived as an  hybrid structu re  from the antiinflammatory imidazole derivative 
tiflamizole and  the bicyclic im m unom odulator levamisole. This com pound 
displayed a  specific and unexpected m echanism  of action, since it was a  weak 
inhibitor of the metabolism of arachidonic acid, b u t exerted an  antiinflam m atory 
effect through inhibition of IL-1 and TNFa production. Later p38 MAPK was 
discovered as the target of th is compouno. \L/ee et at., 1 uoo; Liee et ai., 1 yy«3/. i he 
pyridinil imidazoles bind competitively a t the ATP binding site of p38 MAPK. 
However, unlike ATP, these inhibitors bind with similar affinity to both the 
phosphorylated and unphosphoiylated form of the enzyme. The T hr106 residue of 
p38 MAPK appears to be the determ inant for the potency and selectivity of these 
com pounds versus other kinases. In fact pyridinyl imidazoles display similar 
affinities for isoforms p38MAPK alpha and p38MAPK beta, carrying a  Thr in this 
position, b u t are not effective towards p38MAPK gam m a and  p38MAPK delta, 
displaying a  bulkier Met residue, or ERK2, displaying a  Gin (Bolos, 2005). 
Subsequent modifications of the struc ture  of SK&F 86002 led to the 2,4,5-triaryl- 
imidazoles, more potent and selective com pounds (Bolos, 2005). W ithin th is 
group, SB 203580 displayed good oral efficacy for several models of cytokine 
inhibition and inflammatory diseases and  became the prototypical s tan d ard  for 
other p38 MAPK inhibitors (Badger et al., 1996). The m ain draw back of these 
com pounds was their interaction with cytochrome P-450 isoenzymes, a  
m echanism  th a t led to hepatotoxicity and potential carcinogenicity in  pre-clinical
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trials (Howard et al.} 1991; Adam s et a l, 1998). S tructural modifications have 
subsequently been introduced with the aim of reducing th is side effect: the 
morpholinopropyl derivative SB 210313 represents an example, with potent in 
vivo oral activity and  reduced interaction with m ost cytochrome P-450 
isoenzymes (Boehm et a l, 1996).
Pyrimidinil imidazoles
Based on the fact th a t pyrimidine is a  weaker cP-450 inhibitor com pared to 
pyridine, and th a t it still m aintains the ability to in teract with p38 MAPK, new 
imidazoles derivatives have been generated with pyrimidine substitu tion. SB 
242235 and SB 239063 are two examples; SB 242235 has  entered phase I 
clinical trials (Bolos, 2005).
Other classes o f p381vlAPK inhibitors
Although the imidazole ring plays a  struc tu ra l role in keeping the correct 
conformation for interaction with the active site of the enzyme, its substitu tion  
with heterocyclic scaffolds has been shown to m aintain similar electronic and 
spatial features. Interestingly, these non-imidazole pyridinyl heterocycle 
derivatives, like pyridinyl oxazole, are orally active potent inhibitors of p38 MAPK 
devoid of inhibition of cP-450. A different s truc tu ra l class is constitu ted by 
molecules with a  pyrimidopyridazinone nucleus and other related bicyclic 
analogues. VX 745 is representative compound of this family; it was the first 
inhibitor of p38 MAPK to undergo clinical trials in patients with rheum athoid  
arthritis. However safely concerns about some adverse neurologic effects 
observed in dogs in long term  toxicological studies led to the d iscontinuation of 
its use  (Bolos, 2005). This nervous system toxicity was related to extensive 
penetration across the blood-brain-barrier, which has been a ttribu ted  to the high 
lipophilicity of VX 745. Another class of p38 MAPK inhibitors is represented  by 
N,N’-diaiyl ureas. These molecules exhibit a  unique mode of binding to the
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enzyme: they in teract with a  site near to the ATP pocket b u t d istinct from it. The 
diaiyl u reas represent allosteric inhibitors, since their binding determ ines a  
modification of the enzyme conformation, inducing structu ra l hindrance a t the 
ATP binding site. This m echanism  of action accounts for m uch slower binding 
and dissociation ra tes as compared to imidazoles derivatives (Bolos, 2005).
In contrast to VX 745, com pounds belonging to the other inhibitor classes are 
not blood-brain-barrier permeable. This represents a  severe lim itation for the 
application of p38 inhibitors in neurodegenerative disorders.
Recently CNI-1493, a  tetravalent guanylhydrazone called Semapimod, has 
attracted considerable in terest for the treatm ent of neurodegenerative disorders 
due to its ability to cross the BBB after i.p. delivery. This com pound h as been 
used  since 1995 for its antiinflam m atory properties (Bianchi et a l, 1995), with 
quite encouraging results for the treatm ent of Crohn’s disease. The effect seems 
to be m ediated by inhibition of both p38 and JNK MAPKs (Horames et a l, 2002). 
In the la st few years Semapimod has also been used  in models of 
neurodegenerative disorders, such as AD and  ALS. In an anim al model of AD, 
treatm ent with semapimod produced a  significant reduction of Abeta deposition, 
plaque formation and cognitive deterioration (Bacher et al., 2008). In the 
SOD1G93A mouse model of ALS, th is com pound resulted in downregulation of 
p38 MAPK pathway and substantial protection of motor neurons in the spinal 
cord, b u t did not modify disease progression in a  significant way, although did 
cause a  slight extension of life span (Dewil et al., 2007a). In fact , JNK and  p38 
MAPKs are not direct targets of Semapimod. A detailed in vitro s tudy  has 
determ ined th a t the molecular target of th is com pound is c-Raf, an  upstream  
kinase canonically involved in the activation of the ERK pathway. It w as shown 
th a t Semapimod, through inhibition of c-Raf isoform, was able to reduce 
activation of ERK, JNK and p38 MAPKs in cytokine-stim ulated m acrophages, bu t 
not in T cells (Lowenberg et al., 2005). Therefore, it is likely th a t Semapimod
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may ra ther represent a  good candidate for treatm ent of disorders in which c-Raf 
m ediated inflammatory response is involved.
Table. 1.7
Features o f the m ost com m only used p38 pharmacologic inhibitors
Structural class
Mechanis 
m of 
action
Compound Target
Interactio 
n with P- 
450  
enzymes
BBB
perm
1 Pyridinyl imidazole
ATP
competitive
inhibitor
SK&F 86002
SB203580
SB210313
SB235699*
RWJ-67657*
P38a/b (+) 
P38a/b (++) 
P38a/b (++) 
P38a/b (+++) 
P38a/b (+++)
++++
+++
++
+
+
No
No
No
No
No
2 Pyrimidinylimidazole
Same as 
class 1
RPR203494
RPR238677
SB220025
SB242235*
SB239063
P38a/b (+++) 
P38a/b (+++) 
P38a/b (+++) 
P38a/b (+++) 
P38a/b (+++)
+/- 
+/- 
+/- 
+/- 
+ /-
No
No
No
No
No
3 Non-imidazole pyridinyl heterocycle
Same as 
class 1
Pyridinyl-oxazole
L167307
RWJ68354*
P38a/b (+++) 
P38a/b (+++) 
P38a/b (+++)
-
No
No
No
4 Pyrimidopyridazinone ND
VX 745* P38a/b (+++) ND Yes
5 N,N’-diaryl urea
ATP
allosteric
inhibitor
BIRB 796** 
(doramapimod)
/Ux w w u ./  V ■ ■ ■ • ) ND TYTT*
6 Dyaril ketone Same as class 1
RO 320 1195* P38a/b (+++) ND ND
7 Aromaticcarboxamide
Same as 
class 1
SCIO 323* 
SCIO 469*
P38a/b (+++) 
P38a (++++)
ND
ND
ND
8 Guanylhydrazone c-Rafinhibitor
CNI-1493*
(semapimod)
P38a/b (+++) ND Yes
ND=not described; *=early phases of clinical trials; **=phase III in clinical trials 
(Sitaraman et al, 2003; Bolos, 2005).
1.5 THE PI3K/AKT PATHWAY
Phosphoinositide 3-kinase (PI3K) and  Akt, also called protein kinase B (PKB) are 
key players in the transduction  of signals from m em brane receptors to 
intracellular and nuclear targets. The PI3K-dependent Akt signalling pathw ay is 
of great im portance since it participates in a  myriad of cellular processes, such 
as cell growth, differentiation, motility, insulin action and  cell survival. 
U nderstanding the complex m echanism  of regulation of these kinases is an  
essential step in defining a  strategy for the m anipulation of th is pathw ay in 
disease.
1.5.1 Overview o f th e  PI3K/AKT pathw ay
PI3K comprises a  family of agonist-stim ulated lipid signaling enzymes th a t are 
activated by growth factor receptors through binding of their regulatory subun it 
to phosphotyrosine residues in the receptor. Upon activation the catalytic 
subun it of PI3K phosphorylates Phospho-Inositides (PI) a t the 3-position of the 
inositol ring to generate Phosphatidyl-Inositol-3-phosphate (PI3P), PI(3,4)P2, and 
PI(3,4,5)P3.
Akt possesses a  plextrin homology (PH) dom ain in its struc tu re  th a t allows 
interaction with PIP3 , th u s  mediating the m em brane translocation of Akt. The 
interaction of Akt with PIP3 does not directly activate Akt bu t is thought to induce 
a  conformational change in the kinase th a t facilitates its phosphorylation on 
Thr308 and Ser473 by the upstream  kinases phosphoinositide-dependent k inase 1 
and 2 (PDK1 and PDK2). Once activated, Akt then dissociates from the plasm a 
m em brane and phosphorylates m any substra tes  in the cytoplasm and  the 
nucleus, leading to activation of the appropriate physiological response (Figure 
1.7) {Toker, 2000; Rodgers and Theibert, 2002).
Figure 1.7. Overview of PI3K/Akt pathway.
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Features of PI3Ks
Several isoforms of these kinases have been described. They have been grouped 
under three classes, according to their specificity of function and their 
preferential substrates.
C l a s s  I
This class comprises kinases tha t preferentially phosphorylate PIP2, thus 
generating PIP3 as the final product. These proteins are composed of a  catalytic 
subunit and a regulatory adapter subunit. This class of enzymes has been 
implicated in a  wide range of cellular responses, including cell cycle progression, 
growth, survival, motility and adhesion.
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Class II
PI3Ks th a t use  PI or PIP as substrates, th u s  producing PIP or PIP2, respectively. 
These enzymes share homology with the class I catalytic domain, b u t are larger 
proteins th a t also contain structu ra l domains involved in calcium /lipid 
interactions.
Class III
This class comprises enzymes th a t only phosphorylate PI, th u s  producing PIP as 
final product.
Enzymes of class II and III are believed to be required m ainly for vescicular 
trafficking. It has also been hypothesized th a t PI3Ks class III are involved in 
induction of autophagy-m ediated neuronal death (Petiot et a l, 2000). Therefore, it 
is likely th a t the balance between PI3K class I activity and  PI3K class III may 
represent another m echanism  of m odulation of cellular hom eostasis.
Class I PI3Ks will be described in more detail, since they are the m ost studied, 
and appear to be the class of proteins m ainly involved in survival pathw ays in 
the CNS. Studies conducted in vitro on cell lines and prim ary neuronal cultures 
have identified a  wide range of factors th a t activate PI3K in neurons, such  as 
NGF, BDNF, IGF-1, GDNF, Fractalchine and neurotransm itters. In astrocytes, 
PI3K is instead activated by Neuregulins, m em bers of the family of GDNF and 
IGF-I, and cytokines such as IL-10, and neurotransm itters (Rodgers and Theibert, 
2002).
Regulation of PI3K
The enzyme is composed of a  catalytic subun it (pi 10) and  a  regulatory sub u n it 
(p85). Four isoforms of p i  10 have been identified: alpha, beta, gam m a and  delta,
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and three different genes code for the regulatory subunit: p85alpha, p85beta, 
and p55gamma. The p85alpha gene can be alternatively spliced to produce 
p50alpha and p55alpha. All of the regulatory and catalytic subunits  are 
expressed in the nervous system. The regulatory subun it binds to the catalytic 
subun it and  mediates the interaction with upstream  signaling proteins. Isoform 
diversity seems to modulate the specificity of PI3K-mediated responses through 
differential subcellular localization, variable kinetics of activation and 
recruitm ent of specific receptor signaling pathways.
M echanisms of activation of PI3K
Three m ain strategies of activation have been described. These system s overall 
take advantage of protein-protein interactions to determine translocation of PI3K 
to the plasm a membrane, where PI3K functions by phosphorylating its PI 
su b strate s .
Activation through membrane receptor-tyrosine kinases (RTK)
Extracellular neurotrophic factors in teract with specific RTKs. Upon 
binding, the intracyto plasm atic domain of the RTK undergoes 
phosphorylation of specific Tyr residues. In some cases these residues are 
recognised by the regulatory subun it p85, through interaction with two 
SH2 (src-homology 2) domains. Alternatively, several adaptor proteins 
(She, Grb-2, Gab-1, IRS 1/2) can be recruited to the phosphorylated 
dom ains of the RTK. These adaptors then  recruit PI3K through interaction 
with SH2 domains of the regulatory subunit. In motor neurons growth- 
factor dependent activation of PI3K can also be m ediated by calmodulin, a  
protein involved in calcium hom eostasis (Soler et a l, 1998).
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Activation through non-receptor tyrosine kinases
Some cytoplasmic kinases, such as JAK (Janus Kinases), Syk, Src and 
ZAP70, have been reported to mediate the activation of PI3K, through 
recruitm ent to m em brane associated receptors .
Activation through G-protein coupled receptors (GPCRs) and ionotropic 
receptors
GPCRs have been shown to recruit PI3K to the plasm a m em brane, 
through interaction of the catalytic subun it p i  10 with the beta-gam m a 
subun it of the G proteins. Moreover ionotropic receptors also appear to be 
able to in teract with p85 regulatory subunit, th u s  recruiting PI3K to the 
plasm a m em brane (Rodgers and Theibert, 2002).
Activation of PI3K leads to production of PIPs. These molecules diffuse within the 
lipid bilayer of the plasm a m em brane, th u s  propagating the original extracellular 
signal. From this point of view they are considered “second m essengers”. The 
signal is then transduced  to intracellular targets by PDK-1 and PDK-2 
(phosphoinositide-dependent-kinase-1 and 2). These enzymes, as well as the 
downstream  target proteins, in teract with the m em brane-bound PIPs, th u s  
becoming closely associated. In this way PDK can phosphoiylate and activate the 
downstream  proteins, such  as Akt.
Modulation of the PI3K pathway can also be mediated through the phosphatase  
PTEN, th a t dephosphoiylates PIP2 and  PIP3, or by SHIP, th a t excusively 
dephosphoiylates PIP3. It has been also proposed th a t PDKs can be 
phosphorylated and  inactivated by intracellular enzymes (Toker, 2000; Toker and  
Newton, 2000a).
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As shown in Figure 1.7, among the several targets of PI3K and PDKs:
- Akt/PKB is mainly involved in cellular survival 
PKC plays a  central role for cellular growth
Rho, Rac and Cdc42 are proteins th a t coordinate cytoskeletal 
reorganization
P70S6K is involved in the stabilization of ribosomal complexes, th u s  
influencing synthesis of novel proteins (Rodgers and Theibert, 2002).
Features of Akt
Akt, also term ed PKB or RAC, is a  serine/threonine kinase belonging to the “AGC 
kinase” superfamily. This group of kinases share similarity w ithin their catalytic 
dom ain structu re  and in their m echanism  of activation. Akt was first identified in 
1991 by three groups, independently: one group cloned the cellular homologue of 
the y-akt oncogene from a  transform ing retrovirus (AKT8), and called th is protein 
c-Akt; in two other studies, the authors cloned the cDNA of a  new protein while 
searching for novel members of the protein kinase C (PKC) and  protein kinase A 
(PKA) superfamily as possible participants in signal transduction cascades. 
Accordingly, the novel kinase was called RAC (related to A and C kinases) or PKB 
(protein kinase B) (Bellacosa et al., 1991; Coffer and Woodgett, 1991; Jones et al., 
1991).
In mammals, there are three isoforms of Akt; they share a  high degree of 
aminoacid identity, b u t are expressed in different tissues
A ktl /PKBalpha: predom inant isoform; ubiquitous expression
Akt2/PKBbeta: expressed a t high levels in insulin-responsive tissues
(skeletal m uscles, heart, liver, kidney, adipose) 
Akt3/PKBgamma: highly expressed in the central nervous system  and
testis
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These isoforms are composed of three functionally distinct relevant regions 
(Figure 1.8):
• A PH (Pleckstrin homology) N-terminal domain.
This region is responsible for interaction with m em brane-bound 
phoosphoinositides.
• A catalytic core.
This domain contains the serine/threonine kinase activity of the enzyme. 
Thr308, within this region, is target of phosphorylation, and represents a 
regulatory site.
• A C-terminal region containing a hydrophobic motif (HM).
HM is a regulatory domain involved in interaction with other proteins th a t 
modulate Akt activity. Moreover, HM contains Ser473, target of 
phosphorylation, th a t represents an additional regulatory site.
Figure 1 .8 . Structural features o f  th e  three Akt isoform s.
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Mechanism of activation of Akt
Akt is activated by, and dependent on, m ultisite phosphorylation. In fact Akt 
usually  resides in the cytoplasm in an inactive state. Activation occurs only when 
both the Thr308 and Ser473 sites within Akt are phosphorylated.
Akt is m antained in inactive form in the cytosol, through conformational 
modifications induced by the PH and  HM domains: the PH domain occupies the 
catalytic domain, th u s  preventing Thr308 phosphorylation by PDK-1; HM interacts 
with an  hydrophobic groove in the N-terminal domain of Akt, th u s  stabilizing the 
inactive conformation. Upon receptor binding by extracellular signaling 
molecules, PI3K is recruited to the m em brane and  second m essengers PIP3 and 
PIP2 are produced. The PH domain of Akt can interact specifically with 
phosphates in position D3 and D4 (but not D5) of the inositol ring, when PIP2 
an d /o r PIP3 are produced th u s  the PH domain of Akt recognizes m em brane- 
bound phosphoinosites inducing translocation of the protein from cytosol to the 
plasm a m em brane. The sam e happens for PDK-1, th a t also contains a  PH 
domain in its structure. In this way Akt and PDK-1 are brought into close 
contact on a  lipid-micelle surface. Phosphorylation of Ser473 occurs first although 
the m echanism  leading to phosphorylation of Ser473 is still no t completely 
understood. Some studies have hypothesized th a t interaction of the PH domain 
with m em brane-bound phosphoinositides induces a  conformational change 
allowing autophosphorylation of Ser473 (Toker and Newton, 2000b). It h a s  also 
been reported th a t phosphorylation may be catalysed by other kinases, including 
the integrin-linked kinase (ILK), DNA-dependent protein kinase and  the target of 
Rapamycin complex 2 (TORC2) (Persad et a l, 2001; Feng et a l, 2004; Sarbassov  
et a l, 2005). W hat is clear is th a t Ser473 phosphorylation induces a  
conformational change in the HM domain, th u s  allowing interaction of HM with a  
pocket in PDK-1. This interaction brings PDK-1 into close proximity to Thr308 of 
Akt th u s  enhancing PDK-1 dependent phosphorylation of Thr308. This 
modification causes a  charge-induced change in conformation allowing binding of
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ATP, and  complete activation of Akt (Scheid and Woodgett, 2003). The total 
am ount of negative charges due to the phosphate on Thr308 and the three 
phosphates from the ATP could com pensate the four phosphates of the PIP3 head 
group, and  th u s  trigger the detachm ent of the PH domain, and Akt, from the 
m em brane. In th is stable form, Akt can target substra tes located in the 
cytoplasm and then in the nucleus (Figure 1.9) (Calleja et al., 2009). A PI3K- 
independent activation of Akt has  also been described: PKA agonists can induce 
an increase of intracellular calcium levels, determ ining activation of CaMKK 
(calcium /calm odulin dependent kinase kinase). This enzyme is then  able to 
phosphorylate Akt a t Thr308 in a  PDK-1 independent m anner (Datta et al., 1999; 
Toker, 2000).
FRET analysis has  shown th a t upon stim ulation a  wave of Akt phosphorylation 
s tarts  from the plasm a m em brane, then propagates to the cytoplasm and  finally 
to the nucleus. Moreover, there is a  turnover of Akt activation whereby new 
molecules of inactive Akt translocate to the plasm a m em brane to be activated, 
whereas previously activated molecules detach, and eventually become 
dephosphorylated. This movement of protein continues as long as 3- 
phosphoinositides are being generated (Kunkel et a l, 2005).
Mechanism of deactivation of Akt
Negative m odulation of Akt is achieved through okadaic acid-sensitive 
phosphatases, such  as PP2A. These enzymes de-phosphorylate Ser473 and  Thr308 
th u s  returning Akt to the inactive state. More recently, a  family of okadaic acid- 
insensitive phosphatases, PHLLP, have been found to prom ote de­
phosphorylation of Ser473 (Gao et a l, 2005). An additional m echanism  of 
regulation by phosphorylation of Tyr474 h as also been proposed. It h a s  been 
hypothesized th a t phospho-Tyr474 blocks the action of the putative Ser473-directed 
kinase, or it may prevent HM from packaging into the PIF-pocket, th u s  
increasing its susceptibility to the action of phosphatases (Conus et a l, 2002).
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In addition to dephosphorylation, deactivation of Akt may also be achieved 
through cleavage and in a  cellular model of oxidative-stress-induced apoptosis 
Akt has been shown to be cleaved and inactivated by caspase 3 (Luo e t  a l . , 2 0 0 3 ) .  
In contrast, Heat Shock Proteins seem to play a  central role for the m aintenance 
of Akt activation. Indeed it has been reported th a t Hsp90 and Hsp25 can interact 
with Akt, and stabilize the phosphorylated (activated) form, thus increasing 
duration of the enzymatic activity (M u r a s h o v  e t  a l . , 2 0 0 1 ;  N e w to n , 2 0 0 3 ) .
Figure 1.9. Akt ac tiv a tio n  pathw ay.
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S ch em e o f  A k t a c tiva tio n  p a th w a y :  l . in  its  in a c tive  fo rm  A k t is  in  th e  c y to p la sm ; 2 .u p o n  
PI3K  a ctiva tio n  A k t in te ra c ts  w ith  m e m b ra n e-b o u n d  p h o sp h o in o s it id e s  a n d  tr a n s lo c a te s  to 
th e  p la s m a  m em bran e; 3. p h o sp h o ry la tio n  o f  S er473 w ith in  reg u la to ry  d o m a in  (RD) occurs, 
th en  RD in te ra c ts  w ith  PDK1; 4. PDK1 c a ta ly z e s  p h o sp h o ry la tio n  o f  Thr308 in  A k t c a ta ly tic  
d o m a in  (KD); 5. fu lly  a c tive  A k t d e ta c h e s  fro m  th e  p la s m a  m e m b ra n e  a n d  g o e s  b a c k  to th e  
c y to p la sm  or to th e  n u cleu s to p h o sp h o ry la te  i ts  ta rg e ts , su c h  a s  GSK3J3.
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Downstream targets of Akt
Akt activates num erous proteins involved in metabolism, angiogenesis, cell 
proliferation, growth and survival, as outlined in Figure 1 .10  (M a n n in g  a n d  
C a n tle y ,  2 0 0 7 ) . The substrates usually contain a  conserved R-X-R-X-X-S/T-B 
recognition motif (where X represents any aminoacid and B stands for a  bulky 
hydrophobic residue) ( A le s s i  e t  a l ,  1 9 9 6 a ) .
Figure 1 .10  Cellular functions m ediated by ten  Akt substrates.
S ch em e o f  th e  m a jo r  
p r o c e s s e s  k n o w n  to b e  
re g u la ted  b y  th e  A k t  
p a th w a y .  Ten o f  th e  A k t  
s u b s tr a te s  a re  sh o w n  
(arrow  d e n o te s  activa tion ;  
blocking  a rro w  d e n o te s  
inhibition)
A  num ber of Akt substrates are particularly im portant in regulating nervous 
system physiology, or have been found to be altered in neurodegenerative 
diseases.
Among them:
- GSK3p (Glycogen Synthase Kinase 3) is a  cytosolic enzyme th a t can 
phosphoiylate several proteins, including Glycogen Synthase and Tau, in 
the nervous system. Phosphorylation of Tau has been found to reduce 
binding of the protein to micro tubules. This modification has been 
implicated in formation of toxic protein inclusions in neurones (H o n g  a n d  
L e e , 1 9 9 7 ) . Akt phosphorylates GSK3p a t Ser9, controlling inhibition of the
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kinase, and  th u s  provides protection of the cell against the formation of 
inclusions and prom otes cellular metabolism.
- G lut-4 is a  glucose-transporter highly expressed in in the hypothalam us 
as well as in skeletal m uscle and adipose tissue. It is another substra te  of 
Akt, th a t translocates to the m em brane upon phosphorylation in a  IGF-I 
m ediated m anner. At this level it allows entrance of glucose molecules 
th u s  increasing cellular m etabolism (Komori et a t, 2005).
- P70S6K (p70 ribosomal protein S6 kinase) is another target of Akt 
phosphorylation, and activation of P70S6K increases protein synthesis 
and th u s  is im portant in cell growth and differentiation (Toker, 2000; 
Brunet et a t , 2001).
- C aspase 9 can be phosphorylated, and inhibited, by Akt. This interferes 
with the apoptotic pathw ay downstream  of cytochrome c release (Zhou et 
a t, 2000).
- Akt can selectively phosphorylate BAD a t Ser136. BAD is a  pro-apoptotic 
protein th a t can sequester the pro-survival protein Bcl-xL. Upon 
phosphorylation a t Ser136, BAD enters a  complex with a  chaperone protein 
14-3-3, th u s  releasing Bcl-xL. Bcl-xL is then  free to in teract with the 
m ithochondrial m em brane and  inhibit the release of cytochrome c (Zhou et 
a t , 2000).
- IKK-a is another substrate  of Akt. Phosphorylation of IKKa leads to 
activation of NF-kB transcription factor, th a t is involved in transcrip tion  of 
pro-survival genes.
- In the nucleus Akt can phosphorylate and  activate CREB transcrip tion 
factor, th a t is implicated in transcription of survival genes.
- On the other hand, the forkhead transcription factors, in particu lar the 
FOXOs (forkhead transcription factors, class O), represent transcrip tion  
factors involved in induction of pro-apoptotic and proinflam m atory genes, 
including BIM (Bcl-2-interacting m ediator of cell death) th a t is implicated
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in the release of cytochrome c, or Fas, Fas Ligand, TNFa and its receptors. 
FOXOs are targets of Akt. Their phosphorylation by th is kinase determ ines 
nuclear exclusion and recruitm ent in inhibitory complexes with the 14-3-3 
protein (Brunet etal., 2001).
- ASK1 is a  MAPK3K involved in the activation of p38MAPK and JNK 
pathways. Phosphorylation of ASK1 a t Ser83, catalysed by Akt, inhibits 
ASK1 activity, suggesting th a t there is a  link between the Akt pathway and 
the family of stress-activated kinases (Kim et al., 2001). In fact it has also 
been dem onstrated th a t A ktl can bind to JIP1 (JNK-interactor protein 1) 
in neurons. This interaction prevents binding of JIP1 to JNK, and acts as a  
regulatory gate preventing JNK activation (Kim et al., 2002).
1.5.2 Physiological roles o f Akt pathway
PI3K/Akt pathw ay is a  key m ediator of cell proliferation, survival and  insulin 
responsiveness. Since 2001, the availability of transgenic mice obtained by knock 
out of specific isoforms of Akt has helped to deepen the knowledge about the 
functions of th is kinase in different tissues. Interestingly, although three 
isoforms of Akt are described, in certain tissues loss of function of one of these 
isoforms is not com pensated by the others, so determining relevant dysfunctions. 
A ktl KO mice are small and  have increased spontaneous apoptosis in the 
thym us, and display increased neonatal mortality (about 40%). A ktl has  been 
found to be the predom inant isoform in placenta. Its ablation resu lts in absence 
of spongiotrophoblast cells and loss of vascularization. This negatively affects 
placental development and m aintenance (Chen et al., 2001; Cho et al., 2001). 
Akt2 KO mice display a  more striking phenotype: they develop severe diabetes, 
with hyperglycaemia, hyperinsulinaem ia and glucose intolerance. In fact Akt2 is 
the m ost abundan t isoform in insulin-responsive organs and tissues, such  as 
liver, skeletal m uscles and adipose, and appears to be an isoform specialized in 
regulation of glucose hom eostasis (Yang et al., 2003). In line with the evidence of
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an  involvement of A ktl and Akt2 in growth and development, double knock out 
mice of A k tl/2  show a  more obvious phenotype than  the single knock-outs. They 
display severe growth defects and impaired skin development, skeletal muscle 
atrophy and  abnorm al bone development (Peng et al., 2003). Akt3 deficient mice 
do not exhibit increased perinatal mortality neither apparent growth retardation, 
however they display dram atic reduction of brain size and  weight (25%). 
Interestingly the reduced brain weight is caused by significant reduction of cell 
num ber and  cell size, suggesting th a t Akt3 is critically implicated in postnatal 
development of the brain (Easton et a l, 2005). Accordingly double knock outs for 
A k tl/3  leads to a  drastically more severe phenotype, resulting in embryonic 
lethality (Yang et a l, 2005).
On the other hand, tissue-specific overexpression of Akt in mice h as highlighted 
th a t th is pathw ay is critical for the m odulation of heart growth (Matsui et a l,
2002), for m am m ary gland development during lactation (Schwertfeger et al.,
2003), and for growth of pancreatic islet beta  cells and insulin production (Tuttle 
et a l, 2001). Interestingly, overexpression of Akt in T lymphocytes or prostate 
epithelial cells leads to tumorigenesis (Malstrom et a l, 2001; Majumder et al., 
2003). Actually overexpression or overactivation of Akt h as been docum ented in 
m any solid tum ours and hematological malignancies, such  as prostate  cancer, 
ovarian carcinom as, pancreatic carcinomas, gliomas as well as non-Hodgkin’s 
lymphoma (Table 1.8) (Altomare and Testa, 2005). Several studies have 
highlighted th a t Akt can phosphorylate a  num ber of targets im plicated in 
cell/cycle regulation, including p27, p21, Mdm2 and M ytl, resulting in cell-cycle 
progression and probably contributing to invasiveness of m alignant cells (Brazil 
et a l, 2004). Among the three isoforms, Akt2 has been found m ore frequently 
deregulated in tum ours. This sheds light on the possible involvement of th is 
isoform in mediating PI3K-dependent effects on cellular adhesion, motility, 
invasion and m etastasis formation (Altomare and Testa, 2005). For these reasons
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the Akt pathway has attracted  increasing in terest as a  molecular target for 
cancer therapy.
Table. 1.8 Akt activation in human cancer
Tumor type % Tumors with active AKT
Glioma -5 5
“Thyroid carcinoma 80-100
Breast carcinoma
T f  A A 1 1 1 ¥ -t ** , s .  S'S
20-55
— A'Aantau-ceu rung carcinoma 
Non-small-cell lung carcinoma
 01/ 
30-75
Gastric carcinoma -8 0
Gastrointestinal stromal tumors -3 0
Pancreatic carcinoma 30-70
Bile duct carcinoma -8 5
Ovarian carcinoma 40-70
Endometrial carcinoma >35
Prostate carcinoma 45—55
Renal cel! carcinoma —40
Anaplastic large-cell lymphoma 100
inAcute myeloid leukemia 
Multiple myeloma
IV/f l i  r r n o  r*  t  m n c i A f
— /u 
-9 0
I V i  till L llTchU LIlClI v.» Illd
Malignant melanoma*5
— O  J  .
43-67
(Altomare and Testa, 2005).
1.5 .3  PI3K/Akt pathway in health and disease o f the nervous system
A ktl and Akt3 are the isoforms mainly expressed in the nervous system. Studies 
conducted on anim als in which either or both of these kinases were ablated 
reported th a t Akt is critically involved in neuronal cell survival during 
developmental stages, th u s  influencing norm al growth of the brain. Similarly, 
PI3K, the canonical upstream  activator of Akt, plays a  pivotal role in 
m aintenance of neuronal survival; in fact its expression is already detected 
throughout the nervous system during development stages, and it is increased in 
the adult brain (Rodgers and Theibert, 2002).
In the adult nervous system, the PI3K/Akt pathw ay plays a  crucial role in the 
transduction of survival signals in neurones, and in mediating protection against 
toxic insults. This is particularly evident in some acute neurodegenerative
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disorders, including epilepsy, cerebral ischem ia or peripheral nerve damage. In 
an experimental paradigm  of epilepsy, ra ts  were challenged by microinjection of 
kainic acid in the amygdala. The kainic-induced epileptic insu lt causes neuronal 
death in the hippocam pus. In dying neurons within this brain area a  strong 
activation of pro-apoptotic proteins such  as Bax and BAD has been reported. 
Interestingly, in the cerebral cortex (an area th a t displays resistance to seizure- 
induced neurodegeneration) neuronal cells show strong activation of Akt, and 
increased BAD phosphorylation a t Ser136 (Henshall et a l, 2002). In the case of 
cerebral ischemia, neurodegeneration occurs as a  consequence of reduced 
oxygen supply. Experimentally this is usually  obtained by tem porary or 
perm anent occlusion of an  afferent cerebral artery. Hypoxic insu lts are known to 
be potent inducers of neuronal apoptosis. Often the clinical outcome is 
complicated by propagation of death-inducing signals from the ischemic core to 
the boundary regions (penumbra). Studies on an experimental model of 
perm anent focal ischem ia have reported th a t early after the middle cerebral 
artery occlusion, in the surviving neurons of the penum bra there is a  transien t 
activation of Akt, paralleled by reduced caspase 3 activation. This suggests th a t 
induction of the Akt anti-apoptotic pathw ay is im portant in  susta in ing  
neuroprotection after cerebral ischem ia (Jin et al., 2000; Shibata et a l, 2002). 
Similarly, in transien t ischem ia of the spinal cord in the rabbit, an  activation of 
both cell death and survival pathw ays have been detected. Interestingly, the 
activation of Akt early after reperfusion appears to be one of the factors 
responsible for retarding neuronal death after injury (Sakurai et a l, 2001). On 
the other hand, acute injury of peripheral nerves (such as c rush  or axotomy) 
represents a  common paradigm  of acute damage to the neuronal cells of b rain  
stem  or spinal cord. Axotomy of ra t hypoglossal nerve has highlighted different 
susceptibilities of motor neurons to injury: a t the postnatal stage injury to 
peripheral axons leads to neuronal death, whereas, in contrast, if dam age occurs 
in the adult neurons do not die, b u t ra ther s ta rt a  regenerative process (Ito et a l,
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1996; Namikawa et al., 2000). Also in this case the survival of neurons h a s  been 
associated with concom itant activation of Akt pathway. This is true  also for 
axotomy of the sciatic nerve; in th is case injury determ ines induction of Akt in 
surviving motor neurons of the lum bar spinal cord (Murashov et a t, 2001).
While induction of Akt seems to represent a  physiological response of surviving 
neurons to acute injury, in the case of chronic neurodegenerative diseases, such  
as H untington’s Disease (HD), Alzheimer’s Disease (AD), or Amyotrophic Lateral 
Sclerosis, a  lack of induction of th is pathway is often reported.
HD is characterized by polyQ expansion in huntingtin  protein, which leads to 
aggregation of the m utated  protein in the nucleus and selective apoptosis of 
striatal neurons in the brain (Saudou et a l, 1998). Analysis of Akt in brain 
sam ples from HD patients revealed the presence of both the full-length Akt and 
of a  shorter form predicted to be generated by caspase 3-mediated cleavage of the 
full-length kinase. This suggests th a t compromised Akt pathway m ay accentuate 
the progression of HD. Accordingly, treatm ent with IGF-I, and induction of Akt 
activation, is protective for striatal neurons, and prevents form ation of 
in tranuclear inclusions. Akt-mediated phosphorylation of Ser421 on m utated  
huntingtin  is required for the IGF-I mediated protective effect (Humbert et a l, 
2002). Altered distributions of Akt and PTEN have also been reported in  AD, with 
a  reduction of the levels of activated Akt (Griffin et al., 2005; Steen et al., 2005; 
Lee et a l, 2009). Accordingly, it has  been recently reported th a t intracellu lar 
amyloid-beta can directly interfere with Akt pathw ay activation, by preventing the 
interaction between Akt and PDK-1. The au thors dem onstrated, in vitro, th a t 
amyloid-beta acts upstream  of Akt by inhibiting PDK-1 activity (Lee et a l, 2009). 
Analysis of post mortem sam ples from patients th a t died with ALS showed 
increased activities and protein levels of PI3K in m em brane fractions of spinal 
cord, compared to controls. However the downstream  targets, such  as Akt and  
S6K, were not upregulated in ALS tissues, suggesting th a t there m ay be an 
im pairm ent of th is signal transduction cascade in the disease (Wagey et al.,
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1998). In a  subsequent study, the same group revealed a  reduction of PI3K levels 
and activity, with no modification of Akt, in the spinal cord of pm n mice (a mouse 
model of ALS) (Wagey et a t, 2001). Instead, analysis of hom ogenates from late 
onset SOD1G93A transgenic mice showed reduction of PI3K and  total Akt protein 
levels even a t the presymptomatic stage (Warita et a t, 2001). In a  recent report, 
downregulation of phospho-Akt has also been detected in the spinal cord motor 
neurons of presymptomatic SOD1G93A mice; moreover this has been confirmed 
by im m unohistochem istry in post-m ortem  sam ples obtained from ALS patients 
(Dewil et a t, 2007b). Reduced activation of Akt has been described in m uscles 
from ALS patients, suggesting a  link between inhibition of th is pathw ay and 
progressive atrophy in th is tissue (Leger et a t, 2006). Although there are some 
discrepancies between these studies, overall they highlight th a t an  im pairm ent of 
the PI3K/Akt pathway in motor neurons may be a  common feature in ALS. 
Nevertheless, further studies are needed to better dissect the role played by these 
kinases in the disease process.
1.5 .4  Strategies for targeting PI3K/Akt pathway
Several strategies have been developed to target specific com ponents of the 
PI3K/Akt pathway. Given th a t aberrant activation of one or more Akt isoform has 
been detected in cancer, m ost of the efforts have been spent trying to inhibit th is 
pathway, through small molecule inhibitors, antisense technology or RNAi. On 
the other hand, since increasing evidence reports a  downregulation of the 
pathw ay in neurodegenerative disorders, it h as  been hypothesized th a t induction 
of Akt may be beneficial. In this case growth factors upstream  of PI3K/Akt 
pathw ay have been regarded as potential therapeutic molecules (Sale and Sale, 
2008).
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Small-molecule inhibitors
In recent years, a  num ber of pharmacological inhibitors against Akt have been 
described. However, these molecules often present limited specificity over the 
three Akt isoforms, or side effects due to interaction with unrelated  kinases, or 
poor bioavailability. Despite these drawbacks, great efforts have been spen t to 
develop new molecules, since targeting of the PI3K/Akt pathway is considered a  
good therapeutic strategy for cancer.
Inhibitors targeting the ATP-binding site
These compounds include H-89 and analogues, NL-71-01 and  indazole- 
pyridine-based com pounds (Reuveni et al., 2002; Luo et a t, 2005). They 
show m oderate to high selectively for Akt over PKA, which h as  50% identity 
in the kinase domain and  70% identity in the 25-residue ATP-binding site 
(Kumar and Madison, 2005). However, since the ATP-binding site shows 9 6 - 
100% identity am ongst Akt isoforms, developing isoform-specific inhibitors 
acting a t the ATP binding site is difficult.
Allosteric inhibitors
These molecules represent a  new class of inhibitor recently described. They 
in teract with multiple dom ains on Akt, and do not show inhibitory effects 
on a  range of unrelated  kinases. Moreover, some molecules display 
specificity for A ktl, or Akt2, or both (Barnett et a t, 2005; DeFeo-Jones et a t, 
2005). They are PH domain dependent and are also postulated to bind to 
the linker region th a t connects the PH domain to the kinase domain, 
consistent with the sequence diversity of th is region. The m ain lim itation of 
these compounds is their poor pharm okinetic profile and low solubility, th a t 
have prevented their evaluation in anim al models (Kumar and  Madison, 
2005).
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Chemically modified peptide substrate mimetic inhibitors
These com pounds target the substrate-binding site. This strategy avoids the 
potential specificity problems of targeting the kinase active site b u t does not 
provide specificity over the three isoforms of Akt (Litman et a l, 2007).
Phosphatidylinositol ether lipid analogue (PIA) inhibitors
These molecules inhibit Akt activation by targeting the PH domain (Castillo 
et a l, 2004; Gills and Dennis, 2004). However these com pounds show poor 
solubility, only m oderate potency, aggregation and weak pharm acokinetics. 
Moreover, as PH dom ains are p resent in m any proteins there is also 
concern about the specificity of PIAs.
A num ber of other com pounds have been reported to inhibit the activation of Akt, 
like curcum in (Chaudhary and Hruska, 2003), deguelin (Chun et a l, 2003), indo- 
3-carbinol (Chinni and Sarkar, 2002) and CMEP (Zhang et a l, 2007). However the 
molecular m echanism  of action of these molecules still rem ains unclear.
Knock-down bu genetic avvroaches
Dom inant negative m utan ts  of Akt have been generated. These construct have 
Ser473 and  Thr308 substitu ted  by Ala, an un-charged aminoacid; as an  alternative 
a  m utation in K179->D generates a  kinase-dead m u tan t (Andjelkovic et a l, 1997). 
A num ber of antisense oligonucleotides (typically 18mers) have been developed 
th a t enable the specific and potent knock-down of endogenous Akt isoforms 
individually or in various combinations (Sale et a l, 2006). Knock-down of the 
targeted isoform is routinely higher th an  95%, m aking these extremely powerful 
tools. Akt-targeted siRNAs have also been validated, with quite good resu lts, in  a  
num ber of studies (Jiang et al., 2003; Katome et a l, 2003).
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Strategies aimed a t activating the A kt pathw ay
Akt is activated by several growth factors, th a t are involved in induction of 
proliferation or cell survival. Administration of these com pounds has been 
regarded as a  possible therapeutic strategy for a  num ber of neurodegenerative 
diseases, with some encouraging results. As an alternative approach, genetic 
m anipulation h as been used  to obtain activation of the pathw ay by 
overexpression of constitutively activated m u tan ts  of Akt. This approach has 
been widely u sed  experimentally, to dissect the functions of the Akt pathway, 
however difficulties in m anipulating these constructs have limited their 
development in therapy.
Growth factors
A num ber of growth factors are able to activate PI3K/Akt pathway, 
including IGF-I, GDNF, CNTF, VEGF, EGF, BDNF and FGF2 (Brunet et al., 
2001; Rodgers and Theibert, 2002; Johnson-Farley et a l, 2007). Some of 
these molecules have been successfully used  in experimental models of 
ALS. CNTF intrathecal delivery through encapsulated engineered xenogenic 
cell lines was protective in animal models of ALS, and went into early stage 
of clinical trials (Aebischer et al., 1996b; Aebischer et al., 1996a). 
In tram uscular delivery of an Adeno-Associated Viral vector expressing 
GDNF to G93A mouse model of ALS delayed m otom euron loss, preserving 
neurom uscular junctions and reducing m uscle atrophy (Wang et al., 2002). 
Delivery of IGF-I, using the same viral vector-mediated approach, w as 
protective in the G93A transgenic mouse. The authors reported an  increase 
of activated Akt in the spinal cord of anim als th a t received IGF-I, suggesting 
th a t induction of this pathway may be the key element for delay of the 
neurodegeneration (Kaspar et al., 2003). These resu lts were confirmed by 
another group th a t used  direct intrathecal delivery of IGF-I in  the sam e 
mouse model. An induction of both Akt and  ERK activation were reported in
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th is case (Nagano et al.} 2005). Another growth factor, VEGF, displayed 
protective effects against m u tan t SOD 1-induced neuronal death in vitro, by 
inducing activation of Akt (Li et a l, 2003). Intracerebroventricular treatm ent 
of SOD1G93A ra ts  with VEGF improved motor perform ances and prolonged 
the survival. The au thors also provided evidence th a t VEGF treatm ent 
resulted in an  increase of activated Akt in the spinal cords of the anim als 
(Storkebaum et a l, 2005; Dewil et a t, 2007b).
One of the main drawbacks of the use of growth factors is th a t usually  
these molecules are effective on several cell types, th u s  exerting pleiotropic 
effects in the organism. This has led to the failure of all the clinical trials 
th a t used growth factors in ALS, due to strong collateral effects.
Constitutively activated mutants o f  A k t
Studies conducted to investigate the molecular features of Akt protein have 
led to the generation of m u tan ts  th a t display constitutive activity in the 
cells. One approach is fusion of a  m yristylated/palm itylated sequence a t the 
N-terminal of Akt. This modification induces constitutive translocation of 
the kinase to the m em brane, and  subsequent continuous activation, in a  
PH and PI3K independent m anner. As an  alternative, Ser473 and Thr308 of 
Akt are substitu ted  by Asp, th a t provides the negative charge mimicking 
phosphorylation. This m u tan t displays constitutive activity independently of 
m em brane translocation (Alessi e t a l, 1996b; Andjelkovic et a l, 1997; 
Brodbeck et a l, 1999). These m utan ts  have been shown to be functional in 
several in vitro culture systems, and to mediate cell survival against m u tan t 
SOD1 toxicity in cell lines (Kanekura et a l, 2005). Although these 
constructs have been widely used  to dissect m olecular m echanism s related 
to Akt pathways in vitro, they have raised great concern for u se  in vivo, 
since constitutive activation of Akt pathw ay is implicated in oncogenicity 
(Aoki et a l, 1998; Mende et a l, 2001).
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1.6 USE OF LENT1VIRAL VECTORS FOR TREATMENT OF 
NEURODEGENERATIVE DISEASES
1.6.1. From Lentivirus to a Lentiviral Vector 
The genus “ lentiviridae”
Genus “Lentiviridae” belongs to the Retroviridae family, a  large family of 
enveloped RNA viruses. The virions are 80-100  nm  in diameter, and their outer 
lipid envelope incorporates and  displays the viral glycoproteins. The viral genome 
is a  linear, single-stranded, non-segm ented RNA; it is 7 -12  kb in size with 
positive polarity. The hallm ark of the family is its replicative strategy whose 
essential steps are reverse transcription of the virion RNA into linear double­
stranded DNA and  its subsequent integration into the genome of the host cell. 
Retroviruses are subdivided into seven groups defined by evolutionary 
relatedness, each with the taxonomic rank  of genus (Table 1.9). Most of the 
m em bers of this family are known for their oncogenic potential. In contrast, 
Lentiviruses generally cause a  slowly progressive disease (lenti = slow) by killing 
or inducing loss of function of specific cells and tissues. A representative example 
of this family is hum an immunodeficiency virus (HIV), the etiological agent of 
acquired immunodeficiency syndrome (AIDS) (Coffin, 1997).
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Table 1.9. Classification of Retroviruses
Genus Example Virion morphology Genome
1. Avian sarcoma and 
leukosis viruses
Rous sarcoma virus central, spherical core 
"C particles"
simple
2. Mammalian B-type 
viruses
mouse mammary tumor 
virus
eccentric, spherical core 
"B particles"
simple
3. Murine leukemia- 
related viruses
Moloney murine 
leukemia virus
central, spherical core 
"C particles"
simple
4. Human T-cell 
leukemia-bovine 
leukemia viruses
human T-cell leukemia 
virus
central, spherical core complex
5. D-type viruses Mason-Pfizer monkey 
virus
cylindrical core 
"D particles"
simple
6. Lentiviruses human 
immunodeficiency virus
cone-shaped core complex
7. Spumaviruses human foamy virus central, spherical core complex
The genome of all retroviruses contains long term inal repeats a t the 5' and  3' 
ends (5'LTR and  3'LTR), a  packaging signal located 3' of the 5'LTR (psi) and  three 
major dom ains encoding the virion proteins: gag, which directs the synthesis of 
the virion proteins forming the matrix, the capsid, and the nucleoprotein
structures; pol, which codes the reverse transcrip tase and integrase enzymes;
env, with information for the surface and transm em brane proteins th a t
constitute the viral envelope. An additional coding domain p resen t in all
retroviruses is pro, which encodes the virion pro tease (Figure 1.11). After 
integration, these s tructu ra l genes are expressed through a  strong prom oter 
located in the 5'LTR. Retroviruses are divided into two m ain categories (simple 
and complex), according to the organization of their genomes (Coffin, 1992; 
Blesch, 2004). Simple retroviruses usually  carry only the elem entary genomic 
dom ains described above, w hereas complex retroviruses (like lentiviruses) code 
for additional regulatory non-virion proteins derived from multiply spliced 
m essages.
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Figure 1.11
Schem atic  cross sec tio n  through a retroviral particle.
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The retroviral replication cycle follows the general pattern of enveloped viral 
infections, with some specific features (C offin , 1 9 9 6 ) . Retroviruses enter the host 
cell through the attachm ent of their surface glycoproteins to specific plasm a 
membrane receptors, which leads to fusion of virus and cell m em branes. The 
interaction of virus and cell surfaces is highly specific; it constitutes the main 
determ inant of viral host range, defining susceptible animal species and target 
cells within the host. After penetration into the cell, the RNA genome, still 
contained in a core complex of non-glycosylated proteins and associated with the 
virion reverse transcriptase, is retro-transcribed. Reverse transcription takes 
place in the cytoplasm; and it is the fundam ental step th a t leads to generation of 
a double stranded DNA viral genome, ready for random  integration into the 
genome of host cell.
The steps of the retrotranscription process can be summarized as follows (Figure 
1 . 12 ):
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1. M inus-strand DNA synthesis is initiated using the 3'-end of a  partially 
unw ound transfer RNA which is annealed to the prim er-binding site (PBS) 
in genomic RNA, as a  primer. M inus-strand DNA synthesis proceeds until 
the 5'-end of genomic RNA is reached (R-U5), generating a  DNA 
interm ediate of discrete length term ed m inus-strand  strong-stop DNA 
(sssDNA).
2. The RNA:sssDNA duplex formed during th is first step synthesis is 
degraded by RNase H, th u s  leaving the sssDNA free to anneal to the 3'-end 
of a  viral genomic RNA. This transfer is m ediated by identical sequences 
known as the repeated (R) sequences, which are present a t the 5'- and 3'- 
ends of the RNA genome. The 3 -en d  of sssDNA was copied from the R 
sequences a t the 5'-end of the viral genome and therefore contains 
sequences complementary to R. The annealing reaction appears to be 
facilitated by the nucleocapsid protein.
3. Once the sssDNA has been transferred to the 3'-R segm ent on viral RNA, 
m inus-strand  DNA synthesis resum es, accompanied by RNase H digestion 
of the template strand. This degradation is not complete, however, because 
the RNA genome contains a  short polypurine trac t (PPT) th a t is relatively 
resistan t to RNase H degradation.
4. A defined RNA segment derived from the PPT prim es p lus-strand  DNA 
synthesis. P lus-strand synthesis is halted after a  portion of the prim er 
tRNA is reverse-transcribed, yielding a  DNA called p lus-strand  strong-stop 
DNA (+sssDNA).
5. RNase H removes the prim er tRNA, exposing sequences in +sssDNA th a t 
are complementary to sequences a t or near the 3'-end of p lus-strand  DNA.
6. Annealing of the complementary PBS segm ents in +sssDNA and  m inus- 
strand  DNA constitutes the second strand  transfer.
7. Plus- and m inus-strand  syntheses are then  completed, with the p lus and 
m inus strands of DNA each serving as a  tem plate for the other strand .
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8. At the end of the process a  double stranded DNA is generated. It
encompasses the entire viral genome, plus two Long Terminal Repeats
(LTR) a t both extremities, each composed of the regions U5-R-U3.
Figure 1.12  
Schem e o f  reverse transcription  process
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After retro-transcription, the viral DNA is translocated into the nucleus where the 
linear copy of the retroviral genome is inserted into chromosomal DNA with the 
aid of the virion integrase, thus generating a  stable provirus. With integration, 
the proviral genome achieves the s ta tu s  of a  cellular gene: it is expressed through 
RNA polymerase II and is replicated by cellular en2ym es together with 
chromosomal DNA. Viral m essages are translated  on cellular ribosomes. The 
translation products, together with progeny RNA, are assem bled a t the cell 
periphery into viral particles th a t are released from the cell by budding of the 
p lasm a m em brane. Budding of viruses is followed by proteolytic cleavage of virion 
polyproteins by a  viral protease and by cellular proteases.
Lentivirus: genom e organization and steps o f the replication cycle
The genome organization and  replication cycle of HIV-1 will be described in this 
section, as HIV-1 is the m ost extensively studied lentivirus, and it represents the 
prototype for generation of lentiviral vectors.
HIV-1 is a  complex retrovirus whose genome comprises nine genes: Gag, Pol, 
Env, th a t represent the conventional three open reading fram es of all 
retroviruses; Tat, Rev, Vif, Vpr, Vpu, and Nef th a t are generated by alternative 
splicing of the original genome RNA. These accessory genes are u sed  by the virus 
to control its own gene expression, allowing tem poral separation into early and 
late phases, and to m anipulate the host cell for virus entry, for integration of the 
genetic m aterial into the cell genome, and for virus production.
The HIV-1 genome, like alm ost all retroviruses, contains a  single RNA polymerase 
Independent prom oter in the 5'LTR. It drives transcription of an  initial genome- 
length RNA th a t also acts as an  mRNA for translation of Gag and Pol genes. In 
the case of HIV-1, this initial transcrip t can also be processed into fully spliced 
transcrip ts encoding Tat and Rev regulatory proteins, and  the auxiliary protein 
Nef. Alternatively th is transcrip t can be processed into partially spliced mRNAs
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encoding the other auxiliary proteins Vif, Vpu and  Vpr (Cullen, 2009) (Figure 
1.13).
The Tat protein regulates the prom oter activity of the 5'LTR and is necessary  for 
the transcription from the 5'LTR. It recognises a  50bp transactivation response 
element (TAR) located immediately 3' to the transcription s ta rt site of viral 
genome. Tat first interacts with a  cellular factor called cyclin T l, which, along 
with the kinase cdk9, constitutes the positive transcription elongation factor b 
(P-TEFb). The complex of Tat and  P-TEPb binds the HIV TAR, th u s  increasing the 
stability of RNA-polymerase II. This allows the transcription of the entire viral 
genome (Kao et al., 1987; Barboric and Peterlin, 2005).
The HIV replication cycle requires th a t the single initial transcrip t is exported out 
of the nucleus in several different spliced forms, b u t eukaryotic cells do not 
normally perm it the nuclear export of intron-containing mRNAs. The strategy 
used  by the virus to circum vent the risk  of nuclear retention of no t fully spliced 
RNAs resides in the features of the viral protein Rev. Rev is transla ted  from a 
fully spliced mRNA th a t is constitutively exported from the nucleus. Once 
synthesized, it enters the nucleus and binds to the rev responsive elem ent (RRE) 
within the viral RNA. Rev then  in teracts with cellular proteins involved in 
nucleocytoplasmic transport, th u s  allowing the export of unspliced RNA out of 
the nucleus (Cullen, 2009).
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The overall life cycle of HIV-1 can be summarized as follows (Figure 1.14):
1. Virus attaches to host receptor CD4 through the SU glycoprotein (gpl20), 
with subsequent interaction with a  chemokine coreceptor. TM glycoprotein 
(gp41) mediates fusion with cell membrane.
2. The viral particle is then internalized through the cellular endosomal 
compartment; this process is followed by partial uncoating of the 
nucleocapsid.
3. Once in the cytoplasm, the ssRNA(+) genome is copied into a  linear dsDNA 
molecule by the viral reverse transcriptase.
4. Subsequently the viral dsDNA is transferred into the nucleus, where it is 
covalently and randomly integrated into the cell’s genome by the integrase 
(provirus). The provirus can stay in this form throughout the life of the cell
5. During productive infection the provirus is transcribed by Pol II, thus 
producing viral spliced and unspliced RNAs.
6. Translation of spliced viral RNAs produces tat, rev, and nef proteins.
7. Rev mediates nuclear export of the uncompletely spliced RNAs.
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8. Translation of -unspliced viral RNAs produces Env, Gag and Gag-Pol 
polyproteins.
9. Virions are then assem bled a t the host cellular m em brane, followed by 
packaging of the viral RNA genome.
10. Budding through the plasm a mem brane and release of the virions.
11. Proteolytic processing of the precursors polyproteins by viral protease and 
m aturation of the virions.
Figure 1.14 
Schem e of th e  life cycle o f HIV-1
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Generation o f a lentiviral vector
Lentiviral vectors (LVs) are recom binant lentiviruses produced in vitro; they 
represent valuable tools for adm inistration of genes of in terest to specific cellular 
targets.
Two m ajor points need to be considered when generating a  viral vector starting 
from a  vital virus: 1. the viral vector should retain  the infection properties of the 
virus it derives from; 2. the viral vector should be deprived of the information 
necessary to produce a  replication-com petent retrovirus, for safety 
considerations.
The strategy for generation of viral vectors consists of preparation of a  transfer 
vector plasm id derived from the original viral genome, after deletions of the 
majority of gag coding region, and of the complete coding regions for pol and env 
genes. In th is way the viral genome is reduced to a  backbone containing the 5' 
and 3' LTR, the packaging signal (psi) and  a  small pa rt of the gag coding region 
th a t enhances the packaging of viral RNA (psi+). Transgenes of in terest are 
cloned inside this backbone to allow insertion into viral particles, with the only 
restriction of the lentiviral genome maximal length (not higher th an  9 kilobases). 
Information needed for packaging of viral particles are provided in trans, 
generally on different plasm ids, to prevent the risk  of wild-type virus production 
through recombination (Blesch, 2004). In th is way the new-formed viral particles 
will contain the structu ra l proteins needed to allow infection of host cells, b u t the 
information needed for replication in host cells will no t be present.
The first generation of lentiviral vectors was initially produced by tran sien t 
trasfection of three different plasm ids in producer cell lines: one construct 
contained the wild type HIV genome deprived of the packaging signal (psi) 
sequence and env gene, and with 5'LTR replaced by an  heterologous prom oter 
and  a  polyadenylation signal instead of 3'LTR; an  helper plasm id provided 
envelope information, and a  th ird plasm id contained an expression cassette  for 
the transgene of interest, 5'- and 3'-LTR and  psi. There have been several
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technological improvements since then, with the aim of increasing the biosafety 
of the system: vpr, vpu, nef and  vif have been deleted in second generation 
lentiviral vectors, as these auxiliary genes are crucial for HIV virulence b u t do not 
influence in vitro production (Kim et al., 1998); in third generation vectors the  U3 
region in the 5'LTR has been replaced by a  heterologous enhancer. In th is way 
the activity of 5'LTR is independent of the ta t gene (Dull et al., 1998). Moreover a  
deletion h as been introduced into the U3 region of the 3'LTR resulting in a  self- 
inactivating (SIN) vector (Miyoshi et a l, 1998; Zufferey et al., 1998). In fact, 
removal of the enhancer in U3 leads to a  deleted U3 region in 5'LTR after reverse 
transcription, thereby eliminating the potential influences of LTR on 
neighbouring genes. However, to allow expression of the transgene of interest, an 
heterologous promoter needs to be added in the transfer vector. To fu rther 
diminish the likelihood of recombination, the rev gene has been cloned into a  
separate expression plasm id (Dull et a l, 1998). Moreover, to increase infectivity of 
lentiviral vectors, a  central polypurine trac t (cPPT) is included in the transfer 
vector (Follenzi et a l, 2000); to enhance transgene expression in infected cells, 
the post-transcriptional response elem ent of the Woodchuck hepatitis virus 
(WPRE) is cloned downstream  of the gene of in terest (Donello et a l, 1998).
Figure 1.15  
Diagram o f wild type HIV-1 and plasm ids 
for production o f recom binant LVs
vif
poi
^  rev 
} tat
nef
3' LTR
B
RSV R U5
EZDfrC*
gag
mm Expression cassette m i
RRE cPPT Promoter ntron eGFP WPRE
HUM t..it........ iii^SKm ■i wmmmmmamt►CZIZZIZZ! <RU5\ m
RSV rev poiyA
adapted from Blesch, 2004 , 33:164-172
A. D iagram  o f  th e  g en o m e o f  w ild  ty p e  HIV-1. B. S ch em e o f  a  th ird  g en era tio n  len tiv ira l 
tra n s fe r  vector: en h a n c er  in 5'LTR h a s  b ee n  s u b s ti tu te d  b y  an  h etero logou s p ro m o te r  fro m  
R ou s S arcom a  Virus; U3 region  in 3'LTR h a s  b e e n  d e le te d , to g e n e ra te  a  SIN vector; cPPT  
a n d  WPRE h a v e  b e e n  a d d e d  to in c re a se  viral in fe c tiv ity  a n d  tra n sg e n e  ex p ress io n . C. 
A d ju v a n t p la s m id s  carryin g  in form ation  n e e d e d  f o r  p a ck a g in g .
1.6 .2  Features o f lentiviral vectors
The main feature of lentiviral vectors is that, in contrast with vectors derived 
from other retroviruses, they can easily transduce slowly and non-dividing cells 
(such as neurons). Moreover, LVs have an highly manipulable genome with a 
quite high size of gene-cariying capacity (7-8Kb), and show very low levels of pro- 
inflammatoiy activity, a t variance with other virus-derived vectors like 
adenoviruses, known to be highly immunogenic in hum ans.
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Recent studies have also dem onstrated that, due to the fact th a t the virus 
integrates into the host genome, LVs can m aintain long-lasting expression in the 
brain for several m onths (Bosch et a l, 2000; Deglon et a l, 2000; Kordower et a l, 
2000). For these reasons LVs are considered attractive for gene transfer to the 
central nervous system (CNS) and hold great potential as a  therapeutic gene 
delivery strategy for neurological disorders.
However, due to the characteristics of native lentiviruses, the u se  of LVs for gene 
therapy presents some drawbacks:
1. Although random  integration of vector DNA into the host cell genome 
allows long lasting gene expression, th is process is a t high risk  of deregulating 
neighbouring genes within the genome. Several modifications have been 
introduced into the original viral genome (as described above), however the site of 
integration still cannot be controlled.
2. Most of the studies are based on lentiviral vectors derived from HIV-1, th a t
is a  hum an pathogen. This poses great concern for the risk  of recom bination with 
wild type lentivirus. Fortunately, over years, sequence analysis tools have led to 
the generation of vectors containing very short homology between transfer vector 
sequence and  adjuvant genes from the wild-type virus. Moreover, there is 
accum ulating evidence of the possibility of generating lentiviral vectors starting  
from non-hum an pathogen viruses, like Simian Immunodeficiency Virus (SIV) 
(Mangeot et a l, 2000; Schnell et a l, 2000) or non-prim ate lentiviruses, like 
Equine Infectious Anaemia Virus (EIAV) (Mitrophanous et a l, 1999; Ikeda et a l, 
2002), Feline Immunodeficiency Virus (FIV) (Curran et a l, 2000; Brooks et a l, 
2002) , or Bovine Immunodeficiency Virus (BIV) (Takahashi et a l, 2002).
3. Use of lentiviral vectors in vivo requires high titre preparations. Although 
great technological improvements have lead to the generation of titres in the 
range 109-1010 Transfection Unit/mL, vectors based on other viruses (like 
Adenovirus or Adeno-Associated-Virus) appear to be best suited, from th is  point 
of view (Table 1.10).
-123-
Table 1.10.
Properties o f Viruses Used to Derive Gene Transfer Vectors
Virus Genome
Insert
capacity
(kb)
Specific
integration
Long-term
maintenance
RNA
intermediate Titrea
Retroviruses 8-12kbpssRNA 7 Y Y Y 106-107
Adenovirus 36kbpdsDNA 8 N N N
1011-1012
Adeno-ass. virus 4.7kbssDNA 4.5 Y Y N 106-108
Herpes 
simplex virus
150kbp
dsDNA 25 N Y N
109-1010
“Vector titre is given in transducing units/m l assayed on cultured cell lines. The titer given is for 
virus in medium harvested directly from packaging cells.
1.6.3 Targeting the Central Nervous System  (CNS) is problematic
Access of drugs to CNS has always been a  great challenge in pharmacology, due 
the presence of the blood-brain-barrier (BBB), a  highly specialized struc tu re  th a t 
regulates the trafficking of molecules between blood and CNS parenchym a. Brain 
endothelial cells differ from endothelial cells in capillaries of other organs in two 
im portant ways. First, continuous tight junctions are p resent between the 
endothelial cells, which prevent transcapillaiy  movement of polar molecules 
varying in size from proteins to ions. Second, there are no detectable 
transendothelial pathways. Thus, there is an  absence of transcellu lar channels 
and fenestrations as well as a  paucity of plasm alem m al and  intracellular vesicles. 
As a  result of these special anatom ical features, the endothelial cells in brain  
provide a  continuous cellular barrier between the blood and the interstitial fluid 
(Siegel, 1999). This m eans th a t the CNS is not permeable to substances w ith low 
lipid solubility, thus high polar molecules th a t are essential for CNS survival, like 
glucose, amino acids, or vitamins, can pass the BBB only th rough receptor- 
mediated or carrier-m ediated active transport.
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For this reason, for a  drug to gain access to the brain the molecule m ust possess 
high lipid-solubility (like alm ost all psychoactive drugs), or h as to be able to 
in teract with specific carriers or receptors on the surface of capillaries. A way to 
overcome the BBB may be direct adm inistration in the CSF, through intrathecal 
injection into brain ventricles or in the subarachnoid space a t lum bar level. 
Although th is root of adm inistration is sometimes used  in the clinic, it represents 
an  invasive technique th a t may be problematic when designing a  treatm ent for 
progressive neurodegenerative disorders, like Alzheimer Disease, Parkinson 
Disease or ALS.
The use of viral vector-mediated approaches for treatm ent of neuronal disorders 
linked to genetic defects h as gained great interest, because theoretically a  single 
adm inistration in the brain may determine longlasting expression of the 
transgene, ruling out the necessity for frequent adm inistrations.
Alhough several au thors have dem onstrated th a t rLVs can transduce several cell- 
types within the CNS in vivo in rodents, including neurons, oligodendrocytes, 
astrocytes and adult neuronal stem  cells (Blomer et a l, 1997; Jakobsson et a l, 
2003; Consiglio et a l, 2004), the CNS still poses some particular challenges to 
gene therapy approaches. As already mentioned the BBB precludes the access of 
systemic molecules as large as a  viral vector and the strong interconnection 
between different cell types in the nervous system  could induce de-targeting of 
LVs, leading to infection of cell types other than  those desired.
Interestingly, although there have been a  num ber of studies on LVs delivery in 
the brain (Naldini et a l, 1996a; Baekelandt et a l, 2002; Watson et a l, 2002; 
Jakobsson et a l, 2003), there is still a  lack of information on experim ental 
applications in the lum bar spinal cord. Enhancing knowledge in th is a rea  will be 
relevant for designing gene therapy approaches for motor neuron diseases, like 
Amyotrophic Lateral Sclerosis.
Motor neurons of spinal cord differ from other cell types in the CNS, as their cell 
body is inside spinal cord parenchym a, while axons project out, th rough the
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peripheral nerves, to innervate m uscles. Interestingly, some viruses, like Rabies 
Virus and Herpes Simplex Virus, take advantage of this feature to gain access to 
the nervous system: these viruses enter the nerve cell ending a t the m uscular 
junction or a t skin level, respectively; then  following entiy  into the axon, they can 
be retrogradely transported  along m icrotubules to the neuronal cell body, w ithin 
the CNS parenchym a (Tsiang, 1979; Gillet et a t, 1986; Whitely, 1996; Palmer et 
a l, 2000). For these reasons several strategies have been developed to increase 
the efficiency and specificity of LVs in targeting CNS cells.
1.6 .4  Strategies for broadening in fectiv ity  and increasing specificity .
Pseudotyping
One m echanism  for expanding the cellular tropism  of enveloped viruses is 
through the formation of phenotypically mixed particles (pseudotypes). This is a  
na tu ra l process th a t commonly occurs during viral assem bly in cells infected 
with two or more enveloped viruses (Zavada, 1982).
The first study for pseudotyping of HIV-1 vector particles dates back to 1990, 
with the work of Page and colleagues (Page et a l, 1990). These au thors  
dem onstrated th a t substitu ting native glycoproteins (GP) of HIV-1 with 
glycoproteins of Murine Leukemia Virus (MLV) led to production of recom binant 
viral particles th a t had  lost tropism  of wild-type HIV-1 and acquired th a t of MLV. 
Since then, several researchers have studied various com binations of viral 
pseudotypes (Table 1.11). One of the best known and m ost widely u sed  is VSV- 
G. This glycoprotein derives from Vescicular Stom atitis Virus (a negative s trand  
ssRNA virus, genus Vesciculovims, family Rhabdoviridae). This pseudo type 
in teracts with an  unidentified ubiquitous cellular receptor, and  u ses  
phosphatidylserine in a  postbinding step required for virus entry. This gives the 
vector a  broad host-cell range, including infection of both neurons and  glial cells
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after injection into brain parenchym a (Baekelandt et al., 2002). Moreover, VSV-G 
confers high vector particle stability, allowing concentration by 
ultracentrifugation. The m ost im portant technical drawback of VSV-G is th a t its 
constitutive expression is toxic for cells, th u s  raising problems in establishing 
packaging cell lines for high throughput production of lentiviral vectors. 
Moreover VSV-G pseudotypes are inactivated by hum an  serum  complement. 
Despite these problems, VSV-G-psedotyped lentiviral vectors have recently 
entered clinical application (Manilla et al., 2005).
Of great in terest for potential gene therapy approaches for neurodegenerative 
diseases are LVs pseudotyped with Rabies virus envelope. This virus belongs to 
the Lyssavirus genus, Rhabdoviridae family. Rabies glycoproteins are known to 
in teract with neuronal cell adhesion molecule (NCAM1), p75 neurotrophin 
receptor (p75NTR) and nicotinic acetylcholine receptor (nAChR) (Lafon, 2005). 
These receptors are present on the m em brane of axonal term inals a t the 
neurom uscular junctions; in fact peripheral m uscles represent the m ain way 
through which the virus gains entrance to the CNS.
Of potential clinical im portance for treatm ent of m otor neuron diseases are EIAV- 
based vectors pseudotyped with Rabies glycoprotein. They have dem onstrated to 
be able to target spinal cord motor neurons after delivery to peripheral m uscle, in 
vivo, in rodent models of ALS (Azzouz et a l, 2004a).
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Table 1.11. Tropism m odification o f lentiviral vectors by pseudotyping
Family Genus GP Tropism Reference
Rhabdoviridae
Vesciculovirus VSVG Pantropic (Naldird et al, 1996b)
Lyssavirus RABIES
CNS 
(from peripheral 
muscles)
(Azzouz et 
al, 2004b; 
A zzouz et al, 
2004a)
Arenaviridae Arenavirus LCMV Pancreatic islet cells
(Kobinger et 
al, 2004)
Filoviridae Filovirus EBOLA
Airway
epithelium
Muscle /  
myocytes
(Kobinger et 
al, 2001)
(MacKenzie 
et a l, 2005)
Togaviridae Alphavirus ROSS RIVER
Liver 
(hepatocytes + 
Kupffer cells)
(Kanq et al, 
2002)
Baculoviridae Nucleopolyhedrovirus GP64 Pantropic (Kumar et al, 2003)
Tissue-specific promoters
In parallel with studies aimed a t finding pseudotypes with increased specificity, 
m ost efforts to control vector expression have used  transcriptional targeting by 
tissue-specific prom oters. Usually lentiviral vectors carrying an  expression 
cassette use strong ubiquitous promoters, like CMV. This is a  700bp sequence 
containing the cytomegalovirus immediate early promoter and  enhancer. 
Lentiviral vectors containing the CMV prom oter have been dem onstrated to 
susta in  long-term expression in ra t brain  (Naldini et a l, 1996a). However some 
studies showed th a t CMV is susceptible to transcriptional inactivation over time 
by m ethylation of cytosines in CpG dinucleotides (Prosch et al., 1996). For these 
reasons other prom oters have recently become more widely used  in lentiviral 
vectors: E F la  (1.2Kb long) is the prom oter of Elongation Factor alpha, an  
ubiquitously expressed housekeeping gene th a t plays a  pivotal role in protein 
synthesis; hPGK (500bp) is the promoter of hum an  Phosphoglycerate Kinase, an  
enzyme involved in glycolysis. It has been reported th a t E F la  and  hPGK can 
susta in  strong and stable expression of transgene in several cell types such  as 
stem  cells (Hong et a l, 2007), glial cells and neurons (Deglon et al., 2000;
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Jakobsson et a l, 2003). However, if the aim is to target a  specific cell population, 
and avoid ectopic expression, the use of a  cell-specific prom oter may represen t a  
better approach.
The ra t neuron-specific enolase (rNSE) prom oter (1.5Kb) is one of the m ost well 
characterized neuronal prom oters. Delivery of lentiviral vectors carrying rNSE 
into ra t brain resulted in 98% transduction of neurons, with absence of ectopic 
expression in glial cells. In contrast, the Glial Acidic Fibrillary Protein (GFAP) 
prom oter (2.1Kb), was shown to direct expression specifically to astrocytes 
(Jakobsson et al., 2003).
However, several tissue-specific prom oters comprise quite long sequences th a t 
span the 5' upstream  region and sometimes some intronic sequences of the 
downstream  gene. This poses great lim itations for cloning into a  lentiviral vector. 
As an example, the prom oter of Neurofilament Heavy chain (NF-H) has been u sed  
with success for generation of transgenic anim als with neuron-restricted  
expression. However the sequence is 8.5Kbp long and  is not suitable for cloning 
in a  lentivirus (Hirasawa et a l, 2001). The prom oter of Vescicular Acetyl-Choline 
Transporter (VAChT) has been used  to target expression specifically in 
cholinergic neurons (including spinal cord motor neurons), b u t it is 6.4Kbp long 
(Naciff et a l, 1999). On the other hand, when sufficiently short regulatory 
sequences are available, random  integration of the vector into the h o st cell 
genome may lead to aberran t expression due to prom oter and enhancer trapping.
For these reasons, efforts have been m ade to introduce fu rther regulating 
sequences, like miRNA target sequences, to achieve de-targeting of transgene 
expression in undesired cell-types.
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miRNA techno logy
miRNAs are endogenous small 21-23-nucleotide noncoding RNAs. Biogenesis of 
miRNA is initiated in the nucleus. miRNA genes are found in intergenic regions of 
the genome and in defined transcription u n its  in both the sense and  antisense 
orientations. They are transcribed by RNA polymerase II to form prim ary miRNA 
(pri-miRNA). These stem-loop pri-miRNAs are cropped to 70-nt pre-miRNAs by 
the Drosha-DGCR8 complex. D rosha is a  nuclear RNase III th a t interacts with its 
cofactor, DGCR8, and produces RNA sequences th a t contain 5' phosphate groups 
and  2-n t overhangs a t their 3' ends, starting from transcrip ts th a t contain a  5'- 
end cap structu re  and a  polyA-tail sequence. After processing by Drosha, the 
pre-miRNAs are moved to the cytoplasm by a  nuclear transport receptor complex. 
Once in the cytoplasm pre-miRNAs are processed by Dicer into ~22-nt m ature 
miRNAs th a t are further unw ound by an RNA helicase. Subsequently the 
antisense strand  of so called miRNA/miRNA* duplex is assem bled into an 
effector protein complex (miRNP). The miRNP then  specifically in teracts with the 
target mRNAs, generally a t the 3'UTR, th u s  inhibiting translation (Meister and  
Tuschl, 2004) (Figure 1.16).
Many miRNAs have a  distinct developmental and  tissue-specific expression 
pattern, and they may play a  pivotal role in defining cell identity. Based on this 
evidence, recent works by Brown and colleagues have dem onstrated th a t 
microRNAs (miRNAs) may represent a  new tool to control viral-vector m ediated 
transgene expression (Brown et al., 2006; Brown et a l, 2007). The au thors 
introduced sequences targeted by cell-specific miRNAs into the genome of 
lentiviral vectors with the aim of preventing transgene expression in undesired 
cell lineages. Briefly, four tandem  copies of a  23bp sequence with perfect 
complementarity to either m ir-142-5p or m ir-142-3p were inserted  into the 3'- 
un translated  region of green fluorescent reporter gene inside a  lentiviral vector. 
m ir-142-5p and m ir-142-3p were chosen because they are enriched in 
hematopoietic cell lineages. This strategy dem onstrated th a t miRNA selection can
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selectively de-target viral vector-mediated gene expression in hematopoietic cells 
in vivo.
This technological advancem ent is gaining great interest for the design of more 
selective lentiviral vectors, however studies to identify suitable miRNA sequences 
with tissue-specific expression are still ongoing
Figure 1 .16. Overview o f gen esis  and function  o f miRNA seq u en ces
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1.7 HYPOTHESIS OF THE STUDY
The hypothesis of this study is th a t progressive loss of motor neurons seen in 
ALS is caused or is m ediated by an upregulation of pro-degenerative p38MAPK 
a n d /o r by insufficient activation of pro-survival Akt signalling pathways. 
Therefore, molecular inhibition of p38MAPK signalling or molecular activation of 
Akt could act to inhibit neuronal loss thereby modifying disease progression. In 
order to test th is hypothesis we have developed lentiviral vectors to deliver 
siRNAs against p38MAPK and to deliver constitutive forms of Akt to a  transgenic 
m ouse model of ALS.
1.8 AIMS OF THE STUDY
o To test if selective activation of the Akt pro-survival pathw ay within 
motor neurons can effectively inhibit neurodegeneration and  modify 
disease progression, 
o To determine in vivo if a  knock down of the p38MAPK pathw ay in glial 
cells an d /o r motor neurons in the SOD1G93A overexpressing m ouse 
model of familial ALS influences the neurodegenerative process.
These are specific issues pursued  during the study:
o Development of a  lentiviral vector construct th a t allows selective 
expression of transgenes in motor neurons in vivo 
o Induction of Akt pathway through expression of a  m u tan t constitutively 
active isoform of Akt 
o Intraspinal delivery of lentiviral vectors expressing constitutively active 
Akt in SOD1G93A mice, and analysis of the effect on disease 
progression and motor neuron survival 
o Identification of candidate shRNA sequences targeting m urine p38MAPK 
alpha
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In vitro validation of the potential neuroprotective effect of p38MAPK 
alpha downregulation
Instraspinal delivery of lentiviral vectors expressing p38MAPK-targeted 
shRNA in SOD1G93A mice, and analysis of the effect on disease 
progression and motor neuron survival
CHAPTER 2 
MATERIALS & METHODS
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2.1 MATERIALS AND REAGENTS
2.1 .1  Plasm ids
• pAKT3: cDNA of hum an AKT3 gene, Transcript variant n r.2 (accession 
num ber NM_181690.1) fused at the N-terminal with HA-tag, and cloned in 
pCMV5. The plasmid was kindly provided by Dr. B. Hemmings, FMI, 
Switzerland.
• pMvr.AKTl: cDNA of hum an AKT1 gene (accession num ber NM_001014432) 
fused a t the N-terminal with HA-tag a myristilation sequence, and cloned in 
pcDNA3.1-H+. The plasmid was kindly provided by Dr B. Hemmings, FMI, 
Switzerland.
• LV.NSE: lentiviral vector plasmid containing the ra t Neuron Specific Enolase 
(rNSE) promoter and GFP as reporter gene. The plasmid was kindly provided 
by Dr. C. Lundberg, Lund University, Sweden.
• pHb9: plasmid containing 11 Kilobases of the 5’ flanking region of Hb9 
transcription factor. It was kindly provided by Dr. T. Jessell, Columbia 
University, USA.
• Bg.GFP: plasmid containing the (3-globin minimal promoter and GFP as 
reporter gene. It was kindly provided by Dr. J . Johnson, UT Southwestern 
Medical Center, USA.
A m ap  o f  th e  p la sm id , w ith  re lev a n t f e a tu r e s  a n d  restric tion  s ite s ,  is  s h o w n  b e lo w .
P s tl
Sbf!
T A T A  b o x Ncoi
GFP
po/yAM C S ___
Sal! -  Bglii - N del -  S tu l  -  Sphl -  £ agi -  Not1 - Xbai - Spai - BamHi - Sm ai -  P stl - E coR i
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• pRabies-G: plasmid containing a sequence encoding for Rabies vim s G 
glycoprotein (Rabies envelope). It was kindly provided by Dr. M. Sena- 
Estevez, M assachusetts General Hospital, USA.
• pMD2G: plasmid containing a sequence encoding for Vescicular Stomatitis 
Vims G glycoprotein (VSVG envelope). It was purchased from BD Biosciences 
(San Jose, California, USA).
• pCMVd8.74: adjuvant plasmid, carrying the genes encoding for viral capsid 
(gag) and reverse transcriptase (pol), under a REV-Responsive Element (RRE). 
It was provided by Trono Lab (Lausanne, Switzerland).
• pRSV.REV: adjuvant plasmid, carrying the gene encoding for REV
transcription factor under Rous Sarcoma Vims (RSV) promoter. It was 
provided by Trono Lab.
• pLVTHM: lentiviral vector plasmid, containing GFP reporter gene under 
hEF l alpha ubiquitarious promoter. This plasmid contains also a  cloning site 
for shRNAs (Mlul-Clal), under HI RNA polymerase III promoter. It was 
provided by Trono Lab.
A m ap  o f  th e  p la sm id , w ith  re le v a n t f e a tu r e s  a n d  restric tion  s ite s , is  re p o r te d  b e lo w .
ClBl
Pact
:c-oRl
troocH lV -l LTR E F la lp h a  pro mot]
■h :
HIV- I_p5t_pa?ck
• pWPXLd: : lentiviral vector plasmid, containing GFP reporter gene under 
hEFl a  ubiquitarious promoter. This plasmid also contains the post- 
transcriptional regulatory element of the Woodchuck hepatitis virus (WPRE) 
th a t enhances mRNA translation. It was purchased from Addgene Repository 
(Addgene Plasmid 12257).
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A map of the plasmid, with relevant features and restriction recognition sites, is
Pact
Sivat
dial s.oet A/de/ 
Smsl f  f
EcoRt truncHIV- 1_L IRtruncHIV- i_L.TR EF1 a lp h a  p r o m o te r
G FP
cPPTHP*'-1 -psi pack
r e p o r te d  b e lo w .
pLKO. 1: lentiviral vector plasmid, containing Puromycin resistance gene 
(Puro R) under hPGK ubiquitarious promoter. This plasmid contains also a 
cloning site for shRNAs, under U6 RNA polymerase III promoter. It was 
purchased from Sigma (St. Louis, Missouri, USA).
A m a p  o f  th e  p la sm id , w ith  
re lev a n t f e a tu r e s  a n d  restric tion  
recogn ition  s ite s ,  is  re p o rted  h ere  
on th e  right s id e .
RRE
S'LTR a
shRNA 
Construct 
U6 CPPT
hPGK
P u r o  K
sin  LTR
pUC ori
Anvp R
F1 ori
a o a o w d  from AtMg&fr# n\abaira
TRC-shRNA: set of 5 different lentiviral vector plasmids, derived from 
pLKO.l, each containing a different candidate shRNA sequence targeting 
murine MAPK14. It was purchased from Open Biosystems (Huntsville,
Alabama, USA).
Table 2 .1 . List o f the different vectors produced and utilised in the project
Name
Original
plasmid
Transgene Reporter
Promoter Gene Promoter Gene
WPX.NSE.GFP WPXLd / / / / rNSE GFP
Bg.AB Bg.GFP / / / / Hb9.AB GFP
Bg. 1.6Kb Bg.GFP / / / / Hb9.1.6Kb GFP
W.AB WPXLd / / / / Hb9.AB GFP
W. 1.6Kb WPXLd / / / / Hb9.1.6Kb GFP
Myr.AKT3 pcDNA3.1 CMV Myr.AKT3 / /
HAtag 
(fused to Myr.AKT3)
WPX.Myr.AKT3 WPXLd EF1 alpha Myr.AKT3 / /
HAtag 
(fused to Myr.AKT3)
W.1.6.Myr.AKT3 WPXLd Hb9.1.6Kb Myr.AKT3 / /
HAtag 
(fused to Myr.AKT3)
shRNA nr.7 pLKO.l U6 shRNA nr. 7 hPGK GFP
shRNA nr. 7* pLVTHM HI shRNA nr. 7* EF1 alpha GFP
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2 .1 .2  Antibodies
Actin.
ChAT.
CD l ib .
CNPase
ERK1,2.
GFAP.
GFP.
Mouse monoclonal antibody (Chemicon-Millipore, Billerica, 
M assachusetts, USA). It reacts with all six isoforms of vertebrate 
actin. Working dilution fo r  immunoblot: 1:5000.
Mouse monoclonal antibody (Chemicon-Millipore). It reacts with 
Choline Acetyl Transferase, an  enzyme specifically p resent in 
Cholinergic neurons. Working dilution fo r  immunohistochemistry: 
1:200
Rat polyclonal antibody (made in house). It detects the CD l i b  
antigen also known as Mac-1 antigen, found on m ouse 
macrophages, their precursors and granulocytes. Working dilution 
fo r  immunohistochemistry: 1:1000.
Mouse monoclonal antibody (Chemicon-Millipore). It reacts 
specifically with 2', 3'-cyclic nucleotide 3 '-phosphodiesterase 
(CNPase), an en2yme found alm ost exclusively in oligo-dendrocytes 
and Schwann cells. Working dilution fo r  immunohistochemistry: 
1:400.
Mouse monoclonal antibody (Zymed-Invitrogen, Carlsbad, 
California, USA). It recognizes p42 and p44 isoforms of 
Extracellular regulated kinase. Working dilution fo r  immunoblot: 
1: 1000 .
Mouse monoclonal antibody (Chemicon-Millipore). It reacts with 
Glial Fibrillar Acidic Protein, a  cytoskeletal protein typically found 
in glial cells such as astrocytes. Working dilution fo r  
immunohistochemistry: 1:2500.
Rabbit polyclonal antibody (Molecular Probes-Invitrogen, Carlsbad, 
California, USA). It recognizes Green Fluorescent Protein and  its 
m u tan t isoforms, specifically. Working dilution fo r
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immunohistochemistry: 1:1500.
Mouse monoclonal antibody (Cell Signaling Technology, Danvers, 
M assachusetts, USA). It detects recom binant proteins containing 
the HA epitope tag. Working dilution fo r  immunohistochemistry: 
1:100; fo r  immunoblot:1:1000.
Rabbit polyclonal antibody (Cell Signaling Technology, Danvers, 
M assachusetts, USA). It detects c-jun N-terminal kinase. Working 
dilution fo r  immunoblot:1:1000.
Rabbit monoclonal antibody (Upstate-Millipore). It recognizes p85 
subunit. This protein binds to activated (phosphorylated) protein- 
Tyr kinases, through its SH2 domain, and acts as an  adapter, 
mediating the association of the p i  10 catalytic u n it of PI3K to the 
plasm a m em brane. Working dilution fo r  immunoblot: 1:1000.
Rabbit polyclonal antibody (Cell Signaling Technology). It 
recognizes alpha isoform of p38 MAPK, specifically. Working 
dilution fo r  immunoblot: 1:1000.
Rabbit polyclonal antibody (Cell Signaling Technology). It 
recognizes all four isoforms of p38MAPK. Working dilution fo r  
immunoblot: 1:1000.
Phospho-Akt. Rabbit polyclonal antibody (Cell Signaling Technology). It detects 
A ktl only when phosphorylated a t serine 473, and Akt2 and  Akt3 
only when phosphorylated a t equivalent sites. Working dilution fo r  
immunoblot: 1:1000. For im m unohistochem istiy experim ents a  
rabbit monoclonal (IHC specific) antibody from the sam e com pany 
was used. Working dilution: 1:500.
Phospho-eIF2a. Rabbit polyclonal antibody (Cell Signaling Technology). It detects 
endogenous eIF2a only when phosphorylated a t Ser51, as a  m arker 
of induction of Interferon response. Working dilution fo r  
immunoblot: 1:1000.
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HA-tag.
JNK.
PI3Kp85.
p38  alpha.
p38  tot
Phospho-GSK3fi. Rabbit polyclonal antibody (Cell Signaling Technology). It detects 
endogenous levels of GSK-3b only when phosphorylated a t Ser9, a  
specific target of activated Akt. Working dilution fo r  immunoblot: 
1:1000 .
Phospho-JNK. Rabbit polyclonal antibody (Cell Signaling Technology). It detects 
endogenous levels of JNK only when phosphorylated a t 
Thr183/T yr185. Working dilution fo r  immunoblot: 1:1000.
Phospho-p38. Rabbit monoclonal antibody (Cell Signaling Technology). It detects 
endogenous levels of p38 MAPK only when dually phosphorylated 
a t Thr180 and Tyr182. Working dilution fo r  immunoblot: 1:1000. 
Phospho-STATl/2. Rabbit polyclonal antibody (Cell Signaling Technology). It 
detects phosphorylated tyrosine 701 of p91 S ta tl and  also the p84 
splice variant, as a  m arker of induction of Interferon response. 
Working dilution fo r  immunoblot: 1:1000.
2 .1 .3  Reagents for molecular biology
Restriction Enzym es were purchased from New England Biolab (Ipswich, 
M assachusetts, USA).
T4 DNA Polymerase, T4 DNA Ligase, Thermosensitive Alkaline Phosphatase and  
Polynucleotide Kinase was purchased from Promega (Madison, WI, USA).
Pfx proof-reading DNA polymerase was purchased  from Invitrogen.
DH5alpha bacteria were purchased from Invitrogen.
S C I01 bacteria were purchased from Stratagene (Cedar Creek, Texas, USA). This 
strain , a t variance with DH5alpha is dam-negative. It is u sed  to produce 
plasm ids when cutting with dam-sensitive restriction en2ym es is required.
Kits fo r  MINI- MIDI- and MAXI-preps, and kit fo r  DNA-Clean up  were purchased  
from Promega.
Kit fo r  DNA gel-extraction was from Quiagen (Hilden, Germany).
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All salts and solutions, where not specified, were from Sigma (St. Louis, Missouri, 
USA).
2 .1 .4  Cell lines
HEK293 (human endothelial kidney) cell line, 293T cell line (a cell line derived 
from HEK293 cells by stable trasfection of Large T antigen) and  NIH3T3 murine 
fibroblast cell line were obtained from Dr. Roberto Piva (CeRMS - Turin). The cell 
lines were obtained from Dr. Roberto Piva (CeRMS - Turin). Cells were plated in 
Dulbecco’s Modified Medium, 10% FCS, 1% glutamine, 1% penicillin, 1% 
streptomycin and m aintained a t 37°C in a  humidified 5% CO2 incubator.
293T cells were used  as packaging cell line for lentiviral vector production.
2.2  METHODS
2.2 .1  LENTIVIRAL VECTOR PRODUCTION 
High titre production o f lentiviral vectors
Production of high titre viral vectors was performed by trasfection of 293T cells 
with 4 plasmids: pRSV-Rev and  pCMVdR8.74 encoding gag /po l/rev  proteins, 
pVSV-G for expression of VSV-G protein or pRabies for expression of Rabies G 
protein, and an appropriate transfer vector (pLVTHM, pWPXLd, or pLKO).
Briefly, 293T cells were plated a t 70% confluence in Dulbecco’s Modified 
Medium, 10% FCS, 1% glutamine, 1% penicillin, 1% streptom ycin and 
m aintained a t 37°C in a  humidified 5% C02 incubator. Co-trasfection of the four 
plasm ids was performed with Effectene kit (Quiagen) according to the 
m anufacturer’s instructions. After 16h the m edium  was replaced by fresh 
culture-m edium  containing lOmM Sodium Butyrate. S upernatan ts were 
harvested 24h and 48h post-transfection, filtered through a  0.45 m icron filter
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and stored a t 4°C. New m edium  with lOmM Sodium Butyrate was added to the 
cells after the first harvesting. Concentrated viral stocks were produced by 
ultracentrifugation a t 50,000g a t 4°C for 2h. Viral pellets were resuspended in 
sterile PBS and then  stored a t -80°C until required.
End point dilution assay
This assay used  HEK293 cells to m easure the viral titre (Transfection Unit/mL) 
of each concentrated stock (Blesch, 2004). Briefly, cells were passaged and 
plated in 24 wells plates a t a  concentration of 50,000 cells/well, and then 
infected with 2 pL of serial ten-fold dilutions of each viral vector, in the presence 
of 8 pg/m L polybrene (Sigma). At 72h post-infection the wells infected with the 
highest dilution of virus and still containing cells expressing the reporter gene 
were taken into account. The titre was deduced by the num ber of positive cells 
m easured in those wells, as assessed by visual counting a t fluorescence 
microscope or by FACS.
2 .2 .2 . G93A TRANSGENIC MOUSE MODEL OF ALS
Transgenic mice expressing about 20 copies of m u tan t hum an  SOD1 with a  
Gly93Ala substitu tion (G93A mice) were originally obtained from Jackson  
Laboratories (B6SJL-TgNSOD-l-G93A-lGur); the line is hemizygous for the 
transgene (Gurney et al., 1994). Male G93A mice were repeatedly backcrossed 
with non transgenic female C57BL/6 mice, obtaining transgenic mice on the 
homogeneous C57BL/6 genetic background. The anim als u sed  in the 
experiments are on the homogeneous 129SV genetic background. They have 
been generated in the laboratory by repeated backcross of G93A C57BL/6 m ales 
with non transgenic female 129SV mice.
These mice develop the first signs of neuropathology a t the motor neuronal level 
around 4 weeks of age, while the first symptoms of m uscular dysfunction appear
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around 14 weeks of age, with progressive reduction in the extension reflex of the 
hind limbs, when the mice are raised by the tail. At about 15 weeks of age the 
mice show a  progressive m uscular weakness, revealed by the increasing difficulty 
in staying on a  rotating bar. At 18 weeks of age the anim als show hindlimb 
complete paralysis, and cannot recover if laid on one side.
Mitochondrial vacuolisation and swelling are among the earliest events observed 
a t the histopathological level. Later, b u t still a t the asym ptom atic stage, G93A 
mice show signs of cytoskeletal disorganization in the motor neurons, with the 
accum ulation of phosphorylated neurofilam ents in the perykaria. Reactive 
gliosis, which involves activation of astrocytes and microglia, is detectable with 
the degeneration of motor neurons and becomes prom inent a t symptomatic 
stages, when the cell loss is rem arkable (Bendotti et al., 2001a; Ciavarro et al., 
2003; Tortarolo et a l, 2003).
Procedures involving anim als and their care were conducted in according to the 
institutional guidelines, th a t are in compliance with national (D.L. no. 116, G.U. 
suppl. 40, Feb. 18, 1992, Circolare No.8, G.U., 14 luglio 1994) and  international 
laws and policies (EEC Council Directive 86 /609 , OJ L 358, 1 DEC.12, 1987; 
NIH guide for the Care and use  of Laboratory Animals, U.S. National Research 
Council, 1996). The anim als were housed under standard  conditions (22 ± 1°C, 
60% relative humidity, 12 hour ligh t/dark  schedule), 3-4 per cage, with free 
access to food (Altromin, MT, Rieper) and water.
Mouse genotyping
Genotyping was performed on tail biopsies collected from mice a t weaning age. 
The sam ples were completly digested by overnight incubation a t 55°C in Direct- 
PCR Lysis Buffer (Viagen Biotech, Los Angeles, California, USA) containing 0.1 
p g /p l of Proteinase K (Promega). The following day they were incubated a t 85°C 
for 30 m inutes, to inactivate Proteinase K, and  then  stored a t -20°C  till the
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screening.
PCR screen ing
50 ng of DNA from each animal were u sed  as a  substrate  for qualitative PCR, in a  
mix containing IX PCR buffer, GoTaq DNA Polymerase (0.25 U), deoxyNTPs (250 
pM each), specific forward and reverse prim ers (0.5 pM each) in a  final volume of 
10 pi. All the reagents were purchased  by Promega, except for prim ers th a t were 
synthesized by Invitrogen (Invitrogen).
The prim er sequences and their annealing tem peratures are reported below:
Gene Accession nr. Primers Sequence (5’-3’) Ta
SOD1 NG_008689.1
Forward CATCAGCCCTAATCCATCTGA 58°C
Reverse CGCGACTAACAATCAAAGTGA 58°C
The thermocycling profile used  for amplification is reported below:
1. 94°C for 2 min (denaturation)
2. 94°C for 45 sec (denaturation)
3. 58°C for 45 sec (annealing)
4. 72 °C for 1 min (amplification)
Steps from 2 to 4
repeated for 30 cycles
5. 72 °C for 10 min (final amplification)
PCRs were performed in a  MJ thermocycler (distributed by Bio-rad laboratories, 
Hercules, California, USA). Amplicons were resolved in 1% agarose gel, 2 p g /m l 
Ethidium  bromide in Tris-Acetate-EDTA (40 mM Tris, 0.35% vol/vol acid acetic, 
1 mM EDTA).
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2 .2 .3  SURGICAL PROCEDURES FOR DELIVERY OF LENTIVIRAL VECTORS
IN VIVO
Before delivery the concentrated viral stocks were thawed on ice and 4 jig/mL 
polybrene (Sigma) were added to the viral solution. The mix was then  kept on ice 
during the whole procedure of adm inistration.
All surgical procedures were performed under deep anesthesia  by Equitensin (1% 
phenobarbitol/ 4% (vol/vol) chloral hydrate, 5 jiL/g, ip). After surgery anim als 
were kept on a  warm pad for 30 m inutes and then  placed in separated cages for 
recovery.
Injection in peripheral m uscles
Animals were first shaved in the regions of injection (i.e., gastrocnem ius 
muscles). The viral solution was then  adm inistered through a  30 Gauge needle 
connected to a  10 pL Hamilton syringe and injected inside the muscle, according 
to the procedure already described (Azzouz et al., 2004a).
Injection in the cerebral lateral ventriculi
Mice were placed in a  stereotaxic frame (Kopf Instrum ents, Tujunga, California, 
USA). A midline incision was performed, and the skull was opened with a  dental 
drill a t two sites, 1.0 mm lateral to the bregma. A 30 Gauge needle w as then  
inserted down to a  depth of 2.0 mm under the dura. 5 (iL/site of viral solution 
were then delivered with an infusion pum p a t a  flow rate of 0.5 jiL/min. The 
needle was left in place for an  additional m inute then  gently withdrawn, and  the 
skin was closed with m etal clips.
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Lumbar in trath eca l adm in istration
After shaving of the back at lum bar level, the junction between L6 and sacral 
vertebrae was identified and a transverse cutaneous incision (1 cm) was 
performed at th a t level. A 30 gauge bevelled needle connected to a lOmicroL 
Hamilton syringe was then inserted between L5 and Le spinous process as 
described ( H y ld e n  a n d  W ilcox , 1 9 8 0 ) , and outlined in Figure 2 .1 . The viral 
solution (5 pL) was injected in 1 min.
Figure 2 .1 . Schem e o f th e s ite  o f lumbar in tratheca l in jection
30-Gauge needfe
A d a p ttc ilfw n  Wm-Pkyg Wv of.,
Joutnsi of ffoumsctene* Methods X-04
S ch em a tic  r e p re se n ta tio n  o f  in tra th eca l in jec tion  p ro c ed u re . The n e e d le  w a s  ve r tica lly  
p o s it io n e d  on  th e  sp in o u s  p r o c e s s  o f  Le verteb ra , th en  in c lin ed  to 20°C , a s  re fe rred  to th e  
p la n e  o f  b a ck b o n e, a n d  f in a l ly  in se r te d  f o r  5  m m  th rou gh  th e  s p a c e  b e tw e e n  s p in o u s  a n d  
tr a n s v e r s e  p r o c e s s e s  o f  Ls a n d  L6 verteb ra e . A p p e a ra n c e  o f  ta il f lic k  reflex  d u rin g  in jec tion  
o f  th e  n e e d le  w a s  c o n s id e re d  a s  con firm ation  o f  p r o p e r  p ro c ed u re .
In jection  in to  sp inal cord parenchim a after lam inectom y
Animals back was shaved at dorsal level, and a cutaneous incision (3 cm) was 
performed to expose the backbone. T13 and Li vertebrae were identified, and 
exposed by separation of dorsal and intervertebral muscles. Animals were then 
placed on a Cunningham  Spinal Cord Adaptor (Stoelting, Dublin, Ireland) 
m ounted on a stereotaxic frame, and laminectomy of Li vertebra was done to 
uncover lum bar spinal cord at levels L2 -L4  (Figure 2.2). Using a glass capillary 
(40±5 pm diameter) viral solution was injected bilaterally in two sites separated  
by 2 mm along the spinal cord (1.5 pL/site), with a  flow rate of 0.2 pL/m in.
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Stereotaxic coordinates were referred to the midline of the dorsal horn (DH) of 
spinal cord; the needle was positioned a t + /- 0.5 mm aside from the midline, 
then it was deepened into the parenchym a to 0.8 mm below the pia m ater to 
reach the ventral horn (VH) where motor neurons are located; the injector was 
left in place for 1 min and then retracted for 0.2 mm before starting the delivery, 
as shown in Figure 2.3 . After completion of the injection the needle was left in 
place for additional 2 min and then gently withdrawn. Dorsal muscles were then 
justaxposed by absorbable sutures, and skin su tured  and disinfected.
Figure 2 .2 . V isualisation  o f  the s ite  o f  lam inectom y
Site of laminectomy 
♦
C l 1st cervical vertebra
Sc Scapula
Thl3 13th thoractc vertebra
L6 6th lumbar vertebra
SI 1st sacral vertebra
S4 4th sacral vertebra
Col 1st coccygeal vertebra
C f costae flue mantes
Adapted from Cunningham Sp. Ad. operation manual
Figure 2 .3 . Schem e o f the in jection  s ite s  in sp inal cord parenchim a
- 0.5 mm 0.5 mm
0.0 mm
DH
-0 .6  mm
-0 .8  mmVH
V isu a lisa tion  o f  th e  sp in a l cord  in  th e  
coronal p la n e . The s te re o ta x ic  c o o rd in a te s  
u s e d  f o r  in jection  a re  re fe rred  to  th e  d o rsa l  
lon g itu d in a l m idline, a t  le ve l o f  p ia  m ater. 
D H = dorsa l horn, V H =ven tral horn.
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2 .2 .4  ANALYSIS OF MOTOR PERFORMANCE AND DISEASE PROGRESSION
At the age of 80 days, body weight was recorded and mice were tested for 
extension reflex and for motor performance (rotarod and grid tests) as described 
below. These tests  were initially performed to monitor anim al performance a t the 
pre-symptomatic stage, before surgical operation, and to help anim als to get used  
to post-surgeiy testing sessions.
Extension reflex
Animals were suspended by the tail, and adduction reflex was m onitored for right 
and left hindlimb. A maxim um  of three points/lim b were assigned in case of 
norm al extension reflex; two to one point/lim b were assigned for mild and strong 
deficits, respectively. Zero points were assigned when absence of reflex was 
observed.
Rotarod te st
The test was performed using the accelerating Rotarod apparatus (7650 model, 
Ugo Basile). Once the anim als were positioned on the rotating bar, testing 
commenced and the rotarod was accelerated a t a  constant rate of 4.2 rpm /m in  
from 7 rpm  to 28 rpm  for a  maxim um  of 5 min. The time (seconds) a t which the 
anim al fell from the rotarod was registered. Animals were given a  m axim um  of 
three trials. Mice th a t m anaged to rem ain on the rod for the entire te st duration 
were returned to the cage; their ta sk  was considered fully accomplished. Animals 
falling before 5 min were given 5 min rest and were then  re-tested. The time of 
the best trial was registered and considered for the statistical analysis.
Grid te st
Animals were posed on a  horizontal grid and  supported un til they grabbed the
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grid with both their fore and hind paws; the grid was then inverted so th a t the 
mice were allowed to hang upside down. Time spent hanging, before falling from 
the grid, was taken into account. Timing commenced as the grid was inverted 
and  then  stopped when the anim al fell, for a  maximum of 90 sec. Animals th a t 
fell before 90 sec repeated the trial, for a  maximum of three trials, w ith a t least 5 
min of res t between each. The m easures of the best performance were used  for 
statistical analysis.
At the age of 84 days anim als underw ent surgical operation; laminectom y was 
performed (as already described in section 2.2.3) and viral vectors were injected 
in the spinal cord parenchym a. At the day after operation, anim als were observed 
to check for motor deficits, due to accidental damage to spinal cord. Only healthy 
anim als were kept for further analysis; unhealthy  mice were sacrificed and  not 
further considered in the analysis.
One week after operation, anim als were re-tested for motor perform ances. Tests 
were then  repeated twice a  week until the end stage of the disease. Body weight 
was also recorded before each test session.
Mice a t the end stage of the disease th a t were unable to right them selves within 
30 sec after being placed on one side were euthanized by a  high dose of 
anaesthetic and  perfused for im m unohistochem ical analyses, or decapitated for 
collection of fresh tissues for w estern blot analysis. The age a t death  was 
recorded.
2 .2 .5  IMMUNOHISTOCHEMISTRY 
Preparation o f Tissue
Mice were anesthetized with Equithesin and  transcardially perfused w ith 50 ml 
of phosphate buffered saline (PBS, phosphate buffer 0 .0 1M, 0.9% NaCl) followed
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by 50 ml of 4% paraformaldehyde solution in PBS. Brains and spinal cords were 
rapidly removed, post-fixed in fixative for 3 h, transferred to 20% sucrose 
solution in PBS overnight, then to 30% sucrose solution un til they sank, and 
finally frozen in 2-m ethylbutane a t -45°C and conserved a t -80°C until required. 
Before freezing, spinal cord was divided in cervical, thoracic and lum bar 
segm ents and included in Tissue-tek OCT com pound (Sakura, Zoeterwounde, 
The Netherlands).
Tissues were cu t on a  ciyostat a t -20°C to obtain sections of 30 pm . Brain was 
cu t in the horizontal or coronal plane, while spinal cord was cu t longitudinally or 
in the coronal plane. The lum bar level of the spinal cord was chosen for the 
experiments, because the hindlim bs of G93A mice are affected earlier and  more 
severely compared to the forelimbs.
NISSL staining
This staining highlights the rough endoplasmic reticulum . It is u sed  to view cell 
sizes and num bers in the nervous system.
For the staining procedure, sections were cu t on ciyostat a t -20°C then  m ounted 
on gelatin-covered glass slides, and dried overnight a t room tem perature. The 
following day slides were dipped in w ater for 1 min, then  in a  graded series of 
ethanol (70%, 96% then  absolute ethanol) and finally dipped in xylene. Following 
the xylene step the slides were dipped back to w ater and passed th rough the 
ethanol series in reverse sequence. After dipping in w ater for 1 min, slides were 
imm ersed into cresyl-violet 0.5% solution in w ater for 3 min, then  w ashed 10 
tim es in water, 10 times in 70% ethanol and dipped for 3 min in 3% acetic acid 
solution in ethanol. After 30 seconds slides were moved to 96% ethanol solution 
and then to absolute ethanol, and  finally to xylene. Slides were finally 
coverslipped with DPX m ounting medium  (BDH, Poole Dorset, UK).
For some im munohistochemical experiments, with the aim of obtaining 
quantitative data, NISSL staining was performed on serial sections (1 every 10
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sections, for a  total of 24 sections for animal) from the spinal cord, starting from 
lum bar level L2 .
For colocalization experiments this procedure was substitu ted  with incubation of 
free floating sections in Neuro Trace fluorescent NISSL stain  (Molecular Probes- 
Invitrogen) a t the appropriate wavelenght, dil. 1:500 in PBS for 10 min.
Indirect im m unofluorescence
Free-floating sections were treated for 1 h  with a  blocking solution composed of 
norm al serum  and Triton X-100 a t the appropriate concentration in PBS. 
Subsequently, the sections were incubated overnight a t 4°C with the prim ary 
antibody diluted in PBS containing norm al serum  and Triton X-100. Then, after 
three w ashes in PBS, sam ples were treated for 1 h  with the appropriate 
secondaiy antibody conjugated to fluorochromes with various wavelengths (Alexa 
488, 594 and 647, Molecular Probes-Invitrogen), diluted 1:500 in 1% norm al 
serum  1% in PBS. Finally, sections were m ounted on slides and  coverslipped 
with a  solution of Glycerol 50% in PBS. Control sections were incubated w ithout 
the prim ary antibody.
Amplified im m unofluorescence by streptavidin
Blocking was performed for 1 h  a t RT with norm al serum  and  Triton X-100 a t 
appropriate concentration in PBS. Subsequently, sections were rinsed and  then  
incubated for 15 min a t room tem perature with Avidin Solution (Vector Labs, 
Peterborough, UK), then  rinsed in PBS and incubated for 15 m in a t room 
tem perature with Biotin Solution (Vector Labs) to block endogenous biotins. 
Samples were probed overnight a t 4°C with the prim ary antibody, diluted in PBS 
containing norm al serum  and Triton X-100. The following day, after three w ashes 
in PBS, they were incubated with biotinylated secondary antibody (Vector Labs) 
a t dil. 1:200 in 1% normal serum  and  PBS for 1 hour, then  w ashed three tim es 
with PBS and finally incubated for 30 min with Streptavidin coniugated to
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appropriate Alexa fluorochrome (Molecular Probes-Invitrogen). Subsequently, the 
sections were again washed with PBS and m ounted on slides and coverslipped 
with a  solution of Glycerol 50% in PBS. In each im m unohistochem ical 
experiment, some of the sections were processed w ithout the prim ary antibody, 
in order to verify the specificity of the staining.
Amplified im m unofluorescence by tyramide
Blocking was performed for 1 h  a t RT with norm al serum  and Triton X-100 a t 
appropriate concentration in PBS. Subsequently, sections were rinsed and  then  
incubated for 15 min a t room tem perature with 1% hydrogen peroxide to block 
endogenous peroxidases then  rinsed in PBS. Samples were probed overnight a t 
4°C with the prim ary antibody, diluted in PBS containing norm al serum  and 
Triton X-100. The following day, after three w ashes in PBS, they were incubated 
with biotinylated secondary antibody (Vector Labs) a t dil. 1:200 in 1% norm al 
serum  and PBS for 1 hour, then  w ashed three tim es with PBS and  incubated  for 
90 min in Blocking Reagent (Perkin Elmer, Waltham, M assachusetts, USA). 
Sections were incubated for 30 m in in Streptavidin coniugated to horserad ish  
peroxidase dil. 1:100 in Blocking Reagent. They were then washed three tim es in 
TNT (0.04% Tween in 0.1M Tris/C l pH 7.6); finally reaction was developped by 
incubation for 8 m in in Tyramide (Perkin Elmer) dil. 1:300 in Amplification 
Diluent (0.003% H2O2 in 0.1M Borate pH 8.5). Subsequently, the sections were 
again washed with PBS and m ounted on slides and coverslipped w ith a  solution 
of Glycerol 50% in PBS.
Staining o f nuclei
Samples were incubated for 10 min in Hoescht 33258 dye (Polysciences Inc., 
Epperlheim, Germany) dil. 1:500 in PBS, then  w ashed three times in PBS.
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Image analysis
Fluorescence-labelled sections were analyzed under an  Olympus Fluoview laser 
scanning confocal microscope, using three lasers: Ar with a  488 nm  emission line 
to acquire Alexa 488 signal, He-Ne green laser with a  543 nm  emission line to 
acquire Alexa 594 signal, He-Ne red laser with a  633 nm  emission line to acquire 
Cy5 signal, and  UV-Ar laser with a  351 nm  emission line to acquire Hoescht 
staining. Analysis in double or triple staining was done by sequential scanning in 
order to avoid cross talk  between the channels.
NISSL stained samples, prepared for quantitative analysis, were examined under 
an  Olympus BX61 light microscope and images of the ventral spinal cord were 
collected with a  camera, using  AnaliSYS software (Soft Imaging Systems, ver. 
3.2). M easures of area  and num ber of cells with clear nucleus and  nucleolus in 
the ventral horn spinal cord were performed using ImageJ (public domain 
software) on the calibrated images previously collected. Motor neurons were 
defined as cells with area  higher than  250jim2, similarly to already published 
studies (Azzouz et a l , 2000; Kaspar et a l, 2003).
2 .2 .6  PRIMARY CELL CULTURES
Preparation of prim ary cell cultures from mice embryos were perform ed by Dr 
Massimo Tortarolo, Dr Dario Lidonnici, Dr Gabriella Spaltro and  Dr C ristina 
Daleno of the Lab. of Molecular Neurobiology, Mario Negri Inst., Milan. Neurons 
from ra t pups were prepared by Dr A lessandra Sclip, Dr Alessio Colombo, and  Dr 
Cristina Ploia, of the Lab. of Biology of Neurodegenerative Disorders, Unit of Cell 
Death and  Neuroprotection M echanisms, Mario Negri Inst., Milan.
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A strocytes
Cortical prim ary astrocyte cultures obtained from 15-16 day old m ouse embryos 
(C57/BL6) were prepared in accordance with the protocol in use  in the laboratory 
and previously described (Tortarolo et a l, 2004).
Spinal neuronal-astrocytic co-culture
Primary spinal neurons were prepared from 14 to 15 day old m ouse embryos 
(species). Spinal cords were isolated by dissection and the meninges removed. 
Spinal cords were then  mechanically dissociated using a  fire-polished glass 
Pasteur pipette in phosphate-buffered saline (PBS, Ca2+ and  Mg2+ free) 
supplem ented with glucose (33 mM). The cell suspension was layered onto a  4% 
BSA cushion, centrifuged a t 1,000 rpm  for 10 min, and  the cells from the pellet 
were resuspended in culture m edium  composed of Neurobasal (Gibco) 
supplem ented with 10% inactivated horse serum , 16.5 mM glucose, 1 ng/m L 
BDNF, 2 mM glutamine, 100 pg/m L streptomycin and 60 |ig/m L penicillin. A 
mixture of horm ones and salts composed of insulin (25 pg/mL), transferrin  (100 
jig/mL), putrescine (60 pM), progesterone (20 nM) and sodium  selenate (30 nM) 
(all from Sigma) was also added to the culture medium. Cells were plated (one 
spinal cord /8  wells) positioned in each well of 48-well Nunc multiwell plates th a t 
had  been previously coated with a  confluent monolayer of astrocytes, to help 
neuronal health  and survival. Cells were cultured a t 37°C in a  humidified 
atm osphere of 95% air and 5% CO2 and  used  after 5-6 days in vitro.
Cortical neurons
Primary cortical neurons obtained from the brains of two-day old Sprague- 
Dawley ra t pups, were prepared in accordance with the protocol u sed  in the Unit 
of Cell Death and Neuroprotection M echanisms as previously described (Borsello 
et a l, 2003).
- 155-
2 .2 .7  INFECTION OF CELL CULTURES
Infection o f cell lines
For infection experiments NIH3T3 cells were passaged and plated in 6 wells 
plates a t a  concentration of 100,000 cells/well. Viral supernatan ts, each 
containing a  different shRNA sequence, were adm inistered to cells in the 
presence of 8 |ig/m L polybrene (SIGMA) as adjuvant of infection. At 72 h  post­
infection cells were harvested for protein or RNA extraction, or u sed  for 
subsequent analyses.
Infection o f primary cell cultures
Astrocytes, in 6 well plates, were infected when they reached 60% confluence 
(about 7 days in culture). Viral vector (6xl06 TU/well) was added to the culture 
medium. Medium was then  replaced one day after infection, and  then  every 4 
days until the end of the experiment. Infection of neuronal cu ltures was 
performed one day after plating with concentrated virus (2xl06 TU/well), in the 
absence of AraC. One day after infection fresh medium  was added to the cells; 
araC was added to a  final concentration of lOmM to inhibit glial cell proliferation. 
Cells were tested a t 3-4 days of culture.
2 .2 .8  TRANSFECTION OF CELL CULTURES 
Transfection o f cell lines
One day before transfection cells were passaged in 6 well plates a t 50%
confluence. The following day cells were transfected with purified DNA construct
using Effectene trasfection reagent (Quiagen) according to the m anufactu rer’s
instructions. 0.5 jig and 1.0 i^g of DNA were u sed  for each construct, to assu re
maximal efficiency of expression. Medium was replaced 16 h  after transfection,
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then  a t 72 h  post-transfection cells were fixed with 2% PFA in PBS, or pelleted 
and lysed for analysis of protein expression.
Transfection o f primary cell cultures
Primary m ouse spinal cord neurons were plated on a  confluent monolayer of 
astrocytes in 48 well plates according to the protocol already described. One day 
after plating cells were transfected with purified DNA construct 0.3 pg/well using 
Effectene transfection reagent (Quiagen) according to the m anufacturer’s 
instructions. Medium was replaced 5h after transfection, then  a t 72h post­
transfection cells were fixed with 2% PFA in PBS, or pelleted and  lysed for 
analysis of protein expression.
2 .2 .9  SEMI-QUANTITATIVE PCR 
RNA extraction
Total RNA was extracted using the Trizol reagent (Invitrogen), purified according 
to the m anufacturers’ instruction and resuspended in sterile water. RNA was 
quantified by spectrophotom eter. Moreover, to check its quality, 2 pg  of each 
sample were loaded in electrophoresis gel and  18S and 28S ribosom al bands 
were considered as indicators of RNA integrity.
Synthesis o f cDNA
The cDNA used for semi-quantitative-PCR experiments was obtained by reverse 
transcription of total RNA with a  Moloney m urine leukaem ia virus reverse 
transcrip tase (MuLV RT) from Gene Amplification RNA PCR-core kit (Applied 
Biosystems). Oligo d(T)16 were used  to allow retro-transcription of any m essenger 
harbouring the polyA tail. Briefly, 2 pg  of RNA from each sample were used  as a 
substra te  for cDNA synthesis in a  mix containing IX PCR Buffer, MuLV reverse 
transcrip tase (2.5 U/pL), RNAse inhibitor (lU /pl), oligo dT (2.5 pM), and 
deoxyNTP (1 mM each) in a  final volume of 40 pL. The mixture was incubated  for
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10 min a t RT, then  for 15 min a t 42°C, for 5 min a t 99°C, for 5 m in a t 4°C and 
then  stored a t -20°C until required.
PCR experim ents
Semi-quantitative PCR was performed in a  MJ thermocycler (distributed by Bio­
rad laboratories). 120 ng of cDNA from each sample were u sed  as a  substra te  for 
PCR reaction, in a  mix containing IX PCR buffer, GoTaq DNA Polymerase (0.25 
U), deoxyNTPs (250 pM each), specific forward and  reverse prim ers (0.5 pM each) 
in a  final volume of 10 pL. All the reagents were purchased by Promega, except 
for prim ers th a t were synthesized by Invitrogen (Invitrogen).
Primers were designed to anneal on two different exons on the target sequence, 
in order to obtain a  500bp amplicon from cDNA, and a  m uch larger fragm ent in 
case of amplification from contam inating genomic DNA.
The prim er sequences and  their annealing tem peratures are reported below:
Gene Accession nr. Primers Sequence (5’-3’) Ta
p38-alpha NM 011951.2 Forward CAGGAGAGGCCCACGTTCTAC 64°CReverse CATCATCAGTGTGCCGAGCCA 64°C
Actin NM 007393.1 Forward TGGATGACGATATCGCTGCG 58°CReverse ACAGAGTACTTGCGCTCAGG 58°C
Each sample was tested for the same gene in two or three different PCR reactions 
sim ultaneously. Each reaction differed from the  others for num ber of cycles in 
the thermocycling profile.
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The thermocycling profiles used  for amplification in sem i-quantitative PCR 
experim ents are shown below:
Thermocycling profile Gene Ta Reaction N
1. 94°C for 2 min (denaturation)
2. 94°C for 45 sec (denaturation)
3. Ta for 45 sec (annealing)
4. 72°C for 1 min (amplification) 
Steps from 2 to 4
repeated for N cycles
5. 72 °C for 7 min (final amplification)
p38-alpha 64°C
1st
2nd
3rd
24
26
28
Actin 58°C
1st
2nd
16
18
2 .2 .1 0  DETECTION OF VIRAL GENOME INTAGRETED IN HOST CELLS 
Extraction o f genom ic DNA
Cells were plated in 48wells plates. 3 days after infection medium was removed 
and  cells were w ashed twice with PBS. Then cells were incubated 5 m in with 100 
pL/well of Lysis Buffer (composition described below). A little scraper was u sed  to 
aid lysis. Lysates were then collected and  incubated a t 55°C for 2h, and then  
kept on ice. 30 pL of ice cold Protein Precipitation Solution (Promega) were added 
to each sample. After centrifugation a t 13000 rpm  for 20min the su p ern a tan ts  
were collected, and  then DNA was extracted by ethanol precipitation.
Composition of Lysis Buffer fam out/sam ple):
80uL Nuclei Lysis solution (Promega)
20uL 0.5M EDTA
4uL Proteinase K (Promega)
PCR experim ents
PCR was performed in a  MJ thermocycler (distributed by Bio-rad laboratories),
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applying the protocol already described in section 2.2.2, with a  different set of 
prim ers, listed below.
Gene Accession nr. or reference Primers Sequence (5*-3’) Ta
GFP (Cormack et al., 1996)
Forward ACCACATGAAGCAGCACGACT 58°C
Reverse CTTGTACAGCTCGTCCATGC 58°C
AKT3 AF124141.1 Forward GCTTACCCATACGATGTTCCAG 64°CReverse TTATTCTCGTCCACTTGCAGAGT 64°C
2.2 .11  1MMUNOBLOTTING
Protein extraction from cell lines and tissu es
Ice-cold Lysis Buffer (50 mM Tris/HCl pH 8, 150 mM NaCl, 5 mM EGTA pH 8,
1.5 mM MgC12, 10% Glycerol, 1% Triton X-100, 50 mM NaF, 10 mM NaPP, 10 
mM Na3V04, 100 m g/m L PMSF, 20 m g/m L Leupeptin, 20 m g/m L Aprotinin) 
was added to cell pellets (50 pL/confluent 35mm dish) or to tissue sam ples (8 
pL/mg of tissue). Cells were lysed by incubating on ice for 15 min, while tissues 
were homogenised by a  teflon-on-glass homogeniser. Lysates were then  cleared 
by centrifugation a t 13,000 rpm  for 15 m in a t 4°C. S upernatan ts were then  
collected and stored a t -80°C until required.
Protein concentration of supernatan ts was m easured by BCA protein assay  
(Pierce-Thermo Scientific, Rockford, Illinois, USA) according to the 
m anufacturer’s instructions.
Protein extraction from primary cell cultures
The same protocol described in the previous section was used  with m inor 
modifications. Briefly, m edium was removed and cells were w ashed with PBS 
twice, then ice-cold lysis buffer was added in the wells (150 pL/well). The cell- 
plate was incubated 15 min on ice, aiding cell detachm ent and  lysis by using  a
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scraper. Lysates from two wells treated in the same way were then  collected and 
pooled, and then  clarified as described in the previous paragraph.
SDS-poly-acrylamide gel elecrophoresis (SDS-PAGE)
Prior to electrophoresis, aliquots of homogenate were boiled in SDS sample buffer 
(1.2% SDS, 5% (3-mercaptoethanol, 5% glycerol, 25.5 mM Tris/HCl pH6.8, 0.6% 
glycine) a t 95°C for 5 min. Equal am ounts of total protein (30 pg) were separated 
on 10% Tris-glycine polyacrylamide gels and electroblotted onto 0.2 pM 
nitrocellulose m em branes, 90V for 2h using a  BioRad m ini-transfer system. To 
check for even protein loading and transfer, m em branes were briefly im m ersed in 
Ponceau-S stain  (0.2% Ponceau-S in 3% trichloro-acetic acid) and  rinsed in 
water. Membranes were then  placed between plastic sheets and  scanned for later 
analysis.
Immunoblotting
Membranes were rinsed in PBS to remove Ponceau-S stain  and  im m ersed in 
blocking buffer (5% non-fat milk in TBS pH 7.4, 0.1% Tween). M embranes were 
then  probed with the prim ary antibody diluted in BSA 3% in TBS/Tween, w ashed 
4 times in TBST, and incubated with HRP-conjugated secondary antibody 
(Sigma) 1:2000 for lh  a t RT. M embranes were w ashed 3 tim es in TBST for 5 min 
and  the signal detected by enhanced chemioluminescence (ECL) using  ECL 
reagent (GE Healthcare) for various exposure times to obtain signal w ithin the 
linear range. Films were scanned on an Epson scanner and band intensities 
m easured using Image J  (public domain software). The obtained values were 
normalized to actin staining and expressed as percentage of the basal value 
registered in the control sam ples (i.e. no t transgenic tissues). Mean values were 
used  for statistical analysis by S tudent’s t-test. The statistical analysis w as done 
using Prism 4 for Windows, version 4.03.
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2 .2 .12  PCR-CLONING EXPERIMENTS
The cDNA HA.AKT3 was PCR amplified using pAKT3 plasm id as tem plate, a  
forward prim er containing 39bp coding for a  myristilation sequence, and a  
proofreading Pfx DNA polymerase.
The composition of PCR buffer and thermocycling profile are shown below; the 
sequences of forward and reverse prim ers are shown in the table.
PCR buffer: 
IX
0.3m M
Im M
0.3m icroM  
0.3m icroM  
Pfx DNA pol.
Pfx A m plification B uffer 
dNTPs so lu tio n  
M g S 0 4
F orw ard  p rim er 
R everse p rim er 
1 U nit
W ater to  final volum e of 20  pL
Thermocuclina profile:
1. 94°C for 5 m in  (d en a tu ra tio n )
2. 94°C  for 15 sec (d en a tu ra tio n )
3. 60°C  for 30  sec (annealing)
4. 68°C  for 2 m in  (extension)
5. S tep s  from  2 to  4 re p e a te d  for 29 cycles
6. 4°C
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DNA
template Primers Sequence (5*-3’) Ta
pAKT3
plasmid
Forward
GGGGTACCGCCGCCACCATGGGCTGCGTTTGCT
CGTCGAATCCCGAGGACGACGCTGCTTACCCATA
64°C
CGATGTTCCAG
(the myristilation sequence is in bold; the 
nucleotides annealing to HA.AKT3 sequence are 
underlined)
Reverse
GGTCTAGATTATTCTCGTCCACTT-GCAGAGT
(the nucleotides annealing to AKT3 sequence are 
underlined)
64°C
After the PCR reaction the DNA w as cleaned using  a  PCR-clean up  kit (Promega) 
and digested for 2h a t 37°C with KpnI/Xbal restriction enzymes. The sample was 
then  ru n  on a  preparative 0.8% agarose gel; the band corresponding to the 
amplified DNA was excised using a  Quiquick gel-extraction kit from Quiagen and 
then religated into KpnI/Xbal site of pcDNA3.1H+ vector. The construct was 
finally sequence-verified by using  T7 as sequencing primer.
2 .2 .1 3  DATA HANDLING AND STATISTICAL ANALYSIS
All the statistical analyses were performed using  Prism 4 for Windows, version
4.03 (GraphPad Software Inc.).
In vitro experim ents
Each experiment was repeated a t least three times; in each experim ent any 
condition was tested in duplicate or triplicate. For statistical analysis the m ean 
values of three independent experiments were taken into account. The difference 
between groups was evaluated by one-way ANOVA followed by Tukey Kramer’s 
p ost hoc test.
Sem i-quantitative Reverse Transcription PCR
Three replicates for each experimental group were loaded on the sam e gel, in
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alternate lanes, to correct for inter-gel variability. The ratio of the integrated 
optical densities for each gene tested versus actin of each sample was used  as 
individual da ta  for statistical analysis. The difference between groups was 
evaluated by one-way ANOVA followed by Tukey Kramer’s post hoc test.
Western blot
Three to four replicates for each experimental group were loaded on the same gel, 
in alternate lanes, to correct for inter-gel variability. The ratio of the integrated 
optical densities for each protein tested versus actin of each sample was used  as 
individual da ta  for statistical analysis. The difference between groups was 
evaluated by one-way ANOVA followed by Tukey Kramer’s post hoc test.
Treatm ents in vivo
It is known th a t during colony m aintenance loss of gene copy num bers may 
occur (Alexander et a l, 2004). This determ ines relative milder disease progression 
in litters with lower copy num ber. In order to correct for th is  possible 
confounding effect, anim als from the sam e litter were assigned to different 
experimental group and treated a t the sam e time. Moreover sex can affect 
disease progression in G93A mice (Heiman-Patterson et a l, 2005); for th is reason 
treatm ent was done only on female anim als. The experiment was s tarted  when 
anim als were 12 weeks old. Animals from the sam e litter were treated  a t the 
same time. At least 5 anim als were assigned to each experimental group.
Behavioural tests
Analysis of motor perform ances and disease progression in treated anim als was 
perfomed by a  researcher blinded to the treatm ent. Analysis of neurom uscu lar 
im pairm ent was done by two-way ANOVA for repeated m easures followed by 
Bonferroni post hoc te st for comparison between groups. Moreover the age of the 
anim als when their performance, expressed as percentage of the respective best
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trial, overcame a  specific threshold was considered, as outlined below. The Log- 
ran k  test was used  to compare probabilities in th is case (End point analysis).
Measurement Threshold 1evels considered for end point analysis
Body weight Drop of 5% Drop of 10% Drop of 15%
Extension reflex Drop of 25% Drop of 50% Drop of 75%
Hanging time Drop of 25% Drop of 50% Drop of 75%
Rota-rod Drop of 25% Drop of 50% Drop of 75%
Survival
The survival time of the variously treated  groups of mice was analyzed by the log- 
ran k  test.
Number o f surviving motor neurons
The num ber of surviving motor neurons was evaluated by NISSL staining of 24 
spinal cord sections of 30pm thickness, interspaced of 300pm, and  collected 
between spinal cord level L2 and spinal cord level L4 . The m ean num ber of 
surviving neurons for each animal was then calculated. The m ean of three-four 
anim als for each experimental group was used  in the analysis. The difference 
between groups was evaluated by one-way ANOVA followed by Tukey Kramer’s 
post hoc test, and confirmed by Kruskal Wallis non-param etric test.
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CHAPTER 3 
DEVELOPMENT OF STRATEGIES FOR 
TARGETING MOUSE SPINAL CORD 
MOTOR NEURONS IN VIVO
As already mentioned in section 1.6.3 lentiviral vectors represent a  powerful tool 
to drive expression of potential therapeutic genes or shRNAs in neurons or glial 
cells of CNS. It has already been dem onstrated th a t VSVG-pseudotyped lentiviral 
vectors can efficiently infect cells of the striatum , hippocam pus and thalam us in 
m ouse brain, leading to longlasting expression of the transgene. T ransduction of 
these brain areas is generally obtained by direct injection of the virus into the 
brain parenchym a, through stereotaxic surgery (Watson et al., 2002). This 
methodological approach, though invasive, is not reported to induce relevant 
damage to the injected tissue, with the exception of a  mild inflammatory reaction 
in the area immediately surrounding the injection site (often referred to as the 
needle tract) (Ahordo-Adesida e t a t ,  2005). Nevertheless some drawbacks can be 
observed: a) the spread of the solution injected in the brain parenchym a is 
limited due to high density (high num ber of cells/area) of the tissue; b) the 
injected volume cannot be increased further th an  luL /in jection site, since the 
brain may suffer for an increm ent of intracranic pressure as a  consequence of 
excessive fluid in the parenchyma.
A similar approach h as been recently adopted for delivery of viral vectors to 
spinal cord tissue. In th is case a  laminectomy of the vertebra covering the area of 
in terest is necessary, to allow multiple injections in several adjacent segm ents of 
the spinal cord. A num ber of studies have described the use  of th is technique in 
the rat, mainly in models of spinal cord injury (Zhao e t a t,  2003; A bdellatif e t a l ,  
2006; Hendriks e t a t ,  2007). The first report of the use  of th is technique in 
m ouse is from Guillot and  colleagues (Guillot et al., 2004). The au thors performed 
intraspinal injection of p-Gal-expressing lentivector in two bilateral sites 
separated by 1.5 mm along the spinal cord, in 40-day-old mice. They reported a  
robust reporter gene expression in the neurons, with the signal widely 
distributed in the spinal cord parenchym a, and an absence of deterioration of 
functional motor behaviour in the anim als. Moreover, they provided the first 
evidence th a t the procedure, though invasive, can be used  for assessm en t of
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potential therapeutic genes, such as GDNF, in the SOD1G93A m ouse model of 
ALS. Interestingly, in a  subsequent paper the sam e group delivered lentiviral 
vectors carrying a  hum an  SO D l-targeted shRNA in the spinal cord of 
presym ptom atic SOD1G93A mice. This resulted in a  substantia l reduction of 
m u tan t SOD1 protein level in neurons and glia, with a  delay in the onset and 
progression of the disease (Raoul e t a l ,  2005b). Since these studies dem onstrated 
th a t an  intraspinal delivery approach can be successfully used  in SOD1G93A 
mice, we decided to use  the same strategy to test the effect of new potentially 
therapeutic genes or shRNAs in the sam e model of ALS.
In the following sections the steps for development of lentiviral vectors suitable 
for in vivo delivery will be described.
3.1 Protocol for production o f lentiviral vectors at high titre
Lentiviral vectors for in vivo delivery are usually  produced a t high titres, in the 
range of 108-109 TU/mL (Guillot e t al., 2004; Hendriks et a l ,  2007). This 
concentration is needed due to the fact th a t only small volumes of the viral 
solution can be injected. Moreover, further purification of viral vector-containing 
supernatan ts  is necessary to remove cell debris and serum , th u s  reducing the 
probability of inducing detrim ental inflammatory responses after injection in vivo 
(Baekelandt e t a l ,  2003).
For these reasons several modifications to the standard  viral vector production 
protocols have been suggested; the m ost effective are listed below:
enrichm ent of the culture m edium with cholesterol-containing additives, 
to increase efficiency of budding of enveloped viruses (Mitta e t a l ,  2005), or 
with sodium  butyrate, found to stim ulate the activity of both HIV-1 LTR 
and CMV promoters in transfected plasm ids (Soneoka e t a l,  1995; White e t 
a l, 1995; Gasmi et a l ,  1999);
scale up  of the num ber of cell culture plates used  for virus production, 
followed by ultracentrifugation (or ultrafiltration) of the su p ern a tan t
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c o n ta in in g  th e  viral vector, a n d  re su sp e n s io n  of the  pelle t (or eluate) in  a  
sm all a m o u n t of PBS (Sena-E steves e t al., 2004).
We s ta r te d  a  co llabora tion  w ith  th e  labo ra to ry  of M olecular O ncology of the 
U niversity  of T u rin  w hich  h a s  e s ta b lish e d  a n  efficient p ro ced u re  for v iral vector 
p ro d u ctio n  (Piva e t a l ,  2006). M inor m odifications w ere in tro d u ced , th a t  
m an ag ed  to fu rth e r  in crease  v iral partic le  p roduction : the  n u m b e r  of 293T  cell 
c u ltu re  p la te s  tra n sfe c te d  a t  th e  sam e  tim e w as sca led  u p  to 5, to in c rease  the  
final a m o u n t of viral vector co n ta in in g  s u p e rn a ta n ts ;  c u ltu r in g  m ed iu m  w as 
su p p le m e n te d  w ith  so d iu m  b u ty ra te ; finally th e  v iru s  w as co llected  by 
u ltra ce n trifu g a tio n  a n d  re su sp e n d e d  in  a  very sm all a m o u n t of PBS, lead ing  to a  
final viral titre  of 2 .7 x l0 9 T U /m L  (Table 3.1). T his c o n c en tra tio n  is in  th e  range 
d escrib ed  by R aoul a n d  co-w orkers for th e  delivery of VSV-G vecto rs  in  th e  sp in a l 
co rd  of SOD1G93A m ice (Raoul e t al., 2005b).
Table.3 .1 . High titre production o f  VSVG pseudotyped  lentiv ira l vectors
Storting conditions
Plasmids
Amount of ONA 
(P9)
Trials Additives
Fold concentration of 
supernatant
Titre (TU/mL)
Envelope pVSVS 0.60 1 / / iOOx 2.0x10s
Adjuvant pCMV 1.00 2 lOmM Nln8utyrate 200x 5.8xl03
Adjuvant pREV 0.50 3 lOmM NaBufyrate 400x 2.7xl09
Transfer vector pLVTWM 2.50
3 .2  D irect in jection  in to  sp inal cord parenchym a
In in itia l experim en ts  h igh  titre  len tiv iral vecto rs ex p ressin g  a  GFP rep o rte r  gene 
(see m ap  of WPXLd vector in  sec tion  2.1.1) w ere in jec ted  in to  th e  sp in a l cord  
p a re n c h y m a  of NTg m ice, to verify th e  d is tr ib u tio n  of th e  v iru s  a n d  its  efficiency 
of infection. As d escribed  in section  2 .2 .3 , the  v iru s  w as delivered  a t  th e  L3  a n d  
L4  level of the  sp in a l cord  a fte r lam inectom y of Li verteb ra . Two w eeks a fte r  
in fection  an im als  w ere sacrificed  by p e rfu sion  a n d  lu m b a r  sp in a l co rd  w as 
d issec ted . Serial coronal sec tio n s  w ere c u t  s ta r tin g  from  th e  sp in a l co rd  se g m en t 
co rresp o n d in g  to T 1 3 v e rte b ra  (24 section  of 30gm  th ic k n e ss  w ere collected , 
in te rsp a c e d  of 300fj.m). The specim ens w ere th e n  v isua lized  u n d e r
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epifluorescence microscope to qualitatively assess the extent of GFP expression. 
GFP positive cells were detected from L2 to L4 level, with maximal expression in 
the areas proximal to the injection sites (Figure 3.1). GFP was expressed in both 
neurons and glial cells (astrocytes and oligodendrocytes) of lum bar spinal cord as 
determined by im m unohistochem istry (Figure 3.2).
3.3  Use o f neuron-specific promoters in lentiviral vectors
Preliminary experiments confirmed th a t direct injection of high titre VSV-G 
pseudotyped lentivirus into spinal cord parenchym a guaranteed high efficiency of 
infection of several cell types. One of the aim s of the project was to induce Akt 
pathw ay activation specifically in motor neurons. It has  been dem onstrated th a t 
reporter gene expression can be selectively restricted to neurons, including spinal 
cord motor neurons, by using prom oters such  as those for Choline Acetyl 
Transferase (ChAT) or neurofilam ent heavy chain (NF-H). However, these 
constructs are large (6.4Kb for ChAT and 8.5Kb for NF-H) and although they 
have been used  to produce transgenic mice (Naciff et a l, 1999; Hirasawa et a l, 
2001) they are not suitable for transfer in a  lentiviral vector, as the resulting 
cassette would exceed the maximal cloning capacity. Therefore, as first approach 
we used  a  neuron-specific prom oter of reduced length for replacem ent of the 
original ubiquitous E F la  promoter, in order to restrict transgene expression to 
neuronal cells.
3.3 .1  A ssessm ent o f viral vectors carrying the rNSE promoter
A lentiviral vector construct containing the ra t Neuron Specific Enolase prom oter 
(rNSE) was first described by Jakobsson and colleagues (Jakobsson et a l, 2006). 
They tested its efficiency of expression in vivo, in the ra t brain, revealing strong 
longlasting expression in striatal neurons, with no ectopic expression in glial 
cells. Based on this evidence we decided to use  the same prom oter to obtain 
selective expression of our constructs in m ouse spinal cord neurons. The
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WPX.NSE.GFP vector was generated by subcloning of the Clal/BamHI fragment 
derived from LV.NSE into the C lal/Sw al site of pWPXLd (BamHI and Swal sites 
destroyed). Transfection of these plasm ids in vitro, in mixed neuron-astrocyte co­
cultures, led to specific expression of the GFP reporter gene in neurons, with low 
ectopic expression in astrocytes (Figure 3.3). When the sam e cultures were 
infected with lentiviral vectors generated from th is construct no signal 
corresponding to GFP was detected. To verify w hether the lentiviruses were 
capable of infecting the cells, the sam e experiment was repeated and  the genomic 
DNA was extracted from the culture 3 days later. The presence of GFP as a  
m arker of integration of the viral DNA was confirmed by PCR (primer set listed in 
section 2.2.10). This comfirmed th a t the lentiviral vectors were functional (Figure 
3.4), as we were able to detect the viral DNA integrated into the genome of the 
host cells, although transgene expression was still absent. To control th a t the 
lack of expression was not related to defects of the construct, we used  it to infect 
ra t cortical neurons, and we were able to detect GFP signal, though it was very 
faint (data not shown). Therefore, we tested the vector in vivo, in mice, to 
determine w hether it displayed the sam e efficiency reported by Jackobsson in the 
ra t brain, or w hether it displayed the sam e failure to express as found in the 
m urine cultures. Two weeks after injection of the vector in the spinal cord 
parenchym a of NTg mice, a  fine expression of GFP reporter gene w as detected in 
large neuronal cells of ventral horn spinal cord (Figure 3.5), as confirmed by co­
localization of the signal with Neurotrace staining (arrow in A-C). However, 
expression could also be observed in some very small neurons localized in the 
ventral and in the dorsal area of spinal cord (asterisks in A-C, and  D-F), as well 
as in some non-neuronal (probably glial) cells, localized in the gray and  white 
m atter (arrowheads in A-C). To overcome th is expression in non-neuronal cells 
we decided to develop a motor neuron-specific construct, starting  from the 
already described Hb9 prom oter (Arber et a l, 1999).
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3 .3 .2  Preparation o f lentiviral vectors w ith motor neuron-restricted  
expression
Recently a  3.6Kb enhancer inside the 11Kb prom oter of Hb9 has been identified. 
The 3.6Kb enhancer drives selective expression of reporter genes in spinal cord 
m otor neurons in transgenic mice (Nakano et a t , 2005), and is sufficiently short 
to be suitable for cloning into a  lentiviral vector. A Notl/Sbfl fragm ent containing 
the 3.6Kb enhancer was cloned out of the original l l k b  prom oter of Hb9, and 
transferred into the Notl/BamHI site (BamHI site destroyed) of a  plasm id 
containing the p-globin minimal prom oter and GFP as reporter gene (Figure 3.6). 
Mixed neuronal-astrocyte co-cultures were transfected with Hb9_3.6Kb, in 
parallel with a  plasm id with a  non-specific prom oter (CMV). Cell specificity of 
reporter gene expression was verified 3 days later. The Hb9 construct displayed 
selective expression in neuronal cells, with very low ectopic expression in the 
glial cells in contrast with the CMV prom oter th a t resulted in transgene 
expression in both neurons and astrocytes (Figure 3.7).
In subsequent experiments we tried to sub-clone 3.6Kb enhancer into a  lentiviral 
vector plasm id. A Sall/Sbfl fragment (containing 3.6Kb enhancer and p-globin 
minimal promoter) was excised from Hb9_3.6Kb plasmid. The aim was to ligate 
th is construct into the Sall/Sw al sites of pWPXLd, to substitu te  the constitutive 
E F la  promoter, after blunting of Sbfl extremity. However, th is was no t possible, 
probably due to the high frequency of recom bination when working with large 
inserts. Therefore, we tried to reduce the length of the prom oter w ithout affecting 
its specificity. Nakano and co-workers have described two short sequences (called 
"region A” and  “region B”) within the 3.6Kb enhancer of Hb9 (Figure 3.6), th a t are 
responsible for specificity of expression: region B is an enhancer th a t drives 
expression in motor neurons; w hereas region A behaves as a  repressor in not- 
neuronal cells (Nakano et a l, 2005). In initial experiments region A and  region B 
were cloned by PCR and fused in a  new 500bp prom oter construct (Bg.AB) in 
collaboration with Mami Kurosaki and Mineko Terao from the Lab. of Molecular
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Biology, Mario Negri Institute. Bg.AB was then transfected in mixed neuronal- 
astrocyte co-cultures. 3 days after transfection GFP reporter gene expression was 
detected in neurones (Figure 3.8), however strong ectopic expression was also 
observed in the surrounding astrocytes (Figure 3.9, A-D). As an alternative 
approach, we looked for cloning sites th a t helped to increase the distance 
between the regions A+B, and the p-globin minimal promoter, in a  similar way to 
the pattern  observed in the Hb9_3.6Kb construct. A single-cutting restriction site 
(Ndel) was found a t 1.6Kb within the 3.6Kb enhancer. Ndel was used  to sub ­
clone the resulting Sall/N del 1.6Kb fragm ent (containing regions A and B) before 
the p-globin minimal prom oter in a  new construct (Bg. 1.6Kb). Bg. 1.6Kb 
dem onstrated the greatest selectivity for neurons after transfection in mixed 
neuronal-astrocyte cultures (Figure 3.9, E-H). The new prom oter regions were 
subsequently excised from Bg.GFP plasm id by Sall/Sbfl cut, and then 
successfully religated into the Sall/Sw al site of pWPXLd, after blunting of Sbfl, to 
replace the E F la  promoter. The resulting W.AB and  W. 1.6Kb plasm ids were used  
for the production of high titre lentiviral vectors, and  adm inistered in the spinal 
cord parenchym a of NTg mice. Two weeks after infection, anim als were sacrificed 
and the lum bar spinal cord was sectioned, to verify the efficiency of infection and 
specificity of GFP reporter gene expression. W.AB resulted in expression of GFP 
in some large ventral horn neurons (Figure 3.10, arrow in D-F), although reporter 
gene expression was more frequently detected in sm aller neurons (Figure 3.10, 
asterisks in D-F), and in glial cells throughout the gray and white m atter, and  in 
the dorsal horn (Figure 3.10 arrowheads in A-C). In con trast in anim als treated 
with the W.1.6 vector specific expression of GFP reporter was only detected in 
large (Figure 3.11 arrowheads in A-C) and very large (Figure 3.11 arrows in A-C) 
neurons of the ventral horn spinal cord. Colocalization with ChAT staining 
confirmed th a t these cells were motor neurons. No ectopic expression in glial 
cells was observed.
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Figure 3.1
P a tte rn  o f GFP rep o rte r gene expression 
a fte r in jec tion  in  th e  sp inal cord parenchym a
GFP reporter gene expression in spinal cord 2 weeks after injection of a  lentiviral vector. 
From top to bottom, three subsequent serial sections, separated by 600pm, are shown for 
each of the levels L2 , L3 and L4 . Scale bar = 200pm
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Figure 3.2
Tropism  of VSVG-pseudotyped len tiv ira l vecto r 
a fte r delivery in th e  sp inal cord parenchym a
Laser scanning confocal microphotographs of GFP expression in lum bar spinal cord of 
mice, two weeks after injection. GFP expression in neurons, stained with Neurotrace 
fluorescent NISSL (arrows in A-C) and some neurites (arrowheads in A). GFP expression 
in astrocytes, confirmed by colocalization with a  glial-specific intermediate filament, 
GFAP (arrows in D-F) and oligodendrocytes, confirmed by CNPase staining, which 
recognizes an oligodendrocyte-specific enzyme (arrowheads in G-I). Scale bar in G applies 
to A-I = 100pm
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Figure 3.3.
Use of rNSE prom oter leads to specific transgene expression
in neurons, in vitro
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Representative photographs of reporter gene expression 3 days after transfection of mixed 
neuron/astrocyte co-cultures with rNSE promoter construct. Scale bar = 200pm
Figure 3.4.
Viral vectors carrying the rNSE prom oter efficiently infect cells , in vitro
Viral vectors
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3500 bp
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750 bp
1500 bp Representative PCR to assess the presence of
the lentiviral vector genome in 
neuron/astrocyte co-cultures after infection 
with an empty vector expressing GFP (VSVG 
pLVTHM-GFP), or a vector expressing GFP 
under rNSE promoter (NSE-GFP). A positive 
signal is observed in the DNA samples from
-----------------------------  cultures infected with the viruses.
PCR for GFP
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Figure 3 .5 .Viral vectors carrying rNSE prom oter can infect cells in vivo, in
the mouse
GFP Neurotrace Merge
w m m
mmamm
w m
Laser scanning confocal photomicrographs of GFP expression in lum bar spinal cord of 
mice, two weeks after injection of a  viral vector carrying rNSE promoter. Representative 
images of the different spinal cord levels are shown: L2 (A-C), L3 (D-F), L4 (G-I). The 
construct is able to drive expression in large ventral horn spinal cord neurons (arrows in 
A-C), but also in small neurons of ventral (asterisks in A-C) and dorsal spinal cord 
(asterisks in D-F). Moreover ectopic expression can also be detected in some non­
neuronal cells, probably glial cells (arrowheads in A-C). Scale bar = 100pm
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Figure 3 .6 .
Schem e o f  3.6Kb enhancer derived  from  original 11Kb Hb9 prom oter
Hb9 9.0Kb
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Figure 3 .7
Hb9_3.6Kb-GFP can drive selective expression of transgene
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Representative photographs 
of reporter gene expression 
after transfection of mixed 
neuron /  astrocyte co -
cultures with the CMV 
ubiquitous promoter
construct (A), or with 
Hb9_3.6Kb promoter
contruct (C and E). B, D, F, 
light field picture of the 
culture shown in A, C, E. 
Scale bar = 200pm
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Figure 3 .8 .
Schem e o f  the new con stru cts derived  from  3.6K b enhancer
H b9_3 .6K b
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Figu3.9 . 
Neuron specific expression o f transgene after transfection  
of Bg.AB and Bg. 1.6Kb constructs in mixed co-cultures
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Representative photographs of reporter gene expression after transfection of mixed 
neuron/astrocyte co-cultures with the Bg.AB (A-D) or Bg. 1.6Kb (E-H) neuron specific 
constructs. Bg.AB drives expression of GFP in neurons (arrows in A, C) as well as in 
astrocytes (arrowheads in A, C). In contrast, with Bg. 1.6Kb the reporter gene is mainly 
localized in neuronal cells (arrows in E, G), with low ectopic expression in glial cells 
(arroheads in E, G). Scale bar = 200pm
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Figure 3.10.
Viral vectors carrying the Hb9.AB prom oter can infect motor neurons 
in vivo but lead to ectopic expression in non neuronal cells
Neurotrace
/
Laser scanning confocal photomicrographs of GFP expression in lum bar spinal cord of 
mice, two weeks after injection of a  viral vector carrying the Hb9.AB promoter. 
Representative images of the different spinal cord levels are shown: L2 (A-C), L3 (D-F), L4  
(G-I). The construct is able to drive expression in ventral horn spinal cord large neurons 
(arrow in D-F), as well as in small neurons (asterisks in D-F). However there is prom inent 
ectopic expression in non-neuronal cells throughout the spinal cord and  in the dorsal 
horn (dh) (arrowheads in A-C). Scale bar = 100pm
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Figure 3.11.
Viral vectors carrying the Hb9.1.6Kb prom oter d isp lay higher specificity  
fo r  ventral horn neurons in the spinal cord in vivo
GFP Neurotrace Merge
GFP Merge
1 1
Laser scanning confocal photomicrographs of GFP expression in the lum bar spinal cord 
of mice, two weeks after injection of a  viral vector carrying the Hb9.1.6Kb promoter. 
Representative images of the different spinal cord levels are shown: L2 (A-C), L3 (D-F), L4 
(G-I). The construct drives selective expression in ventral horn spinal cord neurons 
(arrowheads in A-C), as well as in some very large neurons (arrows in A-C, G-I). Little or 
no expression is detected in small neurons (asterisks in A-C), neither in non-neuronal 
cells nor in dorsal horn (dh). Large GFP positive neurons are motor neurons, as 
confirmed by colocalization with ChAT staining (L-N). Scale bar in I applies to A-H = 
100pm; Scale bar in N applies to L, M = 50pm
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3 .4 . D iscussion
We have successfully designed and  developed a  lentiviral vector-based platform 
to target different spinal cord cell populations, in vivo, in the mouse.
Since a  high titre vector preparation is needed for efficient delivery in vivo, we 
developed a  protocol aimed a t increasing viral particle production. According to 
previous reports (Soneoka e t a t , 1995; Gasmi e t a t ,  1999), we observed increased 
titre of VSVG lentivector using sodium  butyrate in culture medium. This is 
probably due to increased transcription of our transfer vectors (plasmids 
pLVTHM or pWPXLd), since they contain a  wild type 5’ HIV-1 LTR sequence, 
whose activity is positively affected by sodium butyrate treatm ent (White e t a t ,  
1995). Moreover, in our production procedure we transfected the pRSV.REV 
plasm id together with the standard  two adjuvant plasm ids (envelope and  gag- 
pol). In our pRSV.REV plasm id the expression is under the control of RSV 
promoter, whose efficiency is known to be enhanced by sodium  butyrate 
treatm ent (Gorman et a t ,  1983). It is th u s  possible th a t sodium  butyrate  may 
also have exerted positive effects by enhanced expression of Rev. Rev is in fact 
necessary for translocation of the viral RNA genome from nucleus to the 
cytoplasm, where viral capsids are synthesized; it has been dem onstrated th a t 
high expression of this adjuvant protein, from a  separate plasm id, aids the 
packaging of full infective viral particles (Dull e t al., 1998). At variance w ith our 
results, in a  recent study it has been shown th a t the use of sodium  butyrate  as 
an  additive in culture m edium does not improve the titre of VSVG-pseudotyped 
lentivectors (Sena-Esteves et a l ,  2004). This discrepancy can be explained by the 
fact th a t in the work by Sena Estevez the transfer vector contained a  5 ’LTR fused 
to CMV, a  modification th a t already enhances transcription of the transfer vector 
genome in a  tat-independent m anner (Naviaux et al., 1996; Blesch, 2004). This 
may account for no further sensitivity to the effect of agents like sodium  
butyrate.
High titre lentiviral vectors, produced with our modified protocol, were delivered 
to NTg mice by direct intraspinal injection. Qualitative assessm ent of GFP 
reporter gene expression after two weeks confirmed the infection of neurons and 
glia, th roughout the gray and  white m atter of the spinal cord. Neurons and 
oligodendrocytes were highly transduced, while GFP-positive astrocytes were 
detected to a  lesser extent in general agreem ent with a  previous study (Guillot et 
a l, 2004).
As second step in the vector development process, we successfully obtained 
neuron targeted gene expression in vivo. This was achieved by substitu tion  of the 
ubiquitous E F la  prom oter within the viral transfer vector, with neuron-specific 
regulatory sequences previously described in the literature.
The ra t NSE prom oter was initially tested, as its u se  in lenvitiral vectors had 
already been validated in ra t brain (Jakobsson et a l, 2006). We found th a t 
lentivectors containing the rNSE prom oter were not suitable for infection of 
m urine neuronal-astrocyte co-cultures in vitro, and dem onstrated th a t the lack 
of reporter gene expression was not due to a  defect in the infectivity of the viral 
particles. In fact we were able to detect the presence of viral DNA integrated in 
the genome of infected cultures. Since expression of the reporter gene was 
detected only after infection of neuronal cultures obtained from rat, or after 
transien t transfection of m urine cultures with the rNSE transfer vector, we 
hypothesize th a t this prom oter may be silenced after integration in the genome of 
m urine cultures, in vitro. Nevertheless, in traspinal injection of rNSE viral 
vectors, in the mouse, dem onstrated th a t this prom oter is highly active in adu lt 
neurons, in vivo. In particular, we observed th a t in the m ouse spinal cord 
reporter gene expression was localised mainly in small neuronal cells, and  less 
frequently in large ventral horn motor neurons. Moreover, we also detected 
ectopic expression in non-neuronal cells.
It has been reported th a t NSE gene expression in neurons increases during 
development with differentiation of adult m ature neurons (Schmechel e t a l,
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1980). Moreover constructs containing 1.8Kb of the NSE prom oter sequence lead 
to specific expression in terminally differentiated neurons, and  progressive 
accum ulation of reporter gene during development in vivo, in the m ouse (Forss- 
Petter e t al., 1990). At variance with the study from Forss-Petter, we used  a 
shorter promoter sequence (Jakobsson et a l, 2003), so it can be hypothesized 
th a t some additional regulatory sequence is lacking, th u s  determ ining inefficient 
expression in mouse cultures in vitro, and  reduced selectivity in vivo.
Due to this lack of specificity for the motor neuronal population, rNSE lenvitiral 
vectors were not developed further.
We provided evidence th a t enhancer sequences derived from the Hb9 prom oter 
can be cloned in lentiviral vectors and are more selective for spinal cord motor 
neurons. Indeed, motor neuron specific expression of (3-Gal h as been already 
described in adult transgenic mice expressing LacZ gene under a  3.6Kb prom oter 
construct derived from Hb9 prom oter (Nakano e t al., 2005). These au thors also 
dem onstrated th a t two short sequences (region A, of 313bp and  region B, of 
125bp) within this construct play a  key role for the specific expression of the 
reporter gene. When these regulatory sequences were in close proximity to the 
open reading frame of the gene located downstream  (construct W.AB), we found 
th a t expression occurred in neurons and glial cells, both in vitro and  in  vivo in 
m ouse spinal cord. It is possible th a t this allocation of upstream  regulatory 
sequences does not allow sufficient bending of DNA. This process is usually  
required for correct regulation of the initiation of transcription. In fact, in the 
original 3.6Kb construct, the A and B regions are more th an  3Kb upstream  of the 
transcription s ta rt site, so they may be considered as long-range regulatory 
sequences, similar to repressor sequences like REST, thyroid horm one receptors 
and the zinc-finger of NK-10 (Thiel et al., 2001; Vilar and Saiz, 2005). As 
confirmation of this hypothesis, we dem onstrated th a t positioning the A and B 
regions 1.6Kb upstream  of transcription starting site was sufficient to increase 
the specificity for neurons in vitro. This construct was successfully subcloned
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into a  lentiviral vector (W. 1.6Kb), and proved to be m otor-neuron specific after 
intraspinal injection in vivo in the mouse.
Overall these experim ents highlight th a t lentiviruses carrying an Hb9 derived 
promoter can be regarded as powerful tool for motor neuron specific expression 
of a  transgene in the spinal cord in vivo.
CHAPTER 4  
INDUCTION OF THE AKT PATHWAY
As highlighted in section 1.3.7 there is emerging evidence th a t im pairm ent of the 
PI3K/Akt signalling pathway may be involved in ALS. However the precise role 
played by Akt in the progressive pathology of ALS needs to be elucidated, as 
there are contradictory reports in the literature. Indeed, a  reduction of PI3K and 
total Akt p ro te in . levels h as been reported in hom ogenates and  m otor neurons 
from the spinal cord of asymptomatic SOD1G93A low-expressing mice, 
suggesting th a t a  downregulation of the PI3K/Akt pathway may occur in ALS 
(Warita et a l, 2001). However, the same group has also reported increased 
nuclear staining for P-Akt in motor neurons in the same anim al model (1lieva et 
a l, 2003). In a  more recent study P-Akt was found to be reduced in the spinal 
cord of SOD1G93A mice even a t the presym ptom atic stage, and these 
observations were confirmed in post-m ortem  tissues from hum an  ALS patients 
(Dewil et a l, 2007b). In contrast, in our own studies we failed to observe changes 
in P-Akt in SOD1G93A mice during disease progression (Peviani et a l, 2007) and 
levels were similar to controls, both a t the pre-sym ptom atic stage and  after 
symptom onset. The differences among these studies may be dependent on some 
methodological issues, such as the use of different anti-P-Akt antibodies, or a  
lack of uniformity between the protocols for tissue homogenisation and  protein 
extraction. Moreover we detected P-Akt staining in some motor neurons showing 
perikarial accum ulation of phosphoiylated neurofilam ents (a sign of 
degeneration), suggesting th a t death of these cells is probably no t simply the 
consequence of a  loss of Akt activation.
Nevertheless, since induction of Akt is part of a  process th a t is norm ally activated 
to m aintain the survival of neurons including motor neurons after an  insult, for 
example an axotomy, it is conceivable th a t a  reduction or no change in the levels 
of activated Akt may contribute to the incapacity of these cells to react to injury, 
th u s  leading to their death. Therefore, we hypothesised th a t the induction of P- 
Akt in motor neurons of SOD1G93A mice could help these cells to counteract the 
m echanism s leading to death, th u s  resulting in a  delay in the pathology. In fact
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delivery of IGF-I to SOD1G93A mice through motor neuron-targeted viral vectors 
(Kaspar et a l,  2003), or through intrathecal infusion (Nagano e t a l ,  2005) 
partially reduced motor neuron loss and delayed disease progression and this 
effect was paralleled by increases of P-Akt in the spinal cord. Similarly, 
adm inistration of a  GDNF-expressing adenovirus in hindlimb m uscles of the 
sam e animal model produced a  sustained  induction of P-Akt in the motor 
neurons of the spinal cord (Manabe e t a l ,  2002); moreover 
intracerebroventricular treatm ent of SOD1G93A ra ts  with VEGF resulted in 
improvement of motor performance, prolonged survival and  increased P-Akt 
levels in the spinal cord (Storkebaum et a l ,  2005; Dewil e t a l ,  2007b).
However, it is currently not clear w hether the above effects, observed in ALS 
rodent models after treatm ent with IGF-I, VEGF and  GDNF, may be dependent 
only on activation of the Akt pathw ay in motor neurons. In fact, several studies 
have shown th a t these growth factors can act also on other kinases, such  as ERK 
and JNK (Derijard e t al., 1994; Sullivan et al., 2008) and  can influence the 
proliferation and survival of glial cells (Mani e t al., 2005; Chesik et a l,  2008). 
Therefore, we decided to develop a  lentiviral-vector m ediated, gene-based, 
approach aimed a t inducing specific activation of the Akt pro-survival pathw ay in 
spinal cord motor neurons of SOD1G93A mice. In order to obtain susta ined  
induction of the Akt pathway, we decided to use  a  m u tan t protein derived from 
the fusion of Akt, a t the N-terminus, with a  short 13 aminoacid sequence, a  
myristylation recognition site. As m entioned in section 1.5.4, th is  s truc tu ra l 
modification leads to constitutive m em brane translocation of the kinase, th u s  
determining continuous activation of the enzyme in a  PI3K-independent m anner. 
Moreover delivery of th is gene through a  lentiviral integrating vector is expected 
to provide longlasting transgene expression, helping to m aintain increased levels 
of Akt phosphorylation during disease progression.
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4.1 Generation of constitutively activated Akt constructs
It has been shown th a t Akt3, one of the three isoforms of Akt, displays specific 
neuroprotective properties in NSC34 cells, antagonizing m u tan t SOD1 toxicity 
specifically, whereas A ktl appears to have a  more generalized anti-apoptotic 
effect (Kanekura et a t, 2005). The sam e group provided further evidence for a  role 
for Akt3 in neuroprotection with the identification of a  novel Akt3-interacting 
protein, called BTBD10. Overexpression of BTBD10 in vitro inhibited PP2A 
activity, th u s  preventing Akt3 dephosphorylation, and leading to suppression of 
m u tan t SOD1 induced cell death (Nawa et al., 2008). Therefore, we decided to 
develop a  constitutively activated Akt3 m u tan t protein (Myr.Akt3) and to 
subclone it in a  lentiviral vector containing a  neuron specific promoter, to allow 
specific expression in spinal cord motor neurons in vivo.
In initial experiments, Myr.Akt3 was prepared by fusion of a  myristylation 
sequence to the N-terminal of hum an HA.AKT3 (a fusion protein containing 
HAtag a t its N-terminal), and  its function tested in vitro, in com parison with 
Myr.AKTl, a  similar fusion protein previously validated in the literature 
(Andjelkovic et a t, 1997). Briefly, the HA.AKT3 construct contained in plasm id 
pAKT3 was amplified by PCR, using  the prim er set and protocol described in 
section 2.2.12. The amplicon was then  cut by Kpnl and Xbal and  ligated into 
plasm id pMyr.AKTl, after KpnI/Xbal excision of the Myr.AKTl construct. 
Myr.AKT3 was first sequence verified, and then  tested in parallel w ith a  control 
empty vector and the pMyr.AKTl plasm id, by transfection into HEK293 cells. 
Cells were lysed 3 days later, and  proteins were extracted for w estern blot 
analysis (protocol described in section 2.2.11). Efficient induction of the Akt 
pathw ay was detected with both Myr.AKTl and Myr.AKT3, as dem onstrated by 
increased levels of Akt phosphoiylated a t Ser473, and corresponding increase of 
GSK3P phosphorylated a t Ser9 (a specific downstream  target of Akt) (Figure 4.1). 
Myr.AKT3 was subsequently excised from pcDNA3.1H+ by KpnI/Xbal cu t and  
religated into Pm el/Spel sites of pWPXLd lentiviral vector, after excision of GFP
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(Pmel and Spel sites destroyed). An initial batch of lentivirus was produced with 
the protocol described in section 2 .2 .1, using the new transfer vector 
(WPX.Myr.AKT3). 5 pL/well of concentrated virus (corresponding to 5 ,0 x l0 6 TU) 
were added to prim ary mixed neuron-astrocytes co-cultures in 48 well plates, to 
te st for infectivity and  function of the new construct. A control GFP expressing 
viral vector (WPXLd) was tested in parallel. 3 days after infection DNA was 
extracted from 4 wells/condition (protocol described in section 2.2.10), and 
proteins were obtained from the remaining 2 wells (protocol described in section 
2.2.11). PCR amplification of integrated viral DNA confirmed th a t WPX.Myr.Akt3 
was fully infective (Figure 4.2,B) while w estern blot analysis of cell lysates 
dem onstrated th a t Myr.Akt3 was functional, as increased levels of P-Akt were 
detected in cells infected with the new construct (Figure 4.2,C).
As a  final step, the enhancer elem ents of Hb9, fused to p-globin minimal 
promoter, were excised from Hb9_1.6Kb plasm id (described in chapter 3) by 
Sall/Sbfl digestion and then  religated into Sall/Sw al sites of WPX.Myr.AKT3 (Sbfl 
and Swal sites destroyed), after excision of the E F la  ubiquitous prom oter. The 
new W.1.6.Myr.AKT3 viral vector construct was then used  to generate high titre 
viral vectors, for delivery in vivo.
4 .2  Effect o f induction o f Akt pathway in vivo, in SOD1G93A m ice
Lentiviral vectors W.1.6.Myr.AKT3 were intraspinally injected in 84day old 
SOD1G93A mice (n=7; Group E), following the protocol described in section 
2.2.3. As control groups, SOD1G93A anim als were injected with an  em pty vector 
expressing GFP (n = 6 ; Group B), and  a  further group of anim als underw ent 
laminectomy b u t did not receive an injection (n = 5; Group A). Motor perform ance 
and disease progression were analysed twice a  week, as outlined in section 2.2.4. 
Treatm ent with Myr.Akt3 did not significantly alter the survival of SOD1G93A 
mice, as compared to the control groups (Figure 4.3)
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We did not detect any difference between the three groups for the progression of 
body weight loss (Figure 4.4 A) or deficits of extention reflex (Figure 4.4 B) or 
rotarod performance (Figure 4.4 D). On the grid test, Myr.AKT3 treated mice 
showed a  trend towards a  better performance th an  control group A starting  at 
107 days of age, while from 118 days they showed a  worst m otor performance in 
respect to the group which received only EV (group B) on the sam e test (Figure 
4.4, C). It is worth to note th a t disease progression in Group B was not 
significantly different from Group A, except for a  tendency to a  less steep 
decrease of motor performance on the grid test, starting  from 111 days of age. 
However, despite the subtle differences observed in Myr.AKT3 treated  group at 
the early phases of the pathology, the onset of disease (as assessed  by endpoint 
analysis of performances) was not significantly delayed by the Myr.AKT3 
treatm ent (Figure 4.5, A). The sam e resu lts were obtained by com parison of the 
probability to reach more advanced stages of the disease (reduction of 
performance below 50% and 75% of the best performance) (Figure 4.5, B, C). 
However a t the end stage, the hindlim bs of anim als from Group A and B 
appeared completely paralysed, as expected with the severe loss of motor 
neurons a t th a t phase of the pathology, whereas mice th a t received Myr.AKT3, 
still retained some movement of the digits.
To analyze the effects of Myr.AKT3 expression on motor neuronal survival, the 
spinal cords from anim als a t the age of sacrifice were collected, and  then  
sectioned for NISSL staining. Neurons were classified according to their area. The 
m ean num ber of motor neurons (with an  a rea  higher th an  250pm 2) was 
considered in the analysis. Interestingly, the num ber of surviving cells in 
Myr.AKT3-treated group (16.53+/- 0.86 cells/hem isection) was significantly 
higher than  the empty vector-treated Group B (12.67+/-1.06 cells/hem isection), 
and  the control Group A (ll,8 1 + /-0 .2 7  cells/hemisection)(Figure 4.6 A). To 
further confirm th a t the observed effect was due to Myr.AKT3, the expression of 
the transgene was visualized by im m unohistochem istry, through staining of the
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HAtag. In the spinal cord of anim als injected with Myr.AKT3 lentivectors a  clear 
expression of Myr.AKT3 could be detected in spinal cord motor neurons, as 
highlighted by colocalization of HAtag staining with MAP2 (Figure 4.7). HAtag 
was mainly localized a t the subm em brane and cytoplasmic level, with a  weak 
signal detected in the nucleus. This is consistent with prevalent m em brane 
targeting of the fusion protein, due to the presence of the myristylation sequence. 
Notably, infected motor neurons also displayed intense P-Akt immunoreactivity. 
This signal was only partially colocalised with HAtag, further supporting the 
evidence of a  basal level of Akt phosphoiylation in the motor neurons of 
SOD1G93A anim als. Nevertheless, P-Akt immunoreactivity appeared to be higher 
in the motor neurons of Myr.AKT3 infected anim als than  in the control group, 
suggesting th a t expression of the transgene had  indeed resulted in increased Akt 
activation (Figure 4.8).
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Figure 4.1
Preparation o f constitu tively activa ted  AKT constructs 
and validation in vitro
A. Myr.AKTl
Myr.AKT3
Optima/ Kozak sap.
Acc ATS S
CMV prom. myr HAtag AKT1 A
Kpni /
Compiata Kozak sap.
1/ \Xoa/
SCC s e e  Acc ATS 6
CMV prom.
Kpni X
myr HAtag AKT3
~[y NX&a/
B.
Myr. AKT 1 
NT 0.5 1.0 CV
Myr.AKT3
KDa
7 5 -
5 0 -
3 5 -
7 5 - mm
P-Akt (Ser473)
Actin 
P-GSK3(3 (Ser9)
HAtag
NT CV 0.5 1.0
A. Schematic representation of relevant features contained in the sequence of Myr.AKTl 
and Myr.AKT3 constructs. B. Representative immunoblots performed on HEK293 cell 
lysates after transfection with Myr.AKTl or Myr.AKT3 (pg of DNA used for transfection 
are indicated), or with a  control empty vector (CV), as compared to not-transfected (NT) 
condition. Strong increase of Akt phosphorylation was detected with Myr.AKTl and 
Myr.AKT3 constructs. This is paralleled by increased phosphorylation of GSK3P at Ser9, 
one of downstream targets of activated Akt.
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Figure 4.2
Lentiviral vectors containing the Myr.AKT3 construct 
are fu lly  infective and functional in vitro
A.
LTR E F1 a, prom oter myr. Akt3
M M
B.
Viral vectors
C.
93o £
=« ■ P-Akt
10000 bp
m o  bp
6000 bp  
4000 bp  
3500 bp
3000 bp
2500 bp
2000 bp
1500 bp
1000 bp  
750 bp
HAtag
PCR for Akt3
A. Schematic representation of the WPX.Myr.AKT3 lentiviral vector construct. B. 
Representative photographs of PCR reactions to confirm the presence of the lentiviral 
vector genome in neuron-astrocyte co-cultures after infection with an  empty vector 
expressing GFP (VSVG pLVTHM-GFP), or a vector expressing Myr.AKT3 (WPX.AKT3). A 
positive signal was observed in the samples from cultures infected with the viruses. C. 
Representative immunoblots performed on lysates from the same cultures as in A. A 
clear increase of P-Akt was observed after infection with WPX.myr.AKT3 lentivector.
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Figure 4.3
Treatment o f SOD 1G93A mice w ith W.1.6.Myr.AKT3 ientivector 
does not significantly modify survival
A.
Survival proportions
B.
150-I
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p  >  0.05
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GROUP B =  124 (116-141) 
GROUP E =  128 (126-140)
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Comparison of survival curves for Group E (Myr.AKT3 treatment), and control Group A 
(Sham operated) (A), or control Group B (injection with Empty vector, EV) (B). Log-rank 
analysis of probabilities showed no significant difference.
Figure 4.4
Effect o f Myr.AKT3 expression on disease progression  
in SOD1G93A mice
BODY WEIGHT GROUP B - EV
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CO
12
10
11090 100 120 130 140
Age (days)
Two-way ANOVA for repeated m easures 
Group E vs Group A: Fint p=0.99
Group E vs Group B: Fint p=0.99
Group A vs Group B: Fint p=0.20
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Two-way ANOVA for repeated m easures 
Group E vs Group A: Fint p=0.95
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Group A vs Group B: Fint p=0.61
C.
GRID test
100
GROUP E - AKT3
90
GROUP A -CTRft 80
CO
m 70 
c
oo 60 
c
Jjj 50 
e 40d)a.to 
CD
£ 20
—x
30
i-
10
100 105 110 11590 95 120 125 135130
Age (days)
Two-way ANOVA for repeated m easures 
Group E vs Group A: Fint p=0.19
Group E vs Group B: Fint p=0.40
Group A vs Group B: Fint p=0.36
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ROTAROD
0— GROUP B- EV
350
GROUPE-AKT3
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Age (days)
Two-way ANOVA for repeated measures 
Group E vs Group A: Fint p=0.85
Group E vs Group B: Fint p=0.99
Group A vs Group B: Fint p=0.65
Body weight (A), extension reflex (B), and performance on grid test (C) and on rotarod (D) 
of Myr.AKT3 treated animals (Group E; n=7), compared to control sham operated mice 
(Group A; n=5) and to animals injected with empty vector (Group B; n=6). For grid test, 
Group B displayed a tendency to a less steep decrease of motor performances starting 
from 111 days of age. Group E shows a slightly better performance than control groups 
at 107 days of age, on the same test. However, statistical analysis by two-way ANOVA for 
repeated measures showed no significant effect for any group in any test.
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Figure 4.6  
Expression o f Myr.AKT3 
increases motor neuron survival in SOD1G93A anim als
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Evaluation of the number of surviving motor neurons in the lumbar spinal cord of 
SOD1G93A at the end stage of disease after treatment with Myr.AKT3 (AKT3; n=5), 
compared to animals that received injection of empty vector (EV; n=3) or sham operated 
mice (CTR; n=3). A. Mean number of surviving cells with area higher than 250jim2 B. 
Number of surviving neurons with small area (range 200-250pm2), considered not to be 
motor neurons. In C, D the distribution of single data used in the analysis is represented. 
Statistical analysis was performed by 1 way ANOVA followed by Tukey Kramer’s post hoc 
test. Results were confirmed with Kruskal Wallis non-parametric test for comparison of 
medians.
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Figure 4 .7
Intraspinal injection o f W.1.6.Myr.AKT3 lentivector in SOD1G93A anim als 
results in specific expression o f the transgene in motor neurons
HAtag MAP2 Merge
Representative confocal microscope microphotographs of HAtag (green) and MAP2 (red) 
immunostaining in lumbar spinal cord sections obtained from end stage SOD1G93A mice 
after treatment with Myr.AKT3 expressing lentivirus. Strong expression of the transgene 
is detected in motor neurons; the signal is mainly localized in the cytoplasm, extending to 
proximal neurites (arrows in A-C and G-I). In some cases HAtag was more intense in 
peripheral regions of the cytoplasm, probably indicating submembrane localization 
(arrowheads in D-I). Very faint or no signal was detected in the nucleus. In the grey 
matter some spot-like immunoreactivity for HAtag was also detected; colocalization of 
this signal with MAP2-positive spots suggests localization in transverse-sectioned 
neurites (asterisks in A-C, G-I). Scale bar= 50pm.
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Figure 4 .8
M yr.AKT3 expression  resu lts  in  increased  P-Akt s ta in in g  
in  m otor neurons o f  SOD1G93A a n im a ls
HAtag
Laser scanning confocal microphotographs of PAkt (red) or HAtag (green) immunostainig 
in SOD1G93A animals treated with Myr.AKT3 expressing lentivirus (G-L), as compared to 
mice injected with empty GFP expressing lentivector (A-F). Strong spot-like PAkt 
immunoreactivity was detected throughout the grey matter in both treated groups, 
probably reflecting activation of the pathway in glial cells (asterisks in A-F and K-L). 
Motor neurons of animals injected with empty vector showed a faint PAkt staining 
(arrows in A-F); in contrast, intense immunoreactivity for PAkt was detected in motor 
neurons expressing Myr.AKT3 (arrowheads in G-L). Scale bars=50|nm.
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4 .3  D iscussion
We successfully produced a  constitutively activated m u tan t form of AKT3. A 13aa 
myristylation sequence was added to the N-terminus of the cDNA of HA.AKT3, 
also containing an  HAtag for tracking of the transgene. The new Myr.AKT3 
construct displayed high efficiency of Akt phosphorylation after transfection in 
vitro, and caused increased phosphorylation of GSK30 a t Ser9, indicating th a t the 
protein expressed from the construct was functional in vivo. With the aim of 
specifically inducing the Akt pathw ay in motor neurons of SOD1G93A anim als, 
we subcloned Myr.AKT3 in a  lentiviral vector plasm id, and finally substitu ted  the 
ubiquitous prom oter with the Hb9_1.6Kb enhancer elem ents, previously 
described in chapter 3. The resulting lentivirus was then delivered by in traspinal 
injection in SOD1G93A mice a t the pre-sym ptom atic stage. Our lentiviral vector- 
m ediated approach resulted in specific sustained  expression of the transgene in 
the lum bar spinal cord motor neurons, and strong increases in Akt 
phosphorylation, as assessed by im m unohistochem istry. However, a lthough the 
induction of Myr.AKT3 expression in SOD1G93A exerted a  significant protection 
of m otor neurons, th is was not paralleled by an  increased survival of the treated 
anim als. The disease progression, in Myr.AKT3-treated mice, was com parable 
with sham  operated anim als or mice th a t received empty GFP expressing 
lentivector.
The lack of a  clear beneficial effect on disease progression by Myr.Akt3 is in 
contrast with previous reports, th a t showed a  protective effect of treatm ents with 
Akt-inducing growth factors, such as VEGF and  IGF-I, both on neuron  survival 
and disease progression (Nagano et al., 2005; Storkebaum et al., 2005; Dewil et 
al., 2007b). Besides the possibility th a t protective m echanism s o ther th an  Akt 
pathw ay could have been activated by growth factors, ano ther possible 
explanation is th a t we specifically targeted a  subset of motor neurons, while in 
the studies from Storkebaum  and Nagano the au thors delivered the growth 
factors intrathecally. This may have produced a  more widepread distribution of
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VEGF or IGF-I. Although the au thors only described effects on the neuronal cell 
population, th is mode of adm inistration may in fact have affected also other cell 
populations of the spinal cord such  as the glial cells, possibly modifying their 
reactivity (Nagano et a l, 2005; Storkebaum et a l, 2005).
By histological analysis we reported a  41.6% increase of surviving motor neurons 
a t the end stage of disease in the anim als treated with Myr.AKT3. The effect we 
observed is in general agreem ent with reports of viral-vector m ediated delivery of 
other pro-survival factors to m otor neurons, such  as bcl-2 or IGF-I (65.2% and 
34% increase respectively) (.Azzouz et a l, 2000; Kaspar et a l, 2003). However in 
these studies a  delay of disease progression and  an  increase in survival was 
respectively reported. Akt induction might m irror the actions of bcl-2 as both are 
predicted to exert anti-apoptotic effects, due to inhibition of Bad and subsequent 
inhibition of cytochrome c release from the m itochondria. The m ain difference 
between the study with bcl-2 and  our own approach is th a t in traspinal delivery 
of the bcl-2 expressing AAV, resulting in a  protective phenotype, was performed 
in 5 weeks old SOD1G93A mice, largely before symptom onset (Azzouz et al., 
2000). In contrast, we injected the mice a t 12 weeks of age, ju s t  2 weeks before 
symptoms appear. So it could be hypothesized th a t a t the age we treated the 
mice some motor neurons may have already activated a  specific pro-degenerative 
pathw ay th a t Myr.AKT3 expression was not able to counteract.
An im portant issue which is worth to underline from the p resent study, is the 
significant, although modest, reduction in spinal motor neurons loss evaluated a t 
the end of the disease in spite of no beneficial effect on disease progression.
There is emerging evidence th a t ALS may display features of a  distal axonopathy. 
In fact, distal axonal degeneration has been reported in the early stages of 
disease in SOD1G93A mice, before neuronal degeneration, and before onset of 
symptoms (Fischer et al., 2004). Moreover, in line with our results, some pre- 
clinical studies conducted on rodent models of ALS have reported a  protection of 
motor neuronal cell bodies, b u t very little or no significant effect on disease
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progression and survival, probably due to an insufficient protection of the 
peripheral axons (Rouawc et al., 2007; Suzuki et al., 2007). Nevertheless th is does 
not explain why Myr.AKT3 expression in spinal cord motor neurons leads to 
preferential protection of the perikarion, while viral m ediated delivery of VEGF or 
IGF-I, factors upstream  of Akt pathway, also exerted an effect on phenotype and 
survival. The m ain difference with these studies is th a t we targeted motor 
neurons by intraspinal injection of a  lentivector, while the au thors of these 
studies infected the spinal cord by retrograde delivery of the virus after 
adm inistration in peripheral m uscles (Kaspar et al., 2003; A zzouz et al., 2004a). 
Through this strategy of delivery the au thors obtained infection of a  high num ber 
of motor neurons in different segm ents of the spinal cord, by simply injecting the 
virus in different m uscular districts, while our intervention was limited only to a  
part of the lum bar spinal cord.
It has been shown th a t different subtypes of motor neuron can be identified, 
depending on the m uscular region they innervate in the hindlim bs (fast- 
fatiguable, fast-fatigue-resistant and slow). Interestingly, in m ouse models of ALS 
axons from fast fatiguable neurons are already affected a t the presym ptom atic 
stage, w hereas axons from fast-fatigue resistan t motor neurons become altered 
a t symptom onset and axons of slow neurons rem ain resistan t (Pun et al., 2006). 
Intraspinal injection leads to generalized infection of spinal cord m otor neurons, 
probably transducing both healthy neurons and neurons th a t have already 
started  the denervation process. Since Myr.AKT3 expression protects the m otor 
neurons b u t has  no or very little effect on motor performance, it is conceivable 
th a t Myr.AKT3 is not able to induce axon regrowth in cells th a t have become 
disconnected from the periphery, and th a t the level of Akt induction in cells still 
innervating the m uscles is probably not sufficient to ha lt the denervation 
process. Since we detected Myr.AKT3 mainly a t the plasm a m em brane or in the 
cytosol of the motor neurons, with only rare translocation to the nucleus, it is 
also possible th a t a  specific nuclear function of activated Akt is required to
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counteract the degenerative process. To better clarify these points another 
constitutively activated Akt construct could be tested by substitu tion  of Ser473 
and Thr308 with Asp. This is known to act as a  perm anently phosphorylated 
(activated) kinase, w ithout the need for m em brane translocation (Alessi et a l, 
1996b).
Interestingly, it h as  been dem onstrated th a t direct injection of a  GDNF 
expressing viral-vector into the lum bar spinal cord could not prevent motor 
neuron loss and  denervation while retrograde delivery of GDNF, through 
expression in peripheral muscles, was sufficient to m aintain in tact axonal 
projections to the periphery and protect motor neurons (Wang et a l, 2002; Guillot 
et a l, 2004). An alternative approach deleted the pro-apoptotic gene Bax, 
resulting in a  rescue of spinal cord motor neuron loss and a  delay in, b u t not 
prevention of, neurom uscular denervation (Gould et a l, 2006).
Overall these da ta  suggest th a t potential therapeutic interventions need to 
combine a  protective effect on neuronal cell body with a  preservation of the 
axonal projections to peripheral muscles. Our findings and other studies have 
highlighted th a t induction of the Akt pathway can be regarded as a  potential 
strategy to susta in  motor neuronal survival in the spinal cord, however further 
studies are needed to identify molecules th a t can intervene effectively in  the 
pathological processes leading to peripheral denervation in ALS.
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CHAPTER 5 
USE OF RNA-INTERFERENCE 
FOR TARGETING P38MAPK PATHWAY
5.1 RNAi, an introduction
One of the biggest recent breakthroughs in biology has been the discovery of RNA 
interference (RNAi). First described in plants, where it was known as post- 
transcriptional gene silencing, RNAi occurs also in a  wide variety of eukaryotic 
organism s (Tijsterman et a l, 2002). It is triggered by dsRNA precursors th a t vary 
in length and origin. These dsRNAs are rapidly processed into short RNA 
duplexes of 21 to 28 nucleotides in length, which then  guide the recognition and 
ultim ately the cleavage of complementary single-stranded RNAs, such  as 
m essenger RNAs or viral RNAs. RNA silencing m echanism s were first recognized 
as antiviral m echanism s th a t protect organism s from RNA viruses, or which 
prevent the random  integration of transposable elements. In nature , dsRNA can 
in fact be produced by RNA-templated RNA polymerization (for example, from 
viruses) or by hybridization of overlapping transcrip ts (for example, from 
repetitive sequences such as transgene arrays or transposons). Such dsRNAs 
give rise to siRNAs, which generally guide mRNA degradation. The m aturation  of 
small RNAs is a  stepwise process catalysed in the cytoplasm by a  dsRNA-specific 
endonuclease, term ed Dicer, which contains catalytic RNase III and  dsRNA- 
binding domains. Processing of dsRNAs by Dicer yields RNA duplexes of about 21 
nucleotides in length, which have 5 -phosphates and  2-nucleotide 3 ’- overhangs. 
Artificial introduction of long dsRNAs or siRNAs h as  been adopted as a  tool to 
inactivate gene expression (Meister and Tuschl, 2004). Viral vectors, th an k s to 
their high efficiency of infection both in cultured cells and in living organism s, 
represent a  system frequently used  to induce RNAi, allowing efficient 
downregulation of gene expression also in the CNS (Van den Haute et a l, 2003). 
In th is case, siRNAs derive from cleavage of a  sm all-hairpin RNA, produced after 
transcription of a  palyndromic sequence by RNA pol. Ill (Snove and Rossi, 2006).
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5 .2  RNAi as a to o l to  stu d y  th e  m olecular m ech an ism s involved  in  ALS 
p ath ogen esis
The m ain technical advantage of RNAi is th a t it can be used  to downregulate 
specific genes in vivo. This m eans th a t it is possible to interfere with specific 
pathways a t a  post-natal level; thing th a t would be very complicate if traditional 
knock-out technologies were applied. Recently, RNAi has been used  to study the 
toxic properties of m u tan t SOD1 in ALS. In particular, siRNAs-mediated 
downregulation of the m u tan t protein in adult transgenic mice h as been 
obtained, to verify w hether the toxic events th a t occur early in the disease are 
reversible or w hether they, once triggered, irreversibly lead to cell death  even in 
the absence of m u tan t SOD1. In a  work by Raoul and coworkers lentiviral vectors 
expressing a  m u tan t SOD 1-targeted shRNA were delivered in the spinal cord of 
40 days old SOD1G93A mice. This determ ined a  considerable delay of disease 
onset of 20 days; it also delayed the progression rate of m otor deficits and  
ameliorated m uscular strenght, though the effect on survival is no t described 
(Raoul et a l, 2005b). Similarly, another group silenced m u tan t SOD 1 by RNAi. In 
th is case a  lentiviral vector th a t can be retrogradely transported  was injected in 
several peripheral m uscles of 7 day old SOD1G93A mice. A rem arkable delay of 
onset (by 115%) and  increase of survival (by 77%) over control groups w as 
reported (Ralph et a l, 2005). Recently, Wang and coworkers have adm inistrated  
chemically modified siRNAs in vivo, in the same m ouse model a t sym ptom  onset 
(Wang et al., 2008). They observed a  6.5% extension of life span, th u s  providing 
evidence th a t chemically modified siRNAs can be delivered and are stable in vivo 
in transgenic mice, and th a t partial ablation of m utan t SOD1 delays disease 
progression. However, since anim als th a t received SOD 1-targeted siRNAs still 
developed the disease and finally died, it is worthy considering th a t other 
proteins should be targeted to efficiently interfere with the disease progress. 
Interestingly, RNAi-mediated downregulation of Fas signalling pathw ay h as  
recently been tested in SOD1G93A mice (Locatelli et al., 2007). The treatm ent,
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initiated a t 90 days of age, significantly improved motor perform ances and 
increased survival of 20 days, further supporting the evidence of an  involvement 
of th is pathw ay in motor neuronal degeneration in ALS (Raoul et a l, 2002; Raoul 
et a l, 2005a; Raoul et a l, 2006). p38MAPK is a  key player of the signalling 
cascades activated upon exposure to stress stimuli, including Fas and  cytokines. 
As already stated in section 1.4.3 we and other groups have provided evidence of 
an  activation of p38MAPK pathway both in post mortem spinal cord specim ens 
from hum an  ALS patients and in m u tan t SOD1 mouse models. Progressive 
increase and activation of p38MAPK is associated with hyperphosphorylation and 
cytoplasmic accum ulation of neurofilam ents, a  pathogenic hallm ark of ALS 
(Tortarolo et al., 2003; Bendotti et a l, 2004; Holasek et al., 2005). A crosstalk 
between p38MAPK pathway and TNFa has been recently described in 
SOD1G93A mice, suggesting th a t th is pathway may be a  key player of the 
neuroinflam m atoiy process involved in the degeneration of m otor neurons in ALS 
(Veglianese et a l, 2006). Moreover, ASKl-p38MAPK pathw ay is also involved in 
ER-stress induced cell death (Sekine et al., 2006). Interestingly upregulation of 
CHOP, an  ER-stress induced pro-apoptotic protein, has been detected in sALS 
patients and ALS m ouse models (Ito et al., 2009), and  crossbreeding of 
SOD1G93A mice with anim als knockout for ASK1 was protective for motor 
neurons and determined a  25 days extension of survival (Nishitoh et al., 2008). 
We hypothesized th a t p38MAPK may function as a  critical molecule implicated 
in the triggering of several toxic responses in motor neurons and glial cells in 
ALS, so interfering with its activation may contribute to prolong life span  by 
delaying the disease progression. In particular, since it h as  been observed th a t 
p38MAPK alpha is directly involved in neurofilam ents phosphorylation in ALS 
(Ackerley et al., 2004), th is isoform may represent a  potential therapeutic  target. 
The availabe pharmacologic p38MAPK inhibitors have poor bioavailability to the 
CNS, and are not selective for one specific isoform (see section 1.4.4). Recently it 
has been dem onstrated th a t Semapimod, a  c-Raf inhibitor, delivered to
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SOD1G93A mice starting from 70 days of age, effectively inhibited p38MAPK 
activation in the spinal cord, resulting in protection of motor neurons, though 
with a  small effect on survival (Dewil et al., 2007a). Since p38MAPK is not a  
selective target of Semapimod, the work by Dewil does not provide complete 
elucidation of the role played by th is kinase in the pathologic process. For these 
reasons we decided to develop an RNAi-mediated approach with the aim to 
downregulate specifically p38MAPK alpha isoform in vivo, in the spinal cord of a  
m ouse model of ALS.
5 .3  Screening o f  p38M APK-targeted shRNA candidate seq u en ces
In the course of identifying more active and  more specific siRNA duplexes to 
guide mRNA cleavage, it has been noticed th a t the sequence composition of the 
siRNA duplex has an  im pact on the ratio of ‘sense’ (same sequence as the target 
gene) and  ‘antisense’ (complementary to the target gene) siRNAs entering the 
RISC complex. Effective siRNAs show reduced therm odynam ic stability a t the 5’- 
end of the antisense siRNA relative to the 3 ’- end within the duplex (Dykxhoom et 
a l, 2003; Cheng and Chang, 2007).
To our knowledge, there are no shRNA sequences already validated for targeting 
m urine p38MAPK alpha, in the literature. For th is reason we initially chose a  set 
of five already described shRNAs targeting the hum an  protein, num bered 1 to 5 
(Table 5.1). According to the rules described above we m utated these sequences 
to obtain perfect m atching with m urine p38MAPK alpha w ithout loosing the 
potential to induce RNAi. Some of the sequences were 29nts long, a t variance 
with the commonly used  19nts oligomers. The design of these 29n ts sequences 
h as  been done according to the description of Siolas et al., th a t dem onstrated 
th a t 29-m ers can be more effective th an  19-mers in the triggering of RNAi (Siolas 
et a l, 2005). In order to easily detect a  shRNA sequence effective in m urine 
p38MAPK-alpha downregulation, lentiviruses each carrying one of these 
sequences were used  to infect NIH3T3 cell line (as described in section 2.2.7).
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p38MAPK alpha protein and mRNA levels were analysed 3 days after infection by 
w estern blotting and RT-PCR respectively. Since none of the first five candidate 
shRNAs proved to be effective in downregulating p38MAPK alpha, we moved to 
another set of 5 shRNAs (numbered 6 to 7 in Table 5.1), cloned in pLKO.l 
plasm ids. The puromicine resistance, in these plasm ids, was excised by 
BamHI/Kpnl cu t and  substitu ted  with GFP reporter gene. Lentiviral vectors, each 
containing one of these candidates, were used  to infect NIH3T3 cell line in the 
same experimental setting as before.
Table 5 .1 . L ist o f  cand idate shRNA seq u en ces  
targeting  m urine p38MAPK alpha
Seq ID Nrntds
Target sequence (5*->3’) 
BLAST on p38MAPK alpha sequence
Reference artic le / 
designed by... N otes
1 19 CCCCAGAGATCATGCTGAA865
(Siolas e t al., 
2005)9}5)
The authors 
designed 
shRNas for 
human 
p38MAPK. Some 
of these 
sequences have 
been chosen and 
modified to 
adapt to murine 
p38MAPK gene.
2 29 ACCGTTTCAGTCCATCATTCACGCCAAAA467
3 19 CCGAAGATGAACTTCGCAAAT1092
Seq. 1092, designed 
by the Broad 
Institute
/ /
4 19 CCAACAATTCTGCTCTGGTTA3168
Seq. TRC55223, 
designed by the 
Broad Institute
/ /
5 19
CCTCTTGTTGAAAGATTCCTT
1463
Seq.TRC23119, 
designed by “The 
RNAi Consortium”
/ /
6 19 CCTGACCTATGATGAAGTCAT1313
Seq. TRC23122, 
designed by “The 
RNAi Consortium”
Purchased from 
Open Biosystem
7 19 GCTGAATTGGATGCACTATAA878
Seq. TRC23123, 
designed by “The 
RNAi Consortium”
Purchased from 
Open Biosystem
8 19 CTCAGAGTCTGCAAGAAACTA1049
Seq. TRC55224, 
designed by “The 
RNAi Consortium”
Purchased from 
Open Biosystem
9 19 GTCTGCAAGAAACTACATTCA1055
Seq. TRC55225, 
designed by “The 
RNAi Consortium”
Purchased from 
Open Biosystem
10 19 CGAGGGCTGAAGTATATACAT702
Seq. TRC55227, 
designed by “The 
RNAi Consortium”
Purchased from 
Open Biosystem
Three days after infection we detected by w estern blot a  80% reduction of 
p38MAPK alpha with sequence nr.7. This effect was not due to generalized 
reduction of protein synthesis, since seq.nr.7 downregulated p38MAPK a lpha
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isoform w ithout any influence on the levels of other proteins, like PI3Kp85, or 
ERK and  w ithout inducing interferone response, as dem onstrated by lack of 
increase of P-STAT and P-eIF2a (Figure 5.1, A). RT-PCR preform ed on RNA 
extracted from the sam e cultures confirmed th a t sequence n r.7 was able to 
reduce the mRNA of p38MAPK alpha by 45% rate (Figure 5.1, B). To provide a  
complete validation of the RNAi effect, three point m utations were introduced 
into sequence nr.7  with the aim  to dysrupt the m atching with the mRNA of 
m urine p38MAPK alpha (Figure 5.2). Lentiviral vectors containing the new 
sequence, nam ed shRNA nr.7*, were used  to infect prim ary m urine astrocyte 
cultures under basal non-stim ulated conditions, in parallel with shRNA nr.7  and 
a  GFP expressing empty vector. Lysates extracted from these cu ltures a t three 
days post infection showed a  70% reduction of p38MAPK alpha in shRNA nr.7  
infected cells by western blotting, and no changes of the protein levels with 
shRNA nr.7*, as predicted (Figure 5.3).
5 .4  shRNA nr.7  se lec tiv e ly  in h ib its  TNFa induced  p38MAPK  
phosphorylation
TNFa signaling has been strongly implicated in ALS, and p38MAPK is one of the
key m ediators of the effects induced by cytokine stim ulation, such  as in the
regulation of transcription of several pro-degenerative genes including nitric-
oxide synthase, TNFa, TNFa receptors, and IL-1. In addition, TNFa exposure in
cultured astrocytes produces a  strong activation of p38MAPK and  the other
stress-induced kinases, JNK and ERK (Da Silva and Silva, 1997). To fu rther
validate the activity and  specificity of shRNA nr.7, we decided to s tudy  the effect
of TNFa exposure in cells following p38MAPK downregulation. In particu lar we
investigated w hether shRNA nr.7  knockdown was sufficient to m ain tain  low
levels of p38MAPK phosphorylation upon cytokine-stimulation and also w hether
th is may influence the activation of JNK kinase which shares common upstream
activators with p38MAPK, such as ASK1 (Mielke and Herdegen, 2000). M urine
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astrocyte cultures were infected with lentiviruses expressing shRNA nr.7, shRNA 
nr.7* or an  empty GFP expressing vector (as described in section 2.2.7) in 
triplicate, or left un treated  as a  negative control. After three days (when sufficient 
downregulation of p38MAPK by shRNA nr.7  is expected) the m edium  was 
replaced with fresh m edium  containing lOOng/mL TNFa and  then  incubated for 
15min or 60min a t 37°C. The concentration of TNFa and tim es of exposure were 
chosen according to previously published reports (Da Silva and Silva, 1997), and  
from our own prelim inary observations, showing th a t a  short time of exposure 
(15min) to TNFa was sufficient to stim ulate p38MAPK phosphorylation, w hereas 
a  longer time of exposure (60min) was needed to stim ulate JNK phosphorylation 
(data not shown). Exposure to TNFa for 15min caused a  5-fold increase of 
p38MAPK phosphorylation in non-infected astrocytes compared with basal levels. 
A similar increase in p38MAPK phosphorylation was also detected in cells 
infected with shRNA nr.7*. In contrast, in cells infected with shRNA nr.7  the 
levels of p38MAPK phosphorylation rem ained very low following exposure to 
TNFa (Figure 5.4 A, B). However exposure to TNFa for 60min was sufficient to 
induce a  clear and robust 2-fold increase in phosphorylated JNK (Figure 5.4 C, 
D) both in shRNA nr.7* and shRNA nr.7  infected cells, over non-stim ulated 
control cultures. This effect was significant only for astrocytes infected with 
shRNA nr.7. Expression of p38MAPK-targeted shRNA did not modify the levels of 
total JNK (Figure 5.4 C, E).
- 213 -
5 .5  shRNA nr.7 p rotects cu ltured  neurons against co lch ic in e  induced  
to x ic ity
Colchicine is a  microtubule dysrupting agent th a t induces apoptosis in several 
cell types, including neurons. This paradigm  of cell toxicity can be used  to 
mimick the alterations of cytoskeleton observed in m any neurodegenerative 
diseases, including Alzheimer’s disease and ALS (Bonfoco et a l, 1995; Williamson 
and Cleveland, 1999; Ackerley et a l, 2004). A recent paper revealed th a t 
p38MAPK and JNK pathways are involved in the apoptotic process induced by 
colchicine in ra t cortical neurons (Yang et al., 2007). In particular, the au thors 
showed th a t pharmacologic inhibition of p38MAPK or JNK was able to reduce 
neuronal loss after treatm ent with colchicine. This effect was synergistic if 
p38MAPK and JNK were both inhibited a t the same time. We used  the same 
experimental paradigm to test w hether the shRNA targeting p38MAPK exerted a  
similar protective effect. Primary ra t cortical neurons, obtained from the brains of 
two-day old ra t pups, were prepared in collaboration with the Unit of Cell death 
and Neuroprotection M echanisms of Mario Negri Institute, in accordance with the 
protocol described in section 2.2.6. In initial experiments neurons a t day 1 after 
plating were infected by lentiviruses expressing p38MAPK-targeted shRNA nr.7 , 
or with empty GFP expressing vector, or left un trea ted  as negative control. At day 
6, cells were lysed and proteins extracted. Analysis by western blot dem onstrated 
th a t shRNA nr.7  retained the ability to downregulate p38MAPK alpha also in rat- 
derived cells, w ithout activation of proteins of the Interferon response, such  as P- 
e lF la  (Figure 5.5 A). Subsequently neurons a t day 1 after plating were infected 
by lentiviruses expressing shRNA nr.7, or shRNA nr.7*, or left no t infected as 
negative control. At day 6, cells were challenged by exposure to colchicine lpM 
for 24h according to the procedure already described by Yang (Yang et a l, 2007). 
The rate of cell mortality in th is case was m easured by LDH assay  (Roche, Basel, 
Switzerland). In uninfected neurons, colchicine determ ined a  2.6-fold increase of 
LDH release as compared to un treated  cells. Infection with shRNA nr.7  reduced
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colchicine-induced neuronal death  (as m easured by LDH release) by 40%, as 
compared to uninfected colchicine-treated neurons whereas shRNA nr.7* was 
completely ineffective (Figure 5.5 B).
5 .6  E ffect o f  p38MAPK dow nregulation  in  v ivo , in  SOD1G93A m ice
Based on the da ta  obtained in the in vitro studies, lentiviral vectors containing a  
GFP-expressing empty vector, or shRNA nr.7* or shRNA nr.7  were delivered by 
intraspinal injection in anim als a t the presymptomatic stage (84 days). In order 
to allow direct comparison of the effect of each sequence, lentivectors expressing 
shRNA nr.7  or shRNA nr.7* were adm inistered in the right side of the spinal 
cord, whereas a  GFP-expressing empty vector was delivered in the contralateral 
side. The surgical procedure was as described in section 2.2.3 with m inor 
modifications (outlined in Figure 5.6 B). To further monitor possible effects 
induced by the in traspinal injection of lentivectors, a  GFP-expressing empty- 
vector was adm inistered monolaterally in the spinal cord of a  separate group of 
SOD1G93A and NTg anim als, and the contralateral side was left un trea ted  (sham 
operated), as outlined in Figure 5.6 A. Three anim als were treated  for each 
experimental group. Mice were sacrificed 16 days after injection, and the spinal 
cord was collected and sectioned for NISSL staining and counting of surviving 
m otor neurons. The ratio between the num ber of cells in the treated  versus 
control side of spinal cord was calculated, and used  for com parison between 
groups. Interestingly, when we analyzed the effect of GFP-expressing empty 
vector alone, while we did not detect any difference between injected and  sham - 
operated side in NTg anim als, in SOD1G93A mice we noticed a  slight, although 
not significant, decrease of surviving neurons in the injected side. (Figure 5.7 A). 
To better elucidate th is result, we re-calculated the com parison after 
subgrouping the surviving neurons according to the spinal cord level in which 
they were located (the areas surrounding the injected sides, L3 and  L4 segm ent of 
spinal cord, were considered) (Figure 5.7 B). At level L3 there were no significant
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differences between right and left side in NTg and in SOD1G93A anim als. In 
contrast, a t level L4 we detected a  significant reduction of the num ber of motor 
neurons in the empty vector-injected side of SOD1G93A anim als, suggesting th a t 
in transgenic anim als these cells may be susceptible to the traum a generated by 
an injection in the parenchym a. Despite this effect, in SOD1G93A anim als we 
detected a  tendency to protection (1.6-fold increase) of m otor neurons (area 
higher th an  250jim2) in the side of spinal cord injected with shRNA nr.7 , versus 
the contralateral empty vector-injected side, as compared to the treatm ent with 
shRNA nr.7*, th a t was completely ineffective (Figure 5.8 A). This was furtherly 
confirmed when the surviving neurons were subgrouped according to the spinal 
cord level (Figure 5.8 B). No significant difference was observed for neurons of 
small areas, in the range 200-250jim2 (data not shown).
In order to evaluate the effect of p38MAPK alpha downregulation on disease 
progression, a  new experiment was set up  in which high titre lentiviral vectors 
expressing shRNA nr.7  were intraspinally injected in 84day old SOD1G93A mice 
(n=7; Group C), as described in section 2.2.3.4. As control groups, SOD1G93A 
anim als were injected with a  vector expressing shRNA nr.7* (n = 5; Group D). 
Moreover, since these experiments were conducted in parallel with those 
described in section 4.2, Group A (n =5 ; anim als th a t underw ent lam inectom y 
bu t did not receive an injection) was used as a  further control for Group C and 
Group D. Motor performance and disease progression were analysed twice a  
week, as outlined in section 2.2.4.
Surprisingly, the median survival of anim als treated  with shRNA nr.7  (Group C) 
was 8 days shorter than  the control Group A, and  6.5 days shorter th an  control 
Group D. Although this difference was small, it is statistically significant. The 
survival of anim als th a t received shRNA nr.7* was not different from sham  
operated anim als (Figure 5.9).
Animals from all groups displayed a  gradual and comparable gain of body weight 
a t 93 and 97 days of age, probably due to post-operative recovery. However,
-216-
starting  from 100 days, control groups A and D displayed a  comparable 
progressive loss of body weight, w hereas in Group C a  steeper decrease was 
observed (Figure 5.10, A) although th is difference was not significant, by 2-way 
ANOVA analysis for repeated m easures. However, when the cumulative 
probability to reach a  5%, 10% or 15% drop in body weight was analysed, the 
trend for Group C to lose body weight before Group A (Figure 5.11 A) or Group D 
(Figure 5.12 A) became significant.
The treatm ent with shRNA nr.7  also accelerated the progression of motor deficits. 
Extension reflex test highlighted a  tendency of Group C to already show a  deficit 
a t 93 and 97 days, as compared to control groups. This trend  became 
statistically significant from day 100 to day 111 versus both control groups. The 
performance of Group D was not significantly different from Group A, although 
from day 104 the progression of deficits appeared slightly worse th an  the sham  
operated anim als (Figure 5.10, B). The grid test confirmed th a t m otor deficits in 
Group C were m easurable from day 97, as compared to control groups. This 
became significant a t day 104 and 107 (Figure 5.10, C). Similarly, Group C 
displayed a  significantly impaired rotarod performance starting a t day 97 un til 
end stage, as compared with control groups (Figure 5.10 D). The progression of 
motor deficits in the anim als treated with shRNA nr.7* (Group D) was 
comparable with Group A in both tests. These observations were confirmed by 
analysis of the cumulative probability to reach a  25%, 50% or 75% drop of 
performance on the grid (Figure 5.11 B and 5.12 B) and  on the rotarod (Figure 
5.11 C a n d  5.12 C).
In order to verify w hether the phenotype in shRNA nr.7-treated  anim als was 
linked with increased loss of motor neurons, the spinal cords from mice th a t 
reached end stage of disease were collected, and sectioned for NISSL staining. 
The m ean num ber of motor neurons (with an  area higher th an  250pm 2) was 
considered in the analysis. The num ber of surviving cells in shRNA nr.7 -treated  
group (8.03+/-0 .89 cells/hemisection) was lower th an  shRNA n r .7*-treated
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Group D (10.04+/-0.99 cells/hemisection) or Group A (11.81+/-0.27 
cells/hemisection) although th is difference was statistically significant only 
versus Group A. In fact the num ber of surviving neurons in Group D was slightly 
lower than  Group A (Figure 5.13 A). Curiously, for Group C we noticed an 
interesting, though not significant, decrease of neurons with an  area  between 
200 and 250 pm2 (6.71 + /- 0.77 cells/hem isection), as com pared to control 
Group A (10.74 + /- 2.18 cells/hem isection) or Group D (10.37 + /- 1.20 
cells/hemisection) (Figure 5.13 B). Based on th is evidence we decided to 
subgroup the surviving neurons, counted in each group, according to the spinal 
cord level in which they were located (from L2 to L4) (Figure 5.14). In level L2 the 
num ber of cells with an area higher th an  250pm2 was not significantly different 
between groups, however Group D displayed a  slight reduction of cells as 
compared to Group C and control Group A. In level L3 a  loss of cells could be 
observed for Group C as compared to Group D, which in tu rn  showed a  slight 
increase compared to Group A. In level L4 both Group C and Group D showed a  
smaller num ber of cells as compared to Group A; this difference was significant 
only for Group C (Figure 5.14 A). When the num ber of small neurons (area 200- 
250 pm2) was evaluated, no differences were detected between groups a t level L2. 
However, Group C displayed a  m odest decrease of cells a t level L3, as com pared 
to the other groups; this trend was m aintained and became significant a t level L4 
(Figure 5.14 B). Overall these data  suggest th a t the phenotype observed after 
treatm ent with shRNA nr.7  may be in part explained by the m oderate b u t 
significant decrease of motor neurons observed in these mice a t the end stage of 
the pathology. In particular, from the analysis of the different spinal cord 
segm ents it appears th a t delivery of shRNA nr.7  produced a  greater loss of 
neurons in the areas surrounding the sites of injection (level L3 and L4). This was 
not simply due to the traum a induced by the intraspinal injection, because in 
anim als treated with shRNA nr.7*-expressing lentivirus the num ber of m otor 
neurons a t least a t level L3 was comparable with the sham  operated group.
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It is known th a t glial reactivity plays a  critical role during disease progression in 
ALS (Boillee et al.} 2006a; Boillee et a l, 2006b); moreover prom inent activation of 
p38MAPK h as been described in astrocytes and reactive microglia in SOD1G93A 
mice, suggesting th a t th is pathw ay is crucial for induction of neuroinflam m ation 
in ALS (Tortarolo et a l, 2003; Wengenack et a l, 2004). Since shRNA-expressing 
lentiviruses are expected to infect both neurons and glial cells, we decided to 
verify w hether p38MAPK downregulation altered glial reactivity in shRNA nr. 7- 
treated mice. In order to do this, we performed im m unohistochem istry for 
m arkers of astrocytosis (GFAP) and microgliosis (CD lib) on spinal cord sections 
from anim als th a t reached end stage of the disease.
Animals injected with shRNA nr.7* displayed classical reactive astrocytosis, 
similar to th a t observed in un trea ted  SOD1G93A mice a t the end stage of the 
disease, characterized by hypertrophic astrocytes scattered throughout the gray 
and white m atter of the spinal cord. The morphology of these cells was not 
altered by expression of shRNA nr.7* (arrowheads in Figure 5.15 A-C and  D-F). 
In contrast, anim als th a t received shRNA nr.7  displayed strong imm unoreactivity 
for GFAP in the areas surrounding the injection sites (Figure 5.15 H). The 
morphology of astrocytes in these areas was altered, with filamentous-like 
structu res protrudring throughout the spinal cord parenchym a. Interestingly we 
observed th a t these structu res were rarely co-localized with the GFP reporter 
gene signal (asterisks in Figure 5.15 G-I). Moreover, in these regions we observed 
some very small GFAP negative GFP-expressing cells (arrowheads in Figure 5.15 
G-I), and some larger round GFP-positive cells (arrows in Figure 5.15 G-I). In 
contrast, astrocytosis appeared norm al in infected areas th a t were far from the 
injection sites (Figure 5.15 J-L). Interestingly, some motor neurons infected with 
lentivirus expressing shRNA nr.7  could still be detected in these regions a t the 
end stage of disease, as confirmed by GFP staining (arrows in Figure 5.15 J-L  
and M-O). The im m unohistochem istry for CD l i b  revealed an  intense microgliosis 
in anim als treated with shRNA nr.7*, as expected in mice a t the end stage of the
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disease. The expression of shRNA nr.7* in these cells apparently did not alter 
their morphology (arrowheads in Figure 5.16 A-C and  E-G), w hereas in anim als 
treated with shRNA nr.7  the infected microglial cells often appeared larger and 
rounder in the regions surrounding the sites of injection (arrowheads in Figure 
5.16 I-K) as well as in the areas located far from them  (arrowheads in Figure 5.16 
M-O). In particular, in the spinal cord near the site of injection high microglial 
reactivity appeared, with round GFP-positive microglial cells scattered 
throughout the parenchym a. Interestingly, Hoescht nuclear staining highlighted 
an  increase of cells in these areas. Many of these cells appeared organized in 
clusters, often localized in areas not expressing shRNA nr.7  (GFP negative) as 
shown by asterisks in Figure 5.16 O-P. We also detected some surviving motor 
neurons expressing shRNA nr.7  (arrows in Figure 5.16 I, K). Since these motor 
neurons are still p resent a t the end stage of the disease, we hypothesized th a t 
the reduction of neurons evidenced by NISSL staining probably w as not the 
consequence of a  direct toxic effect of p38MAPK downregulation in these cells.
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Figure 5.1
Screening  o f  ca n d id a te  shRNA sequences  
ta rg e tin g  p38M APK a lp h a , in  vitro
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A. Representative immunoblots, and quantification, of p38MAPK alpha, P-STAT and P- 
eIF2a protein levels in lysates from NIH3T3 obtained 3 days after infection with candidate 
shRNA sequences targeting p38MAPK. Seq. 7 downregulated p38MAPK alpha by 80%, 
without inducing activation of anti-viral response, as confirmed by lack of increase of P- 
STAT and P-eIF2a (n=3). B. Quantification of p38MAPK alpha mRNA levels, by RT-PCR, 
in extracts from NIH3T3 cells infected as described in A. Seq. 7 is able to decrease the 
mRNA of p38MAPK alpha by 45% (n=3).
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Figure 5 .2
Sch em a tic  rep resen ta tion  o f  shRNA nr. 7* sequence
S e q u e n c e  shRNA n r .7
( 5 ' - >  3 ' ) :  g c t g a a t t g g a t g c a c t a t a a
S e q u e n c e  shRNA n r . 7 *
( 5 ' - >  3 ' ) :  g c t g a a c t g g a t g c a t t a c a a
Sequence of shRNA nr.7 and shRNA nr.7*. The 3 mutated nucleotides introduced into 
shRNA nr.7 to obtain shRNA nr.7* are highlighted in yellow. These mutations have been 
chosen according to the mRNA sequence of human p38MAPK alpha.
Figure 5 .3  
T est o f  th e  se lec ted  shRNA sequences  
on p r im a ry  cu ltu red  m ouse a stro cy tes
shRNA
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actin
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p38 alpha/actin levels
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1.4
CTR- 7* 7
* = p  < 0.05:1 way ANOVA follow ed by D unnet’s vs CTR-
Representative immunoblots, and quantification, of p38MAPK alpha protein levels in 
lysates from astrocytes obtained 3 days after infection with shRNA nr.7 or shRNA nr.7*. 
Seq. 7 retains the ability to downregulate p38MAPK alpha (by 70%), whereas the 
mutations introduced in shRNA nr.7* completely abolish this effect (n=3).
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Figure 5.4
TNFa-mediated induction o f p38MAPK and JNK
in murine astrocyte cultures; effect o f shRNA nr.7
A.
KDa 
35 - 
5 0 -
CTR- C T R - 7* 
+ +
C.
5 0 -
5 0 -
C T R - C T R - 7* 
+ +
P-p3S
TNFa
KDa
5 0 - P-JNK(p54)
JN K  (pS4)
TNFa
B. P-p38 protein levels
D.
C T R - C T R - 7* 7
TN Fa  -  +  +  +
p < 0.0001 1 way ANOVA followed by Dunnet’s vs (CTR- + TNFa)
JNK(p54) protein levelsP-JNK(p54) protein levels E.
2.00
. 1.50
•i »
£ ? i.oo
=- E
0.50
M .
s  1.00
S »  0.80
C T R - C T R - 7*
TNFa - + +
C T R - C T R - 7*
T N Fa - + +
■ p < 0.05 1 way ANOVA followed by Dunnet’s vs CTR-
TNFa-mediated induction of p38MAPK and JNK in murine primary astrocyte cultures. A. 
Representative immunoblots for P-p38 in lysates obtained after exposure to TNFa 
lOOng/mL for 15’. Cytokine-stimulation leads to strong increase of P-p38 in uninfected 
cultures or in cells infected with shRNA nr.7*. P-p38 are maintained at low basal levels in 
cultures infected with shRNA nr.7. In B the quantification of P-p38/actin ratio for each 
band shown in A is represented (n=3). C. Representative immunoblots for P-JNK in 
lysates obtained after exposure to TNFa lOOng/mL for 60’. This stimulation leads to a 2- 
fold increase of P-JNK in not infected cultures, in cells infected with shRNA nr.7*, as well 
as in cultures infected with shRNA nr.7. Seq. 7 does not modify the levels of total JNK in 
these cultures. In D and E the quantification of P-JNK/JNK ratio and of JNK/actin ratio 
for each band shown in C are represented (n=3).
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Figure 5.5
Test o f shRNA nr. 7 on ra t neuronal cultures
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A. Representative immunoblots for p38MAPK and P-eIF2aIpha in lysates obtained from 
rat primary cortical neurons 3 days after infection with candidate shRNA nr.7 or control 
empty vector (EV). Seq.7 retained the ability to downregulated p38MAPK alpha without 
inducing anti-viral response (no increase of P-eIF2alpha). B. Induction of cell death in rat 
cortical neurons through exposure to lpM colchicine for 24h. Expression of shRNA nr.7 
reduces the death of neurons by 40%, as assessed by LDH release assay, as compared to 
cells infected with shRNA nr.7* or treated uninfected neurons (each column represent the 
mean +/- SEM of four independent experiments). Colchicine-induced LDH release in 
uninfected cells was increased 2.6-fold as compared to untreated uninfected neurons.
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Figure 5 .6
T est o f  shRNA nr. 7 -m ed ia ted  e ffe c ts  a t  sh o r t term :  
sch em a tic  rep re se n ta tio n  o f  th e  in jection  in th e  s p in a l co rd
A. B.
Lumbar spinal cord Lumbar spinal cord
Lj-Lj levels L.-L, levels
E m p ty
vector
ShRNA 
seq. 7* o r  seq. 7 J
I
i
> Injection in m ice at the Pre-sym ptom atic st 
>• Sacrifice 2 w eeks after injection
>- Laminectomy of L, vertebra
> 2 injections only in one side of spinal cord 
>- contralateral side is left untreated
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I
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Injection in mice at the Pre-sym ptom atic stage  
Sacrifice 2 w eeks after injection 
Laminectomy of L, vertebra 
2 injections for each side of spinal cord 
injected volume: 1 pL 'injection site
A. Monolateral delivery of GFP-expressing vector in NTg or presymptomatic SOD1G93A 
mice, to evaluate possible effects induced by lentiviral vector delivery. B. Scheme of the 
injection procedure of viral vectors in the lumbar spinal cord of SOD1G93A pre- 
symptomatic mice, for testing of short-term effect of shRNA nr.7 expression on motor 
neuron survival. Empty vector was injected in the left side of spinal cord, while shRNA 
nr.7* or shRNA nr.7 expressing lentivirus were delivered in the contralateral side.
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Figure  5 .7  
H igher su s c e p tib il i ty  o f  SOD 1G93A m o to r  neu ron s  
to  in tra sp in a l in jec tion  o f  an  e m p ty  v ira l vec to r
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Evaluation of the number of surviving motor neurons in NTg or SOD1G93A animals 16 
days after treatment with empty lentiviral vector, as compared to sham operated 
contralateral side. N=3 for each experimental group. A. Mean number of surviving cells 
with area higher than 250pm2; the ratio between empty vector-injected side versus sham 
is shown. Statistical analysis was performed by Student’s unpaired t-test. B. Mean 
number of surviving cells with area higher than 250pm2, subgrouped depending on the 
spinal cord segment in which they are localized (L3 or L4). Statistical analysis was 
performed by 2 way ANOVA followed by Bonferroni’s post hoc test.
Figure 5 .8  
P ro tec tio n  o f  m o to r  n eu ron s in  th e  s p in a l co rd  s id e  
in jec ted  w ith  shRNA nr. 7
A. B.
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Evaluation of the number of surviving motor neurons in SOD1G93A animals 16 days 
after treatment with shRNA nr.7 or shRNA nr.7*, as compared to empty-vector (EV) 
injected contralateral side. N=3 for each experimental group. A. Mean number of 
surviving cells with area higher than 250pm2; the ratio between shRNA-treated versus 
EV-injected side is shown. Statistical analysis was performed by Student’s unpaired t- 
test. B. Mean number of surviving cells with area higher than 250pm2, subgrouped 
depending on the spinal cord segment in which they are localized (L3 or L4). Statistical 
analysis was performed by 2 way ANOVA followed by Bonferroni’s post hoc test.
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Figure 5.9
Treatm ent o f SOD1G93A mice with lentivectors expressing shRNA nr. 7
significantly reduces life span
Survival proportions
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Comparison of survival curves for Group C (shRNA nr.7 treatment) versus control Group 
A (Sham operated) (A), or control Group C versus control Group D(shRNA nr.7* 
treatment) (B), and Group D versus Group A. Log-rank analysis of probabilities showed a 
significant shortening of survival in Group C, as compared to Group A or Group D. No 
significant difference was observed between Group D and Group A.
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Figure 5.10
Effect o f shRNA nr. 7n on disease progression
in SOD1G93A mice
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2-wav ANOVA for repeated measures: 
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Group C vs Group A: Fint p=0.0048
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2-wav ANOVA for repeated measures: 
Group C vs Group D: Fint p<0.0001 
Group C vs Group A: Fint p<0.0001
Body weight (A), extension reflex (B), and performance on grid test (C) and on rotarod (D) 
of animals treated with shRNA nr.7 (Group C; n=7), compared to control sham operated 
mice (Group A; n=5) and to animals treated with shRNA nr.7* (Group D; n=5). No 
difference in the disease progression was observed between animals of Group D and 
Group A for all measures. In Group C a steeper descrease of body weight was observed 
starting from 100 days, in contrast to the control groups A and D. Group C displayed a 
tendency to have a lower extension reflex score already at 93 and 97 days, as compared 
to control groups. From day 100 to day 111 this deficit became statistically significant 
versus both control groups. The grid test highlighted an anticipation of motor deficits for 
Group C from day 97 till end stage of the disease. The performance of Group C resulted 
significantly lower than the control groups at 104 and 107 days of age. Similarly, the 
rotarod test evidences a significantly worse performance for Group C from day 97 till end 
stage of disease, in contrast with control groups. Comparison of the progression of 
deficits between groups was done by two-way ANOVA for repeated measures followed by 
Student’s t-test at each time point in case of significant interaction (the results of the 
statistical analysis are shown under each graph).
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Figure S. 13
Expression o f shRNA nr.7 causes a m ild decrease  
o f motor neuron survival in SOD1G93A anim als
A. AREA > 2 5 0  p m 2 B. AREA r a n g e  2 0 0 -2 5 0  p m 2
shRNA 7* shRNA 7CTR
15-|
o _o S 10-<D w w co 
E -i
* = p < 0,05:
1 way ANOVA followed by Tukey Kramer's post hoc test
C.
AREA> 250  p m 2
D.
CTR shRNA 7* shRNA 7
p > 0,05; 1 way ANOVA
AREA ran ge 200-250  pm 2
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CTR shRNA 7* shRNA 7 CTR shRNA 7* shRNA 7
p = 0,06; Kmskal Wallis P > 0.05; Kruskal Wallis
Evaluation of the number of surviving motor neurons in the lumbar spinal cord of 
SOD1G93A at the end stage of disease after treatment with shRNA nr.7 (shRNA 7; n=4), 
compared to animals treated with shRNA nr.7* (shRNA 7*; n=3) or sham operated mice 
(CTR; n=3). A. Mean number of surviving cells with area higher than 250pm2; B. Number 
of surviving neurons with small area (range 200-250pm2), considered not to be motor 
neurons. In C, D the distribution of single data used in the analysis is represented. 
Statistical analysis was performed by 1 way ANOVA followed by Tukey Kramer’s post hoc 
test. Results confirmed with Kruskal Wallis non-parametric test for comparison of 
medians.
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Figure 5.14
Analysis o f motor neuron survival in trea ted  SOD1G93A mice 
a t different spinal cord levels
Area > 250
" = p <  0.05: 2 way ANOVA Mowed by Bonferroni's post hoc tost 
Flt\t significative
.2Area range 200-250 ym ‘
0  UI
1
E
Lt
a  ctr
ESI shRNA 7’ 
HQI shRNA 7
Spinal cord level
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Spinal cord level
Evaluation of the number of surviving motor neurons in different lumbar spinal cord 
segments (L2 -L4) at the end stage of disease after treatment with shRNA nr.7 (shRNA 7; 
n=4), compared to treatment with shRNA nr.7* (shRNA 7*; n=3) or sham operated mice 
(CTR; n=3). A. Mean number of surviving cells with area higher than 250(im2; B. Number 
of surviving neurons with small area (range 200-250|un2). Statistical analysis was 
performed by 2 way ANOVA followed by Bonferroni’s post hoc test (no significant 
interaction was observed between the treatment and the spinal cord level).
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Figure 5.15
Effect o f shRNA nr. 7 expression on reactive astrocytosis
in SOD1G93A mice
G FA P M erge
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Representative confocal microscope microphotographs of GFP (green) and GFAP (red) 
im m unostainings in lumbar spinal cord sections obtained from end stage SOD1G93A mice after 
treatment with lentiviruses expressing shRNA nr.7* (A-F) or shRNA nr.7 (G-O). In anim als treated 
with shRNA nr.7* GFP signal is detected in astrocytes (arrowheads in A-F) and surviving neurons 
(arrow in A). Astrocytes are hypertrophic, as expected at this stage of the disease. Expression of 
shRNA nr.7* does not modify astrocytes morphology. In anim als treated with shRNA nr.7 some 
infected motor neurons can be detected (arrows in J  and M). Astrocyte morphology appears normal 
(K and L) except in areas surrounding the sites of injection (H). In these regions GFAP staining  
appears filamentous and highly intense, and rarely colocalized with GFP signal (asterisks in G-I). 
Several GFP-expressing cells of very small area are also detected (arrowheads in G, I), moreover 
some larger round-shaped cells appear (arrow in G,I). Scale bar in F applies to A-E = 100pm; scale 
bar in L applies to G-K = 100pm; scale bar in O applies to M, N = 50pm.
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Figure 5.16
Effect o f shRNA nr.7 expression on reactive microgliosis
in SOD1G93A mice
Representative confocal microscope microphotographs of GFP native signal (green), 
CD l ib  (red) and Hoescht nuclear (blue) immunostainings in lumbar spinal cord sections 
obtained from end stage SOD1G93A mice after treatment with lentiviruses expressing 
shRNA nr.7* (A-H) or shRNA nr.7 (I-P). In animals treated with shRNA nr.7* GFP signal is 
detected in several microglial cells (arrowheads in A-H) and surviving neurons (arrows in 
E, G). The microglia has a classical stellate morphology, as expected for the reactive 
microgliosis already described at this stage of the disease. Expression of shRNA nr.7* 
does not modify this morphology. In animals treated with shRNA nr.7 some infected 
motor neurons can be detected (arrows in I and K). The infected microglial cells display a 
round-shaped amoeboid-like morphology both far (arrowheads in I-L) and near the 
injection site (arrowheads in M-P). In the regions surrounding the injection site a strong 
immunoreactivity for CD l ib  is detected, with almost all infected microglial cells 
displaying a round-shaped morphology. In these areas an increase of cells is also 
detected, as evidenced by nuclear staining (P). Some of these cells are organized in 
clusters (asterisks in O, P), rarely colocalizing with GFP signal. Scale bars = 50|un.
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5.7 Discussion
We have identified a  shRNA sequence (shRNA nr.7) th a t efficiently targets m urine
p38MAPK alpha. Lentiviral vectors carrying this sequence induced u p  to an 80%
reduction in p38MAPK alpha protein levels in cultured cells. TNFa strongly
activates p38MAPK (Da Silva and Silva, 1997) b u t the levels of phosphorylated
p38MAPK were strongly inhibited by shRNA nr.7, even in the presence of TNFa.
Importantly, the levels of JNK, a  closely related MAP kinase family member, were
unaltered by shRNA nr.7  indicating selectivity of action for th is  sequence.
However, upon TNFa stim ulation in prim aiy astrocytes, the phosphorylation
state of th is kinase was slightly higher in shRNA nr.7-treated cells, as compared
to control groups, suggesting th a t reduction of p38MAPK m ay induce a  shift to
increased activation of JNK. Furtherm ore, shRNA nr.7  induced p38MAPK
downregulation in ra t neuronal cultures partially protected against colchicine
induced cell death, confirming findings with conventional p38MAPK inhibitors
(Yang et al., 2007). Exposure to colchicine is a  paradigm of cell death  in vitro
caused by cytoskeletal dysorganization, a  pathological hallm ark th a t is found
also in dying motor neurons in vivo, in ALS. In particular, perikarial
accum ulation of phosphorylated neurofilam ents has been described in  the motor
neurons of ALS patients and in mouse models, and has been associated with
activation of p38MAPK alpha. Therefore, to further dissect the role played by this
kinase in vivo, we delivered lentiviral vectors expressing p38MAPK-targeted
shRNA to presymptomatic SOD1G93A mice and assessed neuronal survival 16
days later. Interestingly, we highlighted a  tendency of protection of motor
neurons in the areas th a t were infected by lentiviruses expressing shRNA nr.7 .
However, when we evaluated the effect of p38MAPK alpha downregulation on
disease progression, in a  separate experiment, surprisingly we observed an
acceleration in motor deficits and a  decreased life span in anim als th a t received
shRNA nr.7. In line with th is effect, histological analysis performed a t the end
stage of disease revealed a  modest b u t significant increase of the m otor neuron
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loss in the spinal cord segm ents corresponding to the sites of injection. However,
infected motor neurons could still be detected a t the end stage of the disease
suggesting th a t p38MAPK downregulation m ight have protected these cells. This
may support the general hypothesis th a t inhibition of p38MAPK in motor
neurons may be protective. However, it does not explain why the disease is
exacerbated by the prolonged downregulation of p38MAPK. Treatm ent of
SOD1G93A mice with non specific pharmacological p38MAPK inhibitors has
resulted in increased survival of motor neurons, although with a  very small effect
on disease progression and life span (Dewil et al., 2007a). The protective effects of
p38MAPK inhibition on motor neurons may be due to reduced microglial
activation (Dewil et a t, 2007a), or by direct anti-apoptotic effects (Raoul et al.,
2002; Raoul et a l, 2005a). A  further m echanism  of protection may be prevention
of cytoskeletal disorganization, although we have no direct evidence for this.
However, in contrast to previous work (Dewil et al., 2007a), we observed a  clear
worsening of symptoms in anim als treated with shRNA nr.7, as com pared to
control groups. Analysis of astrogliosis reactivity in these mice did no t reveal
substantia l morphological alterations of the infected astrocytes, as com pared to
control groups. However in the areas surrounding the injection sites a  strong
GFAP immunoreactivity (with filamentous shape) could be detected. Since this
anom alous staining rarely colocalized with GFP it can be deduced th a t it is no t a
direct consequence of shRNA nr.7  expression in astrocytes. On the other hand,
expression of shRNA nr.7  in microglial cells induced interesting alterations in
their morphology: the cells lost their typical stellate struc ture  and became
rounded. This effect appeared more prom inent in the regions proximal to the
injection sites, where maximal expression of GFP reporter gene w as detected.
Curiously, in these areas, and only in anim als injected with shRNA nr.7 , we
detected a  strong increase of cells, as determ ined by Hoescht nuclear staining.
These cells were often organized in clusters, and were rarely positive for CD l i b
staining or for GFP. It can be excluded th a t these cells may have invaded the
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parenchym a from the peripheral circulation during or immediately after
adm inistration of the lentiviral vector. The intraspinal injection procedure is
quite invasive and causes some bleeding after preparative laminectomy, and the
injection may cause some additional traum a, probably recruiting some
neutrophils, and lymphocytes (Schnell et a l, 1999). Nevertheless, we used
lentiviruses pseudotyped with VSVG, th a t gives broad tropism, so it can be
hypothesized th a t if those cells migrated in the tissue during the injection, they
should have been infected by the virus. Since we observed the opposite effect
(high num ber of non-infected cells), it is conceivable th a t the effect we observed
is in some way linked to p38MAPK downregulation. Reactive microglia are
capable of releasing several molecules, including cytokines and chemokines
(Koistinaho and Koistinaho, 2002). We observed an anom alous morphology for
reactive microglia in anim als treated with shRNA nr.7, so it can be hypothesized
th a t alterations in the microglial cells may have influenced the reactivity of other
cell types. Although we cannot prove this, it is interesting to note th a t similar
morphological alterations are detected in NG2-positive reactive microglial cells
after spinal cord injury (Leskovar et a l, 2000; Hendriks et a l, 2007). It h as  been
recently dem onstrated th a t in spinal cord injury activated microglial cells and
macrophages may cause retraction of damaged axons, th u s  creating a  cellular
barrier to potential regeneration in the CNS (Horn et al., 2008). In ALS it has
been suggested th a t reactive microgliosis may contribute to the worsening of
motor deficits, since reduced induction of microgliosis correlates with delayed
progression of disease (Kriz et a l, 2002; Van Den Bosch et a l, 2002; Clement et
a l, 2003). Indeed, it has also been reported that, depending on the stim uli acting
on the microglial cells, th is population can also exert a  neuroprotective function,
for instance by releasing growth factors (Beers et a t, 2008; Chiu et a l, 2008).
This suggests th a t modulation of the responses induced in microglial cells
critically influences neuronal survival. In a  recent paper SOD1G37R mice were
treated with M-CSF with the aim of inducing a  neuroprotective microglial cell
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phenotype, b u t surprisingly the resu lt was an acceleration of disease progression 
and reduced survival (Gowing et a l, 2009). In line with our results, the au thors 
describe altered microglial cells with amoeboid-like morphology in the spinal cord 
of symptomatic mice treated with M-CSF, suggesting th a t M-CSF may have 
induced a  macrophage-like neurotoxic phenotype. Interestingly the num ber of 
surviving motor neurons was not significantly different in M CF-treated group, as 
compared to control, however an increased denervation of peripheral m uscles 
was reported.
Overall our results indicate th a t p38MAPK downregulation in m otor neurons is 
potentially neuroprotective, since we reported substantial preservation of motor 
neurons shortly after delivery of lentiviruses expressing shRNA nr.7 , and  we 
could detect infected motor neurons still surviving a t the end stage of the 
pathology. However, th is effect is apparently offset by the abnorm al activation of 
microglial cells (evidenced by the altered morphology) which may lead to more 
rapid worsening of the disease. To better dissect the role of p38MAPK pathway, 
and with the aim of potentiating the therapeutic potential of its inhibition in 
motor neurons, alternative strategies may be suggested: 1 ) specific expression of 
shRNA nr.7  in motor neurons may be obtained by adm inistration of Rabies 
pseudotyped lentiviruses (or similar viral vectors capable of retrograde transport) 
in peripheral m uscles 2 ) intraspinal delivery of a  lentiviral vector containing a  
dom inant negative m utan t of p38MAPK (Ludwig et a l, 1998), expressed under 
Hb9.1.6 motor neuron specific prom oter (described in chapter 3). Specific 
inhibition of the p38MAPK pathw ay in motor neurons, obtained through these 
approaches, may then  protect this cell type w ithout the risk of inducing aberran t 
activation of microglial cells.
An additional observation made during p38MAPK downregulation experim ents in
vivo, was th a t the spinal cord of SOD1G93A mice appeared to be highly
susceptible to the intraspinal injection procedure. In fact we detected a  slight
increase of motor neuronal loss in L4 segm ent of the spinal cord, in the site th a t
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received the injection of an  empty vector as opposed to the contralateral sham  
operated side. This damage is probably not sufficient to cause a  significant 
alteration in the pathology as motor performance analysis of anim als injected 
with an  emtpy vector or shRNA nr.7* showed very similar motor deficits to those 
displayed by sham  operated anim als. This effect of the injection procedure on 
motor neuron survival may be explained by the fact th a t the spinal cord is more 
susceptible to traum a than  other CNS regions, like brain. This feature h as  been 
associated with increased induction of inflammatory responses in the spinal cord 
(Schnell et al., 1999); although it is evident th a t the injection of a  small capillary 
is not comparable to the damage caused by the classical paradigm s of spinal 
cord traum a, transien t induction of glial reactivity has been reported for 
intraspinal delivery of lentiviral vectors (Abdellatif et a l, 2006). If th is  is norm ally 
well tolerated, it is conceivable th a t in SOD1G93A animals, where glial cells and 
motor neurons suffer from the toxic effects induced by m u tan t SOD1, a  higher 
susceptibility may be expected. Based on this evidence, caution should be taken  
when considering the strategies for delivery to the spinal cord of SOD1G93A 
animals; probably, where possible, a  procedure th a t is less invasive th an  
intraspinal injection would be preferred.
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CHAPTER 6 
DEVELOPMENT OF 
NON-INVASIVE APPROACHES 
FOR DELIVERY OF VIRAL VECTORS 
TO SPINAL CORD MOTOR NEURONS
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In chapter 5 we reported a  mild increase of motor neuronal degeneration in the 
spinal cord segm ent L4 of SOD1G93A anim als, two weeks after injection of a  GFP 
expressing lentiviral vector. This happened specifically in transgenic animals, 
probably reflecting a  higher sensitivity of m u tan t SOD1G93A expressing motor 
neurons to the traum a caused by the injection, or to some com ponent of the viral 
vector preparation (as already discussed in the previous session). A ssessm ent of 
motor perform ances of treated anim als didn’t  show substan tia l deficits, as 
compared to mice th a t underw ent laminectomy without receiving any injection. 
However, despite the effect on motor neurons may be considered not detrim ental 
for the pathology, this may still represent a  limitation for further development of 
any gene-therapy approach in hum an ALS patients. Since the disease is 
multifocal and progressive, several motor neurons in different spinal cord 
districts should be targeted in order to obtain a  significant effect on the 
pathology. For this reason, direct delivery in spinal cord parenchym a of a  
putative therapeutic viral vector would necessary require a  high num ber of 
multiple injections, th u s  increasing the probability to cause adverse effects due 
to invasiveness of the procedure.
Since the m ain advantage of lentiviral vectors is their ability to drive longlasting 
transgene expression in vivo, they still gain great in terest for treatm ent of chronic 
pathologies, like ALS, because a  single adm inistration may be sufficient to obtain 
the desired therapeutic effect over time. We then  decided to further develop th is 
viral vector system by testing two potential less-invasive delivery approaches, in 
parallel:
delivery of VSVG pseudotyped viral vectors in the cerebrospinal fluid;
use of Rabies-G pseudotyping to allow retrograde transduction  of spinal
cord motor neurons after injection in peripheral m uscles.
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6.1 Delivery in cerebrospinal fluid
Administration of potential therapeutic drugs in the cerebrospinal fluid is often 
described as a  strategy to increase CNS bioavailability for drugs th a t usually  do 
not cross the blood-brain barrier. These com pounds are adm inistered in the 
cerebral lateral ventricles through stereotaxic injection, since CSF potentially 
represents a  good carrier for the wide distribution of molecules through the 
whole CNS. This delivery approach has already been used  successfully in 
SOD1G93A mice, dem onstrating a  protective effect of com pounds such  as 
cyclosporin, or Fas-targeted siRNAs (Karlsson et al., 2004; Locatelli et a l, 2007). 
Since the delay of disease progression, observed after intrathecal delivery of these 
drugs, is paralleled by reduced loss of motor neurons in the lum bar spinal cord, 
it can be hypothesized th a t th is way of adm inistration allows targeting of the 
cells localized in the spinal cord. On the other side, adm inistration in the 
subarachnoid space a t lum bar level can represent a  valid alternative to obtain 
increased delivery to the motor neurons within the spinal cord. In fact, it has  
already been shown th a t intrathecal (IT) adm inistration of drugs to lum bar spinal 
cord can help in obtaining a  high concentration of the molecules a t the lum bar 
level (Hylden and Wilcox, 1980; Bellasio et a l, 2003). In addition treatm ent of 
SOD1G93A mice with IGF-I or TAT-BcL-XL fusion protein, delivered intrathecally 
a t lum bar level, significantly slowed the disease progression and reduced motor 
neuron loss (Nagano et a l, 2005; Ohta et al., 2008).
Therefore, we tested the efficiency of VSVG pseudotyped lentiviral vectors to 
infect spinal cord cells after intrathecal delivery in NTg mice.
6.1 .1  Injection in cerebral lateral ventricles (ICV delivery)
GFP expressing viral vectors were injected in the two lateral ventricles 
(5p.L/injection site), according to the procedure described in section 2.2.3. At one 
and four weeks post-injection anim als were sacrificed by in tracardial perfusion;
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then  brain and lum bar spinal cord were dissected and sectioned to visualize GFP 
signal.
As shown in Figure 6.1, through ICV delivery it was not possible to highlight 
infection of cells within brain or spinal cord parenchym a. GFP signal was 
localized only in choroid plexus and ependymal cells of the lateral, th ird  and 
fourth ventricles, with rare diffusion into the spinal cord. A few GFP positive cells 
were observed inside the spinal cord canal (arrow in Figure 6.1) or a t the 
emergence of spinal nerves (data not shown). This pattern  of d istribution was 
m aintained between 1 and 4 weeks post-injection. Due to the low efficiency of the 
viral vectors for infection of lum bar spinal cord cells, th is delivery approach was 
not further developed, and adm inistration a t lum bar level was considered 
potentially more efficient.
6 .1 .2  Injection in subarachnoid space o f spinal cord at lumbar level (ITL 
delivery)
This procedure of adm inistration was designed according to Hylden and  collegues 
(Hylden and Wilcox, 1980) and through helpful assistance of Dr Elisa Nicolussi 
and Rosalia Bertorelli of Schering Plough Italia. Initial testing w as done by 
injecting 5jiL of a  2% Tiypan-blue dye solution in the subarachnoid  space of 
lum bar spinal cord, according to the procedure outlined in section 2.2.3. Animals 
were sacrificed immediately after adm inistration and backbone was dissected out 
and post-fixed in paraformaldheyde for 24h before spinal cord extraction. A fine 
blue staining was observed on the surface of lum bar spinal cord (Figure 6.2), 
confirming th a t the procedure had been appropriately set up. With the sam e 
procedure VSVG vectors were delivered to NTg mice, and GFP reporter gene 
expression was assessed two weeks after injection. VSVG vector adm inistered 
through this route spread widely along the lum bar spinal cord (from sacral to Li 
portion). However though several GFP positive cells were found in the  m eninges
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and in the outer regions of white m atter, the virus did not penetrate in the spinal 
cord parenchym a (Figure 6.3).
Several au thors have dem onstrated th a t the induction of hyperosmolality in 
blood can help to increase dissem ination of adeno-associated viral vectors into 
brain parenchym a after injection into CSF (Fu et al., 2003; Burger et a l, 2005). 
For th is reason we decided to test th is approach to try to increase lentiviral 
vector distribution.
6 .1 .3  Effect o f m annitol-induced BBB disruption on viral vector  
bioavailability after ITL delivery
Systemic m annitol-induced hyperosmolality is a  well established technique used  
to induce disruption of the blood-brain barrier (BBB) in vivo. This procedure 
determ ines shrinkage of the tight junctions between the endothelial cells th a t 
compose the BBB in vivo, th u s  allowing polar molecules to easily pass from blood 
into cerebral parenchyma. Similarly, an  increase of permeability of the barrier 
between CSF and CNS tissue has also been reported after m annitol treatm ent 
(Ghodsi et al., 1999). However the effect of hyperosmolality on the BBB a t spinal 
cord level, in the mouse, has not been described. In some studies BBB 
impermeable substances, like horseradish peroxidase, Evans Blue dye or C14- 
sucrose, have been delivered intravenously in the mice. The extent of BBB 
opening is generally visualized by leakage of the staining for these substances in 
the brain parenchym a. In a  first set of experiments we defined a  protocol for 
induction of BBB disruption in the mouse, and verified it in vivo. The procedure 
was set up  as already described with minor modifications (Ghodsi et a l, 1999). 
Briefly, we performed a  single intra-peritoneal injection of m annitol (0.03m L/g of 
a  25% m annitol solution in 0.1M phosphate buffer) 10 min prior to intravenous 
delivery of 200pL Evans Blue (2% solution in 0.1 M phosphate buffer). 20 m inutes 
later anim als were sacrificed by intracardial perfusion of PBS, then  the backbone
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was dissected and post-fixed in paraformaldheyde solution for 24h before spinal 
cord extraction. Tissues were then  criopreserved and cut, for visualization of 
Evans Blue staining under epifluorescence microscope. This dye is norm ally not 
fluorescent; however after delivery in the blood flow it binds to serum  album in, 
determining a  red fluorescent signal after green light illumination. As it can be 
noticed from Figure 6.4, the spinal cord parenchim a (A) and the central canal 
(inset in A) of saline treated anim als appears dark, with only some discrete 
p uncta  positively m arked with Evans Blue dye signal. This probably reflect the 
presence of album in-bound dye in CNS capillaries. Upon m annitol injection, a  
clear increase of red fluorescent signal can be observed in the boundaries of the 
capillaries, as it can be deduced by the morphology of the staining. Moreover a  
diffuse increase of fluorescence can be detected in the parenchym a of spinal cord 
and in the central canal (inset in B), probably reflecting the extravasation of 
album in-bound Evans Blue.
Since intraperitoneal injection of m annitol dem onstrated to be sufficient for 
induction of transien t BBB dysruption, as evidenced by Evan Blue dye 
extravasation, th is protocol was used  to increase penetration of VSVG- 
pseudotyped viral vectors in spinal cord parenchym a, after adm inistration in the 
subarachnoid space of lum bar spinal cord. Surprisingly, the GFP reporter gene 
expression in the spinal cord was similar between the mice treated or un trea ted  
with m annitol two weeks after viral vector delivery, and it was only found a t the 
meningeal level. No GFP-expressing cells were detected in white and grey m atter 
of spinal cord.
6 .2  Rabies-G pseudotyping
Rabies virus is an RNA based, enveloped neurotropic virus. It usually  infects
hum ans through the saliva of infected domestic or wild anim als (Leung et a l,
2007). This virus gains access to the CNS by entering in peripheral nerve
term inals, located in m uscles. This is probably m ediated by interaction of Rabies
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envelope proteins with the alpha subun it of acetil-choline nicotinic receptors or 
other surface proteins like NCAM or CD56, or p75NTR (Lafon, 2005). After 
entering in the synaptic term inals, retrograde transport along axons delivers the 
viral particles to the motor neuronal cell bodies when viral genome is released, 
allowing synthesis of new viruses and transynaptic spreading of the infection to 
upstream  CNS areas (Ugolini, 2008). Pseudotyping of lentiviral vectors with 
Rabies-G protein is gaining increased in terest for developing of innovative gene 
therapy approaches, as it h as been dem onstrated th a t this modification allows 
retrograde transport of lentivectors from peripheral m uscular districts, along 
axons, to motor neuronal cell bodies in rodents (Mazarakis et al., 2001; Wong et 
a l, 2004). The m ain advantages of th is strategy are: a) selective targeting of 
spinal cord motor neurons, thanks to the na tu ra l neuronal tropism  conferred by 
the pseudotype; b) dispensability of cell-specific promoters, and  specific targeting 
of shRNA sequences to the motor neurons (HI and U6 RNApol III prom oters are 
regulatory sequences needed for induction of RNAi, th a t would lead to 
ubiquitarious expression if the virus is not targeted to specifc cell types); c) this 
therapeutic approach may be more easily translated  into clinic, since it is 
definitively less invasive than  intraspinal injection; moreover m ultiple spinal 
cord segm ents may potentially be targeted by simply injecting the virus in the 
corresponding m uscular districts.
Interestingly, by using th is gene-therapy approach, Azzouz and co-workers have
reported one of the m ost strong effects ever obtained in SOD1G93A mice with a
conventional therapeutic treatm ent (Carri et a l, 2006). The au thors prepared a
VEGF expressing Rabies-G lentivector and delivered it in different m uscles of
SOD1G93A mice before symptom onset, a t three weeks of age. This determ ined a
delay of onset of 28 days, and a  slow disease progression, with significant
increase of survival of 30% over the empty-vector treated anim als. The effect
observed on the disease phenotype was paralleled by increased expression of
VEGF in spinal cord, and increase of 44% of surviving motor neurons a t the end
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stage of the disease. Remarkably, this effect was retained also when the vector 
was adm inistrated at symptom onset, suggesting th a t this strategy may be 
promising for treatm ent of ALS patiens (A z z o u z  e t  a l ,  2 0 0 4 a ) .  We decided to 
adopt a  similar approach to modify the tropism of our lentiviral vectors.
6.2 .1  Set up o f a protocol for production of Rabies-G lentiviral vectors at 
high titre
Mazarakis and co-workers described the use of a  viral titre in the range of 6 x l0 8- 
3 x l0 9 TU/mL ( M a z a r a k is  e t  a l., 2 0 0 1 ) .  Initial production of Rabies pseudotyped 
lentivectors, performed following the protocol already set up in section 3.1 for 
VSVG, lead to a  titre lower than  th a t described in the literature (Table 6.1 - Trial 
1). To improve viral particle production the original protocol was modified in 
subsequent steps: increase of the am ount of envelope plasmid (with the aim to 
facilitate packaging of viral particles) and progressive increase of the fold 
concentration of the virus-containing supernatants after ultracentrifugation. As 
outlined in Table 6.1 - Trial 5, the modified protocol lead to a  final titre of 3.1x108 
TU/mL, tha t was considered sufficiently high for in vivo delivery.
Table.6 .1 . High titre production of Rabies pseudotyped lentiviral vectors
Trials
Amount of pRabies 
transfected (ng)
Additives
Fold concentration 
of supernatant
Titre
(TU/mL)
1 0.60 / / lOOx 8.4xi06
2 250 lOmM NaBuTyrate lOOx 9.5x10°
3 1.25 lOmM NaBuTyrate lOOx 1.4x10'
4 0.83 lOmM NaBuTyrate I00x 2.1xl07
5 0.83 lOmM NaBuTyrate 200x 3.1xl08
Starting conditions
Plasmids
Amount of 
DNA (pg)
Envelope pRabies 0.60
Adjuvant p cm 1.00
Adjuvant pREV 0.50
Transfer vector pLVTHM 2.50
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6 .2 .2  Delivery o f Rabies-G pseudotyped vectors in peripheral m uscles
Rabies pseudotyped GFP-espressing lentivectors were adm inistered to 
gastrocnem ius m uscles in 10 weeks-old NTg mice. 3-4 weeks post-injection 
anim als were sacrificed by intracardial perfusion and lum bar spinal cord 
sections were analysed for reporter gene expression. GFP positive cells have 
never been observed in the spinal cord of mice injected in the gastrocnem ius 
region. The signal was totally absen t also from the m uscles (data not shown). To 
verify th a t the injection procedure was correct, a  separate group of anim als 
received injection of FluoroGold (a retrograde tracer th a t becomes fluorescent 
upon UV illumination) in right gastrocnem ius, following the sam e protocol used 
for viral vector delivery. The level of spinal cord expected to be stained by the 
FluroGold was highilighted by concom itant injection of Dil in the contralateral 
sciatic nerve. Dil is a  lipophilic dye th a t passively propagate in m em brane 
com partm ents in living anim als as well as fixed tissue specimens. It becomes 
fluorescent upon green light illumination. 5 days after injection of Fluorogold and 
Dil, rem arkable positivity for Fluorogold was detected in the cell bodies of spinal 
cord motor neurons ipsilateral to the injected gastrocnem ius (Figure 6.5). This 
resu lt is consistent with the literature (Sagot et a l, 1998; Haenggeli and Kato, 
2002), and further confirms th a t inefficiency of Rabies lentivectors was not due 
to wrong delivery procedures. In order to verify the extent of retrograde infectivity 
of Rabies lentivectors in the CNS in our condition, we decided to deliver this 
lentivirus in the striatum  of NTg mice and to examine its expression in the cells 
projecting to the striatum  (i.e cortex, su b stan tia  nigra). One pL of a  low titre 
batch of Rabies (titre 0.8x108 TU/mL) was adm inistered in 5 m in according to 
the procedure described in section 2.2.3.2, with an  appropriate set of stereotaxic 
coordinates: +2.0mm laterality, +0.5mm antero-posteriority, -4.0m m  dorso- 
ventrality referred to Bregma. Two weeks after infections anim als were sacrificed 
by perfusion, and brains serially sectioned to visualize GFP reporter gene
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expression. The signal w as observed in  the  s tria tu m , as  expected, m oreover we 
could detect som e positive cells in  the  cortex, in  an  a rea  th a t  w as far from the  
needle tra c t (Figure 6.6). Since n eu ro n s  of the  cortex are know n to project to the  
s tria tu m , th is  re su lt confirm ed th a t  Rabies len tiv irus can  be retrogradely 
tran sp o rted  after adm in istra tion  in  b ra in  parench im a.
Figure 6.1.
Pattern o f GFP reporter gene expression in CNS after ICV delivery
Fimbria hippocarr Hippocampus
Fornix
4th ventricle
Lateral
3rd ventricle
Representative photomicrographs of 
GFP expression in the CNS of mice, 
four weeks after ICV injection of a 
GFP-expressing VSVG-pseudotyped 
lentiviral vector. Sagittal brain 
sections, A-F, bar = 100pm; G-H,
bar=50pm. B. Transverse section of a 
mouse brain stained with NISSL, to 
depict the localization of the infected 
structures highlighted in A (image 
adapted from www.BrainMaps.org).
Figure 6.2.
Trypan-blue dye dystribution after IT delivery a t lumbar level
Representative photographs of spinal cords from mice injected with Trypan-blue dye in 
the subarachnoid space at lumbar level. Animals were sacrificed immediately after 
injection, then spinal cords extracted and post-fixed in 4% phosphate-buffered 
paraformaldehyde. Clear blue staining of the lumbar part of spinal cord can be observed.
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Figure 6.3.
GFP expression in spinal cord 
after IT delivery of lentivectors a t lumbar level
Representative photomicrographs of GFP expression in the lumbar spinal cord of mice 
one week after IT injection of a GFP-expressing VSVG-pseudotyped lentiviral vector. 
Spinal cords have been sectioned following longitudinal direction. A-C,E, bar = 100pm; 
D,F, bar =50um.
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Figure 6.4.
Evan Blue dye distribution after IV delivery 
and concom itant BBB dysruption
Saline Mannitol
■ ■
IBB B
Representative photomicrographs of fluorescence emitted by Evan Blue dye in the ventral 
horn of lumbar spinal cord of mice after IP injection of saline (A) or a 25% solution of 
mannitol (B). Insets in A and B show a detail of the fluorescence detected in the central 
canal of spinal cord. Bar =50pm.
Figure 6.5.
Efficient trasduction o f spinal cord motor neurons 
after delivery of Fluorogold in pripheral muscles
Dil injected FG injected
in left sciatic nerve in right gastrocnemius
Representative photomicrographs of fluorescence emitted by Fluorgold (blue signal in A) 
or Dil dye (red signal in A) in the lumbar spinal cord of mice 5 days after injection in 
gastrocnemius or sciatic nerve, respectively. Remarkable labelling of motor neurons can 
be detected in the side of spinal cord contralateral to Dil staining (A) and ipsilateral to the 
side of injection in the muscles (C). Bar in A=200pm; bar in C applies to B= 100pm.
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Figure 6.6.
Rabies lentivector can retrogradelly infect neuronal cells 
after delivery in brain parenchim a
0>co>
GOgj
03
C£
Representative photomicrographs of GFP expression in the brain of mice one week after 
injection of a GFP-expressing VSVG- or Rabies- lentiviral vectors in the striatum. 
Reporter signal is detectable in the area of injection (A-D); the expression is more 
prominent with VSVG vector than with Rabies. GFP positive signal could be detected in 
cortical neurons only in the side injected with Rabies lentivector (arrows in E, F). Bar in 
C applies also to A = 100pm; bar in E applies to B, D and F=50pm.
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6.3 Discussion
We tested  different strateg ies for obtain ing  good tran sd u c tio n  of m otor n eu ro n s
in  SOD1G93A an im als u sin g  non-invasive delivery of viral vectors to th e  sp inal
cord in  o rder to avoid th e  risk  to induce in jection-dependent n eu ronal sufference.
A lthough adm in istra tion  into the cerebrospinal fluid m ay be regarded  a s  a
po ten tial good app roach  of delivery, we dem onstra ted  th a t injection of
lentivectors ICV or in  the  subarachno id  space a t  lum bar level is n o t su itab le  for
infection of parenchym al cells of nervous system . Injection in  th e  cerebral la tera l
ventricles m ainly leads to tran sd u c tio n  of cells in  th e  ependym al layers and
choroid p lexus of b ra in  ventricles, w ith little diffusion in  the  cen tra l cana l of
sp inal cord. Similarly, w hen we adm in istered  the lentivectors in  the
subarach n o id  space a t  lum bar level, we observed infection only a t  m eningeal
level. This p a tte rn  of expression m ay depend  on th e  hydrodynam ics of CSF flux.
In fact in  norm al conditions CSF ten d s to flow aw ay from CNS paren ch y m a a s  it
is produced by choroid plexus an d  circu lates in  ventricles an d  in  th e
subarachno id  space, an d  th en  it is reabsorbed  into blood a t  venous s in u ses . So
although  the  flux of th is  fluid allows the  d istribu tion  of the  viral partic les  in  the
cavities of the  CNS, it m ay rep resen t an  obstacle to diffusion in  th e  parenchym a.
A nother possibility is th a t  the  th ick  s tru c tu re  of ependym a m ay en trap  th e  viral
particles, reducing  th e  probability of fu rth er diffusion. In th is  case  is w orth  to
notice th a t  tran sd u ce d  ependym al cells m ight rep resen t a  reservoire for
production  an d  release of potential th e rapeu tic  m olecules, su ch  as  grow th
factors. After infection w ith v iruses expressing  these  secretab le p ro teins, th e  cells
of ependym a m ay in  fact perpetually  p roduce an d  release th em  in to  th e
cerebrospinal fluid, allowing a  w idespread diffusion into several CNS areas.
There are few exam ples of positive re su lts  u s in g  ICV injection of engineerised
viral vectors. ICV adm in istra tion  of lep tin-expressing  adenoassocia ted  viral
vectors (AAV) h a s  been proposed a s  a  substitu tive  of insu line  ad m in is tra tio n  to
tre a t hyperglycem ia and  hyperphagia. In fact a  single injection of th e  vector w as
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able to m a in ta in  increased  hypothalam ic levels of leptin, rescu ed  th e  m ortality, 
an d  norm alized body w eight an d  blood glycemia in  a  m ouse m odel of 
hyperglycem ia. These effects were m ain ta ined  for all d u ra tio n  of observation (52 
weeks) (Kojima et al.} 2009). Sim ilarly a  su bstitu tive-therapy  app roach  h a s  been 
te sted  for a  m ouse m odel of M ucopolysaccharidosis VII. This is a  lysosom al 
storage d isease caused  by a  deficiency of p-glucuronidase enzym e. G hodsi and  
co-w orkers injected an  AAV cariy ing  th e  gene for p -g lucuronidase in  cerebral 
ventricles of p-glucuronidase deficient mice. In terestingly  they  reported  a  
correction of the  d isease in the  subependym al region, grey m a tte r of the  b rain  
an d  also in d is ta n t cortex areas, providing evidence th a t  th is  app roach  is usefu l 
for w idespread d istribu tion  of a  pro tein  in th e  CNS (Ghodsi et al., 1999). This 
therap eu tic  strategy  m ay be beneficial also for ALS. In tra theca l adm in is tra tio n  of 
IGF in SOD1G93A mice, th rough  m icroosm otic pum ps, h a s  in  fact determ ined  a  
significant im provem ent of m otor perform ance, re ta rd ed  the  onse t of d isease, an d  
extended survival (Nagano et a l, 2005).
In o rder to enhance spread ing  of th e  viral partic les in  the  p a ren ch y m a we 
explored the  possibility to d y sru p t the  b lood-b rain -barrier th ro u g h  m ann ito l 
system ic adm in istration . Delivery of hypertonic so lu tions in  blood c ircu lation  is  a  
widely accepted techn ique th a t is clinically u se d  to reduce b ra in  hydrodinam ic 
p ressu re  secondary  to trau m atic  in ju ries (Jantzen, 2007). In fact, due  to blood 
hyperosm olality, w ater d ra in s ou t of b ra in  back  into blood capillaries. 
Interestingly, it h a s  been  noticed th a t du ring  th is  phenom enon  CSF flux is 
reversed, so th a t liquids p ou r from su barachno idal space into th e  p a ren ch y m a 
(Milhorat et a l, 1970; Donato et a l, 1994). This stra tegy  h a s  been  successfu lly  
u se d  also to enhance spread ing  of adenoassociated  viral vector (AAV) partic les  in  
the  b ra in  (Fu et a l, 2003; Burger et a l, 2005). We tested  the  sam e p rocedu re  for 
lentiviral vectors delivered in  the  su b arach n o id  space a t lu m b ar level b u t  we 
d id n ’t  repo rt any  m odification of the  p a tte rn  of infection, as  com pared  to saline
-257-
trea ted  an im als. Lentiviral partic les have d im ensions in th e  range of 80-100nm , 
largely bigger th a n  adenoassocia ted  viral particles (20-25nm ). The sm aller 
dim ension of AAV m ay facilitate the  sp read ing  th rough  th e  m eningeal cell layer. 
Alternatively, m eninges m ay d isplay surface recep tors n o t recognised by AAV, 
reducing  th e  probability for th e  viral partic les to infect th e se  cells. Testing w ith 
o ther viral vector types, w ith  different particle d im ensions or trop ism  (like 
Adenovirus or H erpes virus) m ay help elucidating  th is  point.
Targeting of sp inal cord m otor n eu ro n s  from the  periphery  rep resen ts  a  very
in triguing  strategy. We investigated  th is  possibility in the  m ouse by delivering
R abies-pseudotyped HIV-1 b ased  lentiviral vectors in  gastrocnem ius m uscles.
D espite we se t u p  a  correct delivery p rocedure, as  confirm ed by experim ents w ith
Fluorogold dye, we did never m anage to ob ta in  infection of the  m otor n eu ro n s
w ith o u r viral vector system . This is in  co n tra s t w ith w h a t described  by Wong
an d  Azzouz in different w orks (Azzouz et a l, 2004a; Wong et a l, 2004). Referring
to the  papers  from th is  group we observed th a t  the  a u th o rs  u se d  a  viral
p repara tion  w ith a  concen tration  in the  range 6 x l0 8-3 x l0 9 TU /m L. We h a d  to go
th ro u g h  several tria ls  to efficiently increase  the  titre  of ou r Rabies pseudotyped-
vector particles, ending w ith a  concen tra tion  slightly slower th a n  desired  (3 .8 x l0 8
TU/mL). This m ay explain ou r resu lt, since in  the  case of AAV it h a s  been
d em onstra ted  th a t  titre  is crucial for infection of m otor n eu ro n s  afte r peripheral
delivery (Kaspar et a l, 2003). However K aspar described  a  progressive reduction
of infectivity moving from lx lO 10 to 4 x l0 9 viral partic les (0.4 log drop in  the
concentration). The titre  of o u r vector is ju s t  0.3 log lower th a n  the  concen tra tion
u se d  by M azarakis’ group for delivery in  th e  m ouse (Wong et a l, 2004), so
probably  o ther factors m ay have con tribu ted  to determ ine th e  inefficiency of o u r
Rabies lentivectors. In terestingly  the  s tra in  of Rabies u sed  for pseudo typ ing  is
reported  to modify viral infectivity in  the  b ra in  (Yan et a l, 2002). We verified th a t
o u r glycoprotein derives from SAD B19 Rabies s tra in  (Conzelmann et a l, 1990),
while M azarakis’ group u se d  ERA- an d  CVS- pseudotyped  n o n -p rim ate  (EIAV)
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lentivectors. The SAD B19 an d  CVS are reported  to be closely re la ted  (Wu et a l, 
2007) how ever in  ou r system  an o th e r variable h a s  been in troduced : th e  s tra in  of 
ou r tran sfe r vector w as HIV-1 in s tead  of EIAV. We tested  w hether th is  m ay affect 
infectivity by adm in istra tion  in  th e  b rain , and  could dem onstra te  th a t  the  vectors 
we u sed  are  capable of retrograde tra n sp o rt to the  cortex if delivered in  the  
s tria tum ; th is  observation w as confirm ed by o ther groups u s in g  different Rabies 
s tra in  (RV-G) (Kato et a l, 2007). In a  p ap er from M entis a n d  co-w orkers the  
au th o rs  described  fine infection of m uscle fibres an d  sp inal cord m otor n eu ro n s  
after adm in istra tion  of a  HIV-based Rabies pseudotyped vector (s tra in s CVS-N2c 
an d  -B2c) in  th e  gastrocnem ius of m ice (Mentis et a l, 2006). A lhough we u se d  a  
titre  lower th a n  M entis, we never detected  infection of m uscle fibers. Overall 
these  observations suggest th a t  su b stitu tio n  of the  Rabies s tra in  w ith an o th e r 
already  validated  glycoprotein or fu rth e r increase in  titre  m ay be n ecessary  to 
achieve m otor n eu ron  infection in ou r m odel system .
CHAPTER 7  
GENERAL DISCUSSION 
AND CONCLUSIONS
7 .1  GENERAL DISCUSSION
The aim  of th e  w ork p resen ted  in th is  th esis  w as to develop a  lentiviral vector- 
based  platform  to specifically target, in  vivo, in trace llu la r m olecular pathw ays 
critically involved in  ALS.
N um erous signalling pathw ays have been  found to be a ltered  in  ALS, b u t we 
focussed ou r s tud ies  on p38MAPK an d  Akt. p38MAPK is a  s tre ss  activated 
pro tein  k inase  an d  is considered to be a  key m olecule involved in  the  activation 
of several pro-degenerative pathw ays in ALS, including  cytokine-induced 
neuroinflam m ation  an d  cytoskeletal a ltera tions (Bendotti et a l, 2005). On the 
o ther h a n d  Akt is a  lipid activated  pro tein  k inase  th a t  m ediates m any  of th e  pro­
survival activities of trophic factors su ch  as  IGF1 an d  VEGF exhibiting protective 
effect on m otor n eu ro n s in ALS m odels (Nagano et a l, 2005; Storkebaum et al., 
2005; Dewil et al., 2007b). We decided to develop approaches to ta rge t th ese  
pathw ays separately  an d  specifically. We did th is  in o rder to gain a  be tte r 
u n d ers tan d in g  of th e ir overall relevance to ALS pathology an d  also a s  a  first pre- 
clincal step  in  th e  a ssessm en t of the ir th e rap eu tic  potential.
Induction  of Akt w as obtained  by p repara tion  of a  m yristylated m u ta n t th a t  
ancho rs Akt a t the  m em brane and  re su lts  in  a  constitutively active k inase  in 
vivo. Of the  th ree  know n Akt isoform s, Akt3 w as chosen  because  th is  isoform  is 
predom inately  expressed in  the  CNS (Easton et a l, 2005). F u rtherm ore , a  
m yristy lated m u ta n t co n stru c t of Akt3 h ad  already been  u sed  to dem on stra te  its  
neuroprotective function in  a  cell cu ltu re  m odel expressing m u ta n t SOD1 
(Kanekura et al., 2005) w hich gave u s  confidence th a t  th is  approach  could work. 
To res tric t th e  expression of th is  co n s tru c t to m otor n eu rons, we p rep ared  a  
prom oter derived from Hb9 u p stream  regulatory  sequences, an d  dem on stra ted  
for the  first tim e th a t it can  be packaged in to  lentiviral vectors an d  ac t 
specifically in vivo. T rea tm en t of SOD1G93A m ice w ith m otor n eu ro n -res tric ted
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m em brane-targeted  myr.Akt3 c o n s tru c t resu lted  in  a  m odest p ro tection  of m otor 
n eu rons, w ith no significant effects on d isease progression or survival. 
Therefore, we suggest th a t  com bining th is  approach  w ith additional stra teg ies  
also targeting  the  peripheral com partm en t m ay be a  more prom ising strategy. For 
exam ple, it h a s  been show n th a t deletion of Nogo-A expression in th e  m uscles of 
SOD1G86R mice reduces th e  denervation of peripheral m uscles a n d  in creases 
survival (Jokic et al., 2006). Moreover, expression of a  locally acting  isoform  of 
insulin-like grow th factor 1 in  m u scu la r regions of SOD 1-m u ta n t mice helps 
m ain ta in  th e  integrity of the  n eu ro m u scu la r ju n c tio n s , th u s  delaying m otor 
neu ro n  death  and  extending survival (Dobrowolny et al., 2005). In a  recen t repo rt 
p leiotrophin h a s  been proposed a s  a  new  cand idate  neuro troph ic  factor for m otor 
neu ro n  disease, since it im proved peripheral axonal regeneration  in  an im al 
m odels of acu te  nerve in ju ries (Mi et al., 2007). Increased  expression of th is  factor 
in  peripheral m uscles or Schw ann cells m ay aid  the  re innervation  of m otor 
p laques or favour axonal sprouting. It h a s  been  recently  suggested  th a t  selective 
increase  of superoxide d ism u tase  activity in  Schw ann cells of ALS m ouse m odels 
m ay help these  cells to detoxify reactive oxygen species (ROS) g enera ted  by 
m acrophage invasion of peripheral nerves, du ring  axonal re trac tion  (Lobsiger et 
al., 2009). Preserving or increasing  th is  ROS-scavenging activity could  be u sefu l 
in  order to m ain ta in  th e  production  an d  release of trophic factors by  S chw ann  
cells, th u s  providing su p p o rt to m otor neu ro n a l axons affected by th e  d isease . 
The availability of p rom oters an d  viral vectors specific for m uscles (Richard et al., 
2008; Towne et al., 2008), astrocytes (Jakobsson et al., 2003), S chw ann  cells 
(Feltri et al., 2002; Scherer et al., 2005), m icroglia (He et al., 2006), a n d  m otor 
n eu ro n s (our study) rep resen t powerful tools to rapidly  te s t new  cell specific 
the rapeu tic  strateg ies for ALS.
For targetting  the  p38MAPK pathw ay in SOD1G93A mice we u sed  a n  RNAi-based
approach  th a t resu lted  in  a  ra th e r  com plicated p ic ture . In fact, we observed  th a t
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dow nregulation of p38MAPK a lp h a  can  pro tec t m otor n eu ro n s  in  vitro an d  in  
SOD1G93A mice a t  the  early stages of the  pathology, while unexpectedly  we 
found th a t  th is  approach  is no t able to su s ta in  n eu ronal survival du ring  d isease 
progression, eventually  resu lting  in  w orsening of sym ptom s an d  sho rten ing  of life 
span . We th in k  th a t  th is  la te effect is due to the  hyperactivation of detrim en tal 
microglial cells w hich is in  line w ith recen t re su lts  (Gowing et a l, 2009). However 
th is  aspec t needs to be fu rth er carachterized.
Two of th e  four p38MAPK isoform s, p38M APKalpha and  p38MAPKbeta, are
know n to be expressed  in  th e  sp inal cord. A lthough som e s tu d ie s  have ind icated
differential roles for th e se  two isoform s in  th e  induction  of hyperalgesia  an d
neu ropath ic  pain  after acu te  nerve or sp inal cord in ju ries (Svensson et a l, 2005),
there  is still su rprisingly  little know n of th e ir function  in  chronic
neurodegenerative d iseases like ALS. The only available d a ta  suggests  th e
involvem ent of p38MAPK a lp h a  in the  process of perikarial accum ula tion  of
phosphorylated  neurofilam ents in the  m otor n eu ro n s  of bo th  ALS p a tien ts  an d
ALS m ouse m odels (Ackerley et a l, 2004). Therefore, to fu rth e r d issec t th e  role
played by p38MAPK a lp h a  in  ALS, we decided to selectively dow nregulate it in
SOD1G93A mice u sin g  sm all in terference RNA. The shRNA sequence selected  for
u se  in  ou r s tu d y  w as extensively validated by: 1) specific reduction  of mRNA an d
protein  levels of m ouse p38M APKalpha in  cell cu ltu res; 2) absence of th e  RNAi
knockdow n effect following the  in troduction  of th ree  po in t m u ta tio n s  in to  th e
candidate  shRNA sequence, d isrup ting  the recognition of th e  ta rg e t mRNA 3)
partia l neuroprotective effect of p38M A PK alpha-targeted shRNAs ag a in st
colchicine-induced cell death , in  prim ary  cortical n eu ro n s. The pro tection
observed in  prim ary  n eu ro n s  is consis ten t w ith  previously reported  p ro tection
again st colchicine u sin g  pharm acological p38MAPK inh ib ito rs (Yang et a l, 2007).
The au th o rs  w ent on to suggest a  functional in terp lay  betw een p38MAPK a n d
JNK in  the  death  process although it is w orth  no ting  th a t a  n u m b e r of s tu d ie s
have excluded the involvem ent of JNK activation in  the  degeneration  of m otor
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neu ro n s  in  ALS, bo th  in  p a tien ts  an d  m ouse m odels (Migheli et a l, 1997; Holasek 
et a l, 2005; Veglianese et a l, 2006). However, o u r re su lts  do lend  fu rth e r su p p o rt 
to th e  hypothesis th a t specific targeting  of p38MAPK a lp h a  m igh t p reven t or 
inh ib it m otor n eu ro n  loss in ALS. Interestingly, we did de tec t a  partia l 
protection of m otor n eu ro n s  by p38MAPK alpha-targeted  shRNA 16 days after 
trea tm en t, a lthough  a t  th e  end  stage of th e  d isease th is  effect w as no t 
m ain tained , an d  additionally  an  increased  d ea th  of sm all ven tra l h o rn  n eu ro n s  
w as reported . In con trast, o thers  have reported  th a t sem apim od, a n  a n ti­
inflam m atory  d rug  th a t  inh ib its  c-Raf activation an d  red u ces  p38MAPK 
activation, offered significant protection to m otor neu ronal cell bodies in  the  
sp inal cord of SOD1G93A mice a t  the  end  stage of disease, a lthough  w ith  little 
effect on th e  behavioural phenotype (Dewil et a l, 2007a). O n th e  o th e r h an d , 
minocycline, a  second generation tetracycline w ith an ti-inflam m atory  an d  an ti- 
apoptotic properties, decreased  the  levels of activated  p38MAPK an d  microglial 
reactivity in  the sp inal cord of SOD1G37R mice resu lting  in  a  slow er d isease 
progression  an d  increased  survival (Kriz et a l, 2002; Zhu et a l, 2002). 
M inocycline an d  sem apim od are non-selective inh ib ito rs of p38MAPK an d  
certain ly  do no t d iscrim inate betw een p38MAPK isoform s. It is possible, 
therefore, th a t  the  protection observed w ith th ese  d rugs is u n re la ted  to p38MAPK 
inhibition  or th a t the  lack  of isoform selectivity re su lts  in  a  g rea te r overall 
efficacy. Indeed, since ventra l ho rn  n eu rons, including  m otor n eu ro n s , express 
bo th  p38MAPK a lp h a  an d  p38MAPK b e ta  it is possible th a t  o u r strategy , aim ed 
a t  specific dow nregulation of a lp h a  isoform, does n o t provide sufficient inh ib ition  
of p38MAPK signalling due to the  residual activity provided by th e  b e ta  isoform . 
It is in  fact quite conceivable th a t  u p s tream  stressfu l stim uli m ay  sh ift th e ir 
signalling preference to the  induction  of the  non-targe ted  p38MAPK b e ta  isoform  
in th e  absence of p38MAPK a lp h a  expression. A s tu d y  on a d u lt m ouse  b ra in  h a s  
highlighted th a t  p38MAPK a lp h a  is preferentially  localized to th e  cy top lasm  an d
n u c leu s  of n eu rons, while p38MAPK b e ta  is m ainly  concen tra ted  in  th e  n u c leu s
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of n eu ro n s  an d  in  microglial cells (Lee et a l, 2000). A sim ilar cellular localization 
of th ese  isoform s h a s  also been  reported  in  r a t  sp inal cord, a lthough  a t  the  
subcellu lar level th e  sta in ing  for p38MAPK b e ta  in  n eu ro n s  appeared  to be 
m ainly cytoplasm ic in  th is  tissu e  (Svensson et a l, 2005). This evidence suggests 
th a t  the  two isoform s m ay have d istinc t functional roles in  neu ro n s. D ue to 
techn ical problem s w ith im m unohistochem istry  for p38MAPK a lp h a  an d  b e ta  we 
w ere unab le  to d issect th is  issu e  during  o u r study , however we believe th a t  
fu rth e r analyses are  needed to b e tte r d issect th e  role played by p38MAPK b e ta  in  
m otor n eu rons, in  ALS.
Furtherm ore , we also observed su b s tan tia l a lte ra tions in  the  m orphology of
m icroglia a t  the  end  stage of d isease, in  an im als th a t  were trea ted  w ith  p38MAPK
alpha-targeted  shRNA. This w as quite unexpected , since th e  m ain  isoform
expressed  in m icroglia is p38MAPK b e ta  (Svensson et a l, 2005). It h a s  been
reported  th a t  u n d e r pathological conditions, su ch  as  following tra n s ie n t global
b ra in  ischem ia, p38MAPK a lp h a  isoform  is specifically up regu la ted  in  microglia,
w hereas p38MAPK b e ta  is m ainly increased  in  astrocy tes (Piao et a l, 2002).
Reactive m icroglia cells con tribu te  to neu ro p a th ic  pa in  (Mika et a l, 2009) an d
m icroglia expressing  m u ta n t SOD 1 drive neurotoxicity, a s  com pared  to wild type
m icroglia (Beers et a l, 2006; Boillee et a l, 2006b; Xiao et a l, 2007) th u s
m odulation  of m icroglia could be regarded  a s  a  po ten tial th e rap eu tic  strategy .
However, there  is also increasing  evidence th a t  activation of m icroglia m igh t also
be beneficial, bo th  in  m odels of acu te  in jury  (Neumann et a l, 2006a; Lalancette-
Hebert et a l, 2007), and  in  ALS (Beers et a l, 2008; Chiu et a l, 2008). So in s tead
of aim ing a t com plete inhibition  of microglial activation, m ain tenance  of im m une
system  function and  microglial reactivity m ight be preferable an d  m an ip u la tin g
p38MAPK signalling m ight be one w ay achieving th is. CD l i b  im m unoreactiv ity
progressively increases in  the  sp inal cord of m utan t-S O D  1 m ice du rin g  d isease ,
an d  detects different microglial cell subgroups: m a tu re  microglia, m acrophages
an d  G rl+  myeloid p recu rso r cells. Gowing an d  collegues selectively rem oved the
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myeloid population  of sp ina l cord from m utan t-S O D l expressing  mice, 
dem onstra ting  th a t  elim ination of proliferating m icroglia apparen tly  h a s  no effect 
on neurodegeneration  in  SOD1G93A m ice (Gowing et a l, 2008). In a  su b se q u en t 
s tu d y  the  sam e group d em onstra ted  th a t  trea tm en t of SOD1G37R m ice w ith  M- 
CSF resu lted  in  induction  of a  neurotoxic phenotype in  the m icroglia, leading to 
acceleration of th e  d isease (Gowing et a l, 2009). Similarly, LPS-induced 
stim ulation  of in n a te  im m unity  accelera tes the  d isease in  SOD1G37R mice, 
leading to exacerbation  of res id en t microglial reactivity an d  n eu ro n a l death  
(Nguyen et a l, 2004). This suggests th a t  a  fu rth e r clarification of th e  dynam ics of 
microglial reactivity during  the  progression of ALS is needed . The design  of m ore 
selective tools, aim ed a t ta rge ting  only th e  po ten tial neurotoxic m icroglial s u b ­
popula tions, m ay be a  m ore effective w ay of coun teracting  the  pathological 
process. Indeed, induction  of p38MAPK in  m icroglia regula tes th e  tran sc rip tio n  of 
inflam m atory genes, su ch  as  IL-1 an d  TNFa, w hich are  associa ted  w ith  a  reactive 
phenotype. Interestingly, the  m acrophage lineage appears  to be sensitive to 
p38MAPK a lp h a  inhibition. Deletion of p38MAPK a lp h a  in  m acrophages in  vitro 
inh ib its  cellular activation after LPS stim ulation  an d  reduces the  re lease  of pro- 
inflam m atory cytokines su ch  as TNFa, IL-12 an d  IL-18 (Kang et al., 2008); 
deficiency of p38MAPK a lp h a  increases m acrophagic susceptib ility  to E R -stress, 
prom oting cell d ea th  (Seimon et a l, 2009). O ur s tu d y  suggests th a t  expression  of 
p38M APK-targeted shRNA in  m icroglial cells re su lts  in  a  m ore neuro toxic 
phenotype. This m ay re su lt from the loss of a  subgroup  of potentially  
neuroprotective microglia, or could be due to hyper-activation of p38MAPK beta . 
A lternatively, since JNK h a s  been  found activated  in  m icroglial cells a t  th e  end  
stage of the  disease, it is possible th a t  p38MAPK a lp h a  dow nregulation  leads to 
fu rth e r induction  of JNK -pathway. Specific targeting  of p38MAPK b e ta  or JNK in  
m icroglia will be needed in  o rder to clarify w hether th e se  p ro te in s  are  
responsib le for the toxic properties exerted by th is  cell popu la tion  in  ALS.
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In parallel w ith  experim ents aim ed a t targeting  Akt an d  p38MAPK pathw ay, we
also conducted  a n  extensive characterization  of the  p a tte rn  of infectivity of
VSVG-pseudotyped lentiviral vectors in  th e  lu m b ar sp inal cord of mice, an d
provided evidence th a t  th is  approach  allows tran sd u c tio n  of th e  m a in  cell types
p resen t in  th is  tissue , nam ely  astrocytes, oligodendrocytes, m icroglial cells and
n eu rons, including  m otor neurons. We found th a t  adm in istra tion  of a  GFP-
expressing control vector, w ith th is  approach , did n o t significantly influence the
progression of pathology in SOD1G93A mice. However, from histological s tud ies,
we detected  a  m odest loss of m otor n eu ro n s  a t  the  site of injection. T his suggests
th a t  SOD1G93A m otor n eu ro n s are probably  m ore susceptib le to th e  tra u m a
generated  by invasive surgery  of the sp inal cord. This issue is in  line w ith  a  s tu d y
by Azzouz an d  co-w orkers (Azzouz et al., 2000), in  w hich the  a u th o rs  repo rted  an
increased , though  n o t significant, loss of m otor n eu ro n s in  th e  a reas
su rro u n d in g  the  m ost cauda l injection site, for SOD1G93A m ice in jected  w ith
G FP-expressing rAAV or PBS, as  com pared to u n tre a te d  an im als. O ther groups
th a t  applied th e  sam e techn ique for the  delivery of viral vectors or cells, .did n o t
describe th is  effect, m ainly because they  did no t analyze m otor n eu ro n s  survival
in an im als th a t received control vector a s  com pared to sh am  o pera ted  mice
(Willing et a l, 2001; Guillot et a l, 2004; Raoul et a l, 2005b; Franz et a l, 2009).
So, particu la r cau tion  needs to be considered in  the  u se  of in tra sp in a l delivery
w hich h a s  been  proposed  as  a  tool for adm in istra tion  of po ten tial th e ra p eu tic
com pounds, including stem  cells, in ALS patien ts . O ther possib le delivery
strateg ies need  to be developed. For exam ple, retrograde tra n sp o rt to m otor
neu ro n a l cell bodies following adm in istra tion  in  peripheral m uscles, ap p ea rs  to
be an  in triguing alternative. A lthough th is  app roach  w as u n su ccess fu l in  o u r
study, probably  due to insufficient increase of viral vector titre  or p seudo typ ing
w ith a  w rong Rabies s tra in , evidence from th e  lite ra tu re  suggests  th a t  th e
techn ique is feasible (Mazarakis et a l, 2001; Mentis et a l, 2006). In add ition  to
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te stin g  o the r possible m odes of delivery, alternative vector system s, su c h  a s  AAV, 
are  also w orthy of consideration  (Kaspar et a l, 2003). Interestingly, it h a s  been 
recen tly  dem onstra ted  th a t efficient tran sd u c tio n  of sp inal cord m otor neu ro n s 
can  be obta ined  by injection of AAVs into th e  peripheral nerves (Federici and  
Boulis, 2006; Wu et a l, 2009). This new  approach  ap pears  to offer the  advantage 
of increasing  the  probability  of tran sd u c tio n  of CNS m otor n eu ro n s  u s in g  lower 
doses of virus.
7.2 . CONCLUSIONS
This th esis  h a s  provided extensive dem onstra tion  of th e  su itab ility  of viral vector- 
m ediated  approaches for fine dissection, in  vivo, of the  m olecular m echan ism s 
involved in  ALS. N um erous s tud ies  conducted  bo th  on h u m a n  ALS p a tien ts  and  
in  an im al m odels of ALS have con tribu ted  to ou r u n d ers tan d in g  of som e of the 
pathological m echan ism s involved in th e  d isease. However, finding a  tru ly  
effective the rapy  is still challenging. A reaso n  for the  lack  of su ccess  to da te  is 
th a t  it h a s  been  very difficult to identify th e  appropria te  m olecu lar ta rge ts . We 
have concen tra ted  on p38MAPK an d  Akt signalling pathw ays, two of the  
m olecular m echan ism s know n to be a ltered  in  ALS, and  w hose specific roles in  
th e  d isease process have no t yet been com pletely elucidated. U sing a  gene-based  
stra tegy  we have dem onstra ted  th a t  preservation  of m otor n eu ro n a l p e rik a ria  in  
the  sp inal cord, th rough  activation of Akt3, is n o t sufficient to p reven t or re ta rd  
th e  progression of m otor deficits, suggesting  th a t  targeting  of th e  peripheral 
com partm en t m ight be a  m ore successfu l approach . Moreover, we have 
evidenced th a t  dow nregulation of p38MAPK a lp h a  is protective for m otor 
neu ro n s, b u t we found th a t expression of p38M APK-targeted shRNA in  th e  sp inal 
cord is eventually  detrim ental, probably  due to induction  of m icroglia w ith  a  
m ore neuro  toxic phenotype. We believe th a t  RNAi-mediated cell-specific 
dow nregulation of p38MAPK a lp h a  an d  p38MAPK beta, or ta rge ting  of JNK, will
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clarify the  differential roles played by th ese  k in ases  in  m icroglia an d  n eu ro n s  in 
ALS.
Overall it is an tic ipa ted  th a t  these  s tud ies  m ay help in the  identification of new  
po ten tial th e rap eu tic  ta rge ts  for th is  devasta ting  disease.
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